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ABSTRACT
MTX has been covalently bound to proteins, to determine whether the macromolecular 
derivative could enhance its duration of action and reduce toxicity via changes in the 
pharmacokinetic parameters of the drug. MTX had a short terminal half-life at 102-117 
minutes following IV injection in the rat and a large volume of distribution (1000 to 
1600ml). BSA had a Vd of 26ml and t1#  of 22 hours for the elimination phase. A 
series of conjugates, prepared between MTX and BSA with a range of loadings of MTX 
(3.4-13.6%w/w) were studied. Following IV injection they were all found to 
demonstrate a biexponential clearance from serum. t1/2 were at least ten fold greater 
than MTX and the Vd was reduced to a third. The BSA-MTX conjugates did not 
demonstrate the same pharmacokinetics as free protein. The beta phase t1/2 was found to 
increase with increased %w/w loading of MTX (range 17-33 hours) and there appeared 
to be a linear relationship (t1/2 = 1.312(MTX %w/w) +14.5). There was a tendency for 
the Vd of the tissue compartment to increase with an increased loading of MTX (range 
35 to 600ml). High strength conjugates (e.g. 11.55%w/w) were found to accumulate in 
the liver (70% in the first 15 minutes) and low strength conjugates appeared to exhibit 
a generalised non-specific uptake by most organs. The reason for the increased cellular 
uptake compared to BSA may be due to changes in the physical characteristics of the 
protein or due to a specific effect caused by the MTX, which has allowed the conjugate 
to enter cells via the folate transporter. In addition, FPLC analysis of the conjugates 
showed an increase in the amount of aggregated protein (up to 39% was present in an 
aggregated form) in the higher strength conjugates and this could explain, at least 
partly, the increased uptake by the liver. Other protein-MTX conjugates were studied. 
These included LA-MTX and RSA-MTX and these gave similar results in the rat to 
BSA-MTX.
Separate analysis of the drug and protein portions of the conjugate in the rat using 
125I-BSA-3H-MTX (7.16%w/w) showed that the two isotopes had similar t1/2. This 
suggests that the conjugate was not degraded during circulation. Following 
uptake by the liver, the 125I-BSA portion of the conjugate was degraded and transferred 
to the bile as iodotyrosine or 125I' (65%) or oligopeptides with a molecular weight
below 1800, whereas 3H was selectively retained in the liver. 125I was excreted in the 
urine mainly as iodotyrosine or 125I\ 3H-MTX was excreted at a slower rate than 125I 
(51% of injected 125I was excreted in the urine in 24 hours and 28.5% of 3H).
The ability of the conjugates to extravasate was investigated in vitro using BAE-1 cells 
grown on filters. Free BSA was transported across the cell layer at a faster rate than 
BSA-MTX (4.54%w/w and 11.55%w/w). This could be because of the aggregated 
protein within the conjugates.
ACKNOWLEDGEMENTS
I would like to thank my supervisors, Drs. Lidia Notarianni and Colin Pouton for their 
constant support and enthusiasm throughout the three years spent on this thesis. I would 
like to thank the technicians in the pharmacy department, particularly Gary Cooper and 
Lesley Moore for their assistance in some of the work described. I would like to thank 
Ciba Geigy Pharmaceuticals and in particular, Martin Mackay and Ian Hassan for 
allowing to me to work with them in the ADDR department at Horsham. I would 
like to thank Dr G. Black and Mr D Howes at Unilever Research and Mrs P.Wilmott 
at Glaxo, Ware for carrying out the whole body autoradiography. In addition, I would 
like to thank all members of the Department of Pharmacy at Bath for their friendship 
and advice over the years. I would like to thank William Moss for help with proof 
reading and typing. Finally, I would like to thank S.E.R.C for generous financial 
support and the University of Bath for providing research facilities.
ABBREVIATIONS
ALL Acute lymphocytic leukaemia
AMN Aminopterin
ASGP Asailoglycoprotein
ATP Adenosine triphosphate
BAE-1 Bovine aortic endothelium cell line
BSA Bovine serum albumin
BSA-MTX Bovine serum albumin-methotrexate conjugate
CA Carbonic anhydrase
CEA Chicken egg albumin
CHO Chinese hamster ovary cell line
Cl Clearance
CNS Central nervous system
CPM Counts per minute
CSF Cerebrospinal fluid
CURL Compartment of uncoupling of receptor and ligand
DHFR Dihydrofolate reductase
DNP 2,4-Dinitrophenylalanine
DNR Daunorubicin
DPM Disintegrations per minute
ECDI l-Ethyl-3-[3-(dimethylamino)propyl]carbodiimide
- iv -
ELISA Enzyme-linked immunosorbent assay
FCS Foetal calf serum
FTTC Fluoroscein isothiocyanate
FPLC Fast protein liquid chromatography
FUDR 5-Fluorodeoxyuridine
G-BSA Galactosamine-bovine serum albumin
GIT Gastrointestinal tract
G-HPMA Galactosamine-poly-N-(2-hydroxypropyl)methacrylamide
GPC Gel permeation chromatography
HBGF Heparin binding growth factor
HPLC High performance liquid chromatography
HPMA Poly-N-(2-hydroxypropyl)methacrylamide
HSA Human serum albumin
IgG Immunoglobulin G
IV Intravenous
IP Intraperitoneal
Kel Elimination rate constant
LA Lactalbumin
LA-MTX Lactalbumin-methotrexate conjugate
LDL Low density lipoprotein
mAb Monoclonal antibody
M-BSA Mannose-bovine serum albumin
MCR Molar-conjugation ratio
MMC Mitomycin C
MTX Methotrexate
MTX(GLU)n Polyglutamated methotrexate
MTX-PLL Methotrexate-poly-L-lysine conjugate
7-OH-MTX 7-Hydroxymethotrexate
PBS Phosphate buffer saline
PDL Poly-D-lysine
PEG Polyethyleneglycol
PLL Poly-l-lysine
PVP Polyvinylpyrrolidine
R2 Regression coefficient
RES Reticuloendothelial system
RI Refractive index
RSA Rat serum albumin
RSA-MTX Rat serum albumin-methotrexate conjugate
SC Subcutaneous
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM Scanning electron microscope
SEM Standard error of mean
t1̂  Half life
TCA Trichloroacetic acid
TAA Tumour associated antigen
TEM Transmission electron microscope
Vd Volume of distribution
w/v Weight for volume
w/w Weight for weight
CONTENTS.
Page
Abstract i
Acknowledgements iii
Abbreviations iv
Contents viii
Chapter 1: Introduction
Chapter 2: Materials and Methods 33
Chapter 3: Kinetics of Methotrexate and Proteins in the Rat 66
Chapter 4: Analysis and Pharmacokinetics of
Protein-MTX Conjugates in the Rat 114
Chapter 5: Visualisation and Body Distribution of the Conjugates 173
Chapter 6: Transport Experiments Using 2 Cell Lines in vitro;
Caco-2 and BAE-1 Cells. Uptake of BSA Conjugates 
by Macrophages in vitro. 209
Chapter 7: Conclusions 248
References: 257
Appendix 1: Calibration Curves and Reaction Mechanisms A1
Appendix 2: Formulae and Procedures for
Calculating Pharmacokinetics and statistics A ll
Appendix 3: Experimental Data for Chapters 3-6 A16
- viii -
CHAPTER 1 
INTRODUCTION
Rationale for Drug Targeting.
Most drugs in current use have access to nearly all body compartments. Factors 
controlling drug distribution include the blood flow to a particular organ, protein 
binding of the drug in serum and in addition the inherent properties of the drug (e.g. 
hydrophobicity, electrical charge and molecular weight). Thus drugs can reach not only 
the site where they are pharmacologically active but also other organs where they can 
cause side effects. The majority of drug regimens would be improved if the access of 
the drug was restricted, in particular the targeting of anticancer and antiviral drugs
would be a significant improvement due to the reduction in toxicity and an increase in
I
efficacy. The work in this thesis has involved the covalent binding of methotrexate, a 
much used anticancer agent to large molecular weight carriers in the hope that an 
improvement in the delivery and distribution of the drug can be achieved.
This introduction will begin by describing some of the methods which can be exploited 
to achieve site specific drug delivery, which would occur due to improved distribution 
of the drug. It will then go on to describe methotrexate, the model drug used in this 
work, and some of the problems associated with its administration. The final section of 
the introduction will describe the scope of this project.
1.1 Site Specific Drug Delivery
Several factors may limit the use of a particular drug e.g. the drug may be prematurely 
metabolised or excreted before it has had time to reach its site of action, or it may be 
too hydrophilic to access its active site e.g. MTX cannot pass through the blood brain 
barrier. Conversely, the drug may have no problem reaching its target and likewise it 
can reach many other sites within the body causing side effects. These problems may be 
Overcome by using a targeting agent to selectively deliver the drug to its site of 
pharmacological activity.
Site specific drug delivery has been described as achieving the maximum intrinsic 
activity of drugs by optimising their exclusive availability to their pharmacological 
receptor in a manner that affords protection both to the drug and body alike/1)
Most approaches to drug targeting involve an interaction between a drug and a carrier, 
such that the normal distribution of the drug is altered and it no longer has free access 
throughout the body. Many systems have been exploited in research into site specific 
drug delivery and these may involve the use of a macromolecular carrier where the drug 
can be covalently bound e.g. monoclonal antibodies or particulate carriers where the 
drug is physically entrapped within its matrices. The distribution of drug-macromolecu- 
lar complex will depend on the physicochemical characteristics of the carrier e.g. 
molecular weight, charge and hydrophobicity and these factors can be manipulated in 
order to achieve maximal benefit/2)
There are many examples of particulate carriers eg. liposomes, albumin microspheres, 
erythrocyte ghosts. Since the work in this thesis has involved the use of a soluble 
carrier this section of the introduction will concentrate mainly on the soluble carriers 
which have been used in drug targeting.
A successful drug carrier should exhibit certain characteristics and these include;
1. Protection of drug from metabolism and premature release.
2. Localisation of drug at its target site with subsequent release of the drug in active 
form.
3. It should not cause host toxicity or immunogenicity.
Figure 1.1 shows a model for a soluble drug-carrier conjugate. It is similar to that 
described by Ringsdorf/3)
Figure 1.1: A Diagramatic Representation of the Requirements for a Soluble
Drug-Carrier Conjugate.
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Drug delivery has been classified into 3 phases.1<4) First order drug delivery involves 
distribution of drug-carrier complex to the capillary bed of the target site. Second order 
delivery should bring the complex to the intracellular fluid surrounding the target cells 
and third order delivery should result in the drugs presence within the cytoplasm of the 
target cells.
Another way of classifying the behaviour of a drug carrier complex is to describe the 
ability to actively or passively target the drug/5) Active targeting involves the 
incorporation of a specific agent to deliver the drug e.g. a monoclonal antibody or a 
sugar residue (galactose receptors are found exclusively on hepatocytes)/6) Passive
targeting relies on the inherent nature of the drug complex e.g. particulate and cellular 
carriers are taken up by cells of the RES.
A drug which is delivered to a cell, bound to a macromolecular carrier, cannot simply 
diffuse into the cell. It has to be taken up by pinocytosis. This is a ubiquitous process 
and individual cell types differ only slightly in the rate at which they pinocytose 
solutes/7)
Figure 1.2 describes the process of pinocytosis. It can be of three types: Fluid phase 
(non-specific), adsorptive and receptor mediated. Adsorptive pinocytosis can account 
for the increased cellular uptake of hydrophobic or cationic macromolecules compared 
to non-charged hydrophilic molecules. Pinocytosis always occurs from the area of cell 
membrane known as a coated pit (except in endothelial cells)/7) The membrane 
captures fluid and solutes which are coated on or close to its surface. The vesicle 
formed then loses its clathrin coat and becomes known as an endosome or CURL 
(compartment of uncoupling of receptor and ligand). The endosome has a low pH, 
maintained by an active ATP powered proton pump. The endosome has two functions; 
to deliver ligand to the lysosome and to recycle membrane back to the cell surface. The 
receptor to which ligands are bound can be recycled as in the case of the LDL and 
asailoglycoprotein (ASGP) receptors^8) or the receptor can be transferred to the 
lysosome with the ligand e.g. Epidermal Growth Factor. In this situation, down 
regulation of the receptor occurs.
There are three routes out of the endosome. One leads to the lysosome and the 
proteolytic enzymes which it contains. The other two routes both lead to the cell 
surface; either the section of cell membrane from whence it came or, in polar cells e.g. 
the endothelia, to the opposite side of the cell (transcytosis). The lysosome contains 
approximately 50 different enzymes which can break down most biological molecules 
to their respective monomers/7) The membrane of the lysosome is impermeable to 
macromolecules and to charged or hydrophilic molecules like sucrose. It also has a 
proton pump to maintain a low pH.
Figure 1.2 The Route for Lysosomal Delivery,
Recycling of ( 
Receptors '  
and cell 
membrane
MTX-TA/Vlr 
MTX-vw
Cell Membrane
Coated Pit
Primary
Lysosome
with
enzymes
Wmm
Non-biodegradable 
polymer remains 
in lysosome
Fragments of 
biodegradable 
polymer are released
MTX
MTX
MTX-VW
m rnm
Endosome 
Low pH
Fusion with
Primary
Lysosome
Secondary 
Lysosome 
Low pH + 
Enzymes
MTX Drug is released
m t x a /w v  Methotrexate bound to a biodegradable carrier
mtx-W w  Methotrexate bound to a non-degradable carrier
Most soluble drug-macromolecule conjugates are designed so that they are stable within 
the blood stream, and free drug is only liberated after internalisation of the conjugate 
into the cell, followed by lysosomal degradation. Before a drug-macromolecule 
conjugate can actually get to its target site, it must leave the blood stream. It would 
seem prudent at this stage, to discuss some of the aspects of the vascular compartment 
which should be considered and may be exploited in the design of a targetable form of 
a drug.
1.2 Physiology of Extravasation: The Endothelial Cell Barrier.
The capillaries and other blood vessels constitute a barrier between plasma and 
interstitial fluid. This barrier consists of the blood endothelial interface, the 
endothelium, the basal lamina and the adventitia/9)
Capillaries are the smallest blood vessels and form a barrier that is only one cell thick. 
The microvessels, which are the arterioles, capillaries and post-capillary venules/10) are 
the vessels which are responsible for the exhange of solutes and gases. Capillaries can 
be divided into 3 groups; continuous capillaries are found in the myocardium and brain, 
fenestrated capillaries are usually found in organs whose functions demand a high rate 
of fluid exchange^11) such as the intestine, kidney and adrenal cortex and sinusoidal 
capillaries are found in organs of the RES e.g. liver and spleen.
Endothelial cells are coated on their luminal surface with an adsorbed layer of plasma 
proteins e.g. albumin, fibrin and heparin. Along with the glycocalyx this layer forms the 
blood endothelial interface. The coat continues into the plasmalemmal vesicles which 
open onto the luminal surface of the cells and into the transendothelial channels. It has 
a net negative charge due to the presence of acidic glycoproteins/12)
The endothelial cells are squamous epithelia which are connected by intercellular 
junctions. The junctions are of two types i.e. tight (occluding) and gap junctions. Tight 
junctions are considered to seal the intercellular space thus preventing passage along 
this route/9) Most endothelial cells are connected by tight junctions, but up to 30% of
the junctions found in venules have been found to exhibit gap junctions up to 6nm in 
diameter.*13)
Endothelial cells are metabolically active and they are differentiated to mediate and 
monitor bidirectional exchange of substances.*9) They demonstrate a large number of 
plasmalemmal vesicles with a diameter of 60-80nm. These can be open on either side of 
the cell and present within the cytoplasm. Fusion of these vesicles can occur, thus 
providing a transendothelial pathway. The density of vesicles within a cell is dependent 
on the organ within which it is found. The number found in brain capillaries is much 
lower than in other organs. The frequency of vesicles is also dependent on the type of 
microvessel in which they are found. Endothelial cells found in capillaries, particularly 
at the venular end, demonstrate the highest number.
In cell types other than the endothelium, the plasmalemmal vesicles would direct 
absorbed solutes to the lysosome. However in endothelial cells the process of 
transcytosis is favoured. Endothelial cells do contain lysosomes and it is other 
organelles within the cell which are responsible for delivery to them. Transcytosis of a 
macromolecule, be it an endogenous protein or an injected macromolecule, brings it 
into the interstitial fluid. From here it is returned to the blood stream via the lymphatics. 
The concentration of macromolecules in the interstitial fluid has been found to be the 
same as pre-nodal lymph in sub-cutaneous sites*14) and may be the same throughout the 
body.
Fenestrae are circular openings of approximately 70nm in diameter. They are found in 
visceral endothelial cells as already described. In all, apart from cells found in the 
glomerulus, the fenestrae have a diaphragm with exposed negative charges, which is 
made up of heparan sulphate proteoglycan.*15*16)
Coated pits (diameter 100-120nm) are found on both endothelial cell surfaces, but are 
more common on the luminal side. They are found in all cell types, particularly 
sinusoidal capillaries. The coat consists of clathrin. In continuous and fenestrated 
capillaries the coat has exposed anionic sites. In sinusoidal capillaries there are areas of
both anionic and cationic charge. Coated pits seem to be associated with the receptor 
mediated endocytosis of certain macromolecules e.g. LDL. The pits direct adsorbed 
material to the lysosome e.g. positively charged molecules. Solutes taken up by fluid 
phase endocytosis do not seem to be processed in this way.
Endothelial cells exhibit receptors for sugars, lectins/17) insulin*18) and histamine. The 
histamine receptors are found on post capillary venules. Following occupancy of this 
receptor the endothelial cells contract*19) and this is an important factor in the 
inflammatory reponse.
The basal lamina forms a rest for endothelial cells. It is 5-8 nm thick and consists of 
components secreted by the endothelial cells themselves e.g. collagen types IV and V 
and fibronectin. The lamina appears as a continuous layer beneath continuous and 
fenestrated capillaries and is patchy beneath sinusoidal capillaries. The basal lamina has 
been demonstrated to form a negatively charged barrier.*20) Figure 1.3 shows the 
structure of a layer of the endothelial barrier.
Figure 1.3 The Structure of the Endothelial Cell Layer.
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KEY:
BM = Basement Membrane,Ch = Channel, Cp = Coated Pit, EC1 = Endothelial Cell (1) 
EC2 = Endothelial Cell (2), F = Fenestra, J = Junction, PM = Plasma Membrane, 
V = Vesicle.
The capillary endothelial barrier has classically been described by physiologists as an 
impermeable layer that is perforated with 2 types of pores/21) These are classified as 
large pores with a diameter of 50-70nm and a frequency of 1 pore/20pm2 and the small 
pores with a diameter of 6-9nm and a frequency of 10-15 pores/pm2. This theory has 
arisen from theoretical considerations which resulted in the proposal of simple 
equations which equate solvent and solute flow across porous barriers. (Kedem and 
Katchalsky 1958 and 1963). In addition Patlak included a selectivity factor in his 
equation since he believed that all macromolecules would not be able to pass through 
the pores at the same rate.(Patlak 1963) This work has been reviewed by Taylor and 
Granger Z11)
Experimental work which has usually involved the simultaneous measurement of 
macromolecules in plasma and lymph has supported the two pore theory. However, 
investigations using the electron microscope have had difficulty in demonstrating them. 
The large pores may be explained by the plasmalemmal vesicles, channels or fenestrae. 
The small pores are more difficult to equate. They may be due to the gap junctions 
which are found in post-capillary junctions/21)
1.2.1 Organ Selectivity in Transcapillary Exchange.
The endothelium is involved in the sorting and gating of molecules/9) It can sort 
molecules according to molecular size, charge, and chemical nature.
It has already been mentioned that organs can demonstrate one of 3 types of capillary 
(fenestrated, continuous and discontinuous). On top of this, each organ demonstrates its 
own inherent differences.
The continuous capillaries exhibit the greatest restriction to the passage of 
macromolecules. This type of capillary is the most widely distributed in the body. It 
appears that continuous capillaries situated in the lung are able to transport larger 
molecules than those found in sub-cutaneous and skeletal muscle. This data was 
determined by measuring the lymph to plasma ratios of endogenous proteins in these
-10-
organs/11̂
Of the fenestrated capillaries the kidney demonstrates the most obvious differences 
from the rest of its type. Its fenestrae are not covered by a diaphragm, yet it has a cut 
off molecular weight for transport of macromolecules at a much lower level than other 
capillaries of this type. Macromolecules with a radius of above 4.4nm are not 
transported from blood into the urine/221 The reason for this size selectivity appears to 
lie with its considerably thicker basement membrane. This membrane also exhibits a 
negative charge. Bohreri231 demonstrated that dextrans with a net positive charge were 
excreted more readily by the kidney than molecules of an equal size which are 
negatively charged or neutral up to a molecular radius of 4.3nm. Figure 1.4 taken from 
this reference^231 demonstrates this.
Figure 1.4 Relationship between Fractional Solute Clearance and Molecular 
Radius in Rat Kidney for Neutral, Anionic and Cationic Dextrans.
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Several investigators have demonstrated, in the intestinal and lung capillaries, the 
increased transport of negatively charged molecules compared to equal sized positively 
charged/24-251 Perry et a /241 believed that their results indicate that the plasmalemmal
-11-
vesicles exhibit a positive charge in the intestine but they had no evidence to 
substantiate this. Parker et al*25), finding similar results in the lung, believed that this 
could be explained by cation exchange of the macromolecule, with the small cations 
known to be found on the anionic sites of the plasmalemmal vesicles. Thus adsorbed 
cationic molecules were not transported. However the anionic molecules were able to 
move freely through the plasmalemmal vesicles.
1.2.2. Tumour Blood Vessels.
An avascular tumour cannot grow to much more than 1 to 2 mm in size. At this size 
passive diffusion can no longer provide nutrients and remove waste products and for 
every new layer of cells that grow on the outside of the tumour a layer must die on the 
interior/26*27)
If a tumour becomes vascularised then tumour cells grow in a cylind rical manner 
around the blood vessel/28) Many tumours are able to promote angiogenesis 
(development of new blood vessels) by a process of sprouting from pre-existing 
vessels/29) Inflammatory cells from the host may also be able to promote angiogenesis.
The first response to an angiogenic stimulus is the dissolution of the basement 
membrane surrounding a pre-existing post-capillary venule. Next the endothelial cells 
migrate out of the old vessel towards the tumour and this is accompanied by cell 
division. The next step is the formation of a three dimensional structure with a lumen. 
This can then differentiate into a capillary loop and then a mature vascular bed, the 
capillaries having a basement membrane/30)
Several factors have been implicated in promoting angiogenesis/26) Some like 
angiogenin, which is produced by the tumoui/31*32), can only induce one aspect of 
angiogenesis, in this case cell migration, while others can induce both mitogenesis*33*34) 
and angiogenesis*35) e.g. Heparin Binding Growth Factor (HBGF). The angiogenic 
properties of HBGF are enhanced by heparin.*36) There are also inhibitors of the 
angiogenic factors e.g. Angiogenin is blocked by placental ribonuclease inhibitoi/37) and 
HBGF is inhibited by protamine and cortisone when it is administered with heparin*36) 
(cortisone alone has no effect).
-12-
It is hardly surprising, because of the way tumour blood vessels develop, that they are 
not like the blood vessels found in the host organ/38) The differences can occur in the 
cellular composition of the vessel - the capillaries found in tumours are made up almost 
entirely of endothelial cells whereas normal capillaries will also contain pericytes. 
Pericytes appear to modulate the growth of endothelial cells*39). Other differences are an 
increase in permeability and changes in vessel stability.
Most tumour capillaries are of a continuous type/40) although it has been demonstrated 
that some tumours, particularly those found in liver, kidney or exocrine glands, can 
induce the angiogenesis of fenestrated or sinusoidal vessels/41) The continuous 
endothelium found in tumours has been shown to be more leaky towards injected 
macromolecules (e.g. dextrans, IgG and fibrin) than normal vessels/42*43) This leakiness 
was shown to be confined to the venules running along the periphery of tumours and at 
the tumour-host interface. However, immature vessels at the periphery and vessels 
within the tumour did not demonstrate the increased permeability/42) It has been 
demonstrated that tumours actually release a factor which increases vascular 
permeability/44"46)
Kinin generation also appears to be important in inducing increased vascular 
permeability in tumours*38). Bradykinin and hydroxyprolyl3-bradykinin have been found 
in the ascitic fluid bathing human tumours/47) When mice bearing ascitic tumours were 
given an IP injection of Soy-bean Trypsin inhibitor (an inhibitor of the production of 
kinins) the ascitic fluid production was suppressed/38) Captopril and enalapril are potent 
inhibitors of the breakdown of kinins. This could be exploited to increase the vascular 
permeability in tumours to allow the entry of antibodies, while blood vessels in normal 
tissue are unaffected since they are not generating kinins/48)
Tumour capillaries exhibit a reduced basement membrane which contains a higher 
concentration of hyaluronic acid and lower concentration of sulphated glycosaminogly- 
cans/49) This gives rise to an altered architecture which has been demonstrated to be 
more leaky.
-13-
Although tumours can induce endothelial cell migration, they cannot induce lymphatic 
invasion/26*50) In addition the existing lymphatics within an organ can becdme 
obstructed by a tumour/51) Thus the increased permeability of the capillaries leadjs to 
drainage of fluid and plasma proteins into the interstitial space and oedema results 
because the extra interstitial fluid cannot be channelled away. A rise in interstitial 
pressure occurs and this could also be due to the increase in tumour cell mass which 
has had to occur in a confined space/26) One consequence of the increase in interstitial 
pressure is an occlusion of the blood vessels in the interior of the tumour with 
consequent ischaemia and tumour necrosis. There are two problems associated with the 
increased pressure; firstly it may facilitate the exit of tumour cells and secondary 
tumour development (metastasis). Secondly, because of the differential between high 
pressure in the interstitium and low pressure in the microvascular circulation, the 
delivery of exogenous drugs may be prevented and the entry of normal host defences 
barred.
|
13 Types of Carrier used in Drug Targeting.
Soluble carriers have been classified into two groups/52) either of natural origin e.g. 
proteins, carbohydrates like dextrans and DNA or of synthetic origin e.g. polyvinyl 
pyrrolidine (PVP), polylysine and poly-N-(2-hydroxypropyl) methacrylamide (HPMA). 
Some examples of these will be discussed below. They can also be categorised into 
their ability to be degraded in vivo. Polymers which are of natural origin are usually 
biodegradable and this is one advantage in using them. They also (apart from the 
polysaccharides) demonstrate little polydispersity. Synthetic polymers are not usually 
biodegradable unless they have been specifically synthesised to include biodegradable 
bonds^53) and because they are man made they are likely to be polydisperse. An 
advantage which synthetic polymers have over natural is that they are less likely to 
evoke an immunogenic response in v/v<?/54) and they can be tailor made to requirements 
of molecular weight, charge and hydrophobicity/55)
-14-
1.3.1 Synthetic Macromolecules as Carriers in Drug Targeting.
A great deal of research has centred around the use of HPMA copolymers as carriers 
for cytotoxic drugs. Seymour et al<56> demonstrated a size selective urine excretion of 
non-biodegradable HPMA copolymers. Copolymers with a molecular weight above 45 
kD were not lost from the blood stream via the kidney, and only disappeared from the 
blood stream very slowly as they extravasated into the tissues. A size-dependent uptake 
of the copolymer by the liver was also demonstrated.
The aim of a drug targeting conjugate is to prevent loss of drug via the kidney and to 
limit cellular uptake to the process of pinocytosis/57) Thus a carrier should have a
i
molecular weight above 45 kD. However for a non-biodegradable carrier, this may 
present toxicity problems, as a molecule of this size cannot get out of the lysosome and 
would be retained for the life of the cell. Subr et al<53) tried to overcome this problem 
by linking sections of copolymer with peptide linkages. The resultant copolymer would 
not be excreted via the kidney until it had reached the lysosome of its target cell, and 
the copolymer bridges had been removed.
Replacing some of the hydroxypropyl groups, during synthesis of HPMA, with drug 
and targeting residues gives rise to a soluble drug-targeting conjugate/58) Drugs that 
have been bound to HPMA include daunomycin/59'61) puromycin/59) adriamycin. (62»63) 
Each drug was successfully attached to the HPMA via a biodegradable peptidic spacer
i.e. GLY-PHE-LEU-GLY-DRUG. This sequence was found to be stable in the blood 
stream but sensitive to lysosomal cysteine proteinases/54) The conjugated form of these 
cytotoxic drugs was found not to distribute to the heart (site of major toxicity for this 
group of drugs and often the reason for prematurely stopping therapy) and this is an 
example of negative targeting.
Targeting groups have been applied to the HPMA-drug conjugates. These include 
antibodies e.g. anti-Thy 1.2(61*64) ^  SUgar residues such as galactosamine^65*66) and 
fucosylamine/60*62)
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Another synthetic polymer which has been the subject of a great deal of research is 
poly-lysine/67'69) Poly-lysine is a cationic molecule at physiological pH and it enters 
cells by the process of adsorptive pinocytosis/70) It can be synthesised in a range of 
molecular weights and utilising either D-Lysine or L-Lysine. Polymers formed from 
L-lysine can be metabolised in vivo whereas poly-D-lysine (PDL) cannot be degraded in 
the body. Arnold et a l/67) using cultured HeLa cells and also Ehrlich Ascites Tumour 
Xenografts growing in mice demonstrated that poly-lysine is cytotoxic in its own right. 
This factor could be a disadvantage since quite small doses (LD50 for 70KD 
poly-L-lysine (PLL) was 5 doses of 30mg) of the polymer were toxic to normal mice. 
The molecular weight of the polymer determines the degree of cytotoxicity; as 
molecular weight increases toxicity increases. The mechanism of this toxicity appears to 
be due to the cationic nature of the polymer since it causes cell aggregation and 
promotes the efflux of small molecules from the cell by creating openings in cell 
membranes/71) There is a degree of selectivity in the poly-lysine toxicity since it has no 
effect on mice inoculated with L1210 leukaemia. Also, cancer cells generally exhibit 
an increased anionic charge which would make them more susceptible to poly­
lysine/67)
Ryser and Shen(7°) conjugated MTX to poly-lysine and used the carrier complex to 
deliver MTX intracellularly to a MTX transport resistant CHO cell line. Galivan et al 
(72> also demonstrated cytotoxicity of a MTX-PLL conjugate in their MTX transport 
resistant H35 cell line. Unconjugated MTX was ineffective at the same concentration. 
The cytotoxicity of the MTX-PLL could be inhibited by leupeptin, a lysosomal enzyme 
inhibitor which prevents the liberation of pharmacologically active drug.
MTX directly conjugated to PDL has no cytotoxicity (apart from that due to the 
polymer) since free drug cannot be liberated from the conjugate. In order to make the 
conjugate cytotoxic, MTX had to be linked to the polymer via a biodegradable spacer. 
Ryser and Shen^70) demonstrated that a tripeptide spacer (GLY-GLY-GLY) was 
sufficient to allow liberation of active drug.
Other drugs have been successfully conjugated to poly-lysine to give conjugates with
cytotoxic activity. These include daunomycin and 6-aminonicotinamide.*67)
i
13.2 Dextrans
Dextran is a naturally occurring polysaccharide which can be obtained from 
Leuconostic mesenteroides. It is highly water soluble, has been used for several years as 
a plasma expander so that its safety in vivo has been established, and it is available in a 
wide range of molecular weights (2 x 103 to 106).*2)
Drugs*73) and enzymes*74) have been successfully coupled to the hydroxyl groups of 
dextran. Takakura et al*75) have bound mitomycin C (MMC) to dextran using a 
6-bromohexanoic acid spacer leading to a conjugate with an anionic charge. This spacer 
gave a bond which could be chemically hydrolysed under physiological conditions, thus 
allowing the gradual release of active drug. The half-life for the cleavage of the 
drug-spacer bond was 35 hours for a dextran with a molecular weight of 70kD. MMC is 
unstable within the environment of the lysosome, so it was inappropriate in this case to 
conjugate the drug to the dextran with a bond which could only be broken down 
enzymatically.*73) The dextran conjugate could be used as a reservoir of drug. The 
release was slow enough to allow the dextran to alter the distribution of MMC in vivo. 
One dose of the conjugate proved to be superior to free MMC at prolonging the life of 
mice innoculated with P388 leukaemia when administered via the same route as the 
tumour but 24 hours later.*7̂ )
Cationic dextran conjugates have also been prepared by incorporating 6-amino caproic 
acid as the spacer.*76) These have enhanced antitumour activity in vitro compared to 
anionic conjugates.*77) However in vivo they have less antitumour activity because they 
are rapidly removed from the blood by the liver*78) and spleen.*76) In local injection 
cationic MMC-dextran conjugates proved to be superior to anionic conjugates since the 
cationic conjugate was retained at the injection site.
13.3 Proteins.
a) Monoclonal Antibodies
Monoclonal Antibodies (mAb) have been the object of a great deal of research in the 
drug-targeting field. They have already established themselves as valuable diagnostic 
agents for both primary and secondary tumour growths/79*80) Most antibodies have little 
activity on the growth of the tumour themselves and so, for the treatment of cancer, 
drugs or toxins are bound to the mAb. Certain factors need to be considered to acheive 
a successful targeting complex/81)
1. Is a specific antigen available for the tumour cell?
2. Does the mAb localise in the tumour in vivol
3. Is the mAb suitable for drug linkage?
4. Does the toxicity or immunogenicity increase after drug is conjugated to the mAb?
5. Does the mAb still localise in the tumour after drug binding?
Problems Associated with the lisp, o f  mAh.
mAbs are usually produced in repsonse to tumour associated antigens (TAA), which are 
commonly found on the surface of neoplastic cells. However they are not found 
exclusively on tumour cells; certain normal cells also demonstrate them, though at a 
much lower level/82) These TAA may dissociate from the tumour and enter the blood 
stream. This would lead to neutralisation of some of the mAb before it had chance to 
reach and interact with the target cell/81)
Another problem associated with the use of mAb to TAA is that some cells within a 
given tumour mass will not demonstrate a particular antigen. Kufe et al <83) 
demonstrated in their mammary carcinoma cell line, using the mAb B6 2 and B38.1, 
that cell binding was cell cycle specific with maximal binding occurring when a cell
was in the S-phase of cell growth. P. Horan Hand et al<84> demonstrated a patchwork of 
antibody binding in their mammary carcinoma cell line with 4 different mAb. If a single 
mAb drug conjugate was administered then all sensitive cells could be killed within a 
tumour cell mass, but cells which did not express the TAA would be unaffected. This 
problem could be overcome by administering two or more different mAb conjugates in 
the hope that each cell would be sensitive to at least one/85)
M.V. Pimm in his recent review^81) has described many reports where only 0.005% of 
the mAb localised in human tumours, even after several days, although these may 
represent tumour to normal tissue ratios of up to 10:1. One of the problems associated 
with the use of mAb is their relatively large molecular weight (IgG=150kD) and thus 
they can only slowly get out of the blood stream. Although mAb are reactive to TAA, 
there are no receptors either for the antigen binding sites or the Fc portion on normal 
vascular endothelia/86) Autoradiography of the tumour following administration of 
radiolabelled mAb showed the radioactivity to be confined to the periphery of the 
tumour mass/87*88) As already described,@2) the vessels at the periphery of the tumour 
are more leaky than the vessels within the interior.
Several investigators have overcome the problem of size of the mAb by treating it with 
pepsin to yield either F(ab)2 or Fab fragments. These should more readily leave the 
vasculature. However they exhibit a decreased binding potential to the TAA which 
results in a decrease in the amount of fragment localised in the tumour/89)
Buchegger et al<9°) demonstrated that their Fab fragment, although showing a lower 
absolute level in the tumour compared to intact IgG, did show a greater penetration into 
the tumour mass. In addition fragment which is not tumour bound may be cleared more 
rapidly avoiding systemic toxicity/89)
One of the problems associated with binding drug to the mAb is that antigen binding 
ability may be reduced if the tertiary structure is altered or drug binds to the active 
site/91) This loss of activity can be-reduced if the active site is blocked reversibly 
before drug conjugation takes place/92) Another way of preventing damage to the
antigen binding site is to conjugate large quantities of drug to a spacer and then bind 
the spacer to the mAb/93*94) However, this has the disadvantage that the complex 
molecular weight is increased significantly, thus restricting extravasation still further:
The drug to be bound to the mAb must have a group which can participate in the 
reaction and the bond that is formed must be cleavable intracellularly so that the drug 
can be released from the conjugate. Garnett et al<95) showed convincing evidence that 
the 791T/36 mAb, after binding to its receptor, was internalised into endosomes or 
lysosomes. This would allow breakdown of the antibody and release of ‘active’ free 
drug.
Another system is the immunotoxin where a mAb has been covalently bound to a toxin 
e.g. ricin A chain/96) diphtheria toxin and abrin/97) The toxins are extremely poisonous. 
It has been estimated that only one ricin molecule is required to kill a cell. Thus, only 
one toxin molecule is required to be bound to a mAb and this may be useful in treating 
cancer cells which express only a low titre of antigen/98) Because of the toxicity, 
stringent purification steps are required to remove traces of unconjugated toxin. Normal 
cells may also take up the immunotoxin by non-specific pinocytosis and this may lead 
to toxicity problems.
b) Albumin.
Chu and W hitele/") covalently bound MTX to BSA or mouse serum albumin using a 
carbodiimide coupling reaction. They tested these conjugates in mice with L1210 
leukaemia and found that they were equally effective as free drug in prolonging the 
survival time when compared to untreated controls. However, when the conjugates were 
tested against L1210 cells in vitro they found that free MTX was approximately 100 
times more active than the conjugated drug. These apparent differences could be due to 
the fact that MTX-albumin gave prolonged serum levels and decreased excretion in 
mice compared to the free drug thus giving the drug more time to reach the tumour 
cells in vivo. Indeed, measurement of drug levels in the extracellular fluid bathing the
tumour cells showed elevated levels of the conjugated drug at 24 hours.
The MTX-BSA conjugate was shown to enter cells by a method other than the folate 
transporter, since cellular uptake was not inhibited by folinic acid or at reduced 
temperature, as it was for free drug/100) It was demonstrated that MTX was not 
liberated from the conjugate until it had been internalised.
IP injections of BSA-MTX were found to be superior to free MTX against Lewis Lung 
Carcinoma, both in reducing the size and number of metastatic nodules in the lung and 
in reducing the size of the SC implanted solid tumour/101) The amount of drug in the 
tumour following administration of the MTX and MTX-BSA was found to be 
equivalent after 1 hour. However, after 8 and 24 hours the conjugate levels were double 
those of the free MTX. In another tumour model, Gardner Lymphosarcoma, MTX 
conjugated to HSA was found to be superior to the free drug in increasing life span/102)
Other drugs have been linked to albumin. Daunorubicin (DNR) was linked to 
succinylated albumin using various peptide s p a c e r s / 103) In an in vitro experiment where 
the conjugated DNR was incubated in the presence of lysosomal enzymes it was shown 
that the spacer had to be at least three amino acids long (in this case Leu-Ala-Leu) to 
allow release of free drug. The activity of the conjugates in vivo against mice with 
L1210 leukaemia was also found to be dependent on the length of the peptide spacer. 
Conjugates with spacers of three or four amino acids in length were superior to free 
daunorubicin and produced long term survivors.
The conjugates between cytotoxic drugs and albumin described here have not 
incorporated a targeting agent. Where thay have been successful in treating mice which 
have been infected with tumours cells, this is probably due to the fact that tumour cells 
have an increased metabolic rate compared to normal cells and as a result are more 
active in pinocytic uptake. In addition by prolonging the circulation half-life of the 
drug, it had more chance to reach its site of action.
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c) Other Proteins.
Chu and Whiteleyf101) demonstrated that conjugates between chymotrypsinogen or 
non-specific IgG with MTX were equally effective in an IP-IP model at prolonging1 the 
life of mice with L1210 leukaemia as free MTX and MTX-BSA.
Conjugates have also been prepared between MTX and fibrinogen/104-105) The rationale 
for using this protein is that it can be converted in vivo to fibrin. Fibrin is found 
deposited in solid tumours/26) It is an insoluble protein which is formed by the action 
of thrombin on fibrinogen. The MTX-Fibrinogen conjugate can also be precipitated by 
the action of thrombin and so this conjugate may become deposited in the tumour 
following administration, thus acting as a slow release preparation. Dyr et al(104) found 
that the conjugate was inactive against HeLa cells in vitro. However, when proteolytic 
enzymes were added to the incubation media (e.g. trypsin), the conjugate was inhibitory 
towards cell growth. Freshly established tumour cell cultures are known to demonstrate 
high levels of fibrinolytic activity and so this conjugate may be effective in the clinical 
setting.
1.4 The Pharmacology of Methotrexate
Methotrexate was chosen as the model anticancer drug for use in this thesis. It was 
chosen because it was readily available, a kind gift from Cyanamid UK, Gosport, 
Hants. It is a relatively non-toxic drug (compared to other cytotoxic drugs) and there is 
an antidote available. In addition it has a carboxylic acid group which can be used for 
linkage to proteins.
1.4.1 Biochemical Activity of MTX.
Anticancer drugs can be conveniently divided into a series of groups e.g. alkylating 
agents, intercalating agents and antimetabolites. Most anticancer agents owe their 
activity to a non-selective inhibition of DNA synthesis.
MTX is an antimetabolite which means that it has a structural relationship to a natural
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cellular metabolite and can thus bind to receptors to prevent the normal functioning of 
the cell. Figure 1.5 shows the structure of MTX. It is an analogue of folic acid.
Figure 1.5 The structure of MTX (4-amino-4-deoxy-10-methyl-folic acid).
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The folate vitamins play an important role in reactions which involve a transfer of a one 
carbon unit. They are vital in the de novo production of thymidylic acid/106) This is 
shown in figure 1.6.
Figure 1.6 The role of the folate coenzymes in the production of thymidylic acid.
R H.
OH N
2-
OH
H
NS-N10-Methylene FH4
O
H
FH*
OH
Me
Thymidilate Synthetase
OH
dUMP
dTMP
The pathways in which the folate coenzymes function is depicted in figure 1.7. This 
figure is similar to those described by Jolivet*1071 and Schweitzer*1081 and includes the 
positions where MTX can block. As well as being necessary for the production of 
dTMP, the folates are also required for the production of purines and amino acids such
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as methionine. Figure 1.7 shows that there are many forms of the folate coenzymes and 
that only the reduced forms are active. Dihydrofolate reductase is the enzyme which is 
responsible for replenishing the stocks of ‘active* reduced folates. The primary site of 
MTX inhibition is thought to be the DHFR enzyme^109) where it is a competitive 
antagonist The affinity for MTX at the active site of the enzyme has been calculatek to 
be 20,000 times greater than dihydrofolate (FH2), its natural substrate/110) The folates 
are polar molecules, which are ionised at physiological pH. In order to enter cells they 
use an active transport system. MTX utilises this same transporter to enter cells and has 
an equal affinity for i t /111) Thus it can also inhibit the entry of the coenzymes into 
cells.
Intra-cellular folates are subject to the actions of the enzyme pteroyl-polyglutamate 
synthetase/112) This enzyme adds one or more glutamic acid residues to the gamma 
carboxylic acid group of the folates. The number of glutamates that are added is 
dependent on the extra-cellular folate concentration. At low folate levels the formation 
of longer chains is favoured. Intra-cellular folates found in the liver have an average 
chain length of 5 glutamates but chains of up to 8 amino acids long have been 
identified/112) Polyglutamation of the folates appears to have a dual function. They act 
as a storable form of the coenzymes since they cannot readily diffuse out of the cell. 
They also appear to have greater affinity for some of the enzymes/113)
MTX can also act as a substrate for pteroyl-polyglutamate synthetase. This is important 
since the addition of three or more glutamate residues leads to a slower rate of efflux 
than MTX(GLU)1 and a selective retention in the cell following removal of 
extra-cellular drug. There is evidence that there is at least equal affinity for DHFR after 
polyglutamation^109). Following addition of one or more extra glutamates it has been 
found that MTX has an increased affinity for thymidylate synthetase/114) Thus it would 
appear that the presence of polyglutamate metabolite of MTX is an important factor in 
the cytotoxicity of the drug.
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Figure 1.7. The mechanism of action of MTX 
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D.H.F.R.: Dihydrofolate Reductase, T.S.: Thymidylate Synthetase, FH4: Tetrahydrofolate
FH2: Dihydrofolate, S-Am: S-Adenosyl Methionine, Glu: Glutamyl, M.S.: Methionine Synthetase
The steps following appearance of MTX in the extracellular fluid are summarised 
below.(115)
1. Saturation of the folate transporter which brings MTX into the cytosol .
2. Saturation of the DHFR receptor and inactivation of the enzyme. This is the only 
enzyme which can convert the inactive dihydrofolate to the active form of the vitamin, 
tetrahydrofolate. The underlying rate of thymidylate synthesis determines the 
cytotoxicity of MTX.
3. Polyglutamation of non-DHFR bound MTX. The ability of a cell to add glutamic 
acid to MTX is another determinant of the cytotoxicity of the drug*116) since 
polyglutamates are retained in the cell long after monoglutamate levels fall. Certain cell 
types have poor pteroyl-polyglutamate synthetase activity (e.g. intestinal epithelia) and 
this may be the basis of a degree of selectivity.
4. Appearance of MTX(GLU)n in the non-exchangeable pool i.e. bound to enzymes 
such as DHFR and thymidylate synthetase.
1.4.2 Clinical Uses of MTX.
MTX is the most widely used anti-metabolite in neoplastic diseases such as acute 
lymphocytic leukaemia (ALL), non-Hodgkins lymphoma, osteosarcoma, choriocar­
cinoma, head and neck cancer and breast cancer. It is often used in combination therapy 
with other drugs such as cytarabine or asparaginase where the combination can actually 
have synergistic activity. It is also used in diseases of an inflammatory nature.
It is administered at a very wide range of doses from 15-33,000 mg/m2.017)It is one of 
the few anti-cancer drugs which has a natural antidote i.e. 5-formyl-tetrahydrofolate or 
folinic acid (Citrovorum factor). Doses of between 500-33,000mg/m2 are followed by 
folinic acid rescue, at equimolar or up to 100 fold increased doses to that of MTX. The 
aim of folinic acid treatment is to time its arrival to normal cells before they have a 
requirement for dTMP synthesis. Cancerous cells however, because of their faster rate
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of metabolism, should have already been affected by the drug. In normal cells folinic 
acid competes with MTX for the transporter, DHFR, Thymidylate Synthetase and 
pteroyl-polyglutamate synthetase. Folinic acid has a greater affinity for the latter 
enzyme and this may be the most important factor in the rescue/118)
1.4.3 Cellular Resistance to MTX.
This is one of the greatest problems limiting the use of MTX. It can be natural or 
acquired after an initial response to the drug. Both of these take the same form/108)
1. MTX is only active on cells which are in the S-phase. If a cell has a naturally slow 
rate of metabolism then it will be difficult to administer the MTX dose at the correct 
time.
2. Some cell lines in vitro have been demonstrated to show a decreased MTX affinity 
for the folate transporter. If this occurs in vivo then it could be overcome by the 
administration of large doses of MTX. Extra-cellular concentrations of above 20pM 
have been demonstrated to cause entry into the cell by a method other than the 
transporter/107)
3. As mentioned previously, some cells only demonstrate low levels of the 
pteroyl-polyglutamate synthetase enzyme. This enzyme is important in maintaining high 
levels of folates and MTX in the cell after extra-cellular levels have dropped. It is 
thought to be important in the cytotoxicity of MTX.
4. Two factors giving rise to resistance have been demonstrated in the DHFR enzyme. 
It has been shown that the enzyme can change so that MTX has less affinity for it. A 
form of natural resistance may occur if the DHFR utilises NADH rather than the usual 
cofactor NADPH. MTX can form a ternary complex with DHFR and NADPH and this 
is very stable/119) The MTX DHFR binary complex (which would result if NADH was 
the only available cofactor) has a much lower affinity/120) In such a system MTX 
would still be inhibitory but significantly higher MTX concentrations would need to be 
achieved.
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Gene amplification can also lead to increased levels of the enzyme/121) Since MTX 
blocks DHFR it leads to an increase in intracellular FH2 levels. These are then available 
for competition with MTX for the enzyme.
1.4.4 Side Effects of MTX Therapy.
Like other anticancer drugs, these are due to the fact that MTX inhibits the growth of 
all rapidly dividing tissue. Thus nausea, vomitting, diaorrhea, myelotoxicity, bone 
marrow suppression and hair loss may all occur. MTX is a very well tolerated drug 
however, even when high dose therapy is employed, and the most common side effects 
seen are ulcerative stomatitis and diarrhoea/107)
1.4.5 Pharmacokinetics of MTX in Man.
After an IV bolus of drug, three phases are seen. The first has a half-life of 2-8 minutes 
and is thought to be due to the distribution of drug. The second has a half-life of 0.9-2 
hours and can be explained by excretion and metabolism. The third phase has a half life 
of 5.3-11 hours and is thought to be due to the gradual release of MTX from cells/117) 
It has been demonstrated that high dose therapy leads to shorter half lives and smaller 
volumes of distribution/117) Greatest tissue distribution occurs in highly vascularised 
organs such as kidney and liver. Lower levels are found in the gastro-intestinal tract and 
skeletal muscle.
Because MTX has limited lipid solubility it has difficulty getting into the b r a i n / 1()7 ) It is 
usual to administer MTX directly into the CSF for diseases of the CNS. However it has 
been demonstrated that large doses of MTX (greater than 5g/m2) will get into the brain 
at appropriate therapeutic concentrations (1 x 10_6M in CSF) in children with ALL/122)
MTX is removed from the body predominantly unchanged by the kidney. However 
some metabolism of MTX does occur. MTX appears in the bile and is metabolised by 
intestinal flora to 4-amino-4-deoxy-10-methyl-pteroic acid (DAMPA). This metabolite 
is reabsorbed (only 1 or 2% of an injected dose is excreted in the faeces) and only has 
l/200th the activity of MTX/117) Another route of metabolism occurs in the liver.
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Aldehyde oxidase metabolises MTX to 7-hydroxy-methotrexate (7-OH-MTX). This is 
actually less water soluble than MTX and can give rise to renal toxicity. Although at 
low doses of MTX this metabolite accounts for only 1-11% of the injected dose, at 
higher doses the 7-OH-MTX levels may exceed the MTX levels by up to 30 tiniest111) 
At this concentration the effects of the metabolite may be more significant. 7-OH-MTX 
has a good affinity for the folate transporter, with a Km approximately twice that of 
MTX, but it has only negligible blocking activity for DHFR (approximately 1/100th of 
MTX). Thus it can inhibit the cytotoxicity of MTX by blocking its entry into the cell. It 
is a good substrate for the folyl-polyglutamate synthetase enzyme and there is evidence 
to suggest that the glutamated form of 7-OH-MTX has a greater affinity for DHFR/123) 
In practise the effects of the metabolite may have no action on the cytotoxicity of MTX 
since it is not produced until MTX has swamped the DHFR receptor.
1.4.6 Problems associated with MTX therapy which would benefit from Drug 
Targeting.
1. Toxicity
One of the major factors that limits the use of MTX, and all other anticancer drugs, is 
the problem of toxicity. Targeting by limiting drug access to its active site would 
reduce the side effects and have the added advantage that lower doses could be 
administered.
2. Resistance
Cancer cells have been demonstrated to acquire resistance to MTX. One mechanism for 
resistance is a reduced affinity of the folate transporter for MTX. Drug targeting would 
achieve cellular access of the drug by other means. Another way of overcoming this 
resistance could be by synthesis of a more lipophilic analogue of MTX which could 
gain access by simple diffusion into the cell and indeed research into a lipophilic 
analogue is in progress/106)
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3. Metabolism
The 7-OH-MTX metabolite interferes with the action of native MTX. By preparing a 
conjugate of MTX which is not metabolisable until it reaches its active site this could 
be prevented.
4. Limited Access to Certain Sites.
Because MTX is a relatively hydrophilic molecule its access into certain sites is 
inhibited e.g. the brain and poorly vascularised organs. Drug targeting usually exploits a 
site specific antigen to achieve access and for example this could be the transferrin 
receptor found on brain microvessels used to gain entry into the brain.
5. Short Half-life.
MTX has a relatively short half-life. A targetable form of the drug could have the added 
advantage that it has a long circulation half-life and therefore more time to reach the 
site of action.
6. Large Volume of Distribution.
MTX has a volume of distribution which is equivalent to 77% of the body mass. This 
could be reduced by conjugation of MTX to a large molecular weight carrier.
1.5 Objectives of this Thesis.
A great deal of research has been carried out in the field of drug-targeting. This 
research has usually involved the interaction of a drug with a carrier molecule and 
subsequent testing of this complex on tumour cells in vitro and in tumour models in 
vivo. Although the conjugates are usually active in these experimental situations, when 
they have been tried in the clinical setting they have not always been successful^81).
The aim of this project has been to form large molecular weight, soluble derivatives of 
methotrexate, a model anti-cancer drug. These conjugates have been administered in
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vivo, using the rat as a model, to determine the distribution and pharmacokinetics. No 
targeting agent was applied to the conjugate initially, so that the distribution could be 
determined in normal healthy rats.
The initial studies described in the thesis involved the administration of drugs 
(methotrexate, digoxin and inulin) to the rat. Their purpose was to gain knowledge of 
the effects of molecular weight on transport of the drug from SC and IP sites into1 the 
blood stream. The molecular weight of methotrexate is 452D, digoxin is 78ID and 
inulin is approximately 5000D. Also, since MTX had been selected as the model 
anti-cancer drug, it was important to determine the pharmacokinetics and distribution of 
the drug prior to its conjugation to soluble carriers.
The next series of experiments involved the administration of a number of proteins to 
the rat. These were mainly of bovine origin and were chosen to include a range of 
molecular weights from 14KD to 66KD, in the hope that some properties if not a 
suitable drug carrier could be identified. In order to detect the proteins in rat plasma 
they were either obtained in a radiolabelled form or were iodinated with 125I. After 
administration to the rat, it was anticipated that the proteins may be catabolised with the 
liberation of some “free” 125I as iodide. To evaluate what effect free iodide would have 
on the plasma levels determined for each protein, a study of the pharmacokinetics of 
125INa was conducted.
Since the proteins used were of bovine origin, they may lead to immune reactions in the 
ra t A number of experiments were performed in order to investigate whether BSA 
could precipitate an immune reaction in the rat.
Covalent conjugates were prepared comprising methotrexate linked to BSA, RSA or 
bovine LA. The pharmacokinetics and distribution of the 125I was determined after 
administration of a range of iodinated conjugates between proteins and MTX, including 
a range of loadings of MTX (%w/w) with each protein. The conjugates Were 
administered by three routes; IV, IP and SC, since route of injection can be exploited to 
alter the distribution of a macro-molecular species. Following administration of the
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conjugates into SC sites, absorption into the blood stream should occur via the 
lymphatics. Thus SC administration could be used where there is metastatic spread of 
the cancer within the lymphatic system. The rationale for employing IP administration 
was that, in theory this would bring drug directly into contact with the organs of the 
cavity and could be used to treat cancers such as ovarian cancer.
The next step was to try to target the carrier-drug complex. It was decided to use the 
galactose receptor present on hepatocytes as the targeting region.
The final section of this work investigated the distribution characteristics of the protein 
drug carriers in vitro. The system used was a model of the capillary and was used to 
determine the ability of the conjugates to extravasate.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 Materials.
2.1.1. Electron Microscopy reagents.
All reagents used were of the appropriate grade and were obtained from BDH, Poole, 
Dorset. Embedding resin was from Taab, Reading, Berks, and Conductive Carbon 
Cement was from Biorad, Watford, Herts.
2.1.2 Gel Chromatography.
Biogel P4 was obtained from Biorad. Sephadex G15 and blue dextran (relative 
molecular weight 2 million) were obtained from Sigma Chemical Company, Poole, 
Dorset. Sephadex G50 was from Pharmacia Ltd, Milton Keynes. PD10 columns and all 
other columns and associated equipment were obtained from Pharmacia.
2.1.3. HPLC.
HPLC analysis was performed using 15cm, 4.5mm i.d., Apex ODS 5p column or 15cm, 
4.5mm i.d., Hypersil ODS 5p columns both of which were obtained from LDC, Stone, 
Staffs. Mobile phase was passed through the column using an LDC Constametric model 
III pump and passed through an LDC spectromonitor III UV detector. Samples were 
injected onto the column using a 7132 rheodyne valve fitted with a 50pl loop. An 
LDC/Milton Roy integrator and plotter was used to calculate peak heights and areas. 
The FPLC analysis was performed using a 30cm, 10mm i.d., Superose 12 column 
(Pharmacia) attached to the pump as above: peaks were detected using a Gilson 113 
variable UV detector and recorded using a Servogor 120 recorder.
All solvents were of the appropriate grade and were obtained from Fisons, 
Loughborough, Leics. Aminopterin was from Sigma. Sep-pak C l8 cartridges were from 
Waters and PEG molecular weight standards were from Polyscience, Warrington, and 
Polymer Laboratories, Church Stretton, Shropshire.
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2.1.4. Proteins.
BSA-Galactosamide (1M protein:26M sugar), A5908 and BSA-p-aminophenyl- 
<<-Mannopyranoside (1M protein:28M sugar), A4664 were from Sigma. BSA (A3294), 
RSA (A6272), CA (C7500) and LA (L6010) were obtained from Sigma. Peroxidase 
linked anti-rat IgG (A9037) was obtained from Sigma. Collagenase (C5138) and 
Protease E (P5147) were obtained from Sigma.
2.1.5. Radioisotopes.
Isotope Source Specific activity
14C-Methylated-CEA (A6418) Sigma 12.3pCi/mg
125I-HSA (IM17P) Amersham 2.5pCi/mg
14C-Carboxy-Inulin (29,757-7) Sigma 2.6pCi/mg
125I-Na (IMS.30) Amersham 13.3mCi/pg iodine
Mannitol D-[1-14C] (NEC 314) NEN 0.29mCi/mg
3H-Methotrexate(TRK.224) Amersham 61.1mCi/mg
PEG 900 [1,2-3H] (NET 404] NEN 6.75 pCi/mg
14C-PEG 4000 (CFA 508) Amersham 60pCi/mg
2.1.6. Tissue Culture.
Gelatin (calf skin) was obtained from Sigma. PBS tablets were from Oxoid, 
Basingstoke, Hants. Synperonic OPIO was obtained from Cargo Fleet Chemical 
Company Ltd, Eaglescliffe, Stockton. All other reagents and media were obtained from 
Flow Laboratories, Irvine, Scotland. Tissue culture flasks were obtained from Flow 
Labs. Six-well and 24-well plates were from Costar, c/o Northumbria Biologicals Ltd, 
Cramlington, Northumbria. Millicell HA Biter inserts were obtained from Millipore.
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All other reagents used were of an analytical grade and were obtained from Sigma.
All biological samples were either analysed immediately or were stored in a freezer at 
-20°C until they were analysed.
2.1.7 Buffer formulae.
1.Phosphate buffer 0.02 M pH 6.8 for HPLC analysis of MTX;
24.5 ml 0.2 M Na2HP04> 25.5 ml 0.2 M NaH2P04, to 1000 ml with water
2. Phosphoric acid buffer for HPLC analysis of PEG;
ImM phosphoric acid + 5 ppm nitric acid
3. Phosphate buffered saline pH 7 .4 ;\
6.79 g KH2P04, 34.5 g Na2HP04, 22.97 g NaCl, to 51 with water
4. Calcium free buffer for hepatocyte separation;
8.3 g NaCl, 0.5 g KC1, 2.4 g Hepes, to 1000 ml with water, pH to 7.4
5. Collagenase buffer;
3.9 g NaCl, 0.5 g KC1, 0.7 g CaCl2, 24 g Hepes, lOOmg Collagenase, to 200 ml with 
double distilled water, pH to 7.6
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2.2 Procedure for Radio-iodination of Proteins.
The method used was a modification of the chloramine T method described by 
McConahey and Dixon .O24)
All operations were carried out in an ice bath in a designated fume hood. lOpl of 
lOOpM HC1 was added to lOpl of 125I (lmCi). To this solution, lOmg of protein in 
200pl of PBS (pH 7.4) was added with lOOpg (in lOpl PBS) of Chloramine T. The 
reactants were left to stand for 10 minutes. To stop the reaction 250pg (in 20pl PBS) of 
sodium metabisulphite was added and 500pg of potassium iodide was used to solubilise 
any unreacted 125I. The reaction mechanism is given in appendix 1 (section A l.l).
2mg and 5mg quantities of proteins have also been iodinated using this method. All 
reactants (excluding 125I) were kept at the same ratio (to protein) as above.
The unbound 125I and other low molecular weight reactants were removed from 
iodinated protein using gel filtration. A 30cm long, 1.5cm i.d. column was packed with 
Sephadex G-15. The void volume was determined using blue dextran with a molecular 
weight of 2 x 106 and was approximately 20ml. The solution containing iodinated 
protein and contaminants was passed down the column and 1ml fractions were 
collected, starting 2-3ml before the void volume was reached. The protein was collected 
in approximately 3ml at the void volume, the unreacted iodine was left on the column. 
The protein fractions were pooled and the volume made up to 5ml in PBS.
The apparent % unbound iodine activity in the protein fraction was determined by using 
trichloroacetic acid (TCA) to precipitate the protein. 20pl of solution was mixed with 
20pl of 20% w/v TCA and allowed to stand for 15 minutes at room temperature. It was 
then centrifuged in an eppendorf microcentrifuge for 2 minutes at 6,600g and 20pl of 
supernatant was assayed for radioactivity. Since it was found that dialysing the protein 
solution against large quantities (approximately 201 over 48 hours) of PBS had little 
benefit in removing any of the 'unbound iodine' it was decided that if the apparent % 
unbound iodine activity accounted for greater than 5% of the total radioactivity, the
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protein solution would be discarded.
125I activity was determined using an LKB-Wallac 1275 Minigamma Counter.
2.3 Preparation of Protein-MTX Conjugates.
Conjugates were prepared between MTX and BSA, RSA or bovine lactalbumin. The 
conjugates were injected into rats and the effect of protein conjugation on the 
pharmacokinetics of the drug was investigated. The use of BSA and lactalbumin gave 
information about the effects of molecular weight of the carrier on the distribution of 
the drug.
The reaction was carried out using the method described by Marriott/125! The reaction 
involved the use of a carbodiimide coupling reagent. The carbodiimide reacted with the 
methotrexate via one of its carboxylic acid groups to give a reactive intermediate. This 
could then react with the albumin via one of the lysine residues and to a lesser extent 
histidine and arginine (see figure 2.1). The resultant conjugate has a covalent bond 
between the MTX and the albumin. By altering the amount of MTX and carbodiimide 
in the reaction mixture, conjugates with a range of loadings of drug could be produced. 
If the pH and temperature of the reaction were standardised then conjugates with a 
reproducible MCR could be synthesised.
The carbodiimide used in the reaction was l-Ethyl-3-[3(dimethylamino)propyl] 
carbodiimide hydrochloride (ECDI).
The reaction was carried out with the following molar ratio (using an albumin
concentration of 150mg in 10.5ml):
Albumin: MTX: ECDI
1: x: x
Provided pH and temperature were constant the amount of MTX and ECDI in the 
reaction mixture determined the degree of MTX substitution in the conjugate. Figure
2.2 shows the molar ratio of methotrexate achieved in the conjugate versus the molar 
ratio of methotrexate (and ECDI) to albumin used in the reaction mixture. This figure is 
taken from the data in table 2.1.
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Fig. 2.1. The Conjugation Reaction Between Methotrexate and Bovine Serum Albumin.
Methotrexate (MTX)
ECDI
NH,
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ECDI = l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide. 
BSA = Bovine serum albumin.
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Figure 2 . i  MCR versus Concentration of MTX in Reaction Mixture.
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Table 2.1 shows the exact starting ratio of reactants and the resultant molarity and 
percent weight for weight loading of MTX in the conjugate produced. It also indicates 
the change in molecular weight of the conjugate compared to free BSA.
Table 2.1: Molarity and Total Molecular Weight of Each Conjugate Produced.
Amount of MTX 
in Reaction
Mixture (M MTX:
1M Protein).
% w/w loading 
of MTX
Moles of MTX 
Bound to 1M
of Protein.
Estimated Tota 
Mol. Weight
of Conjugate.
0 0 0 66296
50 3.4 4.62 68386
50 4.54 6.32 69153
50 5.1 7.15 6951C
50 6.2 8.77 70259
75 7.16 10.26 70933
75 9.18 13.45 72376
100 11.55 17.36 74143
100 11.74 17.64 74269
100 11.76 17.65 74274
150 13.63 20.98 75779
150 13.64 21.00 75788
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2.3.1 Synthesis of a Conjugate.
Conjugates were prepared at a range of %w/w loadings MTX as shown in Table 2.1. 
All conjugates were prepared using the same conditions, but to achieve a higher loading 
of MTX bound to the BSA more MTX and ECDI were added to the reaction mixture. 
As an example, the method of preparation for the 11.55% w/w conjugate is described 
below.
200mg of BSA was dissolved in 5ml of PBS (pH 7.4). To this solution 150mg of MTX 
in 3ml of PBS was added and then 57.8mg of ECDI in 2.5ml PBS. The reaction 
mixture was protected from light and the reaction took place at 4°C in the refrigerator. 
After 24 hours the reaction was stopped by passing the solution down a one metre 
long, 2.5 cm diameter Sephadex G50 column via a calibrated 10ml loop. The 
absorbance of the eluent was monitored at 306nm. The MTX bound to the protein 
eluted at the void volume whereas the free MTX and other low molecular weight 
products of the reaction were substantially retained. The mobile phase on the column 
was water so that the phosphate salts would be removed from the protein. The low ionic 
strength encouraged interaction with the Sephadex which was used to increase the 
retention time of the MTX while the conjugate remained unaffected.
The protein-methotrexate fraction was collected as soon as it started to elute (identified 
using a UV spectrophotometer set at 306nm) and made up to a known volume in water. 
One millilitre of this solution was diluted at least one in two with 0.1M NaOH and the 
UV absorbance at 375nm fanax of MTXNa2) was determined against a blank of 0.1M 
NaOH. The absorbance of the solution was used to determine the actual concentration 
of MTX present as protein conjugate, by using a calibration curve of absorbance of 
standard MTX solutions prepared in 0.1M NaOH at 375nm. (see appendix 1.2) The 
wavelength of 375nm was chosen because of the negligible absorbance of BSA at this 
wavelength. The MCR of the conjugate was calculated, assuming 100% recovery of 
protein from the column (i.e. a known amount of protein with a defined molecular 
weight was injected onto the column) and assuming all the MTX in the conjugate 
fraction was present in a covalently bound form.
-41-
The BSA-MTX conjugate was freeze dried using an Edwards Modulyo freeze drier over 
a 48 hour period.
2.3.2 Preparation of Conjugates using RSA and LA.
Conjugates between MTX and RSA were produced in exactly the same manner as 
MTX-BSA. For LA the concentration of reactants was slightly different. For the same 
molar concentration of LA as for BSA, the actual number of molecules available to 
react would be the same but the number of amino acid residues would be approximately 
one fifth of that of BSA. (The molecular weight of BSA is 66,296 and LA is 14,200). It 
was decided that the number of amino acid residues present was more important than 
the number of molecules. Thus the mass of protein used (rather than the molar 
concentration) was the same as for BSA. An attempt was made to synthesise a 
conjugate between CA and MTX. However the lysine residues in CA must have been 
unavailable for reaction, since so little MTX actually reacted that it could only be 
identified using a UV scan and not using the UV assay at 375nm.
2.3.3 Analysis of the conjugates using FPLC.
After freeze drying a solution of conjugate (500pg/ml in PBS) was prepared. 20pl was 
injected onto a Superose 12 FPLC column using PBS as mobile phase and the peaks 
obtained, detected using a Gilson UV detector at 280nm, were compared to that of 
native BSA. This would determine the degree of cross-linking of the protein that had 
occurred during the reaction with ECDI and MTX.
2.3.4 Analysis of the conjugates using a UV scan.
Solutions of MTX (20pg/ml), BSA (lOOpg/ml) and BSA-MTX (lOOpg/ml) were 
prepared in 0.1M NaOH. A UV scan between 460nm and 180nm was obtained using a 
Perkin-Elmer lambda 3 scanning spectrophotometer. The scans for the free drug and the 
conjugates were compared.
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2.3.5 Iodination of the conjugates.
This was performed using the method described previously for native proteins (section 
2.2). After separation of the iodinated conjugate from unbound iodine it was found that 
a slightly higher percentage of unbound activity remained in the protein fraction. This 
could be due to a non-specific and easily displaceable interaction with the methotrexate. 
If there was more than 12% TCA soluble 125I activity within the conjugate fraction 
then the batch was discarded.
23.6 Preparation of 3H-MTX-12SI-BSA.
The conjugation reaction was performed as follows:
250pCi of 3H-MTX (8.96 nrtJol or 4.09pg) and 11.28mg of 'cold' MTX were reacted 
with 20mg of BSA and 4.34mg of ECDI in a total volume of 1.5ml. The reaction was 
carried out at 4°C. After 24 hours the reaction was stopped by passing the mixture 
down a PD10 column (Pharmacia). After separation on the column lOOpl of the 
conjugate solution was diluted to 1ml with 0.1M NaOH and the absorbance at 375nm 
was determined. The remaining conjugate fraction was freeze dried and then 
radio-iodinated as previously described.
2.4 In vivo Work.
Most of the animal experiments followed the same format. In order to prevent 
repetition, the salient points are stated below. Where they differed for a particular 
experiment, this is identified in the appropriate section.
Male Wistar rats (Bath University Strain) weighing between 230-250g were used. 
Animals were allowed free access to food and water throughout. They were fed on a 
Labsure (CRM) diet. Generally 24 rats were used in each experiment. These were 
divided into three groups of eight i.e. one for each route of administration IV, SC and 
IP. IV administration was performed into the tail vein with the rats under ether 
anaesthesia. For SC and IP dosage no anaesthesia was required. SC administered drugs
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were delivered into the back of the neck region. Solutions for injection were prepared in 
sterile PBS (pH 7.4) or were filter sterilised before administration. Usually drugs were 
administered in a volume of 0.2ml of PBS for each route.
Blood samples (0.3-0.5ml) were taken from 2 animals in each group for each time point 
by cardiac puncture while the rat was under anaesthesia. If blood samples were taken in 
rapid succession then rats were anaesthetised with an IP injection of a mixture of 1 
volume of Hypnorm (fluanisone lOmg/ml, fentanyl 0.315mg/ml) and 1 volume of 
midazolam (5mg/ml), 2 volumes water (800pl for a 250g rat). Otherwise samples were 
taken while the rat was under ether anaesthesia. A maximum of 4 blood samples were 
taken from each rat. Whole blood or plasma was analysed for drug content and from 
this pharmacokinetic parameters of the drug were determined. For surgical procedures 
(bile duct cannulation and liver perfusion) the rats were anaesthetised with 
hypnorm/midazolam.
When organ distribution was determined for a particular drug (radiolabelled only), the 
rat was first killed using CO2 gas, and then the organs under investigation weie 
removed by dissection, weighed, minced and a known weight was assayed for drug 
content. The organs selected were liver, spleen, heart, lung, kidney, stomach, small 
intestine and thyroid.
In most experiments, three rats from each group were kept singly in metabolic cages so 
that urine and faeces could be collected and the drug excretion could be determined. 
The total volume of urine excreted over the timed period was measured and a portion 
was assayed for drug activity. Total drug excreted in the urine could then be calculated. 
Faeces was collected for drugs labelled with 125I only. The total quantity of faeces 
produced over the experiment was collected and the whole was assayed for drug 
content.
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2.5 Administration of 'Drugs'.
2.5.1 Methotrexate
MTX was administered to rats at two dose levels - 2.5mg and 0.5mg per rat. Blood 
levels in plasma were determined by two methods. For the 2.5mg dose the levels could 
be determined using an HPLC assay. However, because of the limits of the assay, 
identification of the 0.5mg dose in plasma was performed using 3H-MTX. The 2.5mg 
dose was repeated using 3H-MTX to compare results obtained for both methods. A 
solution of MTXNa2 was prepared containing 2.5mg in 0.2ml. This was administered to 
rats by each of the three routes. Blood samples were collected at regular intervals over 
4 hours.
HPLC Analysis.
The method used was a modification of that described by Nellie So et al.O26) Serum 
was diluted with milli Q water to give a concentration that would fall within the limits 
of the assay (0.1-1.0pg/ml). All serum was diluted at least two times so that a “clean” 
chromatogram would be obtained. To each ml of diluted serum, lOOpl of a lOpg/ml 
solution of aminopterin was added as internal standard. Aminopterin was chosen as 
internal standard since its retention time on the column did not interfere with that of 
MTX and also it absorbed at the chosen wavelength.
The serum was prepared for analysis using a Sep-pak C l8 reverse phase column. 
Columns were pre-wetted with 10ml of methanol followed by 10ml of Milli-Q water. 
0.4ml of diluted serum containing internal standard was passed down the column. 
Serum proteins were washed off the column with 5ml of water. MTX and aminopterin 
were eluted with 3ml of methanol. The methanol was evapo rated at 45°C under a 
stream of nitrogen. The MTX and aminopterin were redissolved in 200pl of Milli-Q 
water. This procedure was carried out in duplicate for each sample of rat serum.
For the calibration curve standard solutions of MTX (50ng/ml to l.Opg/ml) were 
prepared in rat serum diluted to half strength with water. Aminopterin was added and
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the samples treated in exactly the same way as for test serum.
HPLC was performed using the 15cm Apex ODS 5p column and using the system 
described in Materials. The UV detector was set at 306nm. The mobile phase used was 
78% 0.02M Phosphate buffer (pH=6.8)/ 22% methanol and a flow rate of 0.8ml/minute.
Each sample was assayed in duplicate. Unknown and calibration samples were extracted 
and assayed simultaneously, so that a new calibration curve was prepared each day. 
Concentration of unknown samples was determined by the method of peak height ratios 
of MTX to aminopterin, and the calibration curve was linear over the range of 
0.1-1.0pg/ml. Coefficient of variation for the O.lpg/ml standard was 1.093% and for 
the l.Opg/ml standard was 0.524%.
Determination of Rate of Excretion of Methotrexate.
Four rats were injected with 2.5mg of MTX into the tail vein. Rats were placed singly 
in metabolic cages. At 6.5, 24 and 48 hours after injection urine was collected, the 
volume was noted and the concentration of MTX in the urine determined using HPLC.
Urine was diluted 1 in 500 with Milli-Q water. To 1ml, lOOpl of aminopterin lOpg/ml 
was added. The resultant solution was taken for HPLC as described above. Peak height 
ratios of MTX/aminopterin were determined in duplicate for each urine sample and the 
corresponding MTX concentration was determined from a calibration curve of Peak 
height ratios vs concentration of standard MTX solutions prepared in 1 in 500 diluted 
urine (obtained from a control rat) containing internal standard. This was linear over the 
range of O.Olpg/ml to 2.5pg/ml.
3H-Methotrexate
3H-Methotrexate was mixed with unlabelled drug to give a specific activity of 9.1 
pCi/2.5mg or a total activity of 10pCi/0.5mg in 0.2ml of sterile PBS . One of these 
solutions were injected by IV, SC or IP routes. Blood samples were taken every 15 
minutes for 1 hour and then every 30 minutes up to 4 hours after injection. lOOpl of
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plasma was added to 5 ml of Optiphase safe liquid scintillant (LKB) and the 
disintegrations per minute (DPM) determined in duplicate for each sample using an 
LKB-Wallac 1215 Rackbeta liquid scintillation counter, programmed to calculate DPM 
from measured CPM values. The plasma concentration of methotrexate for each sample 
was determined by assuming that DPM measured in plasma was equivalent to MTX 
concentration.
Urine excretion of radioactivity was also determined for three rats in each group after 6 
hours and then daily for three days. Urine was assayed as for plasma and total 
methotrexate excreted over this period was determined.
2.5.2 Administration of Digoxin.
Digoxin injection solution was prepared using the British Pharmacopoeia (BP) 
formula/127! 1ml of this solution was diluted to 10ml with water to give a solution 
containing 2 pg/ml. This was filter-sterilised before administration. Rats were injected 
with a 250ng dose by each of the three routes. Digoxin given by IV injection was 
administered slowly to minimise cardiac toxicity. Blood samples were taken from 30 
minutes up to 7 hours after injection.
Serum digoxin levels were measured using an enzyme linked immunosorbent assay 
(ELISA) obtained from Immunodiagnostics Boehringer Mannheim as per the kit 
instructions. The data sheet for this kit is shown in Appendix 1.6
2.5.3 Inulin.
An injection solution of inulin was prepared so that it contained 1.6mg of total inulin 
with an activity of 4 pCi of 14C-Inulin in 0.2ml. This was injected either 
sub-cutaneously or intra-peritoneally into male wistar rats. Blood samples were taken up 
to 10.7 hours after injection and plasma was assayed for 14C content in the LKB 
scintillation counter programmed to calculate DPM from CPM.
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2.5.4 125I-Na.
A solution of 125I-Na obtained from Amersham was diluted in sterile PBS to give a 
final concentration of 0.654ng of iodine and an activity of 8.5 pCi in 0.2ml. The 
solution was injected IV into male wistar rats. Blood samples were taken regularly up to 
48 hours after injection. In addition organ distribution was determined at 4, 7, 27 and 52 
hours after injection. Urine was collected from 4 animals for up to 96 hours post 
injection.
2.6 Administration o f Proteins.
A number of proteins were chosen to give a range of molecular weights from 14kD to 
66kD. These were either obtained in a radiolabelled form or were radio-iodinated with 
125I so that detection in the rat was possible.
Table 2.2 lists the proteins that were injected, gives their approximate molecular weight. 
It also lists the specific activities as injected and whether the proteins were 
radioiodinated in the laboratory or whether they were obtained in a radiolabelled form.
Table 2.2 Proteins injected into male wistar rats.
Protein Source Molecular
Weight
Specific
Activity
LA 125I in laboratory 14,200 1.3pCi/mg
CA 125I in laboratory 29,000 3.3pCi/mg
CEA Sigma (14C) 45,000 2.6pCi/mg
HSA Amersham (125I) 67,000 2.5pCi/mg
BSA 125I in laboratory 66,296 2.3pCi/mg
RSA(5mg) 125I in laboratory 63,000 1.1 pCi/mg
RSA(20mg) 125I in laboratory 63,000 0.85 pCi/mg
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2.6.1 14C-Chicken Egg Albumin.
Rats were injected with 0.04mg of 14C-CEA (0.48pCi) in a solution which contained 
20mg of cold CEA by the IV route only. Blood samples were removed at regular 
intervals over 24 hours and were collected in Li+Heparin tubes. 200 or 300pl plasma 
samples were added to 5ml of Optiphase safe and assayed for 14C content in the liquid 
scintillation counter. Urine was collected up to 144 hours after injection.
2.6.2 125I-HSA
lml of the Amersham solution was added to 4ml of a solution containing BSA 
(lOOmg/ml) in PBS. The resultant solution contained 16mg BSA and 0.8mg 125I-HSA 
(2pCi) in 0.2ml. Rats were injected with 200pl of this solution by each of the three 
routes. Blood samples were collected at regular intervals up to 149 hours post injection. 
Whole blood was analysed in the gamma counter.
2.6.3 Other proteins
lOmg samples of LA, CA, BSA or RSA were radioiodinated using the chloramine 1’ 
method described in section 2.2. Each iodinated protein solution was then mixed with 
140mg of unlabelled protein and the volume was made up to 6ml. Assuming 100% 
recovery of protein after the iodination and purification were complete, the resultant 
solution had a concentration of 5mg in 0.2ml. Rats were injected with 5mg of each of 
the proteins by each of the three routes. Blood samples were collected for up to 72 
hours post injection for LA and for 96 hours post injection for the other proteins. For 
LA, CA and BSA serum was obtained by allowing the blood samples to stand for 2 
hours at room temperature and then centrifuging in an eppendorf microcentrifuge for 1 
minute at 6,600g and analysed for radioactivity. In addition, for RSA, whole blood as 
well as serum was analysed. Urine and faeces were collected daily for each protein. 
Organ distributions were also determined at regular intervals using 2 animals in each 
group at each time point at various times up to 96 hours after administration of the 
proteins.
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In addition to the 5mg dose o f RSA, a dose o f 20mg was administered by the IV route. 
This was intended to indicate whether the quantity o f protein given as an IV bolus 
actually affects its rate o f elimination.
2.6.4 20mg dose of RSA.
Two milligrams o f RSA were radio-iodinated using the chloramine T method described. 
The iodinated RSA in PBS was used to produce a solution containing 20mg o f total 
RSA and an activity o f 20 pCi in 0.3ml. 0.3ml was injected into male wistar rats by the 
IV route. Blood samples were collected over 96 hours and both whole blood and plasma 
were assayed for radioactivity. Urine was also collected over 96 hours.
2.7 Tests to determine the Antigenicity of BSA in the Rat.
Three experiments were performed in order to determine whether BSA injected into rats 
led to an inflammatory response. These are described below.
2.7.1 BSA.
This experiment involved the administration o f BSA to rats at various doses followed  
by a measurement o f  the total serum protein concentration.
2.7.1a Measurement of Protein Levels in Serum.
The method used to determine the protein concentration in rat serum was a modification 
of that described by L ow ry/128) The following solutions were prepared immediately 
prior to use.
Soln. A) 5% w/v CuS 0 4.5H20
Soln. B) 10% w /v Sodium potassium tartrate
Soln. C) 2% w/v Na2C 0 3 in 0.1M NaOH
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Soln. D) 1 volume Folin-Ciocalteau reagent + 2 volumes water
Soln. E) 1 volume o f (A) + 1 volume o f (B) + 8 volumes water 
Soln. F) 1ml o f (E) + 50ml o f (C)
Soln. G) Standard solutions o f BSA in 0.9% NaCl ranging from 20-400pg/ml
0.4ml o f the test solution was added to 4ml o f solution (F). 0.4ml o f solution (D) was 
added and immediately mixed in a vortex mixer. After a 30 minute incubation in the 
dark the absorbances (650nm) o f the solutions were determined in a UV  
spectrophotometer against a reagent blank. The protein concentration o f unknowns was 
determined from a calibration curve o f absorbance versus standard BSA concentration. 
The calibration curve was linear over the range of 20-400pg/ml (see section A 1.7). The 
coefficient of variation for the 20pg/ml standard was 3.58% and for the 400pg/ml 
standard was 1.17%. The solutions were all read in duplicate and a mean was taken.
2.7.1b Administration of BSA to the rats.
15 male wistar rats weighing between 290 and 310g were divided into three groups. 
Group 1 were the control group and were not treated. Group 2 were injected with 300pl 
of 0.9% saline to determine whether the trauma of injection had led to an inflammatory 
response and group 3 were injected with 20mg of BSA in 300pl o f 0.9% saline. Each 
rat had a 0.5ml blood sample removed by cardiac puncture after 2 hours, 4 hours and 7 
hours. Serum was obtained, after allowing the samples to stand at room temperature for 
2 hours in an eppendorf tube followed by spinning in a microcentrifuge at 6600g for 2 
minutes. The serum was diluted to 1 in 500 with 0.9% saline to give a protein 
concentration that would fall within the range o f the assay. Protein measurements for 
the diluted serum were obtained as described in section 2.7.1a.
In order to obtain a range o f normal values for total protein serum concentration, a 
0.5ml blood sample was obtained from 10 untreated male wistar rats and the serum 
treated as for those injected with BSA.
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The experiment was repeated using doses o f BSA of 40mg and 80mg.
2.7.2 Administration of Evan’s Blue.
Six male wistar rats weighing between 290 and 310g were injected via the tail vein with 
lm g o f  Evan’s Blue in 0.4ml o f 0.9% saline. At the same time six weight matched rats 
were injected with 0.4ml o f the same solution which contained in addition 20mg of 
BSA. 0.5ml blood samples were removed at timed intervals up to 28.5 hours after 
administration. Plasma was diluted to 1 in 10 with water and the absorbance was 
measured at 612nm against a blank o f 1 in 10 diluted plasma. The concentration of 
Evans Blue was determined from a linear calibration curve of absorbance against 
concentration o f dye in standard solutions (500ng/ml to 20pg/ml) prepared in 1 in 10 
diluted plasma, (see appendix A 1.8)
2.7.3 Blot test to determine Antigenicity of BSA in Rat serum in vitro.
To a sheet of nitrocellulose paper (10cm by 10cm) (Sigma), lpl samples o f BSA at 
concentrations o f 50, 100, 500, 750 and lOOOpg/ml were applied. These were incubated 
on a shaking water bath, in a square 75ml Petri-dish containing 10ml o f PBS (pH 7.4) 
with 0.05% Tween 20 and lOOpl or 1ml o f rat serum, for 1.5 hours. The samples were 
washed three times in buffer (20ml each) without serum. 10ml o f PBS containing 
Tween 20 with lOpl o f peroxidase linked anti-rat IgG was added and the sample was 
incubated for 1 hour. The samples were washed three times (20ml each) in PBS/0.05%  
Tween 20. 10ml o f PBS was then added to the Petri-dish and to this 30mg o f nickel 
chloride, 5mg of diaminobenzidine and 200pl o f 30% hydrogen peroxide were added. If 
any rat IgG was present then a black spot on the nitrocellulose would develop at this 
stage.
2.8 Administration of 125I-BSA-MTX to male wistar rats.
Solutions o f iodinated conjugates were prepared containing 5mg o f BSA-MTX with 
between 5 and lOpCi o f activity in 0.2ml o f PBS. This was injected into rats by IV, IP 
or SC. Blood samples were taken at regular intervals for 96 hours. At timed intervals
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over the experiment 2 animals in each group were killed and the organ 125I activity was 
determined. Three animals from each group were kept separately in metabolic cages 
and urine and faeces were collected. Pharmacokinetic parameters were calculated for 
each route of administration and each conjugate administered. The conjugates used in 
these experiments are those listed in table 2.1. In addition for the 11.55%w/w conjugate 
the bile duct was cannulated, 3 hours after administration o f the conjugate in 2 rats. Bile 
was collected for a 20 minute period.
The RSA-MTX and LA-MTX conjugates were administered to male wistar rats as for 
BSA-MTX.
2.8.1 FPLC Analysis of Bile, Serum and Urine.
Analysis o f the molecular weight of the radioactive fraction present in bile after 
administration of the 11.55%w/w and for plasma and urine after administration of the 
7.16%w/w conjugate was performed using the Superose 12 column already described 
(section 2.2.3). 1ml fractions o f eluent were collected immediately after injection o f the 
sample onto the column. Each fraction was analysed in the gamma counter.
2.8.2 125I-BSA-3H-MTX.
0.86mg o f the conjugate (20pCi 125I and 8.4pCi 3H) was administered to 12 rats by the 
IV route. Plasma samples were obtained at regular intervals over 96 hours post 
administration. In addition urine was collected from 3 rats over 4 days. At 1, 6, 24, 48, 
72 and 96 hours post administration 2 animals were killed and the liver, spleen, kidney, 
stomach, small intestine and thyroid were removed for conjugate analysis.
Each sample was analysed twice, first without any further preparation in the gamma 
counter and then using the LKB/Wallac 1219 liquid scintillation counter. Plasma and 
urine samples were analysed unchanged in both counters. Before organ samples could 
be analysed in the 1219 liquid scintillation counter they had to be solubilised and 
bleached. The LKB 1219 counter was pre-programmed to read samples with a dual label 
of 3H and 125I, but before samples could be analysed 2 quench curves were prepared
one for each isotope. The DPM reading for 125I in each sample using the 1219 counter 
was compared to the CPM reading obtained from the gamma counter to ensure the 
results were similar and therefore acceptable.
Organ solubilisation was carried out as follows. 1ml o f hyamine hydroxide in methanol 
was added to 200mg o f tissue and the samples were left over night at 60°C. After 
solubilisation between 0 .6 -1.0ml of 30% H20 2 was added until the sample was a pale 
yellow colour. The sample was warmed to remove excess H20 2 and 15ml o f Optiphase 
safe was added. The resultant alkaline solution was neutralised using 500-700pl o f 1M 
acetic acid in toluene. The samples were left overnight before counting for 3H and 125I, 
to ensure that chemiluminescence had died down.
2.9 Targeting to the Liver.
2.9.1 Administration of G-BSA and M-BSA.
G-BSA and M-BSA were obtained from Sigma. The concentration o f sugar residues 
was 26M and 28M sugar residue to 1M BSA respectively. 5mg o f these were iodinated 
as described for native proteins (section 2.2) except that separation o f the conjugate 
from the free iodine was performed using a Biogel P4 column since it was found that 
the sugar-protein conjugate bound very strongly to Sephadex gels. The Biogel column 
was prewashed with 5mg o f M-BSA or G-BSA before the separation to avoid any loss 
of radio-iodinated protein.
A solution containing 200pg o f iodinated protein in 0.2ml PBS was prepared and 
injected IV into 10 male wistar rats. 4 of the injected rats were first anaesthetised with a 
mixture o f hypnorm and midazolam so that three blood samples could be taken from 
each, over 30 minutes. Ether anaesthetic would have been too slow for these rapid 
sampling times and also would have been particularly unpleasant for the rat. After 15 
minutes and 30 minutes the rats were killed using C 0 2 gas and the organs dissected out 
and the 125I content analysed. The remaining six rats were anaethetised with ether 
before three successive blood samples were taken. Two rats were killed as before at 1
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hour, 3 hours and 5 hours after injection. As a comparison native BSA, LA, BSA-MTX  
(4.55%w/w) and BSA-MTX (11.55%w/w) were administered in a similar manner.
2.9.2 Whole body Autoradiography.
Animals were dosed with the protein under investigation (BSA, BSA-MTX, G-BSA, 
M-BSA or LA) or MTX. For the 125I-proteins approximately 20-30pCi o f activity were 
injected and for 3H-MTX 250pCi were administered. At the required time after 
injection; 15 minutes and six hours for the proteins and 5 minutes for MTX the rats 
were killed using C 0 2 gas. They were rapidly frozen using a mixture o f petroleum ether 
60/80 and dry ice. The rat was embedded in 1% polycell while still frozen and 100pm 
thick sections were taken using a chryomicrotome. The sections were exposed to 
hyperfilm and checked weekly until the required exposure was reached.
2.9.3 Liver Perfusion with CoIIagenase.
The G-BSA and M-BSA were administered because o f their ability to target to the liver. 
To determine which cell type they actually targetted to within the liver, the organ was 
separated into two cell types; the hepatocytes and the non-parenchymal cells. This 
process is described below.
Liver perfusion was performed via the mesenteric vessels according to the method of 
Seglen et a l .O 29) After anaesthetising the rat, the abdomen was opened and a cannula 
was inserted into the mesenteric artery. Approximately 100ml o f calcium free buffer 
was perfused through the cannula into the circulation using a syringe. Blood and excess 
buffer was removed via a cannula in the vena cava. After removal o f blood and calcium 
from the liver approximately 100ml of collagenase buffer was injected slowly (over 
about 10 minutes) into, the circulation using a large syringe. During this time the liver 
swelled to approximately twice its size and small cracks could be seen within the 
structure o f  the liver. The liver was removed from the rat, washed in cold calcium-free 
buffer (see section 2.1.7) and placed on ice until the cells could be separated.
A liver cell suspension in calcium free buffer was obtained by gently teasing the liver
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apart using forceps. Clumps o f cells were removed by filtering the suspension through 
four layers o f fine nylon mesh. The cells were separated using a centrifugation method. 
A suspension containing largely hepatocytes was obtained by centrifuging at 50g for 4 
minutes. The hepatocytes which formed the pellet were washed three times, 
resuspended in 10ml and the cell count determined using a haemocytometer.
The supernatant from the original centrifugation contained a mixture of non- 
parenchymal cells and membrane vesicles which had formed due to the breakdown of 
hepatocytes. A suspension o f non-parenchymal cells was obtained according to the 
method o f van Berkel,03°) by incubating on ice for 1 hour in a buffer solution 
containing 0.25% protease E and 0.4% BSA. Hepatocytes are broken down by this 
enzyme whereas non-parenchymal cells remain largely unaffected. After incubation a 
pellet o f non-parenchymal cells was obtained by centrifuging at 500g for 5 minutes. 
The pellet was washed twice and resuspended in 10ml o f buffer and a cell count was 
determined in a haemocytometer.
G-BSA, M-BSA and MTX-BSA (11.55%w/w) were investigated. The solution under 
investigation was injected into the rat 10 minutes before the perfusion was carried out. 
After separation o f the cells, 1ml of each suspension was assayed in the gamma counter 
for 125I activity. Two different cell suspensions were obtained for each cell fraction for 
the same liver. The radioactivity in lg  o f whole liver was also determined before the 
liver was teased apart. The concentration o f conjugate in each cell type o f the liver was 
determined for three rats.
2.10 Uptake o f the Conjugates by M acrophages in vitro.
Each conjugate was analysed in vitro for its ability to be taken up by rat peritoneal 
macrophages. Resident peritoneal macrophages were obtained from rats which had 
previously been killed using C 0 2. 15ml o f RPMI 1640 containing 50IU/ml penicillin 
and 50pg/ml streptomycin was injected into the peritoneal cavity. After gently 
massaging the abdomen to ensure mixing o f the media with the organs a small slit was 
made through which media containing macrophages could be withdrawn using a plastic
-56-
pipette. If any media containing blood was withdrawn it was discarded. Media 
containing macrophages was pooled and centrifuged at 500g for 5 minutes. The cells 
were resuspended in 10ml o f media which contained 10% v/v FCS and a cell count was 
determined using a haemocytometer. 1 x 106 cells were seeded into each well o f six 
well plates and incubated overnight in 4ml of media. Typically between ten or twenty 
million cells were obtained from each rat.
A solution containing 8pg/2ml of iodinated protein or conjugate in RPMI 1640 without 
FCS was prepared. Media was removed from the macrophages and replaced with 2ml 
o f the media containing 125I- protein. At timed intervals over 1 hour the media was 
removed from three wells and the cells were washed 3 times in PBS which contained
0.02% sodium azide. The macrophages were left overnight at room temperature in 1ml 
of a solution containing 0.1% Synperonic OP10 in PBS. This solubilised the cells. Each 
well was washed with a further 1ml of this solution. The solubilised cells were assayed 
for 125I activity in the gamma counter. In addition 1ml o f media was assayed for 
radioactivity and the percentage o f unbound iodine activity was determined using a 
TCA precipitation. Each experiment was carried out at 37°C and at 0°C. The rationale 
for this was that at 0°C although the protein could bind to the receptor it would not be 
internalised and thus protein breakdown could be prevented/131) The proteins that were 
investigated in this way included BSA, BSA-MTX (4.55% w/w), BSA-MTX (11.54% 
w/w), G-BSA (26M:1) and M-BSA (28M:1).
In order to check that the cells obtained from the rat peritoneal cavity were actually 
macrophages, they were prepared for identification using a scanning electron 
microscope. One million cells were seeded onto a sterile glass cover slip in a 24-well 
plate and incubated in RPMI 1640 with 10% FCS at 37°C overnight. Preparation for 
SEM was carried out exactly as for cells grown on filters (section 2.11.5).
.2.11 Cell Culture Experiments using Caeo-2 and BAE-1 Cell-lines.
Two cell lines were under investigation; the Caco-2 cell line and the BAE-1 cell line. 
The Caco-2 cell experiments were performed in the Advanced Drug Delivery Unit at
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Ciba Geigy Pharmaceuticals, Horsham and utilised an established technique. For the 
BAE-1 cell line the experimental techniques had to be decided. Both cell types were 
grown under the same routine conditions.
2.11.1 Routine Cell-Culture.
Cells were routinely grown in DMEM buffered with 5% C’0 2 gas in air and 2g of 
NaHCO^itre and supplemented with 1% non-essential amino acids, 1% glutamine 
(200mM), 50IU/ml penicillin, 50pg/ml streptomycin and 10% Foetal Calf Serum in 150 
cm2 tissue culture flasks. The media was changed on alternate days and the cells were 
sub-cultured weekly. Three flasks were obtained from each confluent Caco-2 flask 
every week and between three and six flasks from each BAE-1 flask each week 
depending on experimental requirements. Sub-culture was performed using 0.25% 
trypsin and 0.2% EDTA for the Caco-2 cell line and using 0.25% trypsin and 0.02% 
EDTA for the BAE-1 cell line.
Filter culture was carried out as follows. Millicell HA filters (30mm diameter) were 
transferred to six well plates using sterile forceps. To prepare the filter for cell seeding, 
2ml of culture media was pipetted inside each filter chamber and 3ml of media was 
pipetted directly into the well of the six-well plate. The plates were tranferred to an air 
tight plastic container and placed in an incubator at 37°C. Humidity was maintained 
inside the container using water soaked tissue. This ensured adequate wetting of the 
filter, whilst the cells were prepared for seeding. Both Caco-2 and BAE-1 cells were 
seeded at a density of 2 x l0 6 cells in 2ml of media into the filter chamber. Figure 2.3 
shows the apparatus used for filter culture.
Figure 2.3 The Apparatus used for Culture of Cells on Filters.
Well of six-well 
plate
Basolateraf
Fluid
Apical Fluid
monolayer o f
Confluent
Plastic support 
of Millicell HA
Cells
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The high cell density was chosen so that cells would already be confluent after seeding 
and during the incubation time cells could differentiate. Experiments were performed 15 
days after cell seeding for Caco-2 cells. For the BAE-1 cells an incubation time had to 
be ascertained by means o f comparative experiments at timed intervals after cell 
seeding. During incubation the media was removed from both inside and outside the 
Millicell HA insert using a suction pump and replaced with new media on alternate 
days.
2.11.2 Transport Experiments using cells grown on cellulose filters.
Radiolabelled drug was used to allow easy identification in the basolateral fluid. 
Between 0.5 and 2 pCi o f each drug was applied to the apical surface o f the cell layer. 
Appearance o f drug in the basolateral fluid was determined at timed intervals for three 
filters for each time point. At the same timed intervals electrical resistance 
measurements were taken for each cell coated filter. The uptake o f the drug by the cells 
and the filter combined was determined at the same times by washing and then 
removing the filter using a scalpel and assaying for radioactivity.
2.11.3 Caco-2 Filter Culture.
The transport o f mannitol, PEG 900 and PEG 4000 was investigated. PEGs are 
notoriously polydisperse polymers. Two HPLC systems were used to investigate the 
degree o f polydispersity of the two molecular weights.
HPLC using Reverse Phase C1S Column.
This method was a modification o f that described by van der W af132) and was only 
suitable for polymers with a molecular weight below 1200 and thus the PEG 4000 was 
not investigated in this way. A 15cm hypersil ODS 5 micron column was attached to 
the system described in Materials. The detector was set at 190nm. An LDC/Milton Roy 
integrator and plotter was used to calculate peak heights and areas. The mobile phase 
used consisted o f 20% acetonitrile (far UV grade) in phosphoric acid (see buffers 2.1.7). 
lOOpl samples were injected onto the column and the PEG was separated into its
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individual oligomers.
HPLC using GPC.
This GPC assay separated PEGs according to their molecular weight. It could not 
identify the individual oligomers, but could be used to identify the mean molecular 
weight o f a sample. Separation was performed using a TSK 3000 column with 
precolumn. The mobile phase was 0.1M LiBr containing 45ppm triton-X 100. Flow rate 
was 0.5ml/min. The PEGs were detected using their refrative index. For radiolabelled 
PEG samples, 0.25ml samples were collected after measurement o f RI, 5ml o f lumogel 
was added and their radioactivity was assayed in a Beckman liquid scintillation counter. 
A series o f standard molecular weight PEGs were injected onto the column and the 
retention times were identified. A graph of log molecular weight against retention time 
gave a straight line for PEGs o f 600 to 20,000D. (Appendix A 1.9).
Transport o f mannitol by Caco-2 cells grown on filters.
A solution o f mannitol containing approximately 0.25pCi/ml (4.9nmol/ml) 14C-Mannitol 
was prepared in media. 2ml o f this solution was pipetted onto the apical surface o f the 
cells (P97). 2ml o f normal media was pipetted into the basolateral chamber o f the cells. 
At timed intervals over 24 hours, apical and basolateral fluids were removed from three 
filters, centrifuged in an eppendorf microcentrifuge to remove cell debris and 1ml was 
added to 10ml o f  lumogel and assayed for 14C content.
After removal o f the media, fresh normal media was added (5ml inside the insert and 
3ml outside) and the resistance measurements taken using the WPI Evom. Filters and 
cells were washed three times in PBS azide, the filter was removed from the insert and 
assayed whole for 14C content in 10ml o f lumogel.
PEG 900 Transport.
To a 15 day culture o f Caco-2 cells (P87) grown on nitrocellulose filters approximately 
2pCi (295.9nmol) o f 3H-PEG 900 in 2ml of media was applied to the apical surface.
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Samples of 200pl of baso-lateral fluid were removed at timed intervals over 24 hours 
and were replaced with 200jil o f fresh media. Cell/filter uptake and resistance 
measurements were determined as for mannitol.
PEG 4000 Transports
A solution containing 2pCi/2ml (8.4nmol) in media was prepared. 2ml was applied to 
the apical surface of the cells (P97). There were 36 filters for the experiment and three 
filters were analysed for each time point. Cell/filter uptake and resistance measurements 
were taken as for mannitol experiment.
2.1X.4 BAE-1 Filter Culture.
Caco-2 cell filter culture procedures had been established at Ciba Geigy. Electron 
microscopy techniques, electrical resistance measurements^133) and the transport o f low  
molecular weight fluid phase markers had ascertained that the incubation period and the 
number o f cells seeded had resulted in a confluent and differentiated cell monolayer at 
15 days after cell seeding. Since the BAE-1 cell line had recently been obtained from 
the ECAC (Porton Down) these parameters had to be established before filter culture 
experiments could be performed.
Many references to endothelial cells used in transport experiments utilised a 
collagen/fibronectinfi34) or gelatin^135) coated filter to allow the cells to adhere and form 
a confluent monolayer. Experiments were performed to ascertain whether coating the 
M illicell HA filter was necessary.
Gelatin conring the Millicell HA filter.
The method for gelatin coating filters was obtained from Millipore and is summarised 
below. A  solution was prepared containing 5%w/v calf skin gelatin and 5%w/v sucrose 
in double distilled water by heating on a water bath. Aliquotes were stored at -20°C and 
defrosted in a 37°C water bath as required. The millicell HA filter inserts were 
transferred to six-well plates and just enough o f the gelatin solution was applied to the
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filter to cover it. Excess gelatin was removed immediately using a suction pump. The 
gelatin coated filters were air dried under the laminar flow for approximately 15 
minutes.
The six well plate was placed on ice and washed in sterile PBS for 10 minutes. The 
PBS was removed and 2ml o f fixative was added. The fixative consisted o f 25% v/v 
glutaraldehyde in PBS.
After 30 minutes the fixative was removed and the filter was washed 5 times in sterile 
PBS over a 20 minute period at room temperature. The fixative was quenched using a 
solution of glycine (0.76%w/v) in sterile PBS. After 30 minutes the glycine solution 
was removed and the filters were washed twice with sterile PBS. Finally the filters were 
washed three times in culture medium and were then ready for cell seeding as above.
The transport o f 125I-HSA by BAE-1 cells grown on coated nitrocellulose filters was 
compared 3.75 days, 7 days and 10 days after cell seeding. In addition, the HSA 
transport for gelatin coated and non-coated filters was compared at 7 days after cell 
seeding. The permeation o f HSA across gelatin-coated or non-coated filters which had 
not been seeded with cells was also determined.
Transport o f HSA.
2 x 106 BAE-1 cells were seeded onto each o f 36 gelatin coated filters. At the same 
time cells were seeded onto 12 uncoated filters. After the required incubation time, 
200pg of 125I-HSA (Amersham) was applied to the apical surface o f 12 filters for each 
filter type and the appearance o f the 125I-HSA in the basolateral fluid was measured at 
8 time points over 24 hours after addition o f the protein. The protein was applied in 
normal media. The HSA transport was analysed twice for each filter during the 
experiment. The first time the basolateral fluid was sampled, 200pl was removed and 
replaced with 200pl o f fresh media. The second time all the fluid could be removed and 
analysed. A correction step was brought into the calculation to allow for the initial 
removal o f HSA.
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lOOpl or 1ml o f media was analysed for 125I content in the mini gamma counter. lOOpl 
was used to determine the amount o f non-protein bound iodine within the sample by 
using TCA to precipitate the 125I-HSA. lOOpl of 20%w/v TCA was added, incubated 
for 15 minutes, centrifuged in an eppendorf microcentrifuge and lOOpl of supernatant 
was assayed for 125I activity. The total 125I activity in the basolateral fluid was 
corrected for that found to be present as non-protein bound activity.
The uptake o f 125I-HSA by the filter and cells combined was estimated. After removal 
of experimental media the filters and cells were washed three times in cold PBS azide. 
The cell coated filter was removed from the plastic insert using a scalpel and assayed 
whole in the mini gamma counter. The permeability o f the gelatin-coated and non- 
coated filter without cells for 125I-HSA was determined. Twelve filter inserts were 
transferred to six-well plates. Six were coated with gelatin. 4ml o f media was pipetted 
inside the insert and 3ml was pipetted into the well. The plates were placed inside an 
air-tight plastic container and placed in an incubator over night to ensure adequate 
wetting o f the filter. The experiment was performed as for the cell coated filters.
Cell and filter resistance measurements.
After completion o f the experiment but before washing filters in PBS azide, the 
electrical resistance o f the endothelial cell layer was determined on both the gelatinised 
filter and the non-gelatinised filter. The reistance of the filters without cells was also 
determined. 5ml o f normal media was pipetted into the insert, 3ml was pipetted outside 
(into the well). Resistance was measured using the World Precision Instruments 
voltohmmeter. An alternating current o f ± 20 pA at 12.5 Hz was applied to the cell 
monolayer. Ohms.cm2 was calculated by first subtracting the resistance determined for a 
filter without cells (ohms2) from the resistance measured for the cell monolayer (ohmsj) 
and then multiplying by the area o f the filter.
Ohms.cm2 = (ohmsj -ohms2) x 4.2
BSA transport hv B AF.-1 cells grown on nnmated filters
BSA was radio-iodinated with 125I as described under section 2.2 and a solution 
containing 33pg/2ml was prepared. This solution was applied to 4, 7, and 10 day old 
cultures of BAE-1 cells (P29) grown on uncoated nitrocellulose filters. At timed 
intervals over 24 hours samples o f basolateral fluids were removed from 3 filters at 
each time point. Resistance measurements and cell/filter uptake was determined as 
described previously. The percentage o f TCA-precipitateable 125I was also determined.
Transport of BSA and BSA conjugates.
The permeability o f a monolayer o f BAE-1 cells (P28-P32) grown on millicell HA 
filters for 125I-BSA, 125I-BSA-MTX (4.55 %w/w), 125I-BSA-MTX (11.54 %w/w), and 
125I-LA was determined. Although the age o f the cells on the filter did not appear to 
alter the rate o f transport it was decided to use 7 day old cultures as a standard. 9.23pg 
o f iodinated protein or iodinated protein conjugate was applied to the apical surface of 
the cells and the basolateral compartment of the cells was sampled as before.
2.11.5 Preparation of Cell Samples Grown on Nitrocellulose Filters for Electron 
Microscopy.
Cells were seeded on to millicell HA filters (2 x l0 6 per filter) and media was changed 
every other day until confluence was reached (Caco-2 = 1 5  days and BAE-1 = 7 days). 
Filters were removed from the plastic holders using a scalpel and cut into quarters. 
Filters were fixed in 2.5% glutaraldehyde, 4% formaldehyde in 0.1M cacodylate buffer 
(pH 7.4) for 1 hour at room temperature. Cells were washed twice (5 minutes each) in 
cacodylate buffer, then fixed in 1% osmium tetroxide in cacodylate buffer for 1 hour. 
During this time the cells went brown. Next cells were washed twice (5 minutes each) 
in distilled water.
At this stage cells prepared for scanning electron microscopy (S.E.M.) were fixed in 1% 
tannic acid in cacodylate buffer for 0.5 hours. Cells both for transmission electron 
microscopy (T.E.M.) and S.E.M. were dried in graded ethanol as shown below:
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% v/v Ethanol Time (minutes)
0 2 x 5
30 2 x 10
50 2 x 10
70 2 x  10
100 3 x 10
Cells prepared for S.E.M were critical point dried from 100% ethanol and then a thin 
coat of gold was applied in an Edwards Sputter Coater S150B. Small sections of cell 
coated filter were glued onto 10mm x 10mm stubs (Jeol) using conductive carbon 
cement (Leit C) and examined using Jeol JSM 35C Scanning Electron Microscope.
Preparation of cells for T.E.M. was continued by embedding the filter quarters in 50% 
Taab embedding resin in 100% Ethanol and then rotating. Over the following 48 hours 
the resin was changed twice to 100% resin and rotation was continued. During this 
period the filters rolled up like swiss rolls. After 72 hours each quarter of filter was 
placed in a separate Taab Embedding mould (CO50) and the mould was topped up with 
resin. The moulds were placed in an oven at 50°C for 48-72 hours.
Sections were taken using a C. Reichert OM U3 microtome with a glass knife. 90nm 
sections were taken and placed on grids. The sections were stained in the dark with 2% 
uranyl acetate for 7 minutes, washed 4 times with distilled water and stained for 7 
minutes with Reynolds Lead Citrate in a petri dish lined with filter paper soaked in 1M 
NaOH. The sections were washed 4 times in distilled water, dried and viewed in a Jeol 
1200 Ex Transmission Electron Microscope.
In addition some slightly thicker sections were studied under the light microscope. The 
sections were dried on a glass slide on a hot plate and stained with 1% toluidine blue in 
1% borax. The stain was washed off and the section was mounted in D.P.X. and viewed 
using a Zeiss Ultraphot microscope fitted with a 35mm camera.
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CHAPTER 3:
KINETICS OF METHOTREXATE AND PROTEINS IN THE RAT.
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All calibration curves used in the calculation o f values in this chapter are shown in 
Appendix 1. The method o f calculation o f the pharmacokinetic parameters is shown in 
Appendix 2. All tables of data are listed in Appendix 3. These tables have the prefix A.
3.1 Pharmacokinetics of Methotrexate
Methotrexate was chosen as the model drug for the work in this thesis. In later sections 
(see Chapter 4), experiments are described, in which the drug was bound to protein 
carriers, in order to change the pharmacokinetics o f the drug. The pharmacokinetic 
parameters o f ‘free* MTX were calculated first.
Plasma concentrations o f MTX were determined using two methods. (HPLC and using 
radiolabelled MTX). A dose o f 2.5mg o f MTXNa2 was administered to rats by IV, IP 
and SC injection and the plasma concentration o f the drug was determined using HPLC. 
A typical chromatogram obtained after injection o f a rat plasma sample containing 
MTX, onto the column is shown in figure 3.1.1. This sample had been spiked with the 
internal standard, aminopterin. Table A3.1.1 gives the plasma levels determined by 
HPLC for rats dosed with 2.5mg o f MTX. The plasma levels following administration 
o f  a 2.5mg dose to rats were also determined using 3H-MTX, as described in section
2.5.1 in the methods. The plasma concentrations obtained are listed in table A3.1.2 for 
each o f the routes.
3H-MTX was also administered at a total drug dose o f 0.5mg/rat and plasma levels 
were determined as described above. These are shown in table A3.1.3.
Figure 3.1.2 is a plot of log concentration o f 3H-MTX in plasma against time for the 
2.5mg dose, for each of the routes o f administration. For the other doses o f MTX the 
plot (not shown) was very similar. Figure 3.1.3 compares plasma concentrations 
attained after administration o f a 2.5mg dose o f MTXNa2, with HPLC detection and 
using 3H-MTX. Figures 3.1.2 and 3.1.3 show that there was very little difference 
between plasma levels achieved for each route o f administration and each dose. Each 
plot shows a biexponential clearance. Phase 1 was believed to be the distribution or
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Figure 3.1.1: A typical chromatogram obtained after injection of a sample of plasma 
from a rat which had been injected with 2.5mg of MTXNa2. The plasma was extracted 
as described in the methods (2.5.1) and was spiked with AMN as internal standard.
IEEE NO SAMPLE METHOD TIME DATc
31 9 00 7  METHOD 1 1 1 * 10s 37 2 7 : 0 6 : 8 8
RUN TIME 8 .2 1
DEFAULT 8
NORMALIZATION METHOD USING AREA
TIME HEIGHT AREA ■'.AREA
2 .1 2 323 7 140580 1 7 . 3 1 1 0 7 8 0
? lO•_< . i  o 7852 537499 6 6 . 2 2 5 5 3 1 0
6. 06 2349 133620 1 6 . 4 6 3 3 8 9 0
TOTAi 811 61 9 1 0 0 . 0 0 0 0 0 0 0
The peak with a retention time of 3.18 minutes was due to AMN. 
The peak with a retention time of 6.06 minutes was due to MTX.
Figure 3.1.2 Log Concentration o f3 H-MTX after administration 
of 2.5mg total drug to male wistar rats by one of three routes. 
n=8 for each route. Each point represents data from one rat.
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Figure 3.1.3:Log concentration of 3H-MTX and MTXNa ^with 
HPLC detection) following IV administration to male wistar 
rats. 2.5mg of total drug was administered. (n=8 for each dose). 
Each point is a concentration determined from one rat
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alpha phase and phase 2 was believed to be the elimination or beta phase. Following SC 
and IP administration no initial absorption phase was seen, indicating that absorption 
was very rapid from these sites and probably occurred directly into the blood stream. 
Over the elimination phase the plot of log plasma concentration against time is linear 
and pharmacokinetic parameters could be calculated for each route of administration 
and for each dose of drug. These are shown in table 3.1. The pharmacokinetic 
parameters for the distribution phase were also calculated. The method for this 
calculation is described in appendix 2.
Table 3.1 The pharmacokinetic parameters calculated for each dose of drug and
for each route of administration.
1. IV Route for each dose.
Dose 0.5mg 3H-MTX 2.5mg 3H-MTX 2.5mg MTX (HPLC)
a> Alpha Phase
time span 15-80minutes 15-60minutes 10-90minutes
R2 0.9679 0.9091 0.9654
m* (min*1) -0.0211±0.0014 -0.0206±0.0027 -0.0174±Q.0015
c* (Log Co) -0.0597±0.0695 -0.225 ±0.109 -0.137 ±0.067
n# 10 8 8
kel (min*1) 0.0485 0.0474 0.040
t1/2(min) 14.28 14.61 17.33
Vd (ml) 114.7 167.9 137.1
Cl (ml/min) 5.56 7.96 5.48
b} Beta Phase
time span 120-240m in 90-210min 90-195min
R2 0.9408 0.6463 0.6418
m* (min*1) -0.00256±0.0002 -0.00262±0.001 -0.00294±0.001
c* (log Co) -1.2083±0.034 -1.0394±0.11 -1.1603±0.078
n# 12 10 7
kel (min*1) 0.00589 0.00603 0.00677
t1/2(min) 117.5 115.0 102.4
Vd (ml) 1615 1094 1446
Cl (ml/min) 9.51 6.59 9.79
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A
Table 3.1: Continued (Pharmacokinetic Parameters for MTX).
2. IP Route for each dose.
Dose 0.5mg 3H-MTX 2.5mg 3H-MTX 2.5mg MTX (HPLC)
Alpha Phasp,
time span 7-84minutes 15-90minutes 15-90minutes
R2 0.9036 0.9453 0.8277
m* (min-1) -0.0115±0.0011 -0.0159±0.0013 -0.0173±0.0025
c* (log Co) -0.4187±0.053 -0.4224±0.076 -0.158±0.0025
n# 12 10 12
kel (min-1) 0.0264 0.0367 0.0398
t1/2 (min) 26.21 18.90 17.39
Vd (ml) 262.3 264.5 144.0
Cl (ml/min) 6.92 9.44 5.73
M Reta Phase*
time span 107-240m in 120-225min 105-180min
R2 0.7154 0.8780 0.8310
m* (min-1) -0.00248±0.0004 -0.0026±0.0005 -0.00298±0.0005
c* (Log Co) -0.9296±0.078 -1.1215±0.084 -1.1249±0.078
n# 14 6 8
kel (min-1) 0.00571 0.00592 0.00686
t1/2 (min) 121.3 117 101
Vd (ml) 850.3 1323 1333
Cl (ml/min) 4.86 7.83 9.14
-71-
Table 3.1: Continued (Pharmacokinetic Parameters for MTX).
2. IP Route for each dose.
Dose 0.5mg 3H-MTX 2.5mg 3H-MTX 2.5mg MTX (HPLC
a'l Alpha Phase
time span 7-84minutes 15-90minutes 15-90minutes
R2 0.9036 0.9453 0.8277
m* (min-1) -0.0115±0.0011 -0.0159±0.0013 -0.0173±0.0025
c* (log Co) -0.4187±0.053 -0.4224±0.076 -0.158±0.0025
n# 12 10 12
kel (min-1) 0.0264 0.0367 0.0398
t1/2 (min) 26.21 18.90 17.39
Vd (ml) 262.3 264.5 144.0
Cl (ml/hr) 6.92 9.44 5.73
b) Beta Phase
time span 107-240min 120-225min 105-180min
R2 0.7154 0.8780 0.8310
3 # 3 3 1 w 10.00248±0.0004 -0.0026±0.0005 -0.00298±0.0005
c* (Log Co) -0.9296±0.078 -1.1215±0.084 -1.1249±0.078
n# 14 6 8
kel (min*1) 0.00571 0.00592 0.00686
t1/2 (min) 121.3 117 101
Vd (ml) 850.3 1323 1333
Cl (ml/hr) 4.86 7.83 9.14
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Table 3.1 Continued (Pharmacokinetic Parameters for MTX).
3. SC Route for each dose.
Dose 0.5mg 3H-MTX 2.5mg 3H-MTX 2.5mg MTX (HPLC)
â  Alpha Phase.
time span 10-90minutes 15-90minutes 15-105minutes
R2 0.9102 0.8455 0.9760
m* (min-1) -0.0121±0.001 -0.0158±0.002 -0.0171±0.0008
c* (Log Co) -0.386±0.05 -0.243±0.135 0.0128±0.052
n# 16 10 14
kel (min*1) 0.0279 0.0365 0.0394
t1/2 (min) 24.83 19.01 17.6
Vd (ml) 243.2 175.1 97.1
Cl (ml/min) 6.78 6.23 3.83
M Reta Phase, 
time span 120-240m in 120-225min 120-180min
R2 0.9302 0.7802 0.6022
m* (min*1) -0.0024±0.0002 -0.0023±0.0006 -0.0030±0.0012
c* (log Co) -1.1659±0.042 -1.3195±0.108 -1.2258±0.194
n# 10 6 6
kel (min*1) 0.00543 0.00592 0.00691
t1/2 (min) 127.5 129 100.3
Vd (ml) 1465 2087 1682
Cl (ml/min) 7.95 12.35 11.62
Notes: * Slopes or constants are quoted ± Standard Error. 
# n= number of points used in the calculation.
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Only two phases were seen in these experiments. In man it is known that MTX 
demonstrates a triexponential clearance/117) It may be that the third phase began when 
the plasma concentrations were too low to be measured by this assay or the first phase 
had already occurred before plasma samples were taken.
There was little difference between the pharmacokinetic parameters calculated for each 
dose and the different routes of administration. MTX was shown to have a large volume 
of distribution (approximately 1.51 in a 250g rat). This volume is a hypothetical term 
which, in this case probably indicates that following its wide distribution, MTX was 
sequestered by a tissue or tissues. Upon entry of MTX into most cell types, it becomes 
bound to DHFR. Any remaining MTX is poly-glutamated. The poly-glutamated form of 
drug cannot readily leave the cell/112) MTX also has a very short half-life (101 to 129 
minutes for the beta phase). By binding the drug to a targeting agent both of these 
factors could be improved.
Urinary Excretion o f MTX.
Table A3.1.4. shows the excretion of MTX in the urine with HPLC detection after 
administration by the IV route to male wistar rats. The HPLC assay was used only to 
determine the excretion of MTX itself and not any metabolites. After 48 hours 
approximately 89% of the MTX dose had been excreted unchanged in the urine. This is 
similar to the percentage excreted in man/136) and to the results obtained by Chu and 
Whiteley(") for 3H-MTX excretion in the urine of mice.
Table A3.1.5 shows the urine excretion of 3H- activity after administration of 2.5mg 
3H-MTX by each of the three routes. These results are shown graphically in Figure 
3.1.4. Any metabolites of MTX as well as unchanged MTX were measured using this 
procedure. There was no significant difference in the amount of 3H activity excreted for 
each of the three routes. Between 13 and 17 % of administered 3H was excreted in the 
urine over 72 hours for each route of administration
A Student’s t-test was performed on the IV data for urine excretion with HPLC
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Figure 3.1.4:
The urine excretion of 3H activity following administration 
of 2.5mg of3 H-MTX to rats by IV, IP and SC routes.
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Figure 3.1.5:
The Urine Excretion of MTXNa2 followed by HPLC analysis compared to 
the Urine Excretion of two doses of 3H-MTX (0.5mg and 2.5mg) followed 
by measurement in a Liquid Scintillation Counter.
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detection and for 3H-MTX excretion at 24 hours and 48 hours after administration. At 
both time points the t values calculated were highly significantly different (p <0.001). 
Figure 3.1.5 compares the urine excretion for MTXNa2 and 3H-MTX (both 2.5mg and 
500pg doses).
The urine excretion of 3H activity after administration of 0.5mg of 3H-MTX by each of 
the three routes (Table A3.1.6) was also determined. The cumulative % excreted was 
compared at each time point to the 2.5mg dose for each route by means of a non-paired 
t-test. All results were non-significant.(p>0.05).
It is difficult to explain why less of the 3H-MTX was excreted than the MTXNa2. Since 
the 3H activity excreted could actually be metabolites of MTX as well as drug, it was 
anticipated that the 3H activity excreted would overestimate the excretion of MTX. It 
may be that, following administration of 3H-MTX, the 3H exchanged with hydrogen 
molecules on endogenous compounds and thus was more slowly excreted. The 3H-MTX 
used was labelled on positions 3’, 5* and 7. One of the metabolites of MTX is 
7-OH-MTX. If this metabolite was formed in the rat, and it was excreted, then less 3H 
activity would be excreted per molecule of MTX. Since the calculated elimination 
half-lives and volumes of distribution were similar for both the 3H-MTX and the 
MTXNa2, then it seems unlikely that part of the activity was retained in vivo.
3.2 Digoxin
Digoxin was administered to rats as a model drug with a larger molecular weight 
(78 ID) than MTX (452D) so that effects of molecular weight on rate of absorption 
from IP and SC sites could be identified. However it is difficult to directly compare the 
pharmacokinetics calculated for digoxin with those calculated for MTX because of the 
different nature of the 2 drugs. MTX is a polar molecule and digoxin is hydrophobic.
Table A3.2.1 lists the plasma levels determined for digoxin following administration of 
250ng by each of the three routes. These results are shown graphically in Figure 3.2. 
Following administration by the SC route peak plasma levels were achieved
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Figure 3.2
Serum Concentration (Log % dose/ml) after injecting male wistar rats 
with 250ng of Digoxin by one of three routes.
Levels were determined using an ELISA.
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Figure 3.3: Plasma Concentration of ,4C activity following administration 
of 1.6mg of 14C-Inulin to rats by SC and IP routes.
0.0800
0.0700
% of
activity 0.0600 
remaining
perml 0.0500
0.0400
0.0300
0.0200
0.0100
0.0000
0.00 1.25 2.50 3.75 5.00 6.25 7.50 8.75 10.00 11.25
Time (hours)
Points were determined from a single rat, except for 5 and 7.5 hours (n=3 or 4) 
IP and 7.5 and 10.66 hours SC (n=3). Bars are S.E.M.
SC
IP
-76-
approximately 2 hours after injection. Peak plasma levels were achieved within 30 
minutes o f IP injection. This indicates that absorption from SC sites occurred at a 
slower rate than from the peritoneal cavity, and in addition, absorption was slightly 
slower than for MTX. Following IV administration o f 250ng o f digoxin to rats, two 
phases were seen over the time period investigated. These were assumed to be due to an 
initial distribution (or alpha) phase followed by an elimination (or beta) phase. Table
3.2 lists the pharmacokinetic parameters calculated for digoxin for each o f the routes. 
For IV dosed rats, parameters were calculated for alpha and beta phases and for SC and 
IP dosed rats, parameters were calculated for the beta phase only.
Table 3.2 The Pharmacokinetic Parameters Calculated for Digoxin following IV, 
IP and SC administration of 250ng to rats.
IV (alpha) IV (beta) IP SC
Time span 0.5-2.5hr 2.5-7 0.5-7 2.0-7
R2 0.7872 0.4195 0.8418 0.9250
m* -0.636±0.12 -0.06510.02 -0.09210.016 -0.15910.022
c* 0.47810.185 -0.3210.113 0.006410.06 0.30710.10
n# 10 14 12 7
Kel (h r1) 1.465 0.149 0.212 0.366
t1/2 (hr) 0.473 4.651 3.269 1.893
Vd (ml) 33.27 209 123.6 49.32
Cl (ml/hr) 48.74 31.14 26.20 18.05
Notes: * constants and slopes are quoted ± Standard Error.
#  n= number o f serum concentrations used in calculation.
The volume o f distribution o f digoxin calculated for the beta phase after IV injection 
was high representing the whole body o f a rat. This was because o f the hydrophobic
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nature of digoxin. It rapidly leaves the blood stream and is deposited in muscle tissue 
and adipose/137) The Vd calculated for the alpha and beta phases for each route of 
administration were found to be lower than for MTX. The t1/2 for elimination were 
slower following IV and IP injection than SC injection, which is difficult to explain.
3.3 Pharmacokinetics of Inulin
Inulin has a molecular weight of approximately 5000D. It was administered to rats in 
order to determine the pharmacokinetics and rate of absorption from IP and SC sites, of 
a drug larger than both MTX (452D) and digoxin (78ID).
The plasma concentrations of SC and IP injected 14C-Inulin are shown in table A3.4.1. 
They are represented graphically in Figure 3.3 (page 76). Inulin was absorbed rapidly 
from IP and SC sites with peak plasma levels occurring within 1 hour of injection. 
Inulin has an average molecular weight of 5000 but this does not seem to restrict its 
absorption into the blood stream, probably because it is a highly polar molecule. Table
3.3 lists the pharmacokinetic data for inulin after IP and SC injection.
Table 3.3 Pharmacokinetic Parameters for 14C-InuIin over the elimination phase.
IP SC
Times used 1-10.7 hours 2-10.7 hours
R2 0.7787 0.3725
m* -0.160±0.028 -0.0297±0.009
c* -1.125±0.11 -2.13±0.059
n# 19 14
Kel (h r1) 0.368 0.0685
(hr) 1.881 10.12
Vd (ml) 1333 13459
Cl (ml/hr) 491 922
Notes: * slopes and constants are calculated ± Standard Error. # n= number of points 
used in the calculation.
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There was a great deal of variation in the plasma levels of 14C-inulin achieved between 
different rats. This led to a very poor regression coefficient for the ‘linear’ section of 
the Log plasma concentration versus time plot for 14C-inulin. This large variation was 
probably due to differences in the renal clearance of the drug between rats. Inulin is 
used clinically to determine glomerular filtration rate in man/138) It is rapidly removed 
from the circulation and is predominantly eliminated unchanged by the kidney by 
glomerular filtration, with no reabsorption occurring in the tubules/139) This is 
demonstrated in Table 3.3 by the extremely large clearance (approximately 8-15 
ml/minute). The half life of inulin in man following IV injection has been quoted as 
between 0.53 to 1.17 hours/138) After IP injection the half life was found to be 1.9 
hours and after SC it was found to be 10 hours. These apparent differences may be 
because the inulin was not completely absorbed from the injection sites (and SC 
absorption was slower than IP) and inulin was slowly being released into the blood 
stream during the elimination phase.
3.4 Pharmacokinetics of Proteins.
All conjugates and most of the proteins (this section and chapter 4) were administered 
with an 125I label. Problems envisaged with this label were that any unconjugated iodine 
in the injection solution may interfere with the assay. Also, as the protein was broken 
down in vivo, it was anticipated that iodine or iodinated tyrosine would be released and 
again this may interfere with the assay. The 125I was injected so that the effects of any 
unconjugated iodine could be investigated.
3.4.1 Pharmacokinetics of 125I-Na
125I-Na was administered to rats by the IV route. The serum concentration at various 
time points was determined and this data is listed in table A3.3.1. The results are shown 
graphically in Figure 3.4.1. The clearance of 125I-Na followed a biexponential model. 
Pharmacokinetic parameters were calculated for each phase and are listed in table 3.4.1.
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Table 3.4.1: The pharmacokinetic parameters calculated for an IV dose of 0.654ng 
of 125I-Na administered to male wistar rats.
Alpha Phase Beta Phase
Time span 15-150 minutes 3-48 hour
R2 0.7520 0.9157
m* (hr1) -0.359±0.062 -0.0222±0.002
c* (Log Co) -0.415±0.086 -0.501 ±0.043
n# 16 16
Kel (h r1) 0.826 0.0511
t1/2 (hr) 0.838 13.55
Vd (ml) 260.0 316.9
Cl (ml/hr) 214.8 16.2
Notes:
* Slopes and Constants are quoted ± Standard Error.
# n= Number of points used in the calculation.
The distribution half-life of 125I-Na was very rapid at approximately 50 minutes. The 
volume of distribution for the alpha phase was large and represents the total volume of 
the rat. Plasma clearance was also rapid for the distribution phase at approximately 
3.6ml/minute. Three hours after administration (the start of the elimination phase) the 
plasma level had fallen to 0.32%/ml of the injected dose.
Table A3.3.2 and figure 3.4.2 show the urine excretion of 125I activity. Approximately 
46% of the dose was excreted in the urine in the first 24 hours. Table A3.3.3 lists the 
amount of 125I activity that was excreted in the faeces. Only a small amount (5.6% in 
48 hours) was excreted in the faeces.
Organ distribution in liver, kidney and thyroid was determined for the iodine (tabulated
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in A3.3.4). These results are shown graphically in figure 3.4.3. 125I was sequestered into 
the thyroid but did not accumulate in the liver or kidney.
Because of the rapid clearance of the iodine from the plasma, the rapid uptake by the 
thyroid and lack of accumulation of the iodine in other organs, it was not anticipated 
that the small amount of unconjugated 125I that was injected (less than 10% in all 
experiments) would lead to errors in the 125I assay.
3.4.2 Lactalbumin (LA).
Lactalbumin is a milk protein with a molecular weight of 14.2kD. The LA used in this 
experiment was of bovine origin. Section 3.5 describes experiments which were 
performed, to investigate the possibility of bovine proteins causing an immune response 
in the rat. LA was administered as one of a range of proteins with different molecular 
weights, to determine the pharmacokinetic parameters and rates of transfer from IP and 
SC sites, as a function of molecular weight.
Table A3.5.1 lists the concentration of 125I-LA activity in rat serum. Figure 3.5.1 is a 
plot of Log serum concentration versus time for the 125I activity, for each of the three 
routes. Following IV administration this plot shows a biexponential clearance for LA. 
The first phase (alpha phase) was considered to be due to distribution throughout the 
serum and rapidly equilibrating tissues (central compartment). The second phase (beta 
phase) was due to elimination and distribution into a slowly equilibrating (tissue) 
compartment. Following IP injection absorption was rapid, with peak plasma levels 
being achieved within 1 hour of administration. Absorption from SC sites was also 
rapid. Again, peak plasma levels were achieved within 1 hour of injection. This rapid 
absorption phase implies that the protein was transferred straight into the blood stream 
from these extra-vascular sites, rather than requiring initial absorption into the lymph 
before it could pass into the blood stream. However it could also be explained by 
lymphatic absorption with the rate of transfer from lymph to blood being very rapid.
Following the initial absorption phase in IP and SC dosed rats, the serum concentration
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Figure 3.4.3:
Percentage of mI dose in Thyroid, Liver and Kidney 
following administration of 0.654ng of5 INa to rats 
by the IV route.
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Figure 3.5.1:
Serum Concentration of 125I activity following administration 
of 5mg of1 2 5I-Lactalbumin to rats by IV, IP and SC routes.
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reached similar levels to IV and then began to fall at a similar rate. Table 3.5 lists the 
pharmacokinetic data calculated for 125I-LA injected into rats by each of the three 
routes.
Table 3.5 The Pharmacokinetic Parameters Calculated for 125I-LA administered to
rats by IV, IP and SC injection.
IV (alpha) IV (beta) IP (beta) SC (beta)
Time span (hr) 0.25-3 3-72 4-72 10-72
R2 0.9407 0.9367 0.9026 0.8174
m* -0.319±0.030 -0.0139±0.0008 -0.012310.0009 -0.007710.001
c* -0.046±0.004 -0.374±0.028 -0.43310.0344 -0.72410.045
n# 10 22 20 14
Kel (h r1) 0.735 0.032 0.028 0.0177
t1/2 (hr) 0.943 21.6 24.5 39.08
Vd (ml) 111 236 271 530
Cl (ml/hr) 81.59 7.55 7.59 9.37
Notes: * Slope and Constant are quoted ± Standard Error.
# n= number of points used in the calculation.
125I-LA injected IV or IP gave similar pharmacokinetic parameters during the beta 
phase. Following SC administration, 125I-LA was found to have a larger volume of 
distribution and slower elimination half life than that injected by the other routes, 
although serum levels did appear to be similar during this phase. The alpha half-life 
seen in IV dosed rats was rapid at less than 1 hour and the Vd represented about half 
the body weight of a rat.
Tables A3.5.2 and A3.5.3 list the urine and faecal excretion of 125I activity respectively.
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Faecal excretion of the iodine was low with only between 6 and 8% of the injected dose 
being excreted in 72 hours. Urine excretion of 125I activity accounted for between 45 
and 68% of the total dose in 72 hours (Figure 3.5.2). The urine excretion following IP 
and SC injection was very similar. However, after IV injection the rate of excretion was 
less than for the other two routes. Student’s t-test was used to compare the amount 
excreted by IV dosed rats, at 24 and 72 hours, with the amount excreted by SC dosed 
rats and these were found to be highly significantly different at both time points (p< 
0.001 for 24 hours and p< 0.02 for 72 hours).
Seymour et al<56) demonstrated with HPMA copolymers that polymers up to a 
molecular weight of 45kD can be excreted in the urine. Thus LA has a molecular 
weight low enough to be excreted unchanged in the kidney and so urinary excretion 
would be expected to be rapid for this protein. It is possible that excretion after IP 
injection could be more rapid than after the other routes due to direct uptake by the 
kidney blood vessels, however this would not account for the increased excretion of SC 
dosed rats compared to IV. Thus it is possible that the IV dosed rats are showing falsely 
low urinary excretion.
Table A3.5.4 lists the organ distribution of 125I activity following administration of 
125I-LA by each of the three routes. The organ distribution 28 hours after IV injection is 
shown in Figure 3.5.3. The results are expressed as a ratio, in this plot, of the 125I 
activity in the whole organ divided by the 125I activity in 1ml of whole blood. It was 
hoped that this transformation of the results would allow direct comparison of the organ 
distribution at different time points. For highly vascularised organs the percentage of 
activity in that organ would appear high even without tissue accumulation, if the 
activity in the blood remained high. Thus division by the activity present in 1ml of 
blood would compensate for this. If the organ, itself, had not taken up any of the 125I 
then the ratio obtained would be equivalent to the number of millilitres of blood present 
in that organ.
The ratio at other time points and for the other routes of injection for each of the organs
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Figure 3.5.2:
Percentage of 125I activity excreted in the urine following 
administration of 125I-LA to rats by IV, IP and SC routes.
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Figure 3.5.3:
Organ Distribution oflz5l activity following administration of 5mg of 
l2 5 I-LA by IV injection. Determination was carried out 
at 28 hours after injection. Two rats were analysed.
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was similar to that shown in Figure 3.5.3. At 28 hours after IV injection a small 
proportion of the 125I-LA had been broken down. This is shown by the high ratio in the 
thyroid (actual percentage was 6.75 ±0.679 for 6 rats). This breakdown would probably 
occur in the liver, although levels in the liver were not elevated compared to the other 
organs. Following breakdown, the 125I activity would have been transferred into the bile 
and then would appear in the gastro-intestinal tract and this may account for the high 
ratios in stomach and small intestine.
3.4.3 Carbonic Anhydrase (CA).
The carbonic anhydrase used in this experiment was of bovine origin. It has a molecular 
weight of 29kD and was administered as one of a range of proteins, as described 
previously, to investigate the effect of molecular weight on pharmacokinetics and rate 
of absorption from SC and IP sites. CA is a zinc metalloenzyme and it catalyses the 
conversion of carbonic acid to carbon dioxide and water.
125I-CA was administered to rats by each of the three routes. The serum levels 
calculated for the protein are shown in Table A3.6.1. A plot of Log concentration in 
serum versus time, for each of the three routes, is shown in Figure 3.6.1. This plot is 
very similar to that obtained for LA. Absorption from IP and SC sites appeared to be 
rapid, with peak plasma levels occurring within one hour of administration. Table 3.6 
lists the pharmacokinetic parameters calculated for each route of administration. For IV 
dosed rats parameters for both the alpha and beta phases were calculated and for IP and 
SC dosed rats parameters were calculated only for the beta phase.
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Figure: 3.6.1
Serum concentration of 12T activity following administration 
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Table 3.6 The Pharmacokinetic parameters calculated for 125I-CA injected by IV,
IP and SC routes.
IV (alpha) IV (beta) IP (beta) SC (beta)
Time Span (hr) 1-21 24-97.5 24-97.5 27-97.5
R2 0.9189 0.9238 0.8955 0.8099
m* (h r1) -0.074710.006 -0.010810.0009 -0.010510.001 -0.009410.001
c* (log Co) -0.16710.075 -0.37910.059 -0.48810.058 -0.64410.087
n# 14 12 14 12
Kel (h r1) 0.172 0.025 0.024 0.022
t1#  (hr) 4.03 27.7 28.7 32.1
Vd (ml) 147 240 307 440
Cl (ml/hr) 25.3 5.99 7.43 9.51
Notes: * Slope and Constant are quoted ± Standard Error.
# n= number of points used in calculation.
The pharmacokinetic parameters calculated for IV and IP dosed rats were very similar 
over the beta phase. Like LA, rats dosed with 125I-CA by SC injection were found to 
have larger volumes of distribution than the other routes of administration and longer 
elimination half-lives. The distribution half-life calculated for IV dosed rats was longer 
than that calculated for LA. This may be due to a size selective restriction for transport 
from the blood stream, although the volumes of the central and tissue compartments 
were approximately the same.
Tables A3.6.2 and A3.6.3 list the percentage of 125I activity excreted in the urine and 
faeces of rats dosed with 125I-CA. Figure 3.6.2 is a plot of the percent 125I excreted in 
the urine versus time, for each of the routes. Between 29 and 46% of the 125I activity 
injected was excreted over 72 hours. This was less than for the LA dosed rats. A
-89-
Student’s t-test was used to compare the % excretion of 125I-LA at 72 hours (over all 
routes) with excretion of 125I-CA at 72 hours. The t-value was calculated to be 4.068. 
This value has a probability of less than 0.001 with 16 degrees of freedom and thus the 
excretion of 125I-CA is highly significantly different from 125I-LA. Faeces excretion 
accounted for between 7 and 11 % of the 125I dose over 96 hours.
The organ distribution of 125I activity was determined 24 hours after IV and SC 
injection of 125I-CA. The calculated data is listed in table A3.6.4. Figure 3.6.3 compares 
the organ distribution of IV and SC dosed rats. The results are expressed as a ratio of 
the activity in the whole organ divided by the activity in 1ml of blood. There was little 
difference between the 2 routes. No organ seemed to selectively accumulate the 
125I-CA. The slightly higher levels found in the gut may indicate that some of the 
protein had been broken down in the liver with release of 125I in to the bile. P. Goddard 
et aK14°) measured the organ distribution of a copolymer of N-acylethylenimine 
(molecular weight 29,300 which is similar to CA) and they found that like CA, there 
was no accumulation in the organs investigated.
3.4.4 Chicken Egg Albumin (CEA).
Chicken egg albumin was obtained from Sigma and it was already labelled with a 
14C-methyl group. CEA has a molecular weight of 45kD and was used as part of the 
range of proteins with increasing molecular weights.
The plasma concentrations determined following IV injection of 14C-CEA are shown in 
table A3.7.1. A graph of plasma concentration versus time is shown in figure 3.7.1. The 
plasma levels of 14C activity fell rapidly following IV injection. Over 24 hours two 
phases were seen. Although only 2 time points were used during the elimination phase, 
pharmacokinetic parameters were still calculated. Table 3.7 lists the pharmacokinetic 
parameters calculated for 14C-CEA after IV injection in rats.
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Table 3.7: The Pharmacokinetic parameters calculated following IV administration
of 14C-CEA to rats.
Alpha phase Beta phase
Time span 0.5-6 hours 6-24 hours
R2 0.9400 0.6527
m* (h r1) -0.356±0.0519 -0.013510.0049
c* (Log Co) 0.26610.176 -0.79010.0859
n# 15 6
Kel (h r1) 0.820 0.0311
t1/2 (hr) 0.845 22.3
Vd (ml) 54.2 616.9
Cl(ml/hr) 44.4 19.2
Notes: * Slopes and constants are quoted ± Standard Error.
# n= number of points used in each calculation.
The half-life for the alpha phase was very rapid at 50 minutes. The Vd for the alpha 
phase was smaller than for the other proteins administered. CEA has a molecular weight
of 45,000 and its access out of the blood stream appeared to be restricted compared to
LA and CA. The elimination half life was very similar to that calculated for LA. CEA 
had a larger Vd for the tissue compartment than CA and LA. This may be the result of 
increased cellular uptake. Organ distribution for this protein was not determined 
however, thus the reason for the larger Vd cannot be established.
Table A3.7.2 lists the urine excretion of 14C activity following administration of 
14C-CEA. The urine excretion of 14C activity was extremely low with less than 4% 
being excreted in 144 hours. This is the reverse of what was expected because of the
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rapid loss of activity from plasma. CEA has a molecular weight which is is just small 
enough to be excreted unchanged by the kidney/56) The low excretion of 14C activity 
may be because the amino acid that had been labelled with 14C-methyl in the CEA had 
been reutilised following the breakdown of the protein.
3.4.5 BSA
BSA has a molecular weight of 66296D. Again it was administered to rats as one of the 
series of proteins with a range of molecular weights, to investigate the effects of 
molecular weight on pharmacokinetics and rate of transfer from SC and IP sites. In 
section 3.5, experiments which investigate the possibility of BSA causing an immune 
response in the rat are described.
125I-BSA was administered to rats by each of the three routes. The results obtained for 
the serum concentration of 125I activity are listed in table A3.8.1 Figure 3.8.1 is a plot 
of Log % of 125I dose remaining per ml of serum versus time. Following IV 
administration the plasma clearance followed a biexponential model. The two phases 
were explained by distribution and elimination, as for LA. Absorption from the IP 
injection site occurred more slowly than it did for LA and CA, with peak plasma levels 
occurring 6 hours after administration. Absorption from the SC injection site was 
slower, with peak plasma levels occurring between 11 and 22.5 hours after injection. 
The major factor for the slower rate of absorption of BSA, compared to LA and CA, is 
probably its relatively large molecular weight. BSA with a molecular weight of 66296 
could not be absorbed directly into the blood stream following SC and IP 
administration. Instead it would have been taken up by the lymph and from there it 
would have been transferred to the blood stream.
Pharmacokinetic parameters were calculated using the linear section of Figure 3.8.1. In 
addition parameters were calculated for the alpha phase following IV administration. 
These parameters are listed in Table 3.8.
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Figure 3.8.1:
Serum concentration of 12T activity following administration 
of 5mg of 125I-BSA to rats by IV, IP and SC routes.
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Figure 3.8.2:
Percent of12̂  activity excreted in the urine following 
administration of 5mg of 12T-BSA to rats by IV, IP and SC routes. 
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Table 3.8 The Calculated Pharmacokinetic Parameters for 125I-BSA.
IV (alpha) IV (beta) IP (beta) SC (beta)
Time span 0.75-6hr 23.5-97hr 22.5-97hr 22.5-97hr
R2 0.9190 0.9621 0.9638 0.9818
m* (h r1) -0.0894±0.012 -0.0135±0.0008 ~0.0137±0.0007 -0.0125±0.0004
c* (Log Co) 0.723±0.043 0.575±0.0488 0.587±0.0481 0.392±0.024
n# 7 14 15 18
Kel (h r1) 0.205 0.0311 0.0316 0.0288
t1/2(hr) 3.366 22.29 21.96 24.07
Vd (ml) 18.92 26.61 25.88 40.55
Cl (ml/hr) 3.88 0.827 0.817 1.168
Notes: * Slopes and constants are quoted ± Standard Error.
# n= number of points used in the calculation.
The pharmacokinetic parameters calculated for the elimination phase for each of the 
routes of administration were very similar. 125I-BSA had a very small volume of 
distribution and thus its access into extra-vascular sites appeared to be restricted. The 
calculated volume of distribution was approximately one tenth of CA and LA. The 
half-life of elimination correlated with the reported results that 50-60% of endogenous 
rat albumin is catabolised d a ily .O 41) The alpha phase half-life was similar to the one 
determined by F le s s n e r /142) of 188 minutes, in anaesthetised female Sprague Dawley 
rats.
Tables A3.8.2 and A3.8.3 list the percentage of radioactivity excreted in the urine and 
faeces of rats dosed with 125I-BSA. The percentage excreted in the faeces is roughly 
equal for each route of administration at approximately 7% of the total dose in 96
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hours. Figure 3.8.2 is a plot of % 125I excreted in the urine versus time. The urine 
excretion of 125I activity was between 15 and 19% in 24 hours. The urine excretion for 
all 3 routes of administration for BSA was compared to the urine excretion of CA 
(across all routes) at 24 hours and was significant using Student’s t-test (probability of 
between 0.05 and 0.02). Thus there was a significant difference between BSA and CA 
excretion at 24 hours. This is because CA, with a molecular weight of 29kD, is 
probably small enough to be excreted unchanged by the kidney.
The organ distribution of 125I activity was determined at 25 hours and 97 hours for IV 
and SC dosed rats and at 97 hours for IP dosed rats. Figure 3.8.3 compares the organ 
distribution determined for IV and SC dosed rats at 25 hours. The results in this figure 
are expressed as a ratio of activity found in the whole organ divided by activity in 1ml 
of whole blood. 125I did not appear to accumulate in any organ apart from the thyroid 
gland (actual percentage in the thyroid was 4.95±1.13% for 4 rats). This indicates that 
some of the protein had been broken down, with the release of unconjugated 125I. The 
levels found in the gut were slightly higher than in the other organs. This was probably 
due to biliary secretion. These results are similar to the organ distribution desribed by 
Takakura et al for iodinated albumin in mice/76! There appeared to be no difference 
between the distribution in IV and SC dosed rats. At 97 hours the ratios calculated were 
similar to those of 25 hours.
3.4.6 Human Serum Albumin (HSA).
125I-HSA was obtained in a radio-iodinated form from Amersham. It was used, initially, 
as a check to ensure that the chloramine T method used to iodinate the BSA at Bath, 
had not led to damage of the protein. If it had, then following administration of the two 
proteins, different pharmacokinetics would be seen. Also, the pharmacokinetics were 
compared to the other proteins administered.
The concentration of 125I-HSA was determined in whole blood for each of the routes of 
administration. The results obtained are listed in Table A3.9.1. Figure 3.9 is a plot of 
Log whole blood concentration versus time for each of the routes. The plot is similar to 
that obtained for BSA. Following IV administration a biexponential clearance was seen.
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Organ Distribution of 125I activity following administration of 
5mg of 125I-BSA to rats by IV and SC routes. Analysis was determined 
25 hours post injection from 2 rats for each route.
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Absorption from IP sites was rapid with peak plasma levels being achieved within 3 
hours of administration. Following SC injection peak plasma levels were reached 
between 23 and 30 hours after administration. Table 3.9 lists the pharmacokinetic 
parameters calculated for the 125I-HSA for each of the three routes.
Table 3.9 Pharmacokinetic Parameters calculated for 125I-HSA administered to
rats by IV, IP and SC injection.
IV (alpha) IV (beta) IP (beta) SC (beta)
time span 3-23.5hr 23.5-149 23.5-149hr 30.5-149hr
R2 0.9823 0.9682 0.9047 0.9003
m* (h r1) -0.065910.004 -0.011510.0006 -0.011810.0011 -0.0088410.00088
c* (Log Co) 0.61710.062 0.16410.047 0.17810.086 -0.03810.072
n# 6 18 18 16
Kel (h r1) 0.152 0.0266 0.0271 0.0204
t^flir) 4.57 26.08 25.57 33.97
Vd (ml) 24.15 68.55 66.37 109.2
Cl (ml/hr) 3.67 1.823 1.799 2.228
Notes: * Slopes and Constants are quoted ± Standard Error.
# n= number of points used in calculation.
The pharmacokinetic parameters calculated for the elimination phase of IV and IP 
dosed rats were very similar. They were also similar to those calculated for BSA which, 
assuming that the 125I-HSA had not been damaged during production at Amersham, 
suggests that the BSA was not damaged during the chloramine T iodination procedure. 
The volumes of distribution were larger for the HSA dosed rats than for BSA dosed rats 
because the parameters had been calculated using whole blood rather than serum data.
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3.4.7 Rat Serum Albumin (RSA).
RSA was administered, to compare the pharmacokinetics in the rat to those calculated 
for BSA. Since BSA is a foreign protein in the rat, there is a possibility that it could 
lead to an immune response following injection. If an immune response was 
precipitated by BSA then its fate would be different to RSA. In section 3.5 further 
experiments are described, which would also determine whether BSA was immunogenic 
in the rat.
RSA was administered to rats at a dose of 5mg by IV, IP and SC routes. In addition it 
was administered to rats at a dose of 20mg, by IV injection only. Table A3.10.1 lists 
the serum levels determined for the 5mg dose for each route of administration. Table 
A3.11.1 lists the serum and whole blood concentrations determined for the 20mg dose 
of 125I-RSA. Figure 3.10.1 is a plot of Log 125I activity remaining in serum versus time 
for the 5mg dose. The plot is very similar to those obtained for BSA and HSA. Peak 
serum levels were achieved approximately 4 hours after IP administration and between 
7 and 19 hours of SC injection. Following the absorption phase, the serum levels of IP 
and SC dosed rats closely mirrored the serum levels of IV dosed rats. Pharmacokinetic 
parameters were calculated for each of the routes of administration for the 5mg dose. 
They are listed in table 3.10.1.
Table 3.10.1 The Pharmacokinetic parameters calculated for rats dosed with 5mg
of 125I-RSA by IV, IP and SC injection.
IV (alpha) IV (beta) IP (beta) SC (beta)
time span (hr) 0.25-7.25 18.75-97 18.75-97 30-97
R2 0.9130 0.9628 0.9297 0.8601
m* -0.095710.0104 -0.007810.0004 -0.007410.0005 -0.00810.0009
c* 0.81810.0401 0.44610.0223 0.45110.031 0.43710.059
n# 10 20 19 20
Kel (h r1) 0.220 0.0180 0.0170 0.0186
t1/2 (hr) 3.144 38.38 40.66 37.26
Vd (ml) 15.20 35.81 35.40 36.56
Cl (ml/hr) 3.34 0.644 0.602 0.680
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Notes for table 3.10.1: * Slopes and Constants are quoted ± Standard Error. # n= 
number of points used in each calculation.
The pharmacokinetic parameters calculated for the elimination phase for each route of 
administration were very similar. The elimination half-life calculated for RSA was 
longer than for BSA. These results are consistent with those determined by Matsumura 
and M a e d a / 143) They found that mouse serum albumin had a slightly longer half-life 
than BSA when injected into the mouse but that both proteins had a similar pattern for 
organ distribution.
Figure 3.10.2 is a plot of Log % 125I remaining per ml of serum against time for the 5 
and 20mg dose of 125I-RSA administered by IV injection. The % dose remaining/ml for 
the 5mg dose appeared to be lower than the 20mg dose. The pharmacokinetic 
parameters were calculated for both whole blood and serum data for the 20mg dose. 
They are listed in table 3.10.2.
Table 3.10.2 Pharmacokinetic Parameters for the 20mg dose of 125I-RSA.
Whole Blood 
IV (alpha) IV (beta)
Serum
IV (alpha) IV (beta)
Times span 0.25-6.75 23.5-168 0.25-6.75 23.5-168
R2 0.8975 0.9626 0.9303 0.9838
m* (h r1) -0.06610.009 -0.006510.0004 -0.06810.0078 -0.006310.0003
c* (Log Co) 0.60990.0367 0.42810.0356 0.93010.031 0.67910.0226
n# 8 12 8 12
KeKhr1) 0.151 0.0149 0.157 0.0145
t^flir) 4.587 46.51 4.425 47.69
Vd (ml) 24.60 37.32 8.511 20.94
Cl (ml/hr) 3.715 0.556 1.336 0.304
Notes: * Slopes and Constants are quoted ± Standard Error.# n= number of points 
used in the calculation.
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Figure 3.10.1:
Log %125I remaining/ml of serum following administration of 
5mg oft-RSA by IV, IP and SC routes.
Each point is from one rat. n=8 for each route.
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IV route.
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The pharmacokinetic parameters calculated using whole blood data and serum data 
were very similar, indicating that the RSA did not accumulate in the cellular component 
of blood. Volumes of distribution calculated using whole blood data were double those 
calculated using serum data. This may be attributed to the haematocrit of the rat. The 
elimination half life calculated for the 5mg dose of RSA (38.4 hours) was shorter than 
the 20mg dose (47.7 hours) and the volume of distribution was slightly larger for the 
5mg dose. This was explained by the lower serum levels seen during the elimination 
phase, (see figure 3.10.2) The volume of distribition for the alpha phase following 
administration of 20mg of RSA and using serum data was found to correspond to the 
serum volume which has been quoted for male wistar ratsO44).
The urine excretion of 125I activity following administration of 5mg of 125I-RSA is 
shown in table A3.10.2. Between 31 and 37% of the 125I dose was excreted over 96 
hours. The percentage excreted was lower than for the other proteins administered. 
Table A3.11.2 shows the percentage 125I excreted following administration of a 20mg 
dose of 125I-RSA. Figure 3.10.3 compares % 125I excreted in the urine against time for 
IV administered RSA at doses of 5mg and 20mg. There was no significant difference in 
the percentage of 125I excreted between the two doses administered.
Organ distribution of 125I activity was determined for the 5mg dose of 125I-RSA at 96 
hours after administration. The results are listed in table A3.10.3. Figure 3.10.4 is a 
histogram showing the whole organ distribution of 125I activity 96 hours after IV 
injection. The thyroid appeared to be the only organ investigated that accumulated 125I 
activity. The activity in the other organs could be attributed to that present within the 
blood of the organ. For the other routes of administration a similar distribution of 125I 
was seen.
3.4.8 Summary for the protein data.
It was decided to use an 125I- label for detection of proteins in vivo, for a number of 
reasons. The first reason was the ease of the labelling procedure, with well established 
methods for the chloramine T labelling protocol. Secondly both 14C and 3H labels were
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Figure 3.10.3:
Percentage 125I activity excreted following administration of 
5mg or 20mg of 125I-RSA to rats.
Each point is a mean ± S.E.M. (n=4 for 5mg, n=3 for 20mg)
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Figure 3.10.4:
Organ Distribution of 125I activity 96 hours after administration 
of 5mg of 125I-RSA by IV injection.
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excreted more slowly by rats than expected for the solute to which they were bound, 
(see MTX and CEA experiments).
Margen and Tarver^145) established guidelines for the ideal tracer molecule. These 
include, firstly, that the tracer should not alter biological activity of the protein. The 
tracer should have a high specific activity so that only a small quantity is required. It 
should be a long-lived isotope so that problems with stability are not encountered. 
Labelling should be uniform since heavily labelled proteins may behave like a different 
species. The isotope should not be reincorporated into endogenous proteins after 
metabolism and it should be rapidly excreted after metabolism.
125I appeared to fit in with these guidelines. It has a half life of 60 days so no stability 
problems would be encountered. When it was administered as 125I-Na, it was found to 
have a very rapid initial half-life following IV administration to the rat. During this 
phase serum levels fell to 0.3% of the injected activity/ml. An organ distribution study 
showed that the 125I activity accumulated in the thyroid but not in the liver or kidney. 
Approximately 46% of the injected dose was excreted in the first 24 hours after 
injection.
Another advantage of using the 125I isotope for protein labelling is that organ samples 
can be analysed directly without any further preparation, whereas both 14C and 3H 
activities are quenched in biological samples and so a solubilisation and decolourisation 
step would be required before analysis.
Figure 3.11.1 is a plot of Log serum concentration against time for 125I labelled RSA, 
BSA, CA and LA after IV administration. All of these proteins had a biexponential 
serum clearance. The first phase could be explained by distribution throughout the 
blood stream and into the rapidly equilibrating (central) compartment. The second phase 
was explained by distribution into the slowly equilibrating (tissue) compartment and 
elimination. Table 3.11 summarises the pharmacokinetic data calculated for these 
proteins after IV injection.
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Figure 3.11.1:
Concentration of 12J activity in serum following IV administration 
of 5mg of 125l-labelled protein to rats.
Each point was obtained from a single rat. (n=8 for each protein).
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at times 3 5  
indicated
LA CA BSA RSA
Each bar is the mean of three rats.
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Table 3.11 Pharmacokinetic Parameters for 5mg doses of RSA, BSA, CA and LA.
Protein 
(mol wt)
(alpha phase) 
t1/2 (hr) Vd (ml)
(beta phase)
\>n (hr) Vd (ml)
RSA (63K) 3.14 15.20 38.38 35.81
BSA (67K) 3.37 18.92 22.29 26.61
CA (29K) 4.03 147.0 27.7 240.0
LA (14K) 0.943 111.0 21.60 236.0
HSA and CEA were not included in this table because they were not administered at a 
dose of 5mg per rat and thus direct comparison was not valid. RSA and BSA appeared 
to be very similar over the alpha phase. CA and LA had similar alpha phase Vd (147ml 
for CA and 111ml for LA) which were approximately five times those of BSA and 
RSA (15.2 and 18.9 ml respectively). LA had an extremely rapid distribution half-life 
(56.6 minutes), indicating that it could easily extravasate. Seymour et al<56) injected an 
HPMA co-polymer with a molecular weight of 12000 and found that it had a 
distribution half-life of only 3 minutes. The copolymer injected with a molecular weight 
of 40000 had a half life of 72 minutes and this is closer to the value determined for LA. 
The reason for the rapid clearance of the HPMA copolymer was due to urinary 
excretion. LA was not excreted to the same extent as the polymer and therefore it is 
possible that LA was reabsorbed in the kidney tubule.
RSA gave the longest elimination half-life (38.4 hours). The other proteins were of 
bovine origin and therefore may be metabolised more quickly. (See section 3.5). LA 
had the shortest elimination half-life (21.6 hours), although this was longer than 
anticipated because it is small enough to be excreted unchanged by the kidney.
There appeared to be a size selective rate of transfer of proteins from SC and IP sites. 
For LA and CA peak plasma levels were achieved within 1 hour of administration after 
both routes of injection (see figures 3.5.1 and 3.6.1) and thus it would appear that these
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proteins were absorbed directly into the blood stream from the injection sites. On the 
other hand, for RSA and BSA, peak plasma levels did not occur until 4 hours after IP 
administration, and between 10 and 20 hours after SC injection. This would suggest that 
these proteins are mainly absorbed into the lymph from the injection site and then are 
transferred into the blood stream. Supersaxo et aK146) demonstrated a size selective 
accumulation of proteins in the lymph of sheep, following SC administration. They 
believed that proteins of molecular weight above 16kD were absorbed mainly by the 
lymphatics from this site. In this experiment, it appeared that CA, of molecular weight 
29000, was absorbed directly into the blood stream since peak plasma levels were 
achieved within 1 hour of administration. However the larger proteins did appear to 
undergo lymphatic absorption from both IP and SC sites. The rapid appearance of CA 
in the blood stream could also be due to a rapid uptake by the lymphatics, followed by 
a fast transfer from the lymphatic ducts into the blood vasculature.
Absorption from IP sites occurred more rapidly than SC absorption because there is a 
larger surface area from which absorption can occur in the peritoneal cavity than at the 
SC site of injection. The rates of transfer from IP and SC sites are consistent with the 
results obtained by Seymour et al.<56> They found with their HPMA copolymers that 
peak plasma levels were achieved approximately 4 hours after IP administration and 24 
hours after SC injection.
LA and CA had large volumes of distribution for both the alpha (111 and 147 ml) and 
beta phases (236 and 240 ml) and thus appeared to be widely distributed throughout the 
body. RSA and BSA had much smaller volumes of distribution during both phases 
(35.8 and 26.6 ml for the beta phase) suggesting that they are mainly confined to the 
vasculature, probably due to their higher molecular weight.
Of the proteins investigated, LA showed the greatest rate of excretion in the urine and 
CA was excreted more rapidly than BSA and RSA. This is because both LA and CA 
have a molecular weight low enough to be excreted unchanged in the urine. Figure 
3.11.2 is a histogram comparing the urine excretion of each of the proteins at 24 hours 
after injection and at 96 hours after injection.
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Organ distribution was determined for each of the proteins. There was no significant 
accumulation of 125I activity in any organ investigated (apart from the thyroid) for any 
of the proteins.
3.5 Feasibility of using BSA as a Drug-Carrier in the Rat.
In Chapter 4 a series of experiments, using BSA as a model carrier for MTX, to 
evaluate the effects of the protein on the pharmacokinetics of the free drug are 
described. Before these experiments were performed, it seemed prudent to first 
investigate the suitability of using BSA as a carrier in the rat. The elimination half-life 
after IV injection for 125I-BSA was found to be shorter than that of 125I-RSA, at 22.3 
hours for BSA and 38.4 hours for RSA, although the volumes of distribution were 
similar. Several factors could contribute to the more rapid plasma clearance of BSA.
1. Injection of a foreign protein into male wistar rats may lead to an inflammatory 
reaction with increased vascular permeability and excessive leakage of proteins out of 
the blood compartment into the tissues. Endogenous proteins as well as foreign proteins 
would be affected by this.
2. It has been documented that injection of extra albumin may lead to an increase in the 
rate of protein catabolism until the levels return to normal/147)
3. The BSA may have been recognised by the rat as a foreign protein and removed 
from the bloodstream by normal defence mechanisms without actually causing an 
inflammatory response. This would not affect endogenous protein levels.
Three experiments were carried out in order to verify whether bovine proteins were 
suitable candidates as drug carriers in the rat. The first involved the administration of 
increasing doses of BSA to the rat followed by an analysis of the total protein 
concentration of rat serum at timed intervals. If injection of BSA had led to an increase 
in the rate of protein catabolism until protein levels were adjusted to normal then this 
could be identified using this technique. The maximum dose of BSA that was injected 
was 80mg and this would represent an increase in serum protein concentration of
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approximately 12.5%. In addition, if injection of BSA had led to an increase in vascular 
permeability resulting in protein leakage, this could also be detected using the above 
method.
The second experiment involved the administration of Evan’s Blue, a dye which is 
highly plasma protein bound. Under normal circumstances, Evan’s Blue is lost only 
slowly from the vasculature, at the same rate as the leakage of plasma proteins. 
However, during the inflammatory response, post-capillary venules become leaky/19) 
allowing the escape of plasma proteins along with any dye which may be bound to 
them. The plasma elimination half-life of injected Evan’s Blue was compared to that of 
the dye injected with a 20mg dose of BSA. This would determine whether injection of 
BSA had led to an inflammatory response.
The final experiment determined whether male wistar rats under normal circumstances 
had an antibody against BSA. This utilised a blot test. BSA was pipetted onto a 
nitrocellulose sheet, incubated with rat serum, washed, and then incubated with an 
antibody raised against rat immunoglobulin G (IgG) linked to peroxidase. If there was 
an anti-BSA IgG present in rat plasma then a dark spot would appear on the 
nitrocellulose sheet.
3.5.1 Administration of BSA.
Total protein concentration was determined for the three groups of rats at 2, 4 and 7 
hours. The results obtained are listed in table A3.12.1. Figure 3.12 is a graph of serum 
protein concentration against time for the three groups. This plot also shows the normal 
range of protein concentration determined using 10 control rats. (Normal range was 
68mg/ml to 108mg/ml, mean = 87.2mg/ml and standard deviation was 14.58).
A Student’s t-test was used to compare the serum protein concentrations for each group 
of rats at each time point. The t values and probabilities obtained are listed in Table 
3.12.
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Table 3.12 The t-values determined by comparing the untreated rat group with the
BSA and Saline treated group.
Time
(hr)
BSA vs Untreated Saline vs 
Untreated
BSA vs Saline
2 t 0.6 1.47 1.65
P 0.5632 0.1798 0.1382
4 t 1.43 1.40 0.09
P 0.1900 0.2003 0.9295
7 t 1.72 1.32 0.44
P 0.1234 0.2231 0.6685
All t values were non-significant. Thus administration of 20mg of BSA does not alter 
the total serum protein concentration in male wistar rats. The experiment was repeated 
using 40 and 80mg doses of BSA with similar results.
3.5.2 Evan's Blue.
The serum concentrations determined in rats injected with lmg of Evan sv Blue (group 
1) or lmg of Evan s* Blue plus 20mg of BSA (group 2) are shown in table A3.13.1. The 
serum concentrations versus time are shown in Figure 3.13. The serum concentrations 
determined for the 2 groups were very similar. The plasma clearance data was 
biexponential in both cases and pharmacokinetic data were calculated for both phases. 
These data are listed in Table 3.13.
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Figure 3.12: Total Serum Protein Concentration versus time for Control Rats 
(groupl, untreated), Saline treated rats (group 2) and rats treated with 20mg of 
BSA (group 3). Each point is a mean (n=5) ± S.E.M.
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untreated 
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112.5
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Figure 3.13: Concentration of Evan's Blue in rat plasma following 
administration of lm g of dye alone (group 1) or lmg of dye plus 20mg 
of BSA (group 2)Each point was determined from one ra t
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Table 3.13: The Pharmacokinetic Parameters Calculated in rats injected with
Evans Blue alone and Evans Blue plus 20mg of BSA.
EB only EB + BSA
L. Alpha Phase.
Time span (hr) 0.33-6 0.33-6
R2 0.5727 0.5714
m* (h r1) -0.13710.0528 -0.28210.0924
c* 0.37910.102 0.28110.205
n# 10 12
Kel (h r1) 0.316 0.649
t^2 (hr) 2.193 1.067
Vd (ml) 41.78 52.36
Cl (ml/hr) 13.20 33.98
2. Beta Phase
Time span (hr) 7.5-28.5 7.5-28.5
R2 0.9854 0.9569
m* (h r1) -0.024410.0015 -0.027310.0029
c* 0.65310.0326 0.65410.0635
n# 6 6
Kel (h r1) 0.0562 0.0629
t1#  (hr) 12.33 11.02
Vd (ml) 22.23 22.18
Cl (ml/hr) 1.249 1.395
Notes: *Slopes and Constants are quoted ± Standard Error.
# n= number of points used in each calculation.
The parameters calculated for the elimination phase for groups one and two were 
similar. For the distribution phase the Vd is slightly larger for the Evans Blue plus 
BSA. This may be due to an error which occurred during the injection of the rats. The 
injection solution containing BSA was very viscous and some of the solution may have 
been left in the syringe. In addition, the distribution half life was found to be shorter for 
the Evans Blue plus BSA group. However, because of the very low regression 
coefficients for the slopes used in the calculation of the parameters for the distribution 
phase, a great deal of error has been introduced and so the values calculated could vary 
within large limits.
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To evaluate if injection with BSA increased the plasma clearance of Evan's Blue (this 
could be the result of an inflammatory response making the vascular bed more 
permeable to plasma proteins) an analysis of variance comparing the slopes of the Log 
serum concentration versus time plots for the two groups was performed. A separate 
analysis of variance was calculated for both the distribution and elimination phases. If 
the slopes were found to be parallel then this would indicate that the BSA had not 
increased the loss of Evan's Blue from plasma.
The method used for the analysis of variance,” test for parallelism” was described by 
Wardlaw. O48) For the distribution phase the log serum concentrations at 20 minutes 
and 4 hours were used. The method for calculating the F values for this test are 
described in Appendix 2.2. The F value calculated for parallelism was 1.91 for the 
distribution phase. The tabulated F value from variance ratio tables is 10.13 for 1 and 3 
degrees of freedom at 5% probability. This indicates that there is no deviation from 
parallelism for the two groups.
For the elimination phase the time points used were 6 hours and 24 hours. The 
calculated F value for parallelism was 1.29. This again indicates that the two lines were 
parallel.
For both the distribution and elimination phases the graphs of log10 serum Evan's Blue 
concentration versus time for the 2 groups were parallel. Thus a 20mg dose of BSA 
does not increase the vascular permeability to Evan’s Blue.
3.4.3 Blot test to determine antigenicity of BSA in rat serum in vitro.
Incubation of BSA with rat serum did not result in a black spot after a further 
incubation step which included peroxidase linked anti-rat IgG. Thus normal rat serum 
does not have an antibody to BSA.
The experiments described in this section have established that BSA on a single 
application does not induce an inflammatory response in the rat. Thus it is a suitable 
candidate as a soluble macromolecular carrier for anti-cancer drugs.
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CHAPTER 4:
ANALYSIS AND PHARMACOKINETICS OF PROTEIN-MTX CONJUGATES
IN THE RAT.
-114-
In chapter 3 the pharmacokinetics of MTX and the free proteins were determined. In 
this chapter covalent conjugates between MTX and BSA, RSA or LA were investigated 
in a similar manner. All calibration curves used in the calculation of values in this 
chapter are shown in Appendix 1. All tables of data are listed in Appendix 3. These 
tables have the prefix A. The methods used for calculation of pharmacokinetic data are 
shown in Appendix 2.
4.1 Conjugate Analysis.
4.1.1 FPLC Analysis
The superose 12 column was calibrated using a series of proteins of known molecular 
weight immediately prior to analysis of the conjugates (A1.3). Figure 4.1a shows a 
typical chromatogram obtained for standard BSA (500pg/ml in PBS) on the superose 
column. BSA had two distinct peaks. The larger peak (93.3% of the total area) with an 
elution time of 15.5 minutes corresponded to monomeric BSA. The small peak (6.7% of 
total area) with a retention time of 13.75 minutes was thought to be due to dimers or 
larger protein aggregates of BSA. Figure 4.1b shows the chromatogram obtained for a 
typical conjugate. The conjugate chromatogram was very similar to that of ‘free* BSA, 
again there was an initial peak which was thought to be due to protein aggregates. This 
was slightly larger than for BSA (22.1% of total area). There was also a slight 
displacement to a quicker elution time indicating that the conjugate had a slightly 
higher molecular weight. In addition this peak was broader than for BSA. Following 
injection of the conjugates on to the column, data was captured on an Acorn BBC 
Master Computer. One thousand points were registered by the computer over a 45 
minute period. The computer was programmed to calculate the area occupied by the 
peaks. The chromatogram was first divided manually into 2 sections, so that the major 
(monomeric) peak was separated from the preceding peak (see dotted lines on figure 
4.1b). A read-out was then obtained for the proportion of conjugate which was present 
as aggregates and the proportion which was present as single molecules.
Table 4.1. lists the conjugates which were analysed by FPLC. It gives the proportional
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Figure 4.1a The Chromatogram 
obtained for BSA after injection 
onto the Superose 12 column and 
detection at 280nm. Flowrate= 
0.83ml/minute. Chart Speed= 2mm/ 
minute. Mobile phase = PBS. Con­
centration = 500pg/ml.
Peak 1 had an elution time of 13 
minutes and 45 seconds and peak 2 
had an elution time of 15 minutes 
and 27 seconds.
Figure 4.1b The Chromatogram 
obtained for BSA-MTX (11.76%w/ 
w) after injection onto the Superose 
12 column. Conditions as above.
Peak 1 had an elution time of 13 
minutes and 34 seconds. Peak 2 had 
an elution time of 15 minutes and 
11 seconds.
-116-
area for each of the peaks and the computer calculated weight average molecular weight 
for each of the fractions.
Table 4.1. FPLC analysis of the conjugates.
Conjugate
(%w/w)
Peak 1 
Area
Wt. Average 
Mol Wt
Peak 2 
Area
Wt.Average 
Mol Wt.
calculated 
Mol Wt.
frt BSA and BSA-MTX.
0 (free BSA) 6.67 140-120K 93.33 67000 66296
4.54 23.09 172K 76.91 71740 69153
9.18 32.32 205K 67.68 72830 72376
11.55 33.03 202K 66.97 74523 74143
11.74 34.65 203K 65.35 74891 74269
11.76 22.08 175K 77.92 73765 74274
13.63 39.04 236K 60.96 76560 75779
13.64 36.36 235K 63.64 77030 75788
b) RSA-MTX.
6.94 18.40 154K 81.60 67590 67262
The increase in the size of peak 1 (due to aggregated protein) seen in the conjugates 
could be attributed to the mode of preparation of the conjugate. One of the problems 
associated with the use of carbodiimide coupling reagents is that they can cause 
interaction between neighbouring protein molecules, and thus protein aggregates are 
produced. In every conjugate synthesised there was a peak, determined by FPLC, which 
could be attributed to protein aggregates. On average it was a protein dimer or trimer 
that was produced (molecular weight of BSA dimer is 134000D). Although this peak
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was also present in ‘free’ BSA, it represented a much smaller proportion (6.7%) of total 
protein than it did in the conjugates (18 to 39%). These results are consistent with those 
reported by Halbert and Florence for their BSA-MTX conjugates/149) They analysed 
their conjugates, which were prepared by a similar ECDI conjugation procedure, using 
SDS-PAGE and this technique gave similar profiles for the conjugates as did FPLC. As 
concentration of MTX in the conjugate was increased there appeared to be an increase 
in the amount of aggregate present. This was due to the fact that, for the high strength 
conjugates, there was more ECDI present in the reaction mixture. There is good 
correlation between the expected molecular weight of each of the conjugates and the 
computer calculated weight average molecular weight. They were within 3.6% of each 
other.
After synthesis of the conjugates, free MTX was removed using a gel filtration column 
which consisted of Sephadex G50. In theory gel filtration could be used to separate the 
protein aggregates from monomeric conjugates. However Sephadex G50 did not allow 
separation of the monomeric conjugate molecules from the aggregated protein 
molecules. They eluted together as one large peak. Although the aggregates could be 
separated on the Superose 12 column it was not feasible to separate the large quantities 
of conjugate that were produced in this way. Thus no correction was made for the 
aggregates in later experiments.
4.1.2 UV scans of the conjugates.
The UV scans of free MTX, BSA and LA were compared to scans for BSA-MTX and 
LA-MTX. Figure 4.2a shows the scan obtained for MTX, figure 4.2b shows the scan 
obtained for LA and figure 4.2c shows the scan obtained for LA-MTX. The scans 
obtained for BSA and for BSA-MTX were similar to those shown in figures 4.2b and 
4.2c respectively. Table 4.2 shows the Lambda max of the MTX, LA, LA-MTX and 
BSA-MTX.
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Figure 4.2a. The UV scan (460nm to 180nm) of MTX (20pg/ml) in 0.1 M NaOH.
Figure 4.2b. The UV scan (460nm to 180nm) of LA (lOOjjg/ml) in 0.1M NaOH.
180 460
Figure 4.2c The UV scan OF LA-MTX (4.52%w/w) in 0.1M NaOH.
/
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Table 4.2 The lambda max of MTX, LA, BSA, LA-MTX and BSA-MTX.
No of /max /max 1 /max 2 /max 3
MTX 2 375nm 305nm -
LA 1 280nm - -
BSA 1 280nm - -
LA-MTX 3 374nm 300nm 290nm
BSA-MTX 3 373nm 303nm 280nm
The conjugates were dissolved in 0.1M NaOH. Over the absorbance range covered the 
wavelengths of maximum absorbance for the conjugates were the same or ± lnm to 
those of free MTX. In the conjugate there was an additional small peak which 
corresponded to the protein portion of the conjugate. LA and MTX have peaks at a 
wavelength of 280nm and 305nm and in the conjugate the peaks at 300nm and 290nm 
were coincident. The peak at 375nm for MTX was not affected by conjugation with 
protein. Thus this wavelength was used to calculate the concentration of MTX in the 
synthesised conjugates (appendix 1.2 shows the calibration curve used to calculate 
MTX concentrations).
4.2 Pharmacokinetics of BSA-MTX conjugates.
The pharmacokinetics and organ distribution determined for each conjugate will be 
discussed individually. Section 4.5 summarises the results for BSA-MTX conjugates.
4.2.1 BSA-MTX (3.4%w/w).
Table A3.14.1 lists the plasma concentrations determined for 125I activity following 
administration of 125I-BSA-MTX (3.4%w/w) to rats by IV, IP and SC injection. These 
results are shown graphically in Figure 4.3. A plot of log serum concentration against
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Figure 4.3:
Plasma Concentration of 125I activity following administration of 
5mg of 1 2 5 I-BSA-MTX (3 .4%w /w ) to rats by IV, IP and SC routes. 
Each point was a single determination.
l.UUU
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remaining 0.750 
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Figure 4.4.1:
Serum Concentration of 125I activity following administration of 5mg
of 1 2 5I-BSA-MTX (5.1%w /w ) to rats by IV, IP and SC routes.
Each point was determined from one rat. (n= 8  for each route).
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time for IV dosed rats was biexponential. Absorption following IP injection was faster 
than for SC injection. Peak plasma levels were achieved within 4 to 7 hours of IP 
injection and within 23.5 to 26 hours of SC injection. Pharmacokinetic parameters were 
calculated for each of the routes of administration. These are listed in table 4.3.
Table 4.3 Pharmacokinetic Parameters Calculated for 125I-BSA-MTX (3.4 %w/w)
IV (alpha) IV (beta) IP (beta) SC (beta)
time span (hr) 0.5-6 23.5-48 23.5-96 23.5-96
R2 0.9691 0.9522 0.9635 0.9070
m* (h r1) -0.105±0.0103 -0.016110.0019 -0.014310.001 -0.011910.001
c* (Log Co) 0.75±0.038 0.45710.044 0.34910.0395 0.16110.054
n# 10 6 18 18
Kel (h r1) 0.410 0.0371 0.0329 0.0274
t1/2 (hr) 1.691 18.70 21.04 25.29
Vd (ml) 17.78 34.87 44.77 68.98
Cl (ml/hr) 7.289 1.29 1.48 1.99
after IV, IP and SC injection.
Notes: * Slopes and constants are quoted ± Standard Error.
# n= number of points used in each calculation.
The parameters calculated for the elimination phase were very similar for each route. 
Following SC administration the volume of distribution was larger than for the other 
two routes. This could be explained by incomplete absorption of the conjugate or 
uptake by cells at the site of administration.
The urine excretion of 125I activity was determined for all routes and is listed in table 
A3.14.2. Approximately 60 - 67 % of the 125I injected was excreted over 96 hours.
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4.2.2. BSA-MTX (5.1%w/w).
The serum concentrations of 125I activity determined for BSA-MTX (5.1%w/w) are 
listed in Table A3.15.1. Figure 4.4.1 is a plot of log serum 125I activity/ml against time 
for each route. Peak plasma levels were achieved between 10 and 23.5 hours after SC 
injection and between 5 and 7 hours after IP injection. Pharmacokinetic parameters 
were calculated for the three routes of administration. These are listed in table 4.4.
Table 4.4: The pharmacokinetic parameters calculated for BSA-MTX (5.1%w/w)
administered by IV, IP and SC routes.
IV (alpha) IV (beta) IP (beta) SC (beta)
Time span (hr) 1-7 23.5-97.5 23.5-97 23.5-97
R2 0.8256 0.9440 0.9619 0.9354
m* (h r1) -0.0796±0.015 -0.0141 ±0.001 -0.0156±0.0009 -0.015110.001
c* (log Co) 0.867±0.068 0.124±0.058 0.15110.053 0.15510.057
n# 8 14 14 16
Kel (h r1) 0.183 0.0325 0.0359 0.0348
t1/2 (hr) 3.780 21.32 19.29 19.93
Vd (ml) 13.58 75.16 70.63 69.98
Cl (ml/hr) 2.487 2.443 2.536 2.435
Notes: * Slopes and Constants are quoted ± Standard Error.
# n= number of points used in calculation.
The pharmacokinetic parameters calculated for the elimination phases were very similar 
after each route of administration. The half life for elimination at approximately 20 
hours is very similar to that determined for BSA. The calculated volumes of distribution 
(70 to 75ml) were larger than those calculated for BSA (26ml for the beta phase),
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Figure 4.4.2:
Percentage of 125I activity excreted in the urine following administration of 
5mg of 1 2 5 I-BSA-MTX (5.1%w/w) to rats by IV, IP and SC routes.
Each point is a mean ± S.E.M. (n=3).
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Figure 4.4.3:
Organ Distribution o f 1251 activity follow ing administration o f  5m g o f m I-BSA-M TX (5. l% w/w) 
to rats by the IV route. Results are expressed as a ratio o f  the activity found in the whole 
organ divided by the activity in 1ml w hole blood. Each histogram is the mean of 2  rats.
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indicating that the BSA-MTX (5.1%w/w) could more readily leave the vasculature and 
enter the tissue compartment.
Urine and faecal excretion of 125I activity were calculated following administration of 
125I-BSA-MTX (5.1%w/w) to rats by each of the three routes. These results for percent 
of 125I dose excreted in urine and faeces are listed in tables A3.15.2 and A3.15.3 
respectively. Figure 4.4.2 is a plot of the percentage radioactivity excreted against time. 
Percentage urine excretion was not significantly different for the three routes of 
administration. Approximately 70% of the injected dose was excreted in the urine over 
96 hours. Faeces excretion accounted for between 7 and 10% of the injected activity 
over 96 hours.
Organ distribution of 125I activity was determined 52 hours, 97.5 hours and 193 hours 
after administration for all 3 routes of injection. Figure 4.4.3 is a histogram showing the 
ratio of 125I activity in each tissue investigated divided by the activity in 1ml of whole 
blood, after IV administration of 125I-BSA-MTX (5.1%w/w) to rats. Each bar was the 
mean of the two animals investigated. The range for the rats is shown unless it was 
below 10%. The organ distribution was very similar at 52.5 hours and 97.5 hours. The 
125I activity did not appear to accumulate in any of the organs investigated apart from 
the thyroid. However at 193 hours after administration there appeared to be 
accumulation in the liver and the kidney. Since the whole blood concentration of 125I at 
this time point was only 0.008% of the injected activity, this would probably not have 
any physiological significance. For the other routes of administration the organ 
distribution was not significantly different from IV.
4.2.3. BSA-MTX (6.2%w/w).
The plasma concentration determined for 125I activity following administration of 
125I-BSA-MTX (6.2%w/w) to rats by IV, IP and SC injection are listed in Table 
A3.16.1 and are represented graphically in Figure 4.5.1. Peak plasma levels were 
reached within 11 hours of SC administration and within 2 hours of IP administration. 
Pharmacokinetic parameters were calculated for each route of administration and these
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are listed in Table 4.5.
Table 4.5: The pharmacokinetic parameters calculated for BSA-MTX (6.2%w/w) 
administered to rats by IV, IP and SC injection.
IV (alpha) IV (beta) IP (beta) SC (beta)
time span (hr) 0.5-6.5 22.5-96 22.5-96 22.5-96
R2 0.9732 0.9764 0.9211 0.9571
m* -0.104±0.007 -0.0176±0.0007 -0.0164±0.0013 -0.015210.0008
c* 0.729±0.028 -0.0963±0.038 -0.0976±0.068 -0.13410.0045
n# 8 17 16 16
Kel (h r1) 0.239 0.0405 0.0378 0.0349
t1/2 (hr) 2.893 17.12 18.31 19.85
Vd (ml) 18.67 124.8 125.2 136.1
Cl (ml/hr) 4.462 5.055 4.732 4.750
Notes: * Slopes and constants are quoted ± Standard Error.
# n= number of points used in the calculation.
The parameters calculated for the elimination phase were very similar for each of the 
routes of injection investigated. The plasma elimination half-lives were slightly shorter 
than those calculated for BSA-MTX (5.1%w/w). The volume of distribution represented 
approximately half the body weight of the rat for the 6.2%w/w conjugate.
The urine and faecal excretion of 125I were determined for each of the routes of 
administration. These results are listed in tables A3.16.2 and A3.16.3 respectively. 
There was no significant difference for percent 125I dose excreted for each of the routes 
of administration. Approximately 40-48% of the injected 125I dose was excreted in the
urine over 96 hours and approximately 7% of the 1251 dose was excreted in the faeces in
96 hours.
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Figure 4.5.1:
Plasma Concentration o f12̂  activity following administration 
of 5mg of 1 2 5I-BSA-MTX (6.2%w/w) to rats by IV, IP and SC routes. 
Each point is from one rat. (n= 8  for each route).
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Figure 4.5.2: The ^ 1  activity of 1ml fractions eluted 
from a Sephadex G25 column to which had been applied a sample of 
urine collected for a period of 24 hours after administration 
of ^-BSA-MTX (6.2%w/w) to a rat by IV injection.
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Blue dextran eluted in fractions 2 and 3 and DNP eluted in fractions 13 to 20.
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Molecular Weight Determination of the 125T component o f Urine.
To samples of 24 hour and 72 hour urine obtained from IV dosed rats, an equal volume 
of a solution containing blue dextran (relative molecular weight 2 x 106) and 
2,4-dinitrophenylalanine (DNP) was added. This solution was passed down a 10ml gel 
filtration column consisting of Sephadex G25. The mobile phase was water and elution 
occurred under gravity. As the blue dextran started to elute, 1ml fractions were 
collected until all the DNP had eluted. Each fraction was then measured in a gamma 
counter. Figure 4.5.2 shows the elution profile for a 24 hour sample of urine. The 
majority of 125I eluted in fractions 5 to 9. The blue dextran eluted in fractions 2 and 3 
and the DNP eluted in fractions 13 to 20. The molecular weight range for resolution for 
the Sephadex G25 is 5000 to 1000 molecular weight. Since the elution of the 125I 
activity occurred before the inclusion volume of the column (fractions 13 to 20) it 
would appear that it was conjugated to polypeptide fragments (of between 5000 and 
1000 molecular weight) of the original BSA-MTX conjugate. The 72 hour urine 
samples showed a similar profile to the 24 hour samples.
The organ distribution of 125I activity was determined at 24, 96 and 171 hours after 
administration of the conjugate. The results are listed in Table A3.16.4. Figure 4.5.3 is a 
histogram showing the ratio of activity in lg of organ divided by the activity in 1ml of 
whole blood for IV dosed rats at each time point. At 24 hours the activity in all organs, 
apart from the kidney, was low and represented the blood activity in each case. The 
proximal tubule of the kidney is known to exhibit a high protein uptake and this may 
explain why the kidney at 24 hours showed accumulation of the 125I activity. As 
demonstrated by the urine gel filtration experiment, the 125I excreted in the urine was 
conjugated to oligopeptides of molecular weight between 1000 and 5000. These may 
have been formed by the kidney following uptake of the conjugate. At 96 hours and 
171 hours all the organs investigated, and particularly the liver and kidney, showed an 
elevated ratio compared to 24 hours. It has already been demonstrated that 125I-Na was 
not taken up by the liver and kidney and thus it would appear that, following the uptake 
of the conjugate, the isotope was selectively retained. The activity determined for the
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Figure 4.53: Organ Distribution of 125I activity following administration 
of 5mg of 125I-BSA-MTX (6.2%w/w) to rats by the IV route. Each bar 
is the mean of 2 rats. The range for each ratio is shown. Ratios for 3 time 
points are shown.
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Figure 4.6: Log % 1251 activity remaining per ml of serum following 
administration of 5mg of 1 2 5 I-BSA-MTX (9.18%w/w) to rats by IV and SC routes 
Each point was a single determination.
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organs after IP and SC injection were similar to IV.
4.2.4. BSA-MTX (9.18%w/w).
Table A3.17.1 lists the serum concentrations of 125I activity determined following 
administration of the 125I-BSA-MTX (9.18%w/w) conjugate to rats by IV and SC 
routes. Figure 4.6 is a plot of Log serum concentration versus time for both routes. 
Following IV administration a biexponential serum clearance was seen. Peak serum 
levels appeared to be achieved within 6 hours of SC administration. Following the 
absorption phase, serum clearance closely followed that of IV dosed rats. Table 4.6 lists 
the pharmacokinetic parameters calculated for this conjugate.
Table 4.6: The Pharmacokinetic Parameters Calculated for the 9.18%w/w 
conjugate following TV and SC administration in the Rat.
IV (alpha) IV (beta) SC (beta)
Time span 1-10 23.5-97 23.5-97
R2 0.9380 0.9181 0.8815
m* -0.15310.0124 -0.011910.0009 -0.012810.0012
c* 0.51110.076 -0.77210.052 -0.71210.075
n# 12 18 16
Kel (h r1) 0.352 0.0272 0.0294
tlf2 (hr) 1.967 25.46 23.6
Vd (ml) 30.83 594 515
Cl (ml/hr) 10.85 16.16 15.15
Notes: * Slopes and constants are quoted ± Standard Error. 
# n= number of points used in the calculation.
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The parameters calculated for IV and SC dosed rats for the elimination phase were very 
similar. The elimination half-life was longer than that of the other conjugates 
administered and the volume of distribution was very large, representing twice the body 
volume of the rat. Thus the BSA-MTX (9.18%w/w) underwent a very wide tissue 
distribution.
Urine and faecal excretion of 125I activity was determined for both routes of 
administration. The results are listed in tables A3.17.2 and A3.17.3 respectively. There 
was little difference in the total excretion of 125I for the two routes. Approximately 
40-46% of the injected dose was excreted over 96 hours. Faecal excretion accounted for 
approximately 7% of the injected dose of 96 hours for both routes.
4.2.5 BSA-MTX (11.74 %w/w).
Table A3.18.1 lists the serum concentrations for 125I activity determined following 
administration of BSA-MTX (11.74%w/w) to rats by IV, IP and SC routes. These 
results are shown graphically in Figure 4.7.1. Peak serum levels were achieved within 
19 hours of administration by the SC route and approximately 6 hours after IP 
administration. After the absorption phase for IP and SC dosed rats the serum 
concentration of 125I activity closely followed the serum concentrations for IV dosed 
rats. Pharmacokinetic parameters were calculated for each of the routes of 
administration. These are listed in Table 4.7 (page 133).
The Vd for the elimination phase for each route was large, and represents a volume 
which is greater than the actual rat. Therefore the conjugate had a widespread tissue 
distribution. Elimination half-lives were longer than for the other conjugates 
administered. The half-life for the distribution phase following IV administration was 
very short at 1.6 hours, indicating a rapid initial distribution into the central 
compartment.
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Figure 4.7. ̂ Concentration of 125I activity in serum following administration 
of 5mg of 1 2 5 I-BSA-MTX (11.74%w/w) to rats by IV, IP and SC routes. 
Each point was a single determination.
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Figure 4.7.2: Organ Distribution of 125I activity following administration of
5mg o f125I-BSA-MTX (11.74%w/w) to rats by the IV route. Results are
expressed as a ratio of activity in lg  of organ divided by activity in 1ml of blood
at 3 time points. Each bar is the mean of 2 animals. The range for the two ratios is shown.
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Table 4.7: Pharmacokinetic Parameters calculated for BSA-MTX (11.74 %w/w)
administered by IV, IP and SC injection to rats.
IV (alpha) IV (beta) IP (beta) SC (beta)
time span (hr) 1-6.75 19-96 19-96 24-96
R2 0.8467 0.7776 0.8547 0.9454
m* (h r1) -0.188±0.04 -0.0104±0.0015 -0.0118±0.0012 -0.012510.0007
c* (log Co) 0.387±0.172 -0.751 ±0.087 -0.767±0.0674 -0.60310.042
n# 6 16 18 18
Kel (h r1) 0.433 0.0240 0.0270 0.0288
t1/2 (hr) 1.600 29.03 25.5 24.05
Vd (ml) 41.02 564 583 401
Cl (ml/hr) 17.76 13.54 15.74 11.55
Notes: * Slopes and constants are quoted 1 Standard Error. # n= number of points used 
in the calculation
The urine and faeces excretion for 125I activity was determined for each of the routes of 
administration of the BSA-MTX (11.74%w/w) conjugate. These results are listed in 
Tables A3.18.2 and A3.18.3. There were no significant differences in the percent 
excreted for each of the routes. Approximately 40-46% of the injected 125I activity was 
excreted over 96 hours and approximately 8% of the 125I activity was excreted in the 
faeces over 96 hours for each of the routes of administration.
Table A3.18.4 lists the organ distribution of 125I activity at various time points 
following administration of 125I-BSA-MTX (11.74%w/w). A plot summarising these 
results is shown in Figure 4.7.2. This plot is a histogram for the ratio of 125I activity 
found in lg of organ divided by the activity in 1ml of whole blood after 30.5, 76 and 
168 hours post IV administration. There was a significant accumulation of activity in
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the liver, spleen (both organs of the RES), stomach and small intestine at 30.5 hours. 
The ratio was increased in the liver at 76 hours and 168 hours compared to the 24 hour 
values. Activity probably occurred in the gut after the conjugate had been taken up by 
the liver and then transferred into the bile. For the other routes of administration the 
organ distribution was very similar.
4.2.6 BSA-MTX (11.76 %w/w).
The serum concentrations determined for 125I activity following administration of the 
125I-BSA-MTX (11.76%w/w) to rats by IV, IP and SC routes are shown in table 
A3.19.1 and are represented graphically in Figure 4.8.1. Peak plasma levels were 
achieved within 6 hours of IP administration and between 8 and 23 hours of SC 
injection. A biexponential clearance for IV dosed rats was seen. The pharmacokinetic 
parameters calculated for each route of administration are listed in table 4.8.
Table 4.8: The Pharmacokinetic Parameters calculated for BSA-MTX (11.76% 
w/w) following IV, IP and SC administration to rats.
IV (alpha) IV (beta) IP (beta) SC (beta)
Time Span (hr) 1-4 24.5-96 24-100 23-96
R2 0.9123 0.9652 0.9719 0.9352
m* (h r1) -0.341±0.053 -0.010210.0005 -0.0090410.0004 -0.007510.0005
c* (log Co) 1.091 ±0.14 -0.20510.035 -0.33910.0033 -0.50910.031
n# 6 16 16 16
Kel (h r1) 0.785 0.0236 0.0208 0.0172
t1/2 (hr) 0.883 29.39 33.29 40.20
Vd (ml) 8.11 160 218 322.5
Cl (ml/hr) 6.37 3.79 4.53 5.48
Notes: * Slopes and constants are quoted ± Standard Error.# n= number of points used 
in the calculation.
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Figure 4.8.1:
Serum Concentration of 125I activity following administration
of 5mg of 1 2 5I-BSA-MTX (11.76%w/w) to rats by IV, IP and SC routes.
Each point is from one rat. n= 8  for each route.
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Figure 4.8.2: Organ Distribution o f1251 activity following administration of 
5mg of 125I-BSA-MTX (11.76%w/w) to rats by IV, IP and SC injection. Values were 
determined at 100 hours post injection, as a ratio of activity in lg  of organ divided 
by activity in 1ml o f blood.
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Each bar is the mean o f 2 rats and the range is shown unless the difference was less than 10%.
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The half-life calculated for the distribution phase for IV dosed rats was only 53 
minutes, indicating a rapid distribution into the central compartment. The volume of 
distribution for the central compartment represented the serum volume of a rat. For the 
elimination phase the Vd represented the whole body volume of a rat, thus indicating 
that the conjugate could readily leave the vasculature. The elimination half life was 
longest for SC dosed rats. This may indicate that the conjugate was still being absorbed 
from the injection site during this time. In addition the Vd was found to be larger for 
SC dosed rats, and this may be due to incomplete absorption from the injection site or 
uptake by cells at the site of administration or during its route to the blood stream.
The urine and faeces excretion of 125I was determined for each route of administration. 
The results are listed in tables A3.19.2 and A3.19.3. There was no significant difference 
in the percentage excreted for any route of administration. Approximately 50 to 56 % 
was excreted in the urine over 96 hours and between 7 and 8 % of the dose was 
excreted in the faeces over the same period.
Table A3.19.4 and Figure 4.8.2 summarise the organ distribution of 125I activity after 
administration of the BSA-MTX (11.76%w/w) conjugate. Organ distribution was 
determined for each route of administration at 100 hours after administration. There was 
no significant difference in the ratio (activity in lg of organ divided by activity in 1ml 
of blood) for the three routes of administration. The greatest activity was found in liver, 
kidney, stomach and small intestine. Unexpectedly, the organ distribution of the 
11.76%w/w conjugate followed a different pattern to the 11.74%w/w conjugate. Overall 
levels in the liver and spleen of the 11.76%w/w conjugate were lower than the 
11.74%w/w conjugate and levels in the kidney were approximately two times higher 
than the 11.74%w/w conjugate. On FPLC analysis of these 2 conjugates, the 
11.76%w/w conjugate was found to have considerably less protein aggregates than the 
11.74%w/w conjugate (22% for 11.76% BSA-MTX and 34.7% for the BSA-MTX 
(11.74%w/w)). This could account for the different distribution pattern, more of the 
11.74%w/w conjugate was taken up by the RES.
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4.2.7 BSA-MTX (13.63%w/w)
Table A3.20.1 lists the serum concentrations determined for 125I activity following 
administration of 125I-BSA-MTX (13.63%w/w) to rats by the IV, IP and SC routes. 
Figure 4.9.1 is a plot of Log percentage of 125I activity injected per ml of serum versus 
time for each route of administration. Following IV administration a biexponential 
clearance from serum was seen. Peak serum levels were achieved between 4.75 and 7.5 
hours after IP administration and within 18.5 hours of SC injection. Pharmacokinetic 
parameters were calculated for each route of administration and they are listed in Table 
4.9.
Table 4.9: Pharmacokinetic parameters calculated for BSA-MTX (13.63 %w/w) 
administered by IV, IP and SC injection to rats.
IV (alpha) IV (beta) IP (beta) SC (beta)
Time Span (hr) 0.75-7.5 18.5-94 18.5-94 18.5-94
R2 0.9051 0.8767 0.8859 0.9206
m* (h r1) -0.200±0.0264 -0.0091110.001 -0.0096510.001 -0.009210.0007
c* (log Co) 1.100±0.124 -0.66110.0549 -0.56110.0059 -0.55010.041
n# 8 16 16 17
Kel (h r1) 0.460 0.0210 0.0222 0.0211
t1/2 (hr) 1.508 33.03 31.20 32.78
Vd (ml) 7.956 458 364 355
Cl (ml/hr) 3.661 9.612 8.089 7.772
Notes: * Slopes and Constants are quoted ± Standard Error. # n= number of points used 
in the calculation.
The parameters calculated for the elimination phase for each of the routes of 
administration were not significantly different. The serum elimination half-life was
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Figure 4.9.1 Concentration o f  l2Sl activity in serum follow ing administration
of 5mg of 1 2 5I-BSA-MTX ( 13.63%w /w ) to rats by IV, IP and SC routes. 
Each point was obtained from one rat. (n= 8  for each route).
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Figure 4.9.2:
Organ Distribution o f '2̂  activity fo llow in g administration o f 5m g o f  ,2T B SA -M T X  (13.63% w/w) 
to rats by the IV route. Values were determined at 3 time points and are a ratio o f  the 
activity in lg  o f  the organ divided by the activity in 1ml o f  blood. Each bar is the mean from  
tw o animals. The range is shown.
Ratio CPM  
in lg  organ/4 .000  
CPM  in 1ml 
Blood 3 -500  1
Liver Spleen Heart Lung Kidney Stomach Sm. Int. 
Organs
■24 hours
I48 hours
11 94 hourspost injection
- 1 3 8 -
longer than for the other conjugates investigated. Vd was very large and thus it was 
assumed that the BSA-MTX (13.63%w/w) conjugate could readily leave the 
vasculature. The Vd for the distribution phase of IV dosed rats represented the serum 
volume in a 250g rat. The half-life for the alpha phase was very rapid at 1.5 hours.
Urine and faeces excretion were determined for each route of administration. The 
results are listed in tables A3.20.2 and A3.20.3. There was no significant difference in 
the urine excretion between the different routes (p>0.05) (determined using Student’s 
t-test at each time point for each route). Between 60 and 65% of the injected radioactive 
dose was excreted in 96 hours. Excretion in the faeces accounted for approximately 8 to 
10% of the injected dose in 96 hours.
Table A3.20.4 summarises the organ distribution determined for the 125I activity after 
administration of 125I-BSA-MTX (13.63%w/w). Organ distribution was determined 24, 
48 and 94 hours after administration. Figure 4.9.2 is a histogram for the ratio of 125I 
activity in lg of each organ divided by the activity in 1ml of whole blood, for IV dosed 
rats at each time point. There was no significant difference for this ratio between 
organs, at 24 hours and 48 hours. 125I activity was taken up by liver, spleen, stomach 
and small intestine. At 94 hours the ratio in the liver was slightly elevated compared to 
the other time points. There was no difference in the organ distribution of 125I activity 
for the other routes of administration.
4.2.8 BSA-MTX (13.64 %w/w).
Table A3.21.1 lists the serum 125I activity determined following administration of 
125I-BSA-MTX (13.64%w/w) to rats by IV, IP and SC routes. Figure 4.10.1 is a plot of 
log serum 125I activity versus time for each of the routes of administration. Following 
IV administration, two phases for serum clearance were seen. Peak serum levels were 
achieved approximately 5 hours after administration for IP dosed rats and between 8 
and 23 hours after SC administration. Pharmacokinetic parameters were calculated for 
each route of administration and are listed in table 4.10.
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Figure 4.10.1:
Serum Concentration of 125I activity following administration
of 5mg of 1 2 5 I-BSA-MTX (13.64%w/w) to rats by IV, IP and SC routes.
Each point was determined from one rat. (n= 8  for each route.)
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Organ Distribution o f  I activity follow ing IV administration o f  5m g o f l25I-BSA-M TX  
(13.64% w/w) to rats. Values were determined at 2  time points and are a ratio o f the 
activity in lg  o f organ divided by the activity in 1ml o f  blood. Each bar was determined 
from a single animal.
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Table 4.10: The Pharmacokinetic Parameters calculated for rats dosed with
125I-BSA-MTX (13.64 %w/w) by IV, IP and SC routes.
IV (alpha) IV (beta) IP (beta) SC (beta)
Time Span (hr) 1-8 23-96 23-96 23-96
R2 0.7816 0.8958 0.8956 0.8969
m* (h r1) -0.123±0.027 -0.009110.0008 -0.008410.001 -0.0087110.0008
c* (log Co) 0.180±0.133 -0.56710.045 -0.66310.062 -0.65310.047
n# 8 20 18 16
Kel (h r1) 0.283 0.0210 0.0194 0.0201
t1/2 (hr) 2.449 32.99 35.70 34.53
Vd (ml) 66.04 369.3 460.9 450.2
Cl (ml/hr) 18.69 7.756 8.941 9.049
Notes * Slopes and Constants are quoted ± Standard Error. # n= number of points used 
in the calculation.
The pharmacokinetic parameters calculated for the elimination phase for the three 
different routes of administration were very similar. The half-lives for the elimination 
phases were not significantly different from those calculated for the 13.63%w/w 
conjugate. Volumes of distribution calculated for the 13.64%w/w conjugate were large, 
indicating that it could readily leave the vasculature.
Urine and faeces excretion was calculated for each of the routes of administration and is 
listed in tables A3.21.2 and A3.21.3. There was no significant difference for the 
percentage of activity excreted for any of the routes of administration at 48 to 96 hours 
after administration. However, at 24 hours the % excreted by the SC dosed rats was 
found to be significantly lower (p< 0.05 by Student’s t-test) from rats dosed IV. This 
difference could be due to the lower levels of conjugate reaching the kidney over the
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first 24 hours (serum levels were lower than IV over this period) during the absorption 
phase. However, by 48 hours the SC rats had excreted approximately the same amount 
of activity as the other groups. Between 63 and 72% of the injected radioactivity was 
excreted in 96 hours. Approximately 10 to 12 % of the radioactive dose was accounted 
for by faeces excretion in 96 hours.
Organ distribution was determined over 97 hours for each route of administration. The 
results are listed in table A3.21.4. Figure 4.10.2 (page 140) is a histogram summarising 
the results for IV dosed rats. The distribution for the other routes of administration was 
not significantly different from IV. Activity did not accumulate in heart, lung or kidney. 
There were slighdy elevated levels of activity in liver, spleen and gut. The ratios 
calculated for these organs were not as high as for the BSA-MTX (13.63%w/w) 
conjugate.
4.3. FPLC determination of Plasma, Urine and Bile samples.
For rats that had been dosed with an injection of the 7.16%w/w conjugate, the 
molecular weight of the 125I fraction present in their serum was determined at time 
points ranging from 0.5-48 hours. After 48 hours the activity in the serum was too low 
for accurate measurement of 125I activity since only 20pl was applied to the FPLC 
column. 1ml fractions were collected and the radioactivity determined in each one. 
Radioactivity was found to occur in 2 peaks. The first had an elution time of 
approximately 16 minutes and corresponded to intact conjugate. The second had an 
elution time of 44-45 minutes and corresponded to iodinated tyrosine or 125T (as 
iodide). (Iodinated tyrosine and sodium iodide both interacted with the column and 
eluted together). Figure 4.11 shows the elution profile of a 0.5 hour serum sample. 
Table 4.11 lists the percentage of radioactivity determined for both peaks at each time 
point investigated.
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Figure 4.11: Percentage o f 12SI activity in 1ml fractions 
eluted from the Superose 12 column to which had been applied 
a sample o f serum which had been obtained from a rat, 0.5 hours after 
it had been injected with 125I-BSA-MTX (7.16%w/w).
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Table 4.11: Percentage of Radioactivity eluting in Peak 1 (retention time = 16 
minutes) and Peak 2 (retention time = 44-45 minutes) after eluting rat plasma 
samples containing 12SI-BSA-MTX (7.16%w/w) from the Superose 12 column.
Time of plasma Peak 1 Peak 2
sample (hr) Kav=0.336 Kav=1.72
0.5 89.66 10.54
0.5 89.33 10.67
1.0 87.33 12.67
4.0 76.59 23.41
6.0 78.31 21.69
6.0 73.21 26.79
24.0 80.66 19.34
24.0 70.24 29.76
48 67.56 32.44
48 87.24 12.76
All the serum samples tested contained at least 67% of intact conjugate. There was a 
tendency for the percentage of 125I activity present as iodide or iodinated tyrosine to 
increase as time after administration increased. No intermediate peaks were seen in the 
serum samples.
The molecular weight of the 125I species in urine was also determined in a similar 
manner to serum. Three urine samples were analysed for each time point (24 hours and 
72 hours). The results were similar for both time points. Two peaks of radioactivity 
were seen. The smaller peak had a retention time of 25 minutes (Kav=0.77) and 
corresponded to a molecular weight of approximately 1600. The major peak had a 
retention time of 43 minutes and corresponded to iodinated tyrosine or sodium iodide. 
For the 24 hour samples the percentage of activity in peak 1 was 14.6±1.45 (S.E.M.) 
and the radioactivity present in peak 2 was 85.4±1.45. At 72 hours the percentage of 
radioactivity present in peak 1 was 9.34±0.689 and the radioactivity present in peak 2 
was 90.66±0.689. Thus the BSA-MTX conjugate was degraded into very small fractions 
before excretion and the majority of radioactivity excreted was in the form of 125I~ or
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125I-tyrosine.
Samples of bile which had been obtained from rats that had been given an IV injection 
of 125I-BSA-MTX (11.55%w/w) were analysed using the Superose 12 column. Bile 
was obtained from 2 rats, three hours after the conjugate was administered and bile was 
collected over a period of 15 minutes. The bile flow rate was approximately lOOpl in 15 
minutes. The concentration of the 125I in bile was found to be 1.323%/ml and 
1.247%/ml of the injected dose for the rats. The major peak of radioactivity occurred at 
the same time point as for the urine samples. 65.15% and 64.12% of the radioactivity 
was present as either 125I-tyrosine or 125I-Na. The remainder of the 125I was eluted 
between 24 and 37 minutes after injection onto the column, with 2 peaks at 24 and 27 
minutes. These corresponded to molecular weights of 2400 and 712 respectively. The 
125I species present in bile was found to be mainly 125I-tyrosine or 125I-Na.
4.4 Administration of 125I-BSA-3H-MTX (7.16%w/wk
The serum levels determined in rats after administration of the 125I-BSA-3H-MTX 
conjugate for both isotopes are listed in table A3.31.1. Figure 4.12.1 is a plot of log 
serum isotope concentration versus time for both 125I and 3H. The two isotopes gave 
very similar values for the % of conjugate remaining per ml of serum. Pharmacokinetic 
parameters were calculated using both isotopes for the measurement of conjugate in 
serum. These are shown in table 4.12.
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Table 4.12: The Pharmacokinetic Parameters Calculated for 125I-BSA-3H-MTX
(7.16%w/w) following IV administration to rats.
125i 3H
1. Distribution Phase
time span (hr) 0.5-11.5 0.5-11.5
R2 0.9574 0.8803
m* (h r1) -0.111±0.0071 -0.0993±0.011
c* (log Co) 0.686±0.0434 0.680±0.0679
n# 13 13
Kel (h r1) 0.255 0.229
t1/2 (hr) 2.712 3.030
Vd (ml) 20.61 20.92
Cl (ml/hr) 5.25 4.79
2. Elimination Phase
time span (hr) 24-96 24-96
R2 0.9331 0.887
m* (h r1) -0.0119±0.00085 -0.0108±0.00103
c* (log Co) -0.358±0.0505 -0.445±0.0612
n# 16 16
kel (h r1) 0.0274 0.0248
t1/2 (hr) 25.29 27.91
Vd (ml) 228 278
Cl (ml/hr) 6.25 6.89
Notes: * Slopes and Constants are quoted ± Standard Error. # n= number of points used 
in the calculation.
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The pharmacokinetic parameters calculated using the two different isotopes were very 
similar. During the alpha phase the parameters were all within 10% of each other and it 
can be assumed that both isotopes remained bound to the conjugate during the alpha 
phase and could both be used accurately to determine the concentration of conjugate 
within serum.
During the elimination phase, again both isotopes gave similar values for the 
pharmacokinetic parameters of the conjugate. The elimination half-life, elimination rate 
constant and clearance were all within 10% of each other. The Vd calculated for 3H 
isotope was 18% greater than calculated for 125I. The constants used in the calculation 
of Vd from the linear regression (see section A2.1) were both associated with a standard 
error of 14% and thus the Vd values calculated for 3H could range from 239-316ml and 
the Vd for the 125I isotope could range from 196-260ml. Therefore the pharmacokinetic 
parameters calculated using both isotopes could be considered to be very similar. Since 
the levels of the two isotopes remained at the same ratio in the serum samples it can be 
assumed that both isotopes remained bound to the conjugate and that the conjugate was 
not broken down in serum with release of either the 125I or 3H, unless of course both 
were released from the conjugate at the same rate and then had the same fate. In 
separate experiments the pharmacokinetic parameters were calculated for both 3H-MTX 
and 125I-Na and they were not the same (Cl from plasma, for alpha phase for MTX was 
334 ml/hr and for 125I was 215ml/hr). Thus it was unlikely that either of the two labels 
was cleaved from the conjugate during circulation in serum.
The urine excretion of both isotopes was followed over 96 hours after administration of 
125I-BSA-3H-MTX. The results are shown in table A3.31.2 and are shown graphically 
in figure 4.12.2. Considerably less 3H activity was excreted in the urine than 125I 
activity at 24 hours (51% of the 125I had been excreted in the urine compared to only 
28.5% of the 3H activity). Student’s t-test was used to compare the % of the two 
isotopes that was excreted at 24 hours, 48 hours and 72 hours after injection. The % of 
125I excreted was highly significantly greater than that of 3H at all time points. 125I was 
initially excreted at a faster rate than 3H. The rate of excretion of 125I was 2.13% of the
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injected dose per hour over the first 24 hours and for 3H was 1.17%/hr. After 24 hours 
the rates of excretion for both isotopes decreased and were similar to each other. (Rate 
for 125I excretion over 24 to 96 hours was 0.225%/hour and for 3H was 0.152%/hr).
Table A3.31.3 shows the organ distribution for both isotopes at various time points up 
to 96 hours after injection of the 125I-BSA-3H-MTX conjugate. Five organs were 
investigated. These were the liver, spleen, kidney, stomach and small intestine. In 
addition, the uptake of 125I by the thyroid was measured. After 24 hours approximately 
15% of the 125I dose was found to be located within the thyroid. The percentage of the 
activity did not appear to change from the 24 hour value, up to 96 hours after injection. 
The high concentration of 125I activity in the thyroid implied that some of the conjugate 
had been broken down, with the release of 125I which was in a form which could be 
utilised by the thyroid gland. (Only 7% of the iodine was present as a TCA soluble 
fraction in the original injection solution.)
Figures 4.12.3 to 4.12.6 show the 125I and 3H distribution in each of the organs 
investigated over the 96 hour period. The object of this experiment was to identify the 
fate of the MTX portion of the conjugate, after it had been taken up by the organs. The 
conjugate had a dual label. The 125I was bound to the protein portion of the conjugate 
and should give an indication of the fate of the BSA after cellular uptake. The 3H 
isotope was part of the MTX molecule and would indicate the distribution of the drug 
moiety. If the 3H activity was distributed in a similar way to the activity of 125I in the 
organs, then it could be assumed that the MTX remained bound to the protein fraction 
of the conjugate after it had been taken up intracellularly.
In the liver, up to 48 hours after administration, the 2 isotopes were present at a similar 
concentration. However, at 72 hours and 96 hours after administration, the 3H levels 
within the liver were elevated compared to 125I. At 96 hours, the level of 3H in the liver 
was 1.806% and for 125I it was 0.437% of the injected dose. (Both are means of the 2 
rats investigated). The difference in the concentrations of the 2 isotopes in the liver 
could be explained by degradation of the conjugate after uptake by the liver. Following 
breakdown of the conjugate, it would appear that the 125I degradation products could be
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Figure 4.12.5: Accumulation o f 1251 and 3 H activity in the kidney 
following administration of 1 2 5 I-BSA- 3 H-MTX to rats by the IV routes. 
Each point is a mean of 2 rats. The bars represent individual values 
for each rat
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released whereas the 3H moiety was selectively retained by the liver. A similar pattern 
was seen in the spleen. At 96 hours the level of 3H activity was 0.021% and for 125I it 
was 0.014%.
In the kidney, up to 72 hours after injection, the 3H isotope levels were lower than the 
125I isotope levels. This would explain why the % of 3H excreted in the urine was less 
than that for 125I. At 96 hours after administration, the 3H level in the kidney was 
considerably higher than the 125I level (0.399% for 3H compared to 0.187% for 125I). 
The increase in 3H activity in the kidney was not associated with a corresponding 
increase in the 3H activity excreted in the urine. An explanation for why the 3H level 
was lower than 125I level in the kidney up to 72 hours after injection, could be that the 
isotopes only appeared in the kidney after the conjugate had been degraded. It has 
already been ascertained that the 125I excreted in the urine was present as low molecular 
weight species (less than 1600 molecular weight by FPLC). Degradation of the 
conjugate into low molecular weight polypeptide fragments was expected to occur in 
the liver. The fate of the two isotopes was different in this organ. After the conjugate 
had been taken up by the liver, the 125I could be released (and be distributed to the 
kidney), whereas the 3H activity appeared to accumulate. MTX is known to be 
polyglutamated within the liveri112) and the polyglutamated derivative cannot readily 
leave the cell. This fact could explain why the 3H activity appeared to be retained 
within the liver and thus could not reach the kidney. The accumulation of 3H activity at 
96 hours could also be explained by a selective retention in this organ.
Levels of 125I activity in the stomach and small intestine were elevated compared to 3H, 
up to 72 hours after administration of the conjugate. By 96 hours the levels of 3H had 
begun to rise in the gastro-intestinal tract, and were similar to those of 125I. An 
interesting result was seen for the 125I isotope in the stomach and small intestine. The 
time when maximum levels were reached in the stomach was six hours, and the time 
for maximum levels to be reached in the intestine was 24 hours. Organ distribution was 
determined in different groups of animals for the two time points so this may be due to 
biological variation. However it may also be because the 125I that had reached the
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stomach due to bile secretion into the intestine and then reflux from the intestine into 
the stomach, had passed back into the small intestine by 24 hours. The fact that 125I 
levels in the gut increased over 1 to 6 hours and 3H activity did not, supports the theory 
that the radioactivity had entered the gut via the bile. If the conjugate had been 
selectively taken up by the gut then levels of both isotopes would be expected to be 
similar at initial time points. In fact very little 3H activity appeared in the gut until 72 
hours after administration of the conjugate. This was because 3H appeared to be 
retained by the liver so less could actually enter the bile.
4.5 Summary of BSA-MTX Conjugates
Figure 4.13.1 is a plot of Log serum 125I concentration versus time for 125I-labelled 
BSA, BSA-MTX (5.1%w/w) and BSA-MTX (11.76%w/w). The conjugates demonstr­
ated a serum clearance profile that was similar to free BSA. However the plasma levels 
of free BSA were elevated compared to the conjugates. Table 4.13 summarises the 
pharmacokinetic data calculated following IV administration of each of the conjugates 
investigated.
Table 4.13: Summary of the Pharmacokinetic data calculated after IV administr­
ation of each of the BSA-MTX conjugates to male wistar rats.
Conjugate
(alpha phase) 
t1/2 (hr) Vd (ml)
(beta phase) 
t1/2 (hr) Vd (ml)
Free MTX 0.24 114.7 1.96 1615
Free BSA 3.37 18.9 22.3 26.6
3.4%w/w 1.69 17.8 18.7 34.9
5.1%w/w 3.78 13.6 21.3 75.2
6.2%w/w 2.89 18.7 17.1 124.8
7.16%w/w 2.71 20.6 25.3 228
9.18%w/w 1.97 31.8 25.5 594
11.74%w/w 1.60 41.0 29.0 564
11.76%w/w 0.88 8.11 29.4 160
13.63%w/w 1.51 7.96 33.0 458
13.64%w/w 2.45 66.0 33.0 369
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Figure 4.13.1:
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There was a tendency during the beta phase for the Vd to increase with increased 
loading of MTX in the conjugate and every conjugate investigated demonstrated a 
larger Vd than free BSA.. It would appear that the BSA-MTX conjugates were more 
able to leave the vasculature. This may be due to a non-specific effect because of the 
changed character of the protein. The conjugate would be expected to be more 
hydrophobic than BSA because of the introduction of the large pteridine ring and this 
could increase its interaction with cell membranes e.g. the endothelial cells and aid its 
access out of the v a s c u l a t u r e . r i 5 0 )  The conjugate would be more electro-negative than 
BSA because MTX was covalently bound to lysine residues in the BSA and in addition 
because MTX itself has a free carboxylic acid group. Covalent binding of MTX to BSA 
would be expected to alter the tertiary structure of the protein. All these factors may 
alter the distribution of BSA in the rat. In addition the Vd may be larger for the 
conjugates because of the specific effects of MTX. Protein bound MTX may still be 
able to interact with the folate transporter on cell surfaces. Mell et al ^51) found that 
MTX bound to a soluble, large molecular weight carrier using a carbodiimide coupling 
reaction was still able to bind to DHFR, so this is a realistic possibilty.
For the plasma half-lives, there was a tendency for the alpha phase half-life to be 
decreased compared to free BSA, thus the conjugates more rapidly equilibrated with the 
central compartment. Trouet et alri52) covalently bound daunorubicin to succinylated 
rabbit albumin using an ECDI reaction. They found that their conjugate, for which no 
loading of drug in the conjugate was mentioned, had a plasma distribution half-life of 
91 minutes in the mouse, and this was very similar to the BSA-MTX conjugates with 
loadings above 9.2%.
At initial loadings of MTX in the conjugates there was a tendency for the MTX-BSA to 
have a more rapid elimination half-life than BSA. However, as MTX loading increased 
in the conjugate, half-life increased. Figure 4.13.2 is a plot of the elimination half-life 
versus %w/w loading of the conjugate. There appeared to be a linear relationship. One 
exception to this was the 6.2% w/w conjugate. This was prepared in a slightly different 
manner from the other conjugates. Instead of the reaction taking place in pH 7.4 buffer,
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the reaction was carried out in water. This may have led to a difference in the conjugate 
produced.
MTX was bound to BSA to evaluate the effects of conjugation to a large molecular 
weight, soluble carrier, on the pharmacokinetics of the drug. MTX had a very large Vd 
when injected into rats (for both the alpha and beta phases). Thus, since it can reach 
many tissues in the body, this may contribute to the side effects of the drug. After 
conjugation to BSA, the Vd was reduced for every conjugate investigated, thus access 
into certain sites was limited and this could reduce the toxicity of the drug.
MTX had a very short half-life in the rat and BSA-MTX had a half-life which was at 
least 10 times that of free drug, and thus the conjugates may be able to act as a slow 
release formulation of the drug. Halbert et aK153> investigated the release of MTX from 
two BSA-MTX conjugates (3%w/w and 10%w/w). They found that only 10% of the 
MTX was released in a 72 hour incubation at pH 7.4. Thus the MTX would not be 
released from the conjugates, to any great extent, during circulation in the plasma. This 
is advantageous since the target for MTX is intracellular, and therefore in order to be 
cytotoxic, BSA-MTX would have to be internalised. By conjugating the MTX to BSA, 
entry of the drug into cells is limited to the process of pinocytosis. Fluid phase 
pinocytosis is a relatively slow process compared to receptor mediated pinocytosis.^70) 
If a targeting agent was bound to the conjugate, then it would be taken up by receptor 
mediated pinocytosis, and this may occur before fluid phase pinocytosis could occur in 
cells without the receptor.
Halbert et al<153) also investigated the stability of the conjugates at pH 5, the pH of the 
lysosome, and found that 16% of the MTX was released in 72 hours. This would not 
give a sufficient concentration of MTX to kill the cell, since it has been estimated that 
this requires 10 million molecules per c e l l . 0 5 4 )  However, within the lysosome their are 
numerous hydrolytic enzymes and these would be expected to break down the 
BSA-MTX with the liberation of free, active drug. Marriott^25) demonstrated the 
degradation of MTX-HSA when it was incubated with a solution of tritosomes and 
glutathione at pH 5.6. After 16 hours, 66% of the original conjugate was present as
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species of less than 1500 molecular weight In this chapter proof has been given that the 
conjugate was actually broken down in vivo, since small peptide fragments were found 
to be excreted in the urine, and also different organ distributions of the two isotopes 
were found following administration of the 125I-BSA-3H-MTX conjugate. 3H-MTX was 
selectively retained by cells, whereas 125I fragments were released and appeared in bile 
and urine.
The BSA-MTX conjugates were administered by three routes of injection i.e. IV, IP and 
SC. The rationale for employing IP injection was that diseases that are present within 
the cavity such as ovarian cancer or cancer of the intestine could be “attacked” 
immediately after injection/155) Sub-cutaneous dosage was applied, because of the 
inability of the BSA-MTX conjugates to enter the blood stream directly after injection. 
Flessner et a /142) demonstrated, using FITC labelled dextrans and 125I-BSA, that 
molecules with a molecular weight above 39,000 were absorbed into the lymphatics and 
not into the blood stream after IP administration. They were transferred to the blood 
stream from the lymphatic system at one of the lymphatic ducts. Molecules with a 
molecular weight below 39,000 were absorbed from the peritoneal cavity partially by 
the blood stream and also by the lymphatics. Both SC and IP injection routes could be 
used to get drug into the lymphatic system and to treat metastatic cancer growths which 
have occurred within the lymphatic vessels. However, it was difficult to keep drug 
within the peritoneal cavity and lymphatic vessels. Peak plasma levels were achieved 
within 6 hours of IP administration and within 23 hours of SC administration for all 
conjugates administered. A targeting agent on the conjugate could influence the 
distribution, however and may result in the entire dose being taken up by the target 
organ before it reached the blood stream after SC or IP dosage.
Urine 125I excretion was determined for each of the 125I labelled conjugates. There was 
a tendency for an increase in iodine excretion as conjugate MTX loading was increased. 
Chu and Whiteley(") measured the excretion of 125I activity following administration of 
125I-BSA-MTX (8%w/w) in mice. They found that 55-60% of the dose was excreted in 
24 hours. This was similar to the excretion determined for the 9.2% conjugate used in
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this work, for which 51% was excreted in 24 hours. Chu and Whiteley(") also 
administered a BSA-3H-MTX conjugate. They found a similar rate of excretion for the 
3H isotope as they did for the 125I isotope. This is contrary to the results for the 
125I-BSA-3H-MTX experiment, where 51% of the 125I was excreted but only 28.5% of 
the 3H was excreted and this difference is difficult to explain. Figure 4.13.3 is a 
histogram showing the urine excretion at 24 hours and a later time point, usually 96 
hours for MTX, BSA and the BSA-MTX. All conjugates were excreted more slowly 
than the MTX. Excretion of the conjugates was actually a measure of the metabolism 
since MTX-BSA has a molecular weight above the renal threshold. Also FPLC and 
GPC showed that any 125I excreted in the urine was present as peptide fragments.
The molecular weight of the 125I species in urine was determined for the 6.2%w/w 
conjugate by gel filtration and for the 7.16%w/w conjugate by FPLC. It was found that 
the molecular weight of the 125I in urine for the 6.2%w/w conjugate was greater than 
1000D. For the 7.16%w/w conjugate the majority of the activity was found to elute at 
the same time as iodinated tyrosine. Iodinated tyrosine was found to interact with the 
superose column and eluted at a time similar to potassium iodide. Thus the 7.16% 
conjugate was probably broken down into amino acid fragments before it was excreted. 
The 6.2%w/w conjugate was also degraded but the fragments were bigger than single 
amino acid units. The reason for this could be that the 6.2%w/w conjugate was 
metabolised in the kidney. (This conjugate was found to accumulate in the kidney after 
administration and this can be explained since it is known that proximal tubule cells of 
the kidney demonstrate a high uptake of protein, particularly if it is denatured^156)). The 
7.16%w/w conjugate could have been metabolised to a greater extent by the liver before 
being transferred to the blood for excretion by the kidney. 125I excretion in the urine 
appeared to increase with increased loading of MTX in the conjugate, indicating that 
the conjugate was metabolised more rapidly, as MTX loading was increased.
Organ distribution was determined for most of the conjugates administered. Figure
4.13.4 is a histogram comparing the liver uptake for each of the conjugates. There was 
an increased uptake by the liver compared to free BSA for all of the conjugates
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Figure 4.13.3: Percentage of 1251 activity excreted in the urine o f rats dosed with an IV injection of 
125I-labelled protein or conjugate or with 2.5mg o f MTXNa followed by HPLC detection.
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investigated. There appeared to be a tendency for the ratio (of activity in the liver 
divided by the activity in lml of blood) to increase as the concentration of MTX in the 
conjugate increased. In addition the percentage of conjugate present as aggregated 
protein tended to increase with increased MTX loading and this may explain the 
increased uptake. Fiume et aK157) demonstrated that a phalloidin-Rabbit serum albumin 
conjugate (with 0.8 to 1.9 phalloidin residues per albumin molecule) and conjugates 
between cytosine arabinoside or 5-fluorodeoxyuridine (FUDR) and Rabbit SA058.159) 
were taken up by the liver after administration in mice. The conjugates were found 
mainly in the non-parenchymal cells and also in other cells of the RES. Fiume’s 
conjugates consisted of nearly entirely aggregated protein and thus would have been 
recognised as foreign by the RES and this would have resulted in the uptake of the 
conjugates. The BSA-MTX conjugates used in the present study had less than 35% of 
the conjugate present as polymers. In a comparative experiment, where Fiume 
administered a conjugate between FUDR and albumin which had been prepared using 
the hydroxysuccinimide ester of the albumin, no liver uptake was demonstrated. This 
conjugate did not contain any aggregated material/157) This suggests that the 
accumulation of the BSA-MTX in the liver demonstrated in these experiments may not 
be due to the aggregated protein as first thought, since the BSA-MTX had less 
aggregated protein than the original conjugates produced by Fiume. Chapter 5 describes 
an experiment to determine in which liver cell type the BSA-MTX accumulated in (see 
section 5.2) is described.
In addition to accumulation in the liver, the BSA-MTX conjugates were also taken up 
by the spleen, the gut and to a lesser extent the kidney. Again, there seems to be 
relationship between the concentration of MTX in the conjugate and the amount of 125I 
taken up. As mentioned previously, the increased uptake could be due to the 
non-specific effect of changing the characteristics of BSA which had led to uptake by 
cells of the RES. Another explanation could be that MTX bound to the BSA, helped the 
conjugate to enter the cells by using the folate transporter system.
Following liver uptake, the 125I activity would be expected to be transferred into the
-160-
bile. Analysis of the bile following administration of 125I-BSA-MTX (11.55%w/w) 
showed that quite a high percentage of the injected dose was present in it (1.3%/ml) at 
3 hours after injection and this explained why elevated levels of 125I were found in the 
gut. FPLC analysis showed that a high proportion of the radioactivity was present either 
as iodinated tyrosine or 125I -Na, thus indicating that conjugate taken up by the liver 
was degraded. There was no relationship between the % of activity excreted in the 
faeces and the %w/w loading of MTX in the conjugate. Approximately 8-12% of the 
125I dose was excreted in 96 hours. Thus 125I may be reabsorbed from the gut since 
conjugates which had been taken up by the liver to a greater extent did not demonstrate 
greater loss of activity in the faeces.
4.6 Other Protein-MTX Conjugates.
4.6.1 LA-MTX Conjugates.
LA, as a lower molecular weight protein, was covalently bound to MTX and 
administered to the rat, and the effects on distribution of the drug were compared to 
BSA-MTX. Two LA-MTX conjugates were administered to rats. These had %w/w 
loadings of MTX of 4.52% and 13.69%. They were prepared by reacting 1 molar 
equivalent of protein with 10.7 or 20 molar equivalents of MTX respectively. Tables 
A3.22.1 and A3.23.1 list the serum levels determined for each route of injection for the 
4.52%w/w and 13.69%w/w conjugates respectively. Figures 4.14.1 and 4.14.2 are plots 
of Log serum 125I concentration versus time for each conjugate, for the three routes of 
injection. Like ‘free’ LA itself, peak serum levels were achieved very rapidly after IP 
and SC injection (within 2 hours). Conjugation of MTX to the LA increased the 
molecular weight of the protein but only from 14200 to 14774 for LA-MTX 
(4.52%w/w) and to 16243 for LA-MTX (13.69%w/w) and so it is possible that these 
conjugates could still enter the blood stream directly from extravascular sites. Following 
IV injection a biexponential plasma clearance was seen. The pharmacokinetic 
parameters calculated for each route of administration and both conjugates are shown in 
table 4.14.1.
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Figure 4 .14.1
Concentration of 125I activity in serum following administration 
of 5mg of 1 2 5 I-LA-MTX (4.52%w/w) to rats by IV, IP and SC routes. 
Each value was determined from one rat. (n= 8  for each route.)
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Figure 4.14.2:
Serum Concentration of 125I activity following administration of 5mg 
of 1 2 SI-LA-MTX (13.69%w/w) to rats by IV, IP and SC routes.
Each point was determined from a single rat. (n= 8  for IV and SC, n= 6  for IP).
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Table 4.14.1: The Pharmacokinetic parameters for the LA-MTX (4.52 %w/w and
13.69%w/w) conjugates following IV, IP and SC administration to rats.
IV (alpha) IV (beta) IP (beta) SC (beta)
1. 4.52%w/w  
time span (hr) 1-8 23.5-96 23.5-96 23.5-96
R2 0.3339 0.8956 0.7163 0.8621
m* (h r1) -0.049±0.0199 -0.0109±0.0011 -0.01095±0.0013 -0.0109±0.0013
c* (log Co) -0.516±0.0868 -0.672±0.0606 -0.687±0.112 -0.644±0.0711
n# 14 14 14 14
Kel (h r1) 0.113 0.0251 0.0252 0.0251
t1/2(hr) 6.14 27.6 27.5 27.6
Vd (ml) 328 469 486 441
Cl (ml/hr) 37.1 11.8 12.3 11.1
2. 13.69%w/w
time span (hr) 0.33-6.5 23.5-97 23.5-97 23.5-97
R2 0.9176 0.8605 0.8315 0.7961
m* (h r1) -0.198±0.0209 -0.105±0.0011 -0.00993±0.0014 -0.00785±0.0011
c* (log Co) 0.280±0.0744 -0.916±0.067 -0.840±0.0844 -0.994±0.063
n# 11 16 12 16
Kel (h r1) 0.456 0.0242 0.0229 0.0181
t1/2 (hr) 1.52 28.66 30.30 38.33
Vd (ml) 52.5 824 693 986
Cl (ml/hr) 23.94 19.94 15.86 17.85
Notes: * Slopes and Constants are quoted ± Standard Error.
# n = number of points used in the calculation.
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The parameters calculated for the elimination phases were similar for the IV and IP 
routes of administration. Both conjugates demonstrated a large Vd for this phase which 
was at least twice the body volume of a rat. Following SC administration the 
13.69%w/w conjugate displayed similar pharmacokinetics to free LA administered SC 
but not to the other routes of administration for the conjugate. The half-life for free LA, 
following SC administration, was 39.1 hours and the Vd was 530ml. The reason for the 
longer half-life seen for SC dosed rats must be that protein and conjugate were still 
being transferred from the injection site during the elimination phase. However figure
4.14.2 shows that the serum levels determined over the elimination phase were very 
similar for each route of injection for the 13.69%w/w conjugate, and so the large 
differences in tlf2 calculated between IV and SC injection may be associated, at least 
partly, with the errors involved in the calculation.
Tables A3.22.2 and A3.22.3 list the urine and faeces excretion of 125I following 
administration of the 125I-LA-MTX (4.52%w/w), over 96 hours. There was no 
significant difference in the urine excretion of 125I activity between any of the routes of 
administration at any time point. 54-60% of the total dose was excreted in 96 hours. 
Excretion in the faeces accounted for between 6.6 and 10% of the total activity in 96 
hours. The results for urine and faecal excretion of the high strength conjugate are 
shown in tables A3.23.2 and A3.23.3 respectively. Again there was no significant 
difference in the amount of 125I activity excreted for any route of injection. 
Approximately 7-10% of 125I injected was excreted in the faeces over 96 hours and 
between 47 and 54% was excreted in the urine over 96 hours. Figure 4.14.3 is a plot of 
the % 125I activity excreted in the urine over 72 hours for 125I-labelled LA, LA-MTX 
(4.52%w/w) and LA-MTX (13.69%w/w) following IV injection. At the 24 hour time 
point there appeared to be a greater % of the 125I excreted by the groups of conjugate 
dosed rats than the free LA dosed rats. A Student’s t-test was used to compare the 
excretion of 125I activity for each group of rats (each group included all routes of 
injection) at 24 hours and 72 hours after administration. At both time points and for 
both conjugates and the free LA, the results of the Student's t-test were non-significant 
(p> 0.05).
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Figure 4.143: Percentage of 121 activity excreted in the urine following 
IV administration of 1 2 5 1-LA, 1 2 1-LA-MTX (4.52%w/w) and 
1 2 3 I-LA-MTX (13.69%w/w) to rats. Each point is a mean ± S.E.M. (n=3).
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Figure 4.14.4:Concentration of 125I activity in serum following administration of 
5m gof1 2 5I-LA, 121-LA-MTX (4.52%w/w) and 12f-LA-MTX(13.69%w/w) 
to rats by IV injection. Points were determined from a single rat
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Figure 4.14.4 is a plot comparing the 125I serum levels determined after IV 
administration of 125I labelled LA and both conjugates. The LA showed elevated serum 
levels compared to the conjugates, indicating that it had a smaller volume of 
distribution. Table 4.14.2 summarises the pharmacokinetic parameters calculated for IV 
dosed rats for LA and LA-MTX.
Table 4.14.2 The Pharmacokinetic parameters calculated for LA, LA-MTX 
(4.52%w/w) and LA-MTX (13.69%w/w) after IV administration to Rats.
Alpha Phase 
tl/2 (hr) Vd (ml)
Beta Phase 
tl/2 (hr) Vd (ml)
LA 0.943 111 21.6 236
LA-MTX (4.52%w/w) 6.14 328 27.6 469
LA-MTX (13.69%) 1.52 52.5 28.7 824
Like conjugates between MTX and BSA, covalent conjugates of LA-MTX demonstrate 
different pharmacokinetics to the free protein. These differences follow a similar pattern 
to BSA-MTX. During the elimination phase conjugates were shown to have a longer 
half-life and a larger Vd than ‘free’ protein. There appeared to be a relationship 
between concentration of MTX in the conjugate and the increase in these parameters, 
although too few conjugates were administered to make any firm conclusions. During 
the alpha phase there did not appear to be a relationship between the loading of MTX in 
the conjugate and the changes in pharmacokinetic parameters compared to free LA. 
LA-MTX (13.69%w/w) had a similar alpha phase half-life but its Vd was half that of 
free LA. The LA-MTX (4.52%w/w) had an alpha phase half life which was 6 times 
longer than that of free LA, and its Vd was approximately three times larger. (The 
regression coefficient for the plot used in the calculation of the parameters for the alpha 
phase for 4.52%w/w conjugate was only 0.3339 and so the parameters calculated are 
associated with a large error). Unfortunately organ distribution was not determined for 
the LA-MTX conjugates so it is not known whether the changes in Vd were associated
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with accumulation in organs of the RES or were due to uptake by the kidney.
In the 13.69%w/w conjugate, 4.5 moles of MTX were associated with 1M of protein. In 
the 4.52%w/w conjugate only 1.3 moles of MTX were bound to 1 mole of LA. The low 
strength conjugate would probably demonstrate a difference in tertiary structure 
compared to free LA but its hydrophobicity and molecular charge would not be 
expected to be changed to any great extent. It is difficult to predict what effects this 
would have on the distribution of LA, since it is a milk protein and so which would not 
normally be found in rat serum anyway. The 13.69%w/w conjugate would be expected 
to differ from LA in its hydrophobicity and electrical charge, in addition to changes in 
tertiary structure. These differences probably accounted for the changes in pharmacok­
inetic parameters calculated for the conjugate. The increased beta phase Vd for the 
conjugates was possibly due to uptake by the liver, as demonstrated for BSA-MTX 
conjugates. Free LA, although it was a foreign protein, was not found to be associated 
with the rat liver at 28 hours after injection.
Both LA-MTX conjugates investigated demonstrated lower Vd, and longer elimination 
half-lives, than free MTX. However these differences were not as great as those for 
BSA-MTX. Thus BSA was probably a better choice as a carrier of cytotoxic drugs than 
LA. The beneficial effect of BSA was possibly due to its greater molecular weight. The 
aim of a drug-targeting complex is to prevent the premature removal of drug via the 
kidney and to limit cellular uptake to the process of pinocytosis/57) In practice the ideal 
conjugate should combine characteristics which would allow it to extravasate at its site 
of action but also limit its urinary excretion. Although the LA-MTX would be expected 
to enter cells only by the process of pinocytosis and also it would be able to leave the 
blood stream (this was demonstrated by the rapid uptake into the vasculature following 
IP and SC administration), with a molecular weight of approximately 16,000 it would 
also be expected to be excreted unchanged from the kidney.
4.6.2 RSA-MTX.
One conjugate was prepared between RSA and MTX. The concentration of MTX in the
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reaction was 100 molar equivalents to 1 molar equivalents of protein. This resulted in 
the preparation of a conjugate of 6.94%w/w MTX. (9.3 molar equivalents of MTX were 
covalently bound to 1 molar equivalent of RSA). The conjugation efficiency was 
considerably less than for BSA-MTX. Using the same ratio of reactants a conjugate 
containing 17.64 molar equivalents of MTX to 1 molar equivalents of BSA was 
prepared. Unfortunately there is no data available on the structure of RSA but it would 
be expected to be different from BSA and it may contain less lysine residues than BSA. 
A conjugate between CA and MTX was attempted using the same reaction conditions 
as for BSA-MTX. However, although the CA was expected to have a number of lysine 
residues (human CA contains 18, compared to BSA which has 59 but is twice its 
size)(16°), very little MTX actually reacted with it. It was assumed that the lysine 
residues in CA were sterically hindered so that they could not react with the large MTX 
molecule.
The RSA-MTX (6.94%w/w) was analysed by FPLC and found to contain a low 
percentage of aggregated protein, 18.4% of the total protein being aggregated. The 
conjugate was radioiodinated and administered to rats by IV injection. The serum levels 
determined for 125I activity are shown in Table A3.24.1. Figure 4.15.1 is a plot 
comparing the serum levels determined following administration of free RSA and 
RSA-MTX by IV injection. The serum clearance of RSA-MTX followed a 
biexponential model. The serum levels determined over 96 hours were considerably 
lower for the conjugate than for the free protein. Table 4.15 lists the pharmacokinetic 
parameters calculated for the RSA-MTX and RSA.
The pharmacokinetic parameters calculated for the distribution phase were very similar 
for RSA and the RSA-MTX. RSA-MTX had a slightly faster distribution half-life, but 
the Vd was not significantly different. During the elimination phase, the half-life for the 
RSA-MTX was shorter (31.7hr for RSA-MTX compared to 38.4hr for RSA). The Vd 
for the elimination phase for the conjugate was ten times larger than that calculated for 
RSA. This significant difference could be due to changes in the protein characteristics 
or could be due to a specific action of MTX, as already described for BSA-MTX 
conjugates.
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Figure 4.15.1 Serum concentration (log % I activity remaining/ml)
after administration of 5mg of 125I-RSA or 5mg of 121-RSA-MTX
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Figure 4.15.2:Percentage of 125I activity excreted in the urine following 
IV administration of 5mg of 1 2 SI-RSA or 5mg of l2 ^-RSA-MTX 
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Table 4.15 The Pharmacokinetic Parameters Calculated for RSA-MTX and RSA
following IV administration to Rats.
Alpha Phase Beta Phase
RSA RSA-MTX RSA RSA-MTX
time span (hr) 0.25-7.25 1-5.75 18.75-97 18-95
R2 0.9130 0.9625 0.9628 0.9230
m* -0.0957±0.0104 -0.15710.00122 -0.007810.0004 -0.009510.00065
c* 0.818±0.0401 0.76510.0455 0.44610.0223 -0.55710.0339
n# 10 8 20 20
Kel (hr-1) 0.220 0.362 0.018 0.022
tl/2(hr) 3.144 1.917 38.4 31.7
Vd (ml) 15.2 17.15 35.8 360
Cl (ml/hr) 3.34 6.212 0.644 7.885
Notes: * Slopes and constants are quoted 1 Standard Error. # n=number of points used 
in the calculation.
Tables A3.24.2 and A3.24.3 list the urine and faeces excretion of 125I activity following 
administration of radioiodinated conjugate. Approximately 41% of the injected 
radioactivity was excreted in the urine and 10% was excreted in the faeces over 96 
hours. Figure 4.15.2 is a plot of % 125I excreted in the urine of rats that had been 
injected with the 125I labelled conjugate or with RSA. At 24 hours the % excreted by 
RSA dosed rats was significantly less than RSA-MTX dosed rats (p<0.02). However by 
the 96 hour time point the difference non-significant.
Organ distribution of 125I activity was determined for the RSA-MTX conjugate at 24
and 48 hours after administration. The results are listed in table A3.24.4. Figure 4.15.3
is a histogram showing the ratio (activity in lg of organ divided by activity in 1ml of
whole blood) for each of the organs investigated at 24 hours and 48 hours. The ratio in
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the organs was approximately the same at both time points. The activity in all the 
organs investigated, apart from the gut, was low and was possibly due to the blood 
within the organ. The stomach demonstrated higher levels than the small intestine. The 
ratio in the stomach for the 4 rats investigated was 3.84±0.426 and in the intestine was
I.55±0.48. This was an unexpected result since activity in the gut was thought to occur 
due to bile secretion and the bile duct opens out into the intestine. Other workers have 
also demonstrated high levels in the stomach following administration of 125I-BSA<143)- 
This effect could be explained by reflux of the intestinal contents into the stomach.
The RSA-MTX did not appear to accumulate in the liver anymore than RSA did itself, 
The ratio (activity in lg/activity in 1ml of blood) was similar for both RSA and 
RSA-MTX. (Ratio for RSA in the liver was 0.616 and 0.710 for the two rats 
investigated at 96 hours and for RSA-MTX was 0.79±0.035 for 4 rats at 24 and 48 
hours). However, direct comparison of RSA and the conjugate at the time points of 24 
and 96 hours may not be valid since an increase in accumulation of 125I activity in liver 
at 97 hours compared to 24 hours was noted for BSA and may also occur for RSA. 
Indeed, the ratios in the liver were similar for the RSA-MTX and the BSA-MTX 
(7.16%w/w) conjugate and so it is possible that the RSA was taken up to a small extent 
by the liver.
The conjugates prepared from BSA and MTX tended to accumulate in the liver (see 
Figure 4.13.4, page 159) and this accumulation appeared to be associated with the 
concentration of MTX in the conjugate. The accumulation of the conjugate in the liver 
may also have been associated with the percentage of protein aggregates that were 
present in the conjugate since these also tended to increase with increased loading of 
MTX in the BSA conjugates. The fact that the RSA-MTX had a low percentage of 
aggregates and only a low accumulation in the liver was seen supports the latter theory. 
The RSA-MTX conjugate demonstrated similar pharmacokinetics after IV administr­
ation, as did the BSA-MTX conjugates of similar MTX loading. It also tended to 
accumulate in the gut, as did some of the BSA-MTX conjugates (e.g. BSA-MTX
II.74%w/w and 13.63%w/w). Thus it appeared to be treated in vivo in a similar manner 
to the BSA conjugates. This may be because, after coating the RSA molecule with 
MTX, it is indestinguishible from BSA-MTX.
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CHAPTER 5:
VISUALISATION AND BODY DISTRIBUTION OF THE CONJUGATES
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5.1 Targeting tn the liver
In the previous chapter the pharmacokinetics of conjugates between MTX and proteins 
(BSA, LA and RSA) were described. The distribution of the conjugates was determined 
over a period of 96 hours. The next step seemed to try to target the conjugates and the 
galactose and mannose receptors found on hepatocytes, and macrophages were chosen 
as the receptors for targeting. In this chapter the distribution of conjugates between 
BSA and galactosamine or mannose are described. In addition, the distribution of two 
BSA-MTX conjugates at time points up to 6 hours after administration is described 
using both organ distribution and whole body autoradiography.
5.1.1 G-BSA and M-BSA.
G-BSA and M-BSA were obtained from Sigma and contained 26 moles galactosamine 
or 28 moles mannose per mole of BSA. These were administered to rats as described in 
section 2.9. Tables A3.28.1 and A3.29.1 show the 125I serum levels determined 
following administration of 125I-labelled G-BSA and M-BSA respectively, over 300 
minutes after administration. The serum levels were compared to those of ‘free* BSA 
(table A3.25.1). Figure 5.1.1 is a plot of log serum concentration versus time for the 
two conjugates and BSA. The concentration of 125I-BSA in serum only dropped from 
13% of the injected dose per ml at 1 minute after injection to 10.8%/ml after 15 
minutes, an actual loss of only 17% of the injected dose. For the G-BSA conjugate the 
levels dropped from 5.23%/ml at 1 minute to 0.3%/ml at 15 minutes. This represented a 
loss of 94% of the original serum concentration. The serum concentrations for M-BSA 
over the experimental period were similar to those of G-BSA. At 1 minute after 
injection the concentration of 125I-M-BSA was 3.6%/ml and at 15 minutes after 
injection was 0.5%/ml. This represented a loss of 86% of the dose. Both G-BSA and 
M-BSA rapidly left the vasculature after IV injection. The loss of serum activity for 
G-BSA was similar to that shown by Duncan et atf65*66-161), for rats that had been 
injected with HPMA copolymers to which had been bound galactosamine linked via a 
diglycyl spacer (4mol% galactosamine per HPMA) and to that described by S to well and 
Lee<162) for G-BSA and M-BSA (30 moles to 1 mole) in female wistar rats.
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Figure 5.1.1:
Concentration of 12J activity in serum following administration 
of 250pg of ^ -B SA , 1 2 3[-M-BSA and 1 2f-G-BSA to rats by 
the IV route. Each point was determined from one rat (n=10 for each protein)
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Organ distribution of 125I activity was determined for BSA, G-BSA and M-BSA at 
various time points up to 5 hours after injection. The results are listed in tables A3.25.2, 
A3.28.2 and A3.29.2 respectively. The reason for the rapid loss of 125I activity from 
serum for both the G-BSA and M-BSA became evident on examination of the organ 
distribution results. Figures 5.1.2 and 5.1.3 show the organ distribution of 125I following 
administration of G-BSA to rats at 15 minutes after injection and at 5 hours. At 15 
minutes the majority of the 125I dose was found to be located within the liver. For the 
two rats investigated at this time point, the actual % of the injected dose present within 
the whole liver were 81.2% and 87.6%. The spleen had taken up approximately 2.5% of 
the injected dose and when compared weight for weight to the liver, the spleen had 
taken up approximately half as much as the liver. The percentage of activity present 
within the heart could be attributed to the blood pool within this organ. For the other 
organs investigated, 125I levels within the organ were greater than could be attributed to 
the contribution of the blood pool. The organ distribution of G-BSA was similar to that 
described for galactosamine linked to HPMA (G-HPMA) (11 mol%)061) (where 90% of 
injected dose was found in liver within 10 minutes). At 5 hours after injection, the 
distribution pattern for the 125I activity had changed. The percentage within the whole 
liver had fallen to 2.3% of the injected dose. It is possible that this activity could have 
been due to the blood within the organ. Indeed for all the organs investigated apart from 
the gut, the activity present in each organ at 5 hours was probably due to the blood pool 
within the organ. Duncan et al(65> also measured levels of radioactivity at 5 hours after 
injection for G-HPMA and found a similar redistribution pattern as described here.
In the stomach and small intestine the 125I levels were elevated compared to the other 
organs. There was approximately 10% of the injected dose present in both the stomach 
and small intestine at 5 hours after injection. At 15 minutes after injection the total % of 
125I activity present in the stomach and small intestine ranged from 0.9 to 3 %. This had 
increased at 30 minutes after injection to between 1.6% and 12% and at 1 hour after 
injection the activity within the gut appeared to peak (actual concentrations were 11 to 
22% of the dosein both the stomach and small intestine). The reason for the progressive 
accumulation of the 125I in the gut with time was attributed to bile secretion following
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Figure 5.1.2:
Organ Distribution of 125I activity, 15 minutes after administration
of 250pg of 1 2 5I-G-BSA to rats by the IV route. Each
bar was determined from a single rat Results are expressed
as a ratio of activity in lg of organ divided by activity in 1 ml of blood.
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Figure 5.1.3:
Organ Distribution of ,25I activity, 5 hours after IV administration 
of 250pg of 1 2 5I-G-BSA to rats. Each bar was determined from a single animal. 
Results are expressed as a ratio of activity in lg of organ divided 
by activity in lml of blood.
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the rapid uptake of the G-BSA by the liver.
Figures 5.1.4 and 5.1.5 show the organ distribution for M-BSA at 15 minutes and 5 
hours after injection. There were subtle differences in the distribution of 125I after 
administration of M-BSA compared to G-BSA. At 15 minutes 71.4% and 62.7% of the 
injected dose for M-BSA had accumulated in the whole liver of the two rats 
investigated. This is slightly less than for the G-BSA. The difference in activity 
between G-BSA and M-BSA was found to be present mainly in the spleen but also in 
the lung and kidney. When compared on a gram for gram basis the percentage 
accumulated in the spleen was approximately the same as the liver for M-BSA. (An 
average of 5.3% of the injected dose was present in lg of liver and 4.2%/g for spleen). 
But for kidney and lung the levels were at least one third of those in the liver. Duncan 
et al(65> administered an HPMA copolymer which contained 2 mol% mannosamine and 
found that after 1 hour only 11 % of the injected dose was present in the liver in rats 
(compared to 69 % of G-HPMA with 2 mol% sugar). This difference could be 
explained by the receptor which takes up mannose terminating substrates in the liver is 
less sensitive than the receptor for galactose terminating substrates. In this experiment 
it was found that the M-BSA and G-BSA were taken up to a similar extent.
The % of 125I present in the gut of animals dosed with 125I-M-BSA was less than for 
animals dosed with G-BSA. The stomach and small intestine of animals dosed with 
M-BSA both had ratios (activity in lg of organ divided by activity in lml of whole 
blood) of approximately 0.5 at 15 minutes. (This activity could be attributed to the 
blood pool within the organ). However the stomach and small intestine of animals 
dosed with G-BSA had ratios of approximately 1.0, at 15 minutes although the peak of 
radioactivity in the gut for M-BSA appeared to occur at the same time as for G-BSA at 
between one and three hours. Like G-BSA, at 5 hours after administration of 
125I-M-BSA the majority of the 125I activity was found to be present in the stomach 
(7.2-7.7% of the injected dose) and small intestine (2.6-8%). The activity in the liver 
had fallen to approximately 3.4% of the total activity injected. At 5 hours the level of 
125I activity present in lg of spleen was approximately 0.5% and was actually more
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Figure 5.1.4
Organ Distribution o fI2̂  activity 15minutes after administration 
of 250pg of 12 5I-M-BSA to rats by the IV route. Each bar 
was determined from a single rat. Results are expressed as a ratio 
of the activity in lg of organ divided by the activity in lml blood.
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Figure 5.1.5:
Organ Distribution of 125I activity 5 hours after administration 
of 250pg of 1 2 3 I-M-BSA to rats by the IV route. Values are 
expressed as a ratio of activity in lg of organ divided by activity 
in lml of blood. Each bar was determined from a single rat.
Ratio CPM 9 
in lg of 
organ/CPM 8  
in lml of 
blood 7
Liver spleen heart lung kidney stomach sm. int.
-179-
than twice that present in lg of liver (0.21%). This may be because of the rapid release 
of 125I following degradation of the M-BSA by the liver. The liver has two mechanisms 
for removing break-down products. It is able to secrete substances into the bile, and 
substances can be removed by the blood stream. The spleen only has one mechanism 
and would pass its break-down products back into the blood stream. This may be a 
slower process than the secretion process.
Both G-BSA and M-BSA could be used as targeting agents to selectively deliver 
substances to the liver. The fact that there are subtle differences in the organ 
distribution pattern for the conjugates suggests that they have a different fate once they 
reach the liver. In addition to targeting to the liver, the M-BSA also accumulates in the 
spleen. The spleen forms part of the RES and is rich in phagocytosing cells. The liver is 
composed of several cell t y p e s / 163) The parenchymal cells or hepatocytes are known to 
have a receptor for galactose on their cell surface/6) The other major cell types in the 
liver are the Kupffer cells and the sinusoidal endothelial cells. The Kupffer cells are 
sometimes referred to as liver macrophages and they also form part of the RES. 
Macrophages are known to have a receptor for mannose terminating glycoproteins^1)- 
In addition, macrophages have a receptor for galactose bearing substrates, particularly if 
they are particulate in n a t u r e 0 6 4 ,i6 5 ) .  Since the characteristics of the G-BSA were 
unknown, with regard to the amount of aggregated protein present, it was possible that 
the G-BSA could have been taken up by this cell type. However, because of the 
differences in organ distribution of G-BSA and M-BSA, it was predicted that the 
G-BSA had targeted to the hepatocytes of the liver and the M-BSA had targeted to the 
Kupffer cells and so these two BSA conjugates could be used to selectively deliver 
MTX to different cell types within the liver. In order to verify this prediction, a 
collagenase perfusion of the liver was carried out following administration of the 
G-BSA or M-BSA. The perfusion was carried out 15 minutes after injection, because at 
this time the highest 125I levels were seen in the liver.
Following the collagenase perfusion, the liver could be separated into 2 fractions. One 
of these consisted almost entirely of hepatocytes and the other, it was hoped, consisted
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of non-parenchymal cells. When the perfusion was carried out initially, it was found 
that there was no problem in separating the hepatocytes from the other cell types using 
differential centrifugation techniques. However, after removal of the hepatocytes from 
the other cells, it was found that the cell suspension was contaminated with a large 
number of vesicles which formed due to the breakdown of the parenchymal cells. These 
vesicles sedimented at 500g, the same g force that centrifuged the non-parenchymal 
cells. Van Berketf130) used protease E to selectively breakdown the hepatocytes and 
vesicles which contaminated this cell suspension. However when this technique was 
tried on the cell suspension, it was unsuccessful since it also seemed to remove any 
non-parenchymal cells that had been in the cell suspension, leaving what could only be 
described as a gunge when viewed under the microscope. A photograph was taken of 
the hepatocytes, which had been stained with toluidine blue, and viewed under the light 
microscope. This is shown in Figure 5.2.
Because of the difficulties in obtaining a suspension which contained non-parenchymal 
cells, it was hoped that the % of 125I activity which had been taken up by this cell 
fraction could be calculated after examination of the parenchymal cell suspension. The 
number of parenchymal cells present within the rat liver has been calculated at 128 ± 7 
x 106 cells per gram*129). After calculation of the activity present within a known 
number of hepatocytes, the fraction of activity taken up by non-parenchymal cells could 
be determined from the total activity which had been taken up per gram of liver.
The 125I activity taken up by the heptocytes of a rat dosed with 125I-G-BSA was 3060 
CPM/106 cells. One gram of liver, determined after the blood pool had been removed 
from the liver contained 392600 CPM. If it is assumed that the rat, used in this 
experiment, did have 128 x 106 hepatocytes per gram of liver, then the radioactivity 
present within this cell-type accounted for 99.8% of the dose present in the liver. The 
G-BSA perfusion was repeated on two other rats. The percentage of the liver uptake 
which was due to uptake by the hepatocytes was found to be 103.7% and 99.4% 
for these two rats. 101 ± 1.372 % of the total activity within the liver was taken up by 
the hepatocytes in the three rats investigated. It could be assumed that very little G-BSA
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Figure 5.2: Hepatocytes viewed under the light microscope. Cells were stained with 
toluidine blue and viewed using a Zeiss Ultraphot fitted with a 35mm camera.
a. Magnification 440X
b. Magnification 720X
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was taken up by other cells of the liver.
The % of 125I taken up by hepatocytes following administration of 125I-M-BSA was 
20.35±0.664% of the total liver activity. Providing total radioactivity was recovered, 
this meant that 79.65% of the liver activity had been taken up by non-parenchymal 
cells. Hepatocytes represent approximately 92% of the volume of the liver<166> and so 
this is an explanation for why these cells took up some of the radioactivity (it could 
have occurred purely by non-specific pinocytosis). Duncan et aK66) investigated the 
uptake of mannose-HPMA by two fractions of liver cells in a similar manner to 
described here. They demonstrated that 67% of the total liver radioactivity was present 
in non-parenchymal cells. The liver perfusion experiment has pro ved that G-BSA 
could be used as a selective targeting agent to deliver drugs to the hepatocytes. The 
majority of M-BSA was assumed to accumulate in the non-parenchymal cells of the 
liver. In addition, this conjugate was found to accumulate in the spleen. This conjugate 
could be used to target drugs in the treatment of diseases which affect the RES.
An attempt was made to covalently bind MTX to M-BSA and G-BSA using the 
carbodiimide reaction described previously. However, in both cases, following addition 
of the MTX solution to a solution containing the BSA conjugate, and before ECDI had 
been added, there was extensive precipitation of the protein. Although this precipitation 
occurred, it may still have been possible to form a conjugate between M-BSA or 
G-BSA and MTX, so the ECDI was added and incubation was carried out for 24 hours 
at 4°C. However, separation of the MTX and protein fractions after incubation, on a 
Biogel P4 column and analysis of each fraction in a UV spectrophotometer at 375nm 
showed that no reaction between the protein and MTX had occurred. It is difficult to 
explain why the precipitation of the protein had occurred. The pH of the solution did 
not alter, when MTX was added. The only explanation could be that the MTX 
interacted with the protein and led to its aggregation.
In the experiments where BSA-MTX conjugates were administered to rats and serum 
levels were measured over a period of 96 hours, it was found that a proportion of the 
radioactivity did accumulate in the liver. Ratios of activity in lg of liver divided by
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activity in lml of whole blood ranged from 0.5 to 2, at 24 hours after administration of 
the conjugates. After performing the experiments with G-BSA and M-BSA it became 
apparent that they were taken up very rapidly indeed, within 15 minutes of injection. If 
one of the mechanisms which accounted for the uptake of G-BSA or M-BSA also 
accounted for the uptake of the MTX-BSA by the liver, then it may be that the 
accumulation in the liver was in fact more significant than at first realised. The earliest 
time point where levels of conjugates were measured was at 24 hours. It was shown 
using the G-BSA and M-BSA that by 5 hours the levels in the liver were significantly 
less than at 15 minutes. It was decided to carry out a similar experiment using two 
BSA-MTX conjugates of different MTX loadings and to compare the organ distribution 
of these to that of free BSA and the G-BSA and M-BSA.
In addition the distribution of LA following IV administration (as described in section 
2.9.1) was determined. This protein rapidly left the blood-stream following administr­
ation to rats, but excretion in the urine did not account for the clearance. Although 
levels of LA in serum decreased from 1.15%/ml at 15 minutes to 0.43%/ml at 4.5 hours 
(the end of the distribution phase), an actual loss from plasma of 63%, only 45-50% of 
the dose was excreted in 24 hours. In addition a 250g rat has approximately 9.7 ml of 
seru m O 44), the serum concentration determined at the 15 minute time point was only
1.15%/ml and this would only account for 11.2% of the dose in the blood stream. The 
remainder of the dose must have accumulated in a location outside the blood stream. 
Analysis of the organs at 28 hours did not elucidate where the remainder of the dose 
had accumulated and so it was decided to analyse organ samples at earlier time points 
after injection.
5.2 Organ Distribution o f BSA-M TX Conjugates and I.A.
5.2.1 BSA-MTX
Table A3.25.1 lists the serum concentrations determined over a 5 hour period, for 125I 
activity following IV administration of 125I-BSA to rats. Tables A3.26.1 and A3.27.1 
list the serum levels determined for the 4.54%w/w conjugate and the 11.55%w/w
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Figure 5.3.1:The Log %125I activity/ml of Serum following administration of
200pg of125I-BSA,125I-BSA-MTX (4.54%w/w) and125I-BSA-MTX (11.55%w/w)
to male wistar rats by the IV route.
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conjugate respectively. Figure 5.3.1 is a plot of log serum 125I levels versus time for 
both conjugates and ‘free* BSA. Both conjugates demonstrated lower plasma levels than 
'free' BSA. There appeared to be a relationship between concentration of MTX in the 
conjugate and the actual serum levels achieved since the 11.55%w/w conjugate 
demonstrated lower levels than the 4.54%w/w conjugate.
Clearance of the 11.55%w/w conjugate was associated with a rapid initial loss of 
radioactivity. At 1 minute, the serum levels were 6.95 and 7.3% of the injected dose for 
the two rats investigated. By 20 minutes the levels had fallen to 1.24% and 0.91% of 
the radioactivity. This represented a loss of approximately 85 % of the original plasma 
concentration in the 19 minute period. For the 4.54%w/w conjugate, the clearance from 
serum was less rapid. At 1 minute the concentration of 125I was 9.6% and 10% of the 
injected dose and this had fallen to 6.36%±0.095 at 20 minutes after injection (a loss 
from serum of only 34.7% from the one minute value). The BSA was cleared even less 
rapidly. Levels were 12.7 and 13% of the injected activity at 1 minute and 10.9 and
11.4%/ml at 20 minutes. This represented a loss from serum of only 13% of the 1 
minute value.
Organ distribution of 125I following administration of the 125I labelled BSA and 
conjugates was determined, to ascertain where the conjugates had accumulated after 
leaving the blood stream. Table A3.25.2 lists the organ distribution of BSA and Tables 
A3.26.2 and A3.27.2 list the organ distribution of the conjugates at various time points, 
up to 5 hours after administration. Figures 5.3.2 and 5.3.3 are histograms showing the 
organ distribution of the BSA and conjugates at 15 minutes and 5 hours after 
administration.
15 minutes after administration of BSA, the activity found in each of the organs, if 
compared on a gram for gram basis, was very similar and could be attributed to the 
blood pool within the organ. The actual percentages present in lg of liver, spleen, heart, 
lung and kidney ranged from 1 to 2 % of the injected radioactivity. For the G.I.T., the 
percentages within the organs were slightly lower at between 0.25 and 0.39% per gram 
of organ.
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Figure 5.3.2: Organ Distribution o f 1251 activity, 15 minutes post administration 
of 125I-Labelled BSA, BSA-MTX (4.54%w/w) and BSA-MTX (11.55%w/w) to rats, b; 
IV injection. Each bar is a single determination.
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Figure 5.3.3: Organ Distribution of 1251 activity 5 hours post administration 
of 123I-Labelled BSA, BSA-MTX (4.54%w/w) and BSA-MTX (11.55%w/w) to 
rats by IV injection. Each bar is a single determination.
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15 minutes after injection, for the 4.54%w/w conjugate, the radioactivity in each of the 
organs appeared to be elevated when the ratios (activity in lg of organ/ activity in lml 
of blood) were compared to ‘free* BSA, although the actual % of the injected dose in 
each organ were similar. (Range 0.9 to 1.9% for liver, spleen, heart, lung and kidney 
and 0.14 to 0.34% for the G.I.T.). No particular organ appeared to selectively take up 
the 125I.
For BSA-MTX (11.55%w/w) the majority of radioactivity appeared to have 
accumulated in the liver and spleen. The actual percentage of the injected dose found in 
the whole liver, at 15 minutes was 67.15 and 61.43% for the two animals investigated. 
The spleen had taken up between 3.3 and 3.9% of the injected dose. The other organs 
all demonstrated a higher ratio (activity in lg/activity in lml blood) than for the BSA 
and the 4.54%w/w conjugate, but the actual percentages taken up were similar.
By 5 hours after administration, the distribution pattern for the 125I activity had changed 
for the 11.55%w/w conjugate. Levels in the liver had fallen to 5.1 and 4.2% of the 
injected dose for the two animals investigated, and although the ratio was still elevated 
compared to the other conjugate and free BSA the actual percentage of the dose present 
was less for the 11.55%w/w conjugate. In the whole spleen the percentage had fallen to 
0.2% of the injected dose, again the ratio was elevated compared to BSA and the 
4.54%w/w conjugate but the actual percentage of the dose was less. For BSA the 
percentage in whole liver was 8.2% and 11.9% and for spleen was 0.52% and 0.63% 
for the two animals investigated. For the BSA-MTX 4.54%w/w conjugate the levels in 
the whole liver were 7.5% and 7.3% and the spleen were 0.35% and 0.43% of the 
injected dose for the two animals investigated. Both BSA and BSA-MTX (4.54%w/w) 
actually exhibited higher serum levels at 5 hours, compared to the 11.55%w/w 
conjugate, and this could, at least partly, explain why higher % of activity were found 
in the organs of rats which had been dosed with BSA and the low strength conjugate.
It appeared that most of the activity which had originally been present in the liver 
following administration of BSA-MTX (11.55%w/w) had been transferred to the G.I.T. 
At 5 hours after administration, actual percentages were 12.3% and 13% in the stomach 
and 6.1% and 8.0% in the small intestine. Figure 5.3.4 is a plot showing the 125I ratio in
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Figure 5.3.4: Uptake of 12SI activity by the liver following administration of 125I-BSA 
,25I-BSA-MTX (4.54%w/w) and 12̂ -BSA-MTX (11.55%w/w) to rats by IV 
injection. In addition the uptake by the gut (stomach + intestine) is shown for 
BSA-MTX (11.55%w/w). Each point is a single determination.
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the liver for each of the conjugates and BSA over the 5 hour experimental period. In 
addition it shows the appearance of activity in the G.I.T., (levels in the stomach and 
small intestine were added together) for the 11.55%w/w conjugate. Ratios in the other 
organs investigated were not significantly different at 5 hours to those calculated at the 
15 minute time point, for the 11.55%w/w conjugate.
For the 4.54%w/w conjugate, the ratios calculated were slightly elevated compared to 
BSA at the 5 hour time point. But in all organs apart from the G.I.T they were not 
significantly different from the 15 minute ratios. Actual percentages present in the 
stomach were 12.9% and 12% for the two rats investigated and in the small intestine 
the levels were 5.5% and 8.6% at 5 hours after administration, compared to levels of 
between 1.7 and 4.7% in the stomach and small intestine at 15 minutes. The 
accumulation of 125I in the gut could be attributed to bile secretion, following uptake of 
the conjugate by the liver. Even free BSA showed elevated levels in the gut 5 hours 
after administration. Levels had risen from between 1.0% and 3.6% at 15 minutes to 
between 5.0% and 6.1% of the injected dose at 5 hours for BSA. Thus it could be 
assumed that even free BSA was taken up to some extent by the liver and then the 
radioactivity was transferred to the bile, to eventually arrive in the gastro-intestinal 
tract. Figure 5.3.5 shows the ratio (CPM in whole organ divided by CPM in 1ml of 
blood) in the liver at 15 minutes after injection for BSA, BSA-MTX, G-BSA and 
M-BSA. The G-BSA was found to exhibit the highest ratio in the liver and this was 
followed by M-BSA. Although BSA-MTX (11.55%w/w) was not as good at targeting 
to the liver as the sugar-BSA conjugates were, a substantial percentage of the 
radioactivity injected did accumulate in the liver. Analysis of these BSA-MTX 
conjugates showed that uptake by the liver was associated with the loading of MTX in 
the conjugate. The 11.55%w/w conjugate was taken up rapidly by the liver. 
Approximately 65% of the injected dose was located within the liver by 15 minutes 
after injection. Analysis of the two conjugates investigated by FPLC (see section 4.1) 
showed that approximately 33% of the protein in the 11.55%w/w conjugate was present 
in an aggregated form and 23.1% of the protein was aggregated in the 4.54%w/w 
conjugate. Protein aggregation may contribute to the liver accumulation of the
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conjugates^159). Since such a high concentration of the conjugate was found to be 
located within the liver for the high strength conjugate, it was decided to carry out a 
collagenase liver perfusion, 15 minutes after administration of the conjugate to rats. The 
method used was the same as for G-BSA and M-BSA.
Three rats were analysed. The activity present in lg of perfused liver for rat (1) was 
327195 CPM. The activity in the hepatocytes was 981 CPM /  106 cells. Thus the % of 
liver radioactivity associated with the hepatocytes (assuming 128 x 106 cells per gram) 
was 38.3%. The % of the liver radioactivity that was found to be present within the 
hepatocytes for the 3 rats investigated was 41.43 ± 3.08%. Thus 58.57% of the liver 
activity had been taken up by non-parenchymal cells assuming all radioactivity had 
been collected, and was present within the two cell types. The suspension containing 
mainly hepatocytes was centrifuged (500g) and supernatant and pellet measured for 
CPM separately. The activity in the supernatant was negligible. The BSA-MTX 
(11.55%w/w) had been taken up by both hepatocytes and non-parenchymal cells. 
Because hepatocytes make up 92% of the volume of the liver, the actual percentage of 
radioactivity taken up by each non-parenchymal cell was greater than the amount by 
each hepatocyte. Thus non-parenchymal cells would be exposed to a greater dose of 
BSA-MTX (11.55%w/w) than the hepatocytes. This could be used as the basis of a 
passive targeting technique to take MTX to diseased cells within the RES. Certain 
viruses are known to accumulate in macrophages e.g. pox viruses begin their infectious 
cycle in this cell type<157) and Leishmaniasis is known to proliferate solely in the 
phagolysosomes of macrophages^167).
The 4.54%w/w conjugate did not appear to accumulate in the liver to a greater extent 
than it did in any of the other organs investigated. It would appear that conjugates with 
a lower concentration of MTX may have a more widespread distribution, than either 
high strength conjugates, which accumulate in the liver or ‘free* BSA. (BSA appeared 
to be retained in the vasculature whereas the 4.54%w/w conjugate had a larger volume 
of distribution which indicates that it could leave the blood stream and would appear at 
higher concentration than BSA in the tissue fluid). Co-conjugation of the BSA-MTX
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with a selective targeting agent may allow specific uptake of the conjugate by the target 
cell. Cells which did not exhibit the receptor for the targeting agent may be exposed to 
extracellular BSA-MTX, but access into the cell would be limited to fluid-phase 
pinocytosis. Cells with the receptor would take up the conjugate more rapidly/70)
5.2.2 LA.
Table A3.30.1 lists the serum concentration of 125I activity determined following IV 
administration of 125I-LA. Figure 5.4.1 is a plot of log % of radioactivity in serum 
versus time for LA and BSA. LA was cleared more rapidly from serum than BSA. One 
minute after administration of LA the serum concentrations of 125I were 8.52% and 
10.51%/ml for the two rats investigated. At 20 minutes after injection the serum 
concentrations of LA were 1.138% and 0.898%/ml for the two rats. The 20 minute 
concentration represented a loss of serum activity of 89.3% from the one minute value. 
Over the same period only 13% of the BSA was cleared from serum. Distribution of the 
125I was determined in order to find out where the radioactivity had gone. Table 
A3.30.2 lists the organ distribution determined for LA at various time points after 
administration.
Figures 5.4.2 and 5.4.3 show the organ distribution of LA at 15 minutes and 5 hours 
after administration. At 15 minutes it was shown that the majority of the 125I was 
located in the kidney. Actual percentage of 125I in this organ was 48.5% and 52.1% of 
the injected dose for the two rats investigated. For the other organs the 125I activity was 
low. The % of 125I activity in lg of the remaining organs ranged from 0.22% (stomach) 
to 0.6% (lung). By 30 minutes after injection the concentration of 125I in the kidney had 
decreased to 11.5%. The activity in the bladder was measured at this time point and was 
found to contain approximately 0.3% of the injected dose, so the loss of activity from 
the kidney was not associated with accumulation in the bladder. Either the 125I had 
already been voided from the bladder at this time point, or the 125I-LA had been 
reabsorbed from the kidney. Levels found in the gastro-intestinal tract at 30 minutes 
after injection were quite high at between 17% to 32% of the injected dose (sum of 
stomach and small intestine activity). At no other time point were the 125I levels in the
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Figure 5.4.1:Serum concentration of 123I activity following IV administration 
of 250pg of l2 5 I-BSA and l2\-LA  to rats.
Each point was determined from a single rat (n=10 for BSA,n= 8  for LA)
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gut found to be as high as this. When the total activity found in all the organs 
investigated was added together, approximately 73% and 78% of the injected 
radioactivity could be accounted for in the two rats investigated at 30 minutes. The 
same calculation was carried out for the 15 minute values and approximately 70% and 
75% of the injected dose was accounted for at this time point. This calculation would 
overestimate the 125I accounted for because the concentration in serum was effectively 
added to the calculation twice, since no correction for the activity within the blood pool 
of each organ was made. Since total activity in the body at both time points was very 
similar, this implies that the LA was reabsorbed from the kidney and not excreted in the 
urine.
Interestingly, at 1 hour after injection, the measured value for 125I in the kidney was 
between 24 and 47% of the injected dose and this was higher than the 30 minute value. 
There are two explanations for this. Either the differences in kidney uptake at the two 
time points were due to between-rat biological variation, or the 125I activity that had 
been taken up at 15 minutes had been reabsorbed from the tubule by 30 minutes. This 
had been reintroduced into the circulation and then had accumulated in the kidney again 
by 1 hour after administration. In order to determine which explanation was correct, the 
urine that was excreted during the experimental period should have been collected and 
analysed. Unfortunately, it was not. Total radioactivity, calculated from the organs 
analysed was 44.1 and 67.2% of the radioactivity for the two rats analysed at 1 hour 
and so unless the radioactivity had redistributed into some of the organs that were not 
analysed, it can be assumed that some of the radioactivity had been excreted.
At 5 hours after administration of the LA (see Figure 5.4.3) the percentage of 125I 
activity present within the kidney had fallen to approximately 1.3% of the injected dose. 
Radioactivity appeared to have accumulated in the gastro-intestinal tract since levels in 
this organ were higher than for the other organs. Between 7.6% and 13% of the injected 
activity was found in the stomach or intestine of the two rats investigated. Addition of 
the activities found in the individual organs accounted for 32% and 40% of the injected 
dose. This implies that some of the radioactivity had been excreted from the body.
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Figure 5.4.2:Organ distribution of 12̂  activity, 15 minutes after IV 
administration of 250pg of 1 2 5I-LA to rats. Each bar was 
determined from one rat Results are expressed as a ratio of 
activity in lg  of organ divided by activity in 1 ml of blood.
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Figure 5.4.3:Organ Distribution of 125I activity, 5 hours after IV 
administration of 250pg of 1 2 5 I-LA to rats. Each bar was 
determined from one rat Results are expressed as a ratio 
of activity in lg of organ divided by activity in 1 ml of blood.
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The seven organs chosen for analysis in the 5 hour organ distribution studies for LA did 
not account for the entire body dose of the protein. Some radioactivity was located 
within other organs which were not investigated. Whole body autoradiography was used 
in order to determine where the remainder of the injected dose was located. It was also 
carried out for the BSA, G-BSA, M-BSA and BSA-MTX. For BSA and the BSA-MTX 
conjugates whole body autoradiography was carried out at 15 minutes and 6 hours after 
administration of the conjugate. For the LA, G-BSA and M-BSA it was carried out at 
15 minutes after administration only. The results are shown in Figures 5.5.1 to 5.5.9.
S3  Whole Body Autoradiography for BSA-Conjugates and LA.
Figure 5.5.1 shows the autoradiogram obtained for BSA, 15 minutes after administr­
ation of 125I-BSA to a 200g rat. The autoradiogram was obtained by exposing 
longitudinal slices of the rat to film. This figure shows that highest concentrations of 
BSA were seen in the blood and highly vascularised organs. The heart contents gave an 
indication of the 125I content of the blood and the interior of the heart was darker than 
for any of the organs. An interesting result is seen in the stomach, the lower part of the 
contents were labelled but the upper part were not. This supports the theory that 125I 
activity entered the stomach due to bile secretion into the intestine followed by reflux 
from the intestine into the stomach. A small amount of radioactivity had localised in the 
thyroid. A trace of radioactivity was found in all organs apart from the CNS.
Figure 5.5.2 shows the autoradiogram obtained 6 hours following administration of 
BSA. There was little obvious difference in the distribution of 125I activity seen at 6 
hours compared to that at 15 minutes. The lower stomach contents were labelled but the 
upper stomach contents were not. The 125I activity had not reached the faeces at this 
point. Even 6 hours after injection the blood vessels could be seen to have a greater 
activity than any of the organs. This is seen most clearly in the liver where the dark 
blood vessels can be seen on the lighter background of the liver. The activity in the 
spleen was lower than in the liver and kidney. BSA had not entered the brain and it had 
not appeared in the eye. The skin appeared to be heavily labelled but this could be 
attributed to the blood supply running through it. A proportion of the radioactivity had
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Figure 5.5.1: Whole Body Autoradiography of a Rat, 15 minutes after administration of
200pg (20pCi) of 125I-BSA. Each section was exposed to hyperfilm for 2 weeks.
HEAD TAIL
Figure 5.5.2: Whole Body Autoradiography of a Rat, 6 hours after administration of
200pg (20pCi) of 125I-BSA. Each section was exposed to hyperfilm for 2 weeks.
HEAD TAIL
Figure 5.5.3: Whole Body Autoradiography of a Rat, 15 minutes after administration of 
200pg (20pCi) of 125I-BSA-MTX (4.54%w/w). Each section was exposed to hyperfilm 
for 2 weeks.
HEAD TAIL
Figure 5.5.4: Whole Body Autoradiography of a Rat, 6 hours after administration of 
200pg (20pCi) of 125I-BSA-MTX (4.54%w/w). Each section was exposed to hyperfilm 
for 2 weeks.
HEAD TAIL
Figure 5.5.5: Whole Body Autoradiography of a Rat, 15 minutes after administration of 
200pg (20pCi) of 125I-BSA-MTX (11.55%w/w). Each section was exposed to hyperfilm 
for 2 weeks.
HEAD TAIL
Figure 5.5.6: Whole Body Autoradiography of a Rat, 6 hours after administration of 
200pg (20pCi) of 125I-BSA-MTX (11.55%w/w). Each section was exposed to hyperfilm 
for 2 weeks.
HEAD TAIL
Figure 5.5.7: Whole Body Autoradiography of a Rat, 15 minutes after administration of
200pg (20pCi) of 125I-G-BSA. Each section was exposed to hyperfilm for 2 weeks.
HEAD TAIL
Figure 5.5.8: Whole Body Autoradiography of a Rat, 15 minutes after administration of
200pg (20pCi) of 125I-M-BSA. Each section was exposed to hyperfilm for 2 weeks.
HEAD TAIL
Figure 5.5.9: Whole Body Autoradiography of a Rat, 15 minutes after administration of
200pg (20pCi) of 125I-LA. Each section was exposed to hyperfilm for 2 weeks.
HEAD TAIL
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appeared in the thyroid. This may have been due to some degradation of the 125I-BSA.
Figure 5.5.3 shows the autoradiogram obtained for the BSA-MTX (4.54%w/w) 
conjugate, 15 minutes after injection. There did not appear to be an obvious difference 
in this autoradiogram compared to that obtained for BSA. The majority of the activity 
was seen in the blood stream and highly vascularised organs such as the liver, lung and 
kidney. It is impossible to determine whether the activity in these organs had actually 
extravasated or was still present in the blood stream. Again the activity in the spleen 
was lower than the liver. The lower stomach contents were labelled but the upper 
contents were not, as for BSA. Figure 5.5.4 shows the autoradiogram, obtained 6 hours 
post injection, for a rat dosed with the 4.54%w/w conjugate. Six hours after injection it 
was seen that a high proportion of the activity was located in the thyroid. This was 
higher than for the free BSA and may indicate a greater degradation of the conjugate 
compared to BSA. The stomach contents were also highly labelled, indicating that the 
125I had been transferred from the liver, which would probably have been the site of the 
degradation. Indeed, the concentration in the liver had decreased compared to the 
concentration at 15 minutes and also it was less than the concentration within the blood 
vessels at this time point.
Figure 5.5.5 shows the autoradiogram obtained for the BSA-MTX (11.55%w/w), 15 
minutes after administration. This autoradiogram showed that highest levels of 
radioactivity were present within the liver and spleen. The lower portion of the stomach 
contents were labelled, indicating that some of the activity had been transferred into the 
bile from the liver, even at this early time point. Levels which could probably be 
attributed to the blood pool within the organ were seen in the lung and bone marrow. 
Low levels were detected in most other organs apart from the brain. Figure 5.5.6 shows 
the autoradiogram obtained 6 hours after administration of BSA-MTX (11.55%w/w). At 
this time point levels in the liver and spleen were considerably lower than at 15 
minutes. The stomach contents were very highly labelled and the thyroid appeared to 
have accumulated a considerable amount of the dose. All other organs demonstrated a 
lower activity than at 15 minutes.
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Figure 5.5.7 shows the autoradiogram obtained 15 minutes following administration of 
G-BSA. Extremely high levels of the conjugate were seen in the liver and spleen. There 
was very little activity present within the blood stream and other organs, but levels in 
the lung, bone marrow and kidney were higher than the other organs.
The autoradiogram obtained for M-BSA, 15 minutes after injection is shown in figure 
5.5.8. The majority of the activity was detected within the liver and spleen. Very little 
activity had remained in the blood stream. The autoradiogram is not significantly 
different from the one obtained for G-BSA.
Figure 5.5.9 shows the autoradiogram obtained 15 minutes after injection of LA. The 
majority of radioactivity was found to be located within the kidney. The remaining 
activity appeared to be evenly distributed throughout the body. There was no evidence 
of uptake by the thyroid. There was a very small amount of activity present within the 
interior of the lower part of the stomach. There did not appear to be any activity present 
within the brain.
Summary of  the Autoradiography results.
The results obtained for the autoradiography experiments were consistent to those 
obtained for the organ distribution studies in the previous section. G-BSA and M-BSA 
were selectively taken up by the liver and spleen and it was difficult to distinguish 
between the two autoradiograms obtained for these conjugates. It was not anticipated 
that the G-BSA would be taken up by the spleen. However if this conjugate contained 
any aggregated protein, this would account for its uptake by this organ. Analysis of the 
G-BSA and M-BSA by FPLC on the Superose 12 column was impossible, since it was 
found that both conjugates bound very strongly to the Superose.
BSA, 5mg, by IV administration did not seem to selectively accumulate in any organ. It 
was mainly found in organs with a rich blood supply and it was impossible to tell 
whether the 125I activity was present in these organs within the blood stream, or 
whether it had actually extravasated into the tissue fluid of the organ. A small
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proportion of the 125I dose was found to have accumulated in the thyroid. This could be 
due to the injection of a small amount of unconjugated iodine present in the original 
solution, or it could be due to break down of the BSA. Further evidence for the 
breakdown of BSA was that it appeared in the stomach at quite a high concentration, at 
6 hours after injection. The fact that the accumulation in the stomach only occurred in 
the lower part of it, implied that the 125I reached the stomach from the intestine and it 
probably reached the small intestine following secretion from the liver. To enter the 
bile, the conjugate would have had to be taken up by the cells of the liver.
The low strength conjugate of BSA-MTX (4.54%w/w) did not demonstrate a different 
distribution pattern from ‘free’ BSA at 15 minutes after injection. However, 6 hours 
after injection a greater proportion of the activity was present in the thyroid and this 
may indicate a greater degradation of the protein. No organ appeared to selectively take 
up the 125I following administration of 125I-BSA-MTX (4.54%w/w).
The BSA-MTX (11.55%w/w) conjugate was found to accumulate in the liver and 
spleen, 15 minutes after administration and the activity in the other organs was very 
low. Six hours after administration, the activity had redistributed. A large proportion 
was found in the gut and thyroid, indicating degradation of the conjugate.
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CHAPTER 6:
Transport Experiments using two cell-Iines in vitro; Caco-2 and BAE-1 Cells. 
Uptake of BSA conjugates by Macrophages in vitro.
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6.1. Caco-2 cells.
Caco-2 cells were used as a model cell-line and the experiments were carried out at the 
ADDR department at Ciba Geigy. Caco-2 cells were originally obtained from an adult 
human colon carcinoma. They spontaneously differentiate in vitro, to form well 
polarised monolayers joined by tight junctions, with well developed apical micro­
villi/168*169) Caco-2 cells express large amounts of disaccharidases and peptidases 
which are typical of the small intestine/170*171) e.g. they secrete sucrase at a 
concentration approximately 50% of the small intestine and 50 times that of the 
colon/170) Cells demonstrate apical microvill/172*173).
As a model for the intestinal enterocytes, Caco-2 cells are probably the most useful 
cell-line which have been found to date. However, when using them as a model of the 
small intestine, care should be taken when interpreting the results. It must not be 
forgotten that they are malignant cells and as such behave differently to non-neoplastic 
cells, in their increased requirements for glucose, their production of large quantities of 
lactic acid and in their accumulation of glycogen/174) Rather than modelling small 
intestinal cells, there is evidence that they may resemble foetal colonic cells/174*175) e.g. 
in their similar functional characteristics for Na+-sugar co-transport in the brush border 
membrane^176) and in their secretion of newly synthesised lipoproteins/177) Since the 
Caco-2 cell-line was used purely as a training exercise these factors did not present a 
problem.
The protocol for filter culture had been established and it was known that a confluent 
monolayer was formed, 15 days after seeding the cells on to the filters/133) Certain 
parameters were measured to ensure that the filters used in each of the experiments did 
actually have a monolayer of cells growing on them. These involved measurement of 
electrical resistance, the transport of mannitol (a fluid phase marker) across the cell 
layer and examination of the cell coated filter under the electron microscope. The filters 
used in these experiments were Millicell HA. These are opaque and therefore cells 
could not be viewed under the light microscope. Thb transport of three solutes across
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the Caco-2 cell barrier was investigated. These solutes were 14C-Mannitol, 3H-PEG 900 
and 14C-PEG 4000. Mannitol is a fluid phase marker. It is a very hydrophilic molecule 
and cannot enter cells by diffusion. Therefore, to crosc the Caco-2 cell barrier, it must 
either be transported by transcytosis (through the cell) or cross the monolayer by 
paracellular passage (between the cells). The two PEG samples would give information 
about the size selectivity of the monolayer. However PEGs are polydisperse polymers 
and the degree of polydispersity can vary from batch to batch, so care must be taken in 
interpreting the results. Two HPLC techniques were used to investigate the 
polydispersity of the PEGs used.
6.1.1 Investigation of PEGs using HPLC.
The HPLC assay using reverse phase (Hypersil 5p) described in section 2.11.3, 
separated PEG samples below a molecular weight of 1200 into their respective 
oligomers. Unfortunately the PEG molecular weight standards that were obtained from 
Polymer Laboratories were found to have a range of molecular weights themselves, and 
so could not be used to identify the molecular weights of the individual oligomers, as 
had originally been intended. It was hoped that the standards would give a major peak, 
which it could be assumed was the average molecule weight stated for the sample. A 
retention time for the molecular weight could then be determined. Figures 6.1a and b 
show the chromatograms obtained for the PEG standard (molecular weight 960, 
polydispersity 1.03) and the sample of 3H-PEG 900 from NEN. There did not appear to 
be a difference between the “standard” PEG and the PEG from NEN. The 3H-PEG 
contained up to 8 different oligomers. It was originally hoped that, after measurement 
of the transport of 3H-PEG 900 into the basolateral fluid, the molecular weight of each 
of the oligomers could be calculated using the PEG standards which were obtained 
from Polymer Laboratories but unfortunately this was not possible.
The GPC assay described in section 2.11 separated PEG samples according to 
molecular weight. It was not sensitive enough to separate out individual oligomers but 
could detect samples which were more polydisperse because the peak obtained would 
be broader. Appendix A 1.9 shows the retention time for several PEG standards injected
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Figure 6.1a: The Chromatogram obtained following injection of the PEG 960
(polydispersity 1.03) (lOmg/ml) on to the Hypersil 5p column. Flow rate was
1 ml/minute. Chart speed was lcm/minute.
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Figure 6.1b: The Chromatogram obtained following injection of 3H-PEG 900 onto the 
column, as above.
onto the column and the calibration curve determined from these samples. The 
14C-PEG-4000 obtained from Amersham was injected onto the column and using 
refractive index, the retention time was found to be 18.5 minutes. This was the same as 
for the PEG standard. After collecting 250pl fractions as they eluted from the 
refractometer, the retention time was found to be 19.5 minutes. The assay was used to 
determine the molecular weight of the PEG-4000, that had been transported to the 
basolateral side of Caco-2 cell monolayers. If the Caco-2 cells acted like a sieve and 
allowed the passage of oligomers of PEG up to a certain molecular weight then a shift 
in retention time of the peak would be seen, (see section 6.1.4).
Electrical resistance measurements were obtained for the monolayers used in every 
experiment after the experiment was complete. Typically the results fell in the range of 
400-600 ohms.cm2 (552 ± 28.9). If a particular filter gave a resistance measurement that 
fell below 300 ohms.cm2 then this filter was considered to have a non-confluent 
monolayer and was not used in the experiment.
6.1.2 Mannitol.
Table 6.1.1 gives the measured % values for the transport of 14C-Mannitol from the 
apical to the basolateral side of 15 day old Caco-2 cells grown on filters. The uptake (% 
of the radioactivity applied to the apical surface of the cells) was also determined for 
mannitol. An error has been introduced into this calculation since activity was measured 
for the cells while they were still bound to the filter and no correction for adsorption of 
the mannitol onto the cellulose filter was made.
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Table 6.1.1 Percentage Transport of 14C-Mannitol to basolateral compartments by 
Caco-2 cells and Uptake of mannitol by filter and cells. 9.61nmol of 14C-MannitoI 
was applied to the apical surface. Results are means ± S.E.M. (n=3).
Time (hr) % transported S.E.M. % taken up S.E.M.
1.0 0.1695 0.0375 0.0131 0.0016
3.0 0.474 0.0435 0.0379 0.0074
5.0 0.615 0.0001 0.1076 0.0326
8.0 1.081 0.0030 0.1358 0.0089
15.3 2.009 0.0240 0.2019 0.0203
Figure 6.1.1 is a graph showing the results for % transport of mannitol by the Caco-2 
cells and in addition it shows the percentage uptake of the mannitol by the cells and 
filters. Transport of mannitol was slow, with only 2% of the total activity applied being 
transferred in 15.3 hours. The Caco-2 cells actually accumulated very little mannitol. 
After 15.3 hours exposure, the cells had taken up only 0.2% of the radioactivity applied. 
The low percentage of transport implied that the Caco-2 cells had formed a confluent 
monolayer. The transport of mannitol by Caco-2 cells appeared to be linear over the
15.3 hours of the experiment. A linear regression analysis was carried out on the plot of 
transport versus time and it had a regression coefficient of 0.9966. From this plot the 
rate of transport was calculated to be 0.128% of the 14C activity per hour. This is lower 
than the value quoted by H idalgo/177) who showed that less than 0.2% Mannitol should 
be transported per hour if the monolayer is to be considered to be confluent.
6.1.3 PEG-900.
The percentage of PEG-900 transported to the basolateral side of Caco-2 cells is shown 
in table 6.1.2. This table also shows the % of 3H-PEG-900 taken up by Caco-2 cells. 
Again no correction was made in the calculation to allow for activity adsorbed to the 
filter.
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Figure 6.1.1 Transport o f 1 4 C-Mannitol by 15 day cultures of Caco-2 
cells grown on Millicell HA filters. Media containing 9.61nmol of 4  C-Mannitol 
was applied to the apical surface of the cells. In addition the uptake of the mannitol 
was determined by filters and the cell combined. Each point is a mean ±S.E.M.(n=3).
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Figure 6.1.2 Transport of ,4C- Mannitol and 3H-PEG-900 
by 15 day cultures o f Caco-2 Cells grown on Millicell HA filters. 
Media containing 295.9nMol o f PEG 900 or 9.61nMol of Mannitol 
was applied to the apical surface of the cells.
Each point is a mean ± S.E.M. (n=3).
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Table 6.1.2 Percentage of 3H-PEG-900 transported to basolateral side of Caco-2 
cells. 295.9nmol of PEG was applied to the apical surface. Percentage taken up by
the cells and/or filter is also listed.
Time (hr) % Transported S.E.M. % taken up S.E.M.
0.25 0.0166 0.0018 ND -
0.50 0.3209 0.159 ND -
1.0 0.4199 0.035 ND -
3.0 0.7695 0.143 ND -
8.0 1.1895 0.016 0.321 0.105
24.0 2.1895 0.116 1.025 0.159
Results are expressed as means ± S.E.M. (n=3).
Figure 6.1.2 is a graph showing a comparison between the transport of Mannitol and 
PEG-900. There appeared to be very little difference in the total transport of the two 
solutes over the experimental period. The percentage transport versus time graph for 
PEG-900 was not linear. The rate of transport decreased with time. In 1 hour 0.42% of 
the radioactivity had been transported for PEG-900 and 0.17% of the mannitol 
radioactivity had been transported. However, after 8 hours exposure, the % of 
radioactivities transported was more similar for the two solutes at 1.08% for the 
mannitol and 1.19% for the PEG-900. The reason for the non-linear transport of the 
PEG-900 could be due to the oligomers within the solution. The lower molecular 
weight oligomers may be transported more rapidly than those of higher molecular 
weight and as more of the lower molecular weight material is transported from the 
apical side, there would be a greater proportion of the radioactivity left, that was high 
molecular weight oligomers. These would be transported more slowly and would lead 
to a slowing down of the rate of transport.
Because, during the experimental period, similar amounts of PEG 900 and mannitol
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were transported, it can be assumed that PEG 900 could be transported by the 
paracellular route, since it is known that mannitol can be transported by this route.
6.1.4 PEG 4000.
Table 6.1.3 shows the percentage of 14C-PEG 4000 transported from apical to 
basolateral compartments by 15 day cultures of Caco-2 cells.
Table 6.1.3 Transport of 14C-PEG 4000 by Caco-2 cells. 8.13nmoI of activity was 
applied to the apical surface of the cells. Appearance of activity in the basolateral 
fluid was monitored. Results are means for three filters.
Time (hours) % Radioactivity transported S.E.M.
0.5 0.00621 0.00032
1.0 0.0128 0.0010
2.0 0.0247 0.0014
3.0 0.0313 0.0010
6.0 0.0547 0.0055
14.0 0.0819 0.0020
16.0 0.0560 0.00060
20.0 0.0699 0.00495
24.0 0.0799 0.00193
28.0 0.0777 0.00226
The transport of 14C-PEG 4000 was very low. Only 0.078% of the radioactivity was 
transported in 28 hours. Figures 6.1.3 and 6.1.4 show the percentage of activity 
transported by the cells versus time. This plot shows that the transport of PEG-4000 
was exponential over the time period investigated. 3H-PEG-900 was also shown to be 
transported at an exponential rate, but 27.5 times more PEG-900 was transported in 24
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Figure 6.1.3: Transport of 1 4 C-PEG 4000 and ^-PEG 900 
by 15 day cultures of Caco-2 cells on Millicell HA filters.
8.13nMol of PEG 4000 and 295.9nMol of PEG 900 were applied to 
the apical cell surface. Results are means for three filters. ± S.E.M.
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hours than PEG-4000. Hidalgo et al 072) applied PEG-4000 to the apical surface of 
Caco-2 cells grown on collagen coated filters and found that during 90 minutes of 
contact the rate of transport of PEG-4000 was 0.07%/hour. In this experiment it was 
shown that only 0.07% of the PEG-4000 was transported in 20 hours. This difference 
may be due to a greater degree of polydispersity in PEG 4000 used in the Hidalgo 
experiment. In addition Hidalgo’s cultures were 13 days old, compared to the 15 day 
cultures used in this experiment and this may account for some of the difference. 
Hilgers et aK178) performed a similar experiment, where they applied PEG 4000 to the 
apical surface of Caco-2 cells grown on collagen coated or non-coated polycarbonate 
filters and found that during the four hour experimental period that the rate of transport 
of PEG 4000 was 0.0825%/ hour for coated filters and 0.0625%/ hour for non-coated 
filters. From these results they concluded that it was not necessary to coat the filters 
before seeding Caco-2 cells onto them. The rate of transport reported by H ilg e r s ^ 78) 
was similar to that demonstrated by Hidalgo. A rtursson079) aiso measured the rate of 
14C-PEG-4000 transport by Caco-2 cells. He found that 0.0125% of the 14C activity 
was transported in 1 hour. This is similar to the amount found to be transported in this 
experiment (0.0128%/hr).
The reason for the extremely low transport of PEG-4000 by the Caco-2 cells was 
probably that the polymer was too big to be transported paracellularly and thus 
transport to the basolateral side was limited to transcytosis of the polymer. There is a 
possibility that the 14C-activity transported was actually bound to PEG oligomers which 
were smaller than PEG-4000, because of the polydispersity of the sample. To check 
this, samples of basolateral fluid were injected onto the TSK 3000 column. If the peak 
was displaced to a later time than the original PEG 4000 solution, then this would 
imply that the Caco-2 cell monolayer had behaved like a sieve and transported lower 
molecular weight material, but not PEG 4000 itself. Despite the very low activity in the 
basolateral fluid, it was possible to discern a peak of activity after elution from the 
column. The peak was coincident with that of PEG 4000.
The filter culture of Caco-2 cells was used with the intention of setting up a model for 
the capillary. However, Caco-2 cells in no way mimic endothelial cells. They produce
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tight junctions which are impermeable to the transport of PEG-4000 whereas it is 
known that molecules as big as serum albumin can extravasate from c a p illa r ie s^ 11). in 
addition the apical surface of Caco-2 cells is coated with enzymes and these would 
break down many of the biological molecules which came into contact with them. 
Endothelial cells do have a glycocalyx but it is not associated with the same enzymes 
which coat the Caco-2 cells.
The reason for preparing a model for the capillary was to compare the transport of BSA 
and the BSA-MTX conjugates to see if an indication could be found to explain why the 
BSA-MTX conjugates had a larger volume of distribution than BSA itself. It has been 
demonstrated that the high strength conjugates were rapidly taken up by the liver and 
this accounts for their increased Vd. However the low strength conjugates were not 
associated with a specific organ accumulation, though they did appear to be found in 
most organs at higher levels than free BSA. A possible explanation for the increased 
general uptake by organs for the low strength conjugates could be that they were more 
able to leave the vasculature and this could be due to the covalently bound MTX which 
allowed the conjugate to be transported across the endothelia using the active folate 
transporter.
6.2 BAE-1 Filter Culture.
The endothelial cell line that was chosen was from bovine aorta endothelia and was 
known as BAE-1. This cell-line was obtained from ECAC Porton Down. It is known to 
secrete collagens, but not much is known about the ability of the cell line to form tight 
junctions in culture. Other workers have used cultures of endothelial cells, obtained 
from different animals or from different blood vessels/180) and these seem to 
demonstrate some of the characteristics expected for endothelial cells such as tight 
junctions.
Electrical resistance was measured as for Caco-2 cells. There was no significant 
difference in the resistance measured for cells grown on gelatin coated filters and cells 
grown on uncoated filters. In addition, measurement of cell resistance for cells 
incubated for 3.75 days, 7 days or 10 days on the filter gave similar values. Values
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determined were 164.98±17.12. This is highly significantly different from the resistance 
values determined for Caco-2 cells (552±28.9) and this may indicate that caco-2 cells 
formed tighter junctions than BAE-1 cells.
6.2.1 Transport of 125I-HSA.
The appearance of 125I-HSA in basolateral fluid was measured over 24 hours for BAE-1 
cells which had been grown on gelatin coated filters. Cell cultures were incubated for
3.75 days, 7 days and 10 days before use. The % of intact 125I-HSA transported over 24 
hours for each of the incubation times is shown in Table 6.2.1.
After 24 hours 13.4% of the 125I-HSA had been transported by cells incubated for 3.75 
days, 16.4% by cells incubated for 7 days and 13.4% by cells incubated for 10 days 
prior to the experiment, t-values calculated at this time point showed that there was no 
significant difference between the 3.75 days and the 7 days incubation times and the
3.75 days and 10 days incubation times. The t-value for the 7 days versus the 10 days 
groups was 3.45 (p <0.05), which is a significant difference. A graph showing the 
125I-HSA transport for each of the incubation times is shown in figure 6.2.1. There 
appeared to be very little difference, overall, in the % transported for each of the three 
groups.
Siflinger-Bimboim et al(181> measured the 125I-BSA transport by sheep pulmonary 
artery cells grown on gelatinised polycarbonate filters and they also found, that there 
was no significant difference in this transport between cells which had been incubated 
for 3 days and 10 days prior to the experiment. Unfortunately not enough data was 
given to be able to directly compare the transport of the 125I-albumin with the results 
obtained in this experiment.
In addition to examining the BAE-1 transport of 125I-HSA for cells grown on gelatin 
coated filters the HSA transport for cells grown on non-coated filters was determined. 
This experiment was carried out 7 days after cell seeding so that it could be compared 
directly to the 7 day cultures grown on gelatin coated filters. The appearance of 
125I-HSA in the well chamber of filters (both gelatinised and non-coated) which had not
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Table 6.2.1: The transport of 125I-HSA by BAE-1 cells grown on Gelatin coated 
Millicell HA filters. 200pg of 125I-HSA was applied to the apical surface of the cells 
and the appearance of intact, TCA insoluble 125I activity was measured in the 
basolateral fluid. The transport experiment was carried out at 3 time points after cell 
seeding. These were 3.75 days, 7 days and 10 days after cell seeding. Each value is a 
mean ± S.E.M.
Time after 
application
% (of total applied)125I-HSA measured in basolateral side
3.75 days 7 days 10 days
0.5hr nd 0.26110.025 nd
lhr 0.0708±0.00055 0.26810.232 0.15910.036
2hr 1.84510.0345 0.63010.135 0.65410.0705
4hr 2.69010.0100 3.5410.225 0.87110.061
6hr 6.53110.429 6.28510.421 nd
7.5hr 6.84110.388 nd nd
8hr nd nd 3.7010.333
9hr nd 6.76511.232 nd
12hr nd nd 5.9710.682
14hr nd 8.9610.327 nd
18hr 7.95511.655 10.9210.231 nd
24hr 13.3912.77 16.4310.883 13.3710.091
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Figure 6.2.1: Percentage of1251 transported to basolateral
side as intact protein following application of 200pg of 12̂ -HSA
to 3.75 days, 7 days and 10 days cultures of BAE-1 cells grown on
gelatin coated, Millicell HA Filters. Each point is mean for 3 filters. ± S.E.M.
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The transport of lzsI-HSA by BAE-1 cells grown on gelatin coated or non-gelatin 
coated Fillers and the transport of the protein by similar Filters which had not 
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been seeded with cells was also determined, in a similar manner to the experiment 
where cells were seeded on to the filter. The results of these experiments are shown in 
table 6.2.2 and they are shown graphically in figure 6.2.2. After 24 hours 37% of the 
125I-HSA had appeared in the basolateral compartment of the BAE-1 cells grown on 
uncoated filters. This was highly significantly greater than the percentage transported by 
cells grown on gelatin coated filters, where 16.4% of the 125I-HSA was transported. 
This difference could be due to the fact that the BAE-1 cells formed better monolayers 
with tighter cell junctions and well differentiated cells when they were grown on gelatin 
or it could be because 125I-HSA not only had to pass through the cell barrier but in 
addition it had to diffuse through the gelatin layer for coated filters and it may be this 
gelatin layer that formed the rate limiting step.
When the appearance of HSA in the ‘basolateral compartment’ (i.e. the well of the 
six-well plate) was monitored in filters which were not coated with cells, a similar 
difference in the amount measured, was seen for the coated and non-coated filters. After 
28 hours the percentage of 125I-HSA in the well for coated filters was 19.3% and for the 
non-coated filters it was 43.2% of the total applied. Using Student’s t-test to compare 
the percentage 125I-HSA which had diffused through the filter for coated and 
non-coated filters at the 28 hour time point showed that there was a highly significant 
difference in the two groups. This implied that the difference in the percentages 
transported between cells grown on gelatin coated filters and cells grown on uncoated 
filters was not because the cells formed a better differentiated monolayer when grown 
on gelatin but because gelatin actually formed a barrier to diffusion.
Student’s t-test was used to compare the percentage 125I-HSA transported by cells 
grown on uncoated filters and the percentage of 125I-HSA which had diffused through 
the filter, for the filters which had not been seeded with cells, at 9 hours after 
application. The t-value determined was 1.48 (p>0.2) and this is a non-significant 
difference. Thus it would appear that the BAE-1 cells did not present a barrier for the 
transport of HSA through the filter. A similar comparison for the coated filters at 9 
hours, showed that the filters with cells had actually transported more than the filters
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Table 6.2.2: The appearance of 125I-HSA in the basolateral fluid following application 
of 200pg to the apical surface of 7 day cultures of BAE-1 cells grown on Non-Gelatin 
coated Millicell HA filters. The transport experiment was also carried out on filters 
without cells and these were either coated with gelatin or non-coated. The 125I-HSA 
concentration in the basolateral fluid was determined after performing a TCA 
precipitation on it, so that only intact (precipitated) 125I was measured. Each tabulated 
value is the mean ± S.E.M. (n=3).
Time after % (of total applied)125I-HSA measured in basolateral side 
application Filter with cells Gelatin coated non-Gelatin
(hours) non-coated filter filter (no cells) filter (no cells)
0.5 0.253±0.22 nd nd
1 3.11511.424 0.30510.115 12.8614.064
1.5 nd 1.44310.399 9.5511.396
2 9.30211.594 nd nd
2.5 nd 1.48410.399 15.2412.11
4 15.0911.207 nd nd
5 nd 3.12810.851 17.7111.87
6 20.6911.140 nd nd
7 nd 5.9910.785 24.9611.07
9 23.5510.352 5.8211.14 25.7611.448
14 22.0112.191 nd nd
18 26.7312.026 nd nd
23 nd 14.9810.778 39.3410.740
24 37.0212.78 nd nd
28 nd 19.3113.97 43.1611.029
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without cells, though the t-value (0.563) determined was not significant This suggests 
that the BAE-1 cells used in these experiments did not form a complete monolayer, 
since it would not be expected that the 125I-HSA would pass through a filter which was 
coated with a monolayer of cells as rapidly as it could pass through the filter without 
cells.
To determine whether incubation time made a significant difference for cells grown on 
non-coated filters, the transport of 125I-BSA was determined on cultures of cells which 
had been incubated for 3.75 days, 7 days or 10 days prior to the experiment. The results 
obtained for this experiment are shown in table 6.2.3 and are represented graphically in 
figure 6.2.3. The plot of % 125I-BSA transported versus time showed that there was 
little difference in transport of the 125I-BSA for any of the incubation times. Student’s 
t-test did not highlight a difference between groups, with between 41 and 43% of the 
125I-BSA, applied to the apical cell surface, being transported in 24 hours. Like HSA, 
the percentage of BSA transported during the experiment was greater than expected. 
Transport was roughly linear over the first 12 hours of the experiment. The rates of 
transport calculated for each of the incubation times were 2.574±0.159%/hour for 3.75 
days, 2.389±0.224%/hour for 7 days and 2.618±0.248%/hr for 10 days. There was 
between 6 and 9 % error involved in the calculation of these rates and because of this 
they can all be considered to be similar. Since no significant difference could be 
detected in the transport of BSA by BAE-1 cells, which had been incubated for the 3 
different times prior to the experiment, it was decided that a compromise of a 7 day 
incubation, for the BAE-1 cells would be used in future experiments. If the amount of 
125I-BSA transported to basolateral side was converted to p 1/minute and a correction 
was made for the surface area of the filter, the transport rate for BSA by the 3.75 days 
culture of cells was 0.189pl/min/cm2. This is similar to the transport rate determined by 
Del Vecchio et al<182) for transport of 125I- labelled albumin by sheep's aortic cell grown 
on gelatin coated polycarbonate filters. Their rate was 0 .2 p l/m in /c m 2 and is 
approximately half the rate quoted by Milton and Knutson^183) in another cell-line 
derived from bovine aorta. Milton and Knutson showed in their experiments, a five-fold 
increase in the percentage of albumin that diffused through a filter without cells 
compared to transport by the cell monolayer. In this study, the same percentage of
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Table 6.2.3: The transport of 125I-BSA by BAE-1 cells grown on Non-Gelatin coated 
Millicell HA filters. 33pg of 125I-BSA was applied to the apical surface of the cells and 
the appearance of intact, TCA insoluble 125I activity was measured in the basolateral 
fluid. The transport experiment was carried out at 3 time points after cell seeding. These 
were 3.75 days, 7 days and 10 days after cell seeding. Each tabulated value is the mean 
± S.E.M. (n=3).
Time after % (of total applied)125I-BSA measured in basolateral side 
application 3.75 days 7 days 10 days
lhr 1.274±0.785 0.37710.096 1.41910.718
2hr 3.199±1.598 5.41711.644 7.32411.540
4hr 7.823±1.626 5.18511.903 9.92011.247
6hr 14.69010.644 13.7010.897 14.0310.712
8hr 22.5110.407 20.1112.786 23.8410.3813
lOhr 23.6510.834 24.7510.338 29.6610.735
13hr 30.9910.750 27.6311.892 31.5011.732
24hr 41.1510.451 42.3510.987 43.3911.451
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125I-BSA was transported by the cell monolayer, as actually diffused through the filter 
without cells. It may be that the BSA diffused more slowly through the filter without 
cells than it should have done.
6.2.3. Transport of the BSA-MTX conjugates.
Table 6.2.4 lists the results obtained for the transport of BSA and BSA-MTX 
(4.54%w/w and 11.55%w/w) by monolayers of BAE-1 cells grown on uncoated 
Millicell HA filters. The results are shown graphically in Figure 6.2.4. Over the first 12 
hours of the experiment the rates of transport for BSA and the conjugates were roughly 
linear. The calculated rates were 2.652±0.229 %/hr for BSA, 1.696±0.055 %/hr for 
BSA-MTX (4.54%w/w) and 1.895±0.118 %/hr for BSA-MTX (11.55%w/w). BSA- 
MTX were transported more slowly than BSA itself, but the two conjugates did have 
very similar transport rates. In 24 hours 30.85% of the BSA-MTX (4.54%w/w) was 
transported to the basolateral side and 31.3% of the BSA-MTX (11.55%w/w), whereas 
for BSA itself, 40.8% of the 125I-BSA was transported. The difference between the 
transport of BSA and BSA conjugates was highly significant. (p<0.05 for BSA-MTX 
(4.54%w/w) and p=0.05 for BSA-MTX (11.55%w/w)).
The reason for the differences in transport between BSA and BSA-MTX conjugates 
could be that the conjugates are associated with a percentage of aggregated protein. 
This aggregated protein would have an overall lower rate of transport than the 
monomeric conjugate. In addition the BSA-MTX in monomeric form have an elevated 
molecular weight compared to ‘free* BSA anyway. (The molecular weight of BSA is 
66296, BSA-MTX (4.54%w/w) is 69153 and BSA-MTX (11.55%w/w) was 74143). 
However it is unlikely that this small increase in molecular weight would account for 
the decrease in the rate of transport. Another possible explanation for the increased 
transport of BSA is that the free protein could occupy the hypothesised ‘albumin’ 
receptor, whereas the BSA-MTX conjugates, because their tertiary structure would be 
expected to be different to BSA, could not occupy the receptor. There is much dispute 
over whether the albumin receptor actually exists however.fi 84«185) Thus the most likely 
explanation is that the aggregated protein fraction in the conjugates was transported 
more slowly.
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Table 6.2.4: The transport of 125I-labelled BSA, BSA-MTX (4.54%w/w) and 
BSA-MTX (11.55%w/w) by BAE-1 cells grown on Non-Gelatin coated Millicell HA 
filters. 9.23pg of 125I-protein or conjugate was applied to the apical surface of the cells 
and the appearance of intact, TCA insoluble 125I activity was measured in the 
basolateral fluid. The transport experiment was carried out at 7 days after cell seeding. 
Each tabulated value is the mean 1 S.E.M. (n=3).
Time after % (of total applied)125I-protein measured in basolateral side 
application ’free’ BSA BSA-MTX (4.54%) BSA-MTX (11.55%)
lhr 1.644±0.021 2.95110.512 2.14110.576
2hr 3.711± 1.475 5.40110.781 0.81410.120
4hr 7.321±1.082 8.7410.401 5.25710.405
6hr 13.88±0.763 12.3511.072 10.8511.831
8hr 23.42±0.760 14.3110.908 14.0111.277
lOhr 26.6910.289 18.8010.137 17.1610.800
12hr 27.7710.750 22.1910.615 21.5310.276
24hr 40.8112.035 30.8511.021 31.3212.178
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Figure 6.2.3:
The transport of 1 2 3I-BSA by BAE-1 cells grown on Millicell HA filters 
33pg of BSA was applied to the apical side, appearance in the basolateral side 
was measured, for 3 filters at each time point. BAE-1 cells were incubated on the 
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The transport of intact protein or conjugate following application of 9.23pg 
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The % of 125I labelled BSA or BSA-MTX taken up by the cells (no correction was 
made for activity which may have been bound to the filter since the cells were not 
removed from the filter before analysis) was determined. After 24 hours this was found 
to be 0.161±0.0199% of the total 125I activity for cells exposed to BSA, 0.468±0.0119% 
for cells exposed to BSA-MTX (4.54%w/w) and 2.174±0.073% for cells exposed to 
BSA-MTX (11.55%w/w). The increased association of the conjugates with the BAE-1 
cells was not due to a greater adsorption of the conjugates to the filter. For BSA and 
BSA-MTX the adsorption to the filter was less than 0.1%. Thus the decreased transport 
of the conjugates compared to the BSA could be because of the increased retention of 
the conjugates by the cells.
The % of the activity which was precipitated by a solution of TCA was also 
determined. This would give an indication as to the degradation of the conjugates and 
BSA. The % of TCA soluble material in the media of cells exposed to BSA-MTX 
(11.55%w/w) was greater than in the other groups. At the beginning of the experiment 
using the 11.55%w/w conjugate the TCA soluble material accounted for 8.61% of the 
total radioactivity. After 24 hours of incubation with the BAE-1 cells the TCA soluble 
fraction had increased to 19.0±0.321%. This represented an increase of 10.4%. For the 
4.54%w/w conjugate, the media at the beginning of the experiment had 7.36% of the 
total radioactivity present as TCA soluble material. 24 hours after exposure of the 
BAE-1 cells to this media, the TCA soluble activity represented 14.43±0.213 of the 
total radioactivity. This represented an increase of 7.07%. Finally for BSA, the TCA 
soluble 125I fraction, represented 4.36% of the total activity in the media at the start of 
the experiment and after 24 hours, the TCA soluble activity had increased to 
8.37±0.829%. The increase in the degradation of the protein following exposure of the 
BAE-1 cells to BSA-MTX conjugates rather than ‘free’ BSA was probably associated 
with the increase in uptake of the conjugates, and would indicate that not only did the 
conjugates enter vesicles for transport across the endothelial cells (transcytosis) but also 
that the conjugates entered coated pits and were transferred to the lysosome for 
degradation. Only a small proportion of the conjugate actually followed the latter route, 
however, since it was demonstrated that only a small % of the total 125I-BSA-MTX was 
degraded (approximately 10% for BSA-MTX (11.55%w/w). The increased association
-231-
of the conjugate with the coated pits may be explained by the increased hydrophobicity 
of the conjugate compared to free BSA(15°).
6.2.4 Transport of Mannitol and LA.
The transport of 14C-Mannitol was determined for the 7 day cultures of BAE-1 cells 
grown on Millicell HA filters The results for the transport of 125I-LA and Mannitol are 
shown in table 6.2.5. Figure 6.2.5 is a plot of % transported versus time by the BAE-1 
cells for LA, Mannitol and the transport of mannitol by Caco-2 cells. Mannitol was 
transported more rapidly by BAE-1 cells than Caco-2 cells. The transport of mannitol 
by BAE-1 cells was linear up to 8 hours after the start of the experiment. The calculated 
rate of transport was 5.851±0.793 %/hr. When the rate of mannitol transport for the 
Caco-2 cells was determined it was only 0.128%/hr. Thus the BAE-1 cells transported 
the mannitol 46 times more quickly than the Caco-2 cells. The transport rate calculated 
for LA was 3.47±0.132%/hr. Thus the monolayer did have a degree of size selectivity 
for transport. This could be due to the filter itself. The Millicell HA filter is composed 
of mixed cellulose esters. The pores in this filter are very tortuous and in addition the 
filter is quite thick compared to the cell monolayer.
Since it was found that solutes were transported more rapidly than anticipated by the 
BAE-1 cell monolayers and in addition the mannitol was transported more rapidly by 
BAE-1 compared to Caco-2, it was decided to investigate both cell monolayers using 
the electron microscope, to see if this could highlight any problems with the BAE-1 cell 
monolayer. The cells were examined under both the S.E.M. and T.E.M. microscopes. 
Figure 6.2.6 (page 236) shows an S.E.M. photograph obtained at low magnification for 
the Caco-2 cell monolayer (magnification was 2000X). This shows that there is great 
difficulty in demonstrating where one cell finishes and the next cell starts. Thus the 
junctions between the cells are tight. Figure 6.2.7 is a photograph taken at a similar 
magnification for the BAE-1 cell monolayer. Examination of this monolayer under the 
microscope has shown that between some of the cells were gaps which were 
approximately the size of a cell while other cells were closely packed. Over the whole 
filter, individual cells could be distinguished quite clearly and thus the cells did not 
exhibit tight junctions like the Caco-2 cells.
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Table 6.2.5: The transport of 125I-LA, and 14C-Mannitol by BAE-1 cells grown on 
Non-Gelatin coated Millicell HA filters. 9.23pg of 125I-LA or lOnMol of mannitol was 
applied to the apical surface of the cells and the appearance of intact, TCA insoluble 
125I activity or 14C activity was measured in the basolateral fluid. The transport 
experiment was carried out at 7 days after cell seeding. Each tabulated value is the 
mean ± S.E.M. (n=3). Separate filters were used for each solute.
Time after 
application
% 125I-LA or 14C-Mannitol found in basolateral side 
LA Mannitol
0.5hr 0.30510.151 2.21810.331
lhr 3.33411.164 12.72510.995
2hr 9.44513.112 14.2413.928
3.33hr 11.6511.079 30.8810.239
5.5hr 20.0110.525 39.4611.102
8hr 28.5911.383 47.510.100
9.5hr 34.3811.452 48.910.943
11.5hr 38.5910.605 49.0710.476
23.33hr 43.3610.985 50.5210.865
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Figure 6.2.5:
The transport of Mannitol and LA from Apical to Basolateral side of 7 day 
cultures of BAE-1 cells grown on Millicell HA filters and the transport of 
Mannitol by 15 day cultures of Caco-2 cells grown on similar filters. 
9.23pg of LA was applied and 9.61 nMol of Mannitol
551
Each point is the mean ± S.EM. transport by three filters.
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Figure 6.2.8 shows a higher magnification S.E.M. photograph of the Caco-2 cells 
(7500X). Two different cells can be made out on this photograph, because they have 
slightly different microvilli, but it is obvious that the cells form very tight junctions 
indeed. Figure 6.2.9 is an S.E.M. photograph of the BAE-1 cell monolayer at a similar 
magnification. This photograph shows three cells, which were separated from each 
other by a distance of approximately 1pm. Many processes had formed which 
connected the cells. It may be, that if the cells had been incubated for a longer time 
before taking the picture, the spacers between the cells would have become smaller.
Figure 6.2.10 is a T.E.M. photograph taken of the Caco-2 cells grown on Millicell HA 
filters. This photograph shows the junction between 2 cells and no gap between them 
can be seen. Figure 6.2.11 is a T.E.M. photograph at a similar magnification for the 
BAE-1 cells. Again this photograph shows the junction between 2 cells. A gap can be 
seen between these cells.
The electron microscope examination of the monolayers has demonstrated that the 
BAE-1 cells did not form a confluent monolayer within 7 days of cell seeding. This 
may be because, the incubation time was not long enough to allow differentiation of the 
cells. Perhaps not enough cells were seeded onto the filter and so they had to undergo 
cell division before they could differentiate. It may be that the BAE-1 cells require 
special growth media supplements. Another reason may be the age of the cells. The 
cells used in these experiments ranged from passage number 25 to 32. It may be that 
the cells had started to dedifferentiate and no longer resembled endothelial cells.
Shasby and Roberts^180) demonstrated tight junctions in 7 day cultures of cells grown on 
gelatin coated polycarbonate filters, using T.E.M. and this was only with the addition of 
the equivalent of 9 x 105 cells to the filter (in this study 2 x 106 cells were added). In 
cultures of 3-4 days, gap junctions were seen and these were very similar to those seen 
in the T.E.M. photograph of Figure 6.5b. They used the same growth media as used in 
these experiments. Shasby and Roberts do not give a passage number for their cell line, 
however and this may be different for the two cell lines.
Figure 6.2.12 and 6.2.13 show photographs taken from the light microscope for the two 
cell lines. Again gaps can be seen between the BAE-1 cells quite clearly.
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Figure 6.2.6: A photograph of Caco-2 cells taken using a Jeol JSM 35C Scanning
Electron Microscope. Cells were incubated for 15 days on Millicell HA filters and then
were prepared for microscopy as described in section 2.11.5. (Mag. 2000X)
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Figure 6.2.7: BAE-1 cells incubated for 7 days prior to preparation as above. (2000X)
I
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Figure 6.2.8: A photograph of Caco-2 cells taken using a Jeol JSM 35C Scanning
Electron Microscope. Cells were incubated for 15 days on Millicell HA filters and then
were prepared for microscopy as described in section 2.11.5. (Mag. 7500X)
Figure 6.2.9: BAE-1 cells incubated for 7 days prior to preparation as above. (7500X)
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Figure 6.2.10: A photograph of Caco-2 cells taken using a Jeol 1200Ex Transmission
Electron Microscope. Cells were incubated for 15 days on Millicell HA filters and then
were prepared for microscopy as described in section 2.11.5. (Mag. 5000X)
Figure 6.2.11: BAE-1 cells incubated for 7 days prior to preparation as above. (5000X)
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Figure 6.2.12: A photograph of Caco-2 cells taken using Zeiss Ultraphot Microscope
fitted with a 35mm camera. Cells were incubated for 15 days on Millicell HA filters
and then were prepared for microscopy as described in section 2.11.5. (Mag. 720X)
Figure 6.2.13: BAE-1 cells incubated for 7 days prior to preparation as above. (720X)
-239-
6.3 Uptake of BSA, BSA-MTX, G-BSA and M-BSA by Macrophages in vitro.
Since the collagenase liver perfusion experiment (chapter 5) was not successful in 
separating out a suspension containing mostly non-parenchymal cells, a major cell-type 
of which would have been the Kupffer cells or liver macrophages, it was decided to 
determine the uptake of the conjugates and free BSA by peritoneal macrophages in 
vitro. Comparison of the uptake by each conjugate or protein may give an indication of 
the ability of Kupffer cells in vivo to selectively take up the conjugates.
For each radioiodinated conjugate and protein the uptake by macrophages was 
determined at 4°C and at 37°C, following solubilisation of the cells and measurement in 
a gamma counter. The rationale for using the two temperatures was that, although the 
protein could occupy the receptor on the surface of the macrophage at low 
temperatures, it could not actually be internalised. Proteins that are rapidly internalised 
at 37°C may also be rapidly degraded intracellularly, and the breakdown products 
released back into the cell media. Therefore, measurement at 37°C only may lead to a 
falsely low reading for protein uptake/186) In addition to measuring the actual uptake by 
the cells, the media was subjected to a TCA precipitation to determine the percentage of 
125I present as TCA soluble, and therefore low molecular weight material. In each of 
the experiments described in this section the procedure was essentially the same. One 
million cells were applied to each well, and determinations were carried out, in serum 
free media, 24 hours later.
Table A3.32.1 (appendix 3) lists the uptake of 125I-HSA by macrophages at 37° and 
4°C over a one hour period. Table A3.32.2 shows the TCA soluble radioactivity present 
in the media over the same time period. The uptake of the 125I-HSA at the two 
temperatures appeared to be very similar and analysis of each time point by a Student’s 
t-test showed that no percentage was significantly different for the two temperatures. 
Figure 6.3.1 is a graph showing the uptake of 125I at the two temperatures, following 
exposure of the cells to 75pg of 125I-HSA. The percentage uptake at 1 hour was 0.173% 
±0.02 for the 37°C temperature and 0.159%±0.0096 at 4°C.
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Figure 6.3.1:
Uptake of 123 activity by rat peritoneal macrophages, exposed to 
75pg of i^I-HSA. each point is a mean uptake for 3 wells ± S.E.M.. The
experiment was carried out at 2 temperatures; 4°C and 37°C.
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Figure 6.3.2:
Breakdown of 1 2SI-HSA following exposure of rat peritoneal 
macrophages, in vitro, to RPMI media, containing 75pg of 1 2 5I-HSA.
Each point is a mean ±S.E.M. from 3 wells. The experiment was carried out 
at 2 temperatures; 4°C and 37 °C.
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Figure 6.3.2 is a graph showing the break-down of the 125I-HSA following exposure to 
macrophages, in RPMI media. The appearance of TCA soluble material containing 125I 
did appear to be elevated in the 37°C experiment. Over the first 30 minutes of the 
experiment the % of low molecular weight 125I did not change for the 4°C 
macrophages. However for the 37°C macrophages there was a high proportion of 125I 
fragments which were soluble in TCA even 15 minutes after exposure of the cells. 
During the 15 minute incubation the % of 125I activity, present as TCA soluble material, 
had increased from 9.6% to 33.5%. The % of TCA soluble 125I at 60 minutes, for both 
temperatures, was compared by means of a Student’s t-test. The TCA soluble material 
was not significantly different (p>0.1) for the two temperatures.
Table A3.32.3 lists the 125I-BSA uptake at 37°C and 4°C over a 1 hour period and 
similar tables for BSA-MTX (4.54%w/w) and BSA-MTX (11.55%w/w) are shown in 
tables A3.32.5 and A3.32.7 respectively. Figure 6.3.3 is a graph comparing the uptake 
of the BSA and conjugates by peritoneal macrophages at 37°C. The concentration of 
BSA and the conjugates was the same at 8pg per well. At 15 minutes after the start of 
the experiment the % of BSA taken up was 0.037710.0036%. At the same time point 
for BSA-MTX (11.55%w/w) the % taken up was 0.16110.0046%. The results at this 
time point were compared by Student’s t-test and were found to be highly significant 
(p< 0.01), and for the other time points, all t-values determined were highly significant. 
Thus the macrophages took up more BSA-MTX (11.55%w/w) conjugate than BSA.
The 4.54%w/w conjugate could only be compared at 30 minutes and 60 minutes (the 
only corresponding time points). At 30 minutes, the t-value obtained from comparison 
of BSA and BSA-MTX (4.54%w/w) was 2.71, this value has a probability of 0.0534, 
which is just non-significant. At 60 minutes the uptake for BSA was not significantly 
different from BSA-MTX (4.54%w/w) (p=0.325). At every time point compared for 
BSA-MTX (4.54%w/w) and BSA-MTX (11.55%w/w) there was a highly significant 
difference for the amount of 125I internalised by the macrophages.
The BSA and BSA-MTX (4.54%w/w) were taken up to a similar extent by rat 
peritoneal macrophages in vitro. The 11.55%w/w conjugate was taken up to a greater
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Figure 6.3.3:
Uptake o f  ,25I-labclled BSA, BSA-M TX (4.54%w/w) and BSA-M TX (11.55% w/w) 
by ra t peritoneal macrophages in vitro a t 37 °C. Each point is the mean determ ined 
for three wells. ± S.E.M.
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extent than either the low strength conjugate or the ‘free’ BSA. The increased uptake of 
the BSA-MTX (11.55%w/w) was also demonstrated at 4°C. It was not associated with 
an increased presence of 125I TCA soluble matter in the media compared to BSA and 
BSA-MTX (4.54%w/w) at 4°C or at 37°C. (see tables A3.32.4, A3.32.6 and A3.32.8). 
Sixty minutes from the start of the experiment, cells exposed to BSA at 37°C had 
44.0±5.33 % of the 125I present as TCA soluble material in the media. Cells exposed to 
BSA-MTX (4.54%w/w) had 47.72%±3.604 of the radioactivity present as TCA soluble 
activity and cells exposed to BSA-MTX (11.55%w/w) had 45.30±4.66%. All of these 
values were non-significant (t-test).
Tables A3.32.9 and A3.32.ll show the 125I uptake by macrophages exposed to 125I 
labelled G-BSA and M-BSA respectively over a 60 minute period. The percentage of 
TCA soluble radioactivity in the media is shown in Tables A3.32.10 and A3.32.12. 
Figure 6.3.4 compares the uptake of 125I activity following exposure of the 
macrophages to BSA-MTX (11.55%w/w), G-BSA and M-BSA. These experiments 
were carried out on the same day, using the same batch of macrophages. The uptake of 
G-BSA by the macrophages was highly significantly different at all time points from 
the uptake of BSA. In addition the uptake of M-BSA by macrophages was highly 
significantly greater than for the G-BSA. At 30 minutes exposure the macrophages had 
taken up approximately 3.4 times more M-BSA than G-BSA. This result is similar to 
that determined by Stahl et a f187), who found for rat alveolar macrophages, following a 
30 minute exposure to 2pg of M-BSA or G-BSA, that approximately three times more 
M-BSA was taken up. The increased uptake of M-BSA, in the present study was not 
associated with an increase in the presence of TCA soluble material in the media, it was 
not significantly different for any of the conjugates. Table 6.3 Compares the rates of 
uptake for each of the proteins and conjugates over the first 10 or 15 minutes of 
exposure at 37°C.
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Table 6.3: The Rates of Uptake for BSA, and BSA Conjugates by rat peritoneal
macrophages in vitro at 37°C.
Conjugate Rate of Uptake (% /  min)
‘free’ BSA 2.51 x 10-3
BSA-MTX (4.54%w/w) 7.22 x 10-3*
BSA-MTX (11.55%w/w) 1.07 x 10-2
G-BSA 0.147
M-BSA 0.513*
*Uptake rate was calculated over the first 10 minutes of exposure. For the other proteins 
and conjugates, it was determined over the first 15 minutes of exposure.
It would appear that macrophages have a receptor for mannose-BSA and they 
selectively ingested this protein. Stahl et al088) demonstrated that 125I-M-BSA was 
taken up in rat alveolar macrophages by the process of receptor mediated endocytosis. 
The endocytosis of 125I-M-BSA could be inhibited by Fucose-BSA, indicating that 
fucose enters the cell using the same receptor, but it was not inhibited by 
galactose-BSA. Tietze 089) ajso demonstrated that the uptake and degradation of 
M-BSA could be inhibited by Chloroquine and ammonium ions, both of which are 
inhibitors of lysosomal enzymes.
The rate of uptake for M-BSA, calculated in this experiment, was over 3 times greater 
than for G-BSA, and 200 times greater than for BSA. The rate of uptake of BSA-MTX 
was 4 times greater than for free BSA, but when compared to M-BSA it was 50 times 
less than M-BSA. Thus although the 11.55%w/w conjugate was taken up to a greater 
extent than the BSA, it would not appear that there was a specific receptor for it. The 
increased uptake could be due to the presence of aggregated protein in this conjugate. 
BSA-MTX (4.54%w/w) did not appear to be taken up to a greater extent than free BSA,
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overall, although the initial rate of uptake was over 2 times higher. The increased 
uptake of the BSA-MTX (11.55%w/w) could also be due to its increased 
hydrophobicity. Duncan et alO50) demonstrated that HPMA polymers with increasing 
hydrophobicity were taken up to a greater extent by rat visceral yolk sacs. This 
increased uptake could be inhibited by 2,4 dinitrophenol an inhibitor of pinocytosis.
This work complements the work done on the conjugates in vivo, on liver uptake. It was 
hoped that macrophages in vitro may behave in a similar manner to Kupffer cells in 
vivo. Although approximately the same percentage of MTX-BSA (11.55%w/w) was 
taken up by the liver as M-BSA, the uptake of the conjugates by macrophages was very 
different. It was shown by the collagenase perfusion of the liver that 40% of the activity 
within the liver for the BSA-MTX was associated with the hepatocytes, whereas for the 
M-BSA only 20% of the activity was associated with the hepatocytes. The remaining 
activity in the liver was assumed to be associated with the non-parenchymal cells. For 
the BSA-MTX, although the non-parenchymal cells do take up more of the conjugate, 
than hepatocytes, the rate of uptake by this cell type may be slower than for M-BSA, 
thus allowing more time for capture by hepatocytes. The rate of uptake by macrophages 
was shown to be slower for MTX-BSA than for M-BSA.
G-BSA was taken up at a faster rate by macrophages in vitro than MTX-BSA. From the 
macrophage results it may have been assumed that Kupffer cells would take up the 
G-BSA in vivo, however, it was shown in the whole liver to be taken up almost entirely 
by the hepatocytes and so the uptake by peritoneal macrophages in vitro alone is not a 
good model for the uptake by Kupffer cells in vivo. This is partly because the liver is a 
complex organ and consists of several cell types.
Photographs were taken of macrophages that were obtained by peritoneal lavage, as 
described in section 2.10. These are shown in figure 6.3.5a and b.
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Figure 6.3.5a: A photograph of rat peritoneal macrophages taken using the Jeol JSM 
35c Scanning Electron Microscope. Cells were prepared for microscopy as described in 
section 2.10. (Magnification 2000X).
25KU X 2 0 0 0  1 7 5 1  1 0 . 0U BATHU
6.3.5b Macrophages photographed as described above (Magnification 7500X).
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CHAPTER 7: 
CONCLUSIONS.
-248-
The aim of this thesis was to produce large molecular weight, soluble derivatives of 
MTX, and to evaluate these derivatives in the rat, for changes in the pharmacokinetic 
parameters, compared to free MTX. It was hoped that these conjugates would 
demonstrate certain beneficial properties compared to free MTX such as an increase in 
circulation half-life giving rise to prolonged levels of the drug in tissue fluid, and 
limitation of cellular uptake reducing drug side effects. Eventual conjugation of a 
specific targeting agent to the drug carrier complex would allow entry into cells by the 
process of receptor mediated pinocytosis which can occur more rapidly than fluid phase 
pinocytosis.
It was shown that all the BSA-MTX conjugates administered to rats did in fact 
demonstrate these beneficial changes in pharmacokinetics compared to free MTX. The 
conjugates had terminal half-lives which were at least ten times those of free drug and 
Vd were less than a third. They, therefore, have potential as drug-carrier systems.
The actual distribution and pharmacokinetics of the conjugates appeared to be related to 
the concentration of MTX. At low loadings of MTX in the conjugate the elimination 
half-life was decreased compared to free BSA, however there was a linear relationship 
between the terminal half-life for the conjugates and the loading of MTX. BSA-MTX 
with a loading above 7.16%w/w had a half-life that was greater than that calculated for 
BSA (see figure 4.13.2). There was a tendency for the volume of distribution to 
increase with increased concentration of MTX in the conjugate. Whole body 
autoradiography (figures 5.5.1 to 5.5.9) and organ distribution studies showed the 
reason for the increased volume of distribution. For low strength conjugates (e.g. 
4.54%w/w) there was a generalised increased uptake of the conjugate by most organs 
investigated compared to free BSA and the higher strength conjugates (e.g. 11.55%w/w) 
were associated with a rapid uptake by the liver (61-67% in the first 15 minutes).
The reason for the changed distribution pattern compared to free BSA has not been 
discovered, but may be due to the changed characteristics of the protein. The possible 
changes include an increased hydrophobicity which could lead to a greater association 
with cell membranes (this could explain the non-specific accumulation for the low
Vs.
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strength conjugates). The conjugates would be expected to exhibit a greater anionic 
charge than BSA itself. There is conflicting evidence on whether this would increase or 
decrease its ability to extravasate. It has been demonstrated that positively charged 
molecules can enter the urine from the kidney more readily than equally sized negative 
ones up to a molecular radius of about 4.4nm(23>. However, in the lung and intestine, it 
has been demonstrated that negatively charged molecules are lost from the blood stream 
more readily than positively charged molecules/24*25) The BSA-MTX conjugates would 
be expected to have a changed tertiary structure compared to free BSA and this may 
lead to the conjugates being recognised as foreign and being taken up by the RES 
(liver, spleen, and bone marrow). Increased uptake by these organs was demonstrated 
for the 11.55%w/w conjugate. Another change in the conjugates compared to free BSA 
was the increase in the presence aggregated protein (up to 39% in the 13.6%w/w 
compared to only 7% in free BSA). This may also cause increased uptake by the RES. 
The generalised increase in organ uptake for the low strength conjugates may be due to 
the specific effect of methotrexate itself, which has helped the conjugate to enter the 
cells using the folate transporter.
BSA and the conjugates were administered with a 125I label so that they could be 
detected in serum. There were two problems associated with the use of this label. 
Firstly, there was the possibility of injecting a small amount of unconjugated 125T along 
with the iodinated conjugate and secondly it was anticipated that the proteins and 
conjugates would be degraded in vivo and this would be followed by the release of 125I 
either as iodide or as iodinated tyrosine from the protein. 125I-Na was administered to 
rats to investigate, if any unconjugated 125I would lead to errors in the assay of 
125I-BSA or 125I-BSA-MTX.
125I-Na was shown to have a rapid alpha phase half-life at approximately 50 minutes 
and a large Vd of 260ml. At 3 hours after injection (the end of the alpha phase) the 
levels of 125I in serum had fallen to 0.3%/ml, and this represents only 2.7% of the 
injected dose in the blood stream. Organ distribution was determined for the liver, 
kidney and thyroid. 125I did not accumulate in the liver or kidney but was sequestered
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by the thyroid (5-6% of the injected dose in 4 hours), this would be expected to be 
released at a later stage as 125I-thyroxine. From these results 125I (as iodide) present in 
the original injection solution was not expected to cause a problem at early time points 
because there was never more than 10% of free iodide in the injection. This iodine 
would rapidly leave the vasculature and be taken up by the thyroid.
The molecular weight of the serum 125I was determined following injection of 
BSA-MTX (7.16%w/w). The majority of radioactivity (more than 67%), measured up to 
48 hours after injection was present as conjugate-bound 125I. The remainder of the 
radioactivity was present as either iodotyrosine, iodide or possibly 125I-thyroxine. In 
addition the longer t1/2 for proteins and conjugates, compared to free 125I, suggests that 
it is the actual protein that is being followed and not free tracer.
46% of the injected 125I-Na was excreted by the kidney in 24 hours. For 125I-BSA only 
15-19% of the radioactivity was excreted in the urine in 24 hours and this again pro ves 
that the 125I was not cleaved from the protein immediately following administration 
(otherwise the amount excreted would be the same as for unconjugated iodide). For the 
proteins and conjugates, the excretion by the kidney was actually a measure of their 
catabolism because they are too large to be excreted unchanged. This explains why 
more of the conjugate was excreted than BSA (see figure 4.13.3) because the increased 
uptake by the liver would be expected to result in increased degradation of the protein.
Separate analysis of the protein and drug portions of the conjugate was investigated 
using a dual label. The BSA was labelled with 125I as before and the MTX was labelled 
with 3H. The concentration of the two isotopes was measured in serum and the ratios of 
the two isotopes was found to be similar over the 96 hours of the experiment. This 
suggests that neither of the labels was cleaved from the conjugate during circulation. 
The fate of the two isotopes was not the same however, following uptake of the 
conjugate by the liver and spleen. 3H was found to accumulate in the liver and spleen, 
whereas the 125I portion of the conjugate was found to be released. 125I appeared in the
G.I.T. rapidly, following administration (within 6 hours) and was identified to be 
present in bile as iodide or iodotyrosine. The rate of appearance of the 3H isotope in the
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gut was slower and levels did not begin to rise to similar levels to the 125I isotope until 
72 hours after injection. Likewise the excretion in the urine of the 3H isotope occurred 
more slowly than the 125I isotope (51% of the 125I was excreted in the urine whereas 
only 28.5% of the 3H was excreted in 24 hours).
These results suggest that the conjugate was degraded following cellular uptake. The 
125I isotope was released and 3H was retained by the cell. It is not known whether the 
3H retained by the cell was still bound to MTX. Neither is it known whether the whole 
BSA molecule had been degraded or perhaps just 125I had been cleaved from it. If the 
BSA had been degraded it was not known whether the MTX had been cleaved from it 
and was present intracellularly as active free drug, or was still bound to oligopeptides. 
The fact that the 3H was retained by the cell supports the theory that it was bound to 
MTX. MTX is known to be sequestered by cells since it becomes polyglutamated and 
bound to DHFR.
Further experiments utilised RSA and LA as drug carriers for MTX. Only one 
RSA-MTX was synthesised, so no firm conclusions can be drawn. However, it did 
appear to show the same distribution characteristics to a BSA-MTX conjugate with a 
similar loading. Two LA-MTX conjugates were synthesised with loadings of MTX of 
4.52%w/w and 13.69%w/w. These were found to have larger Vd than BSA-MTX and 
this was probably due to the decreased molecular weight (BSA has a molecular weight 
of 67kD and LA has a molecular weight of 14kD. The LA-MTX (13.69%w/w) was 
found to have a larger Vd than the lower strength conjugate and ‘free* LA, this is a 
similar pattern for that seen for BSA-MTX conjugates and may be the result of 
increased organ uptake. Unfortunately organ distribution studies were not carried out for 
LA-MTX and so the reason for the increased Vd cannot be concluded.
Conjugates between BSA and galactosamine or mannose were administered to rats and 
the organ distribution determined. It was found that both of these conjugates rapidly 
targeted to the liver (70 to 80% in 15 minutes). It was hoped that these conjugates could 
be used to selectively target MTX to 2 cell types; namely the hepatocytes for the 
G-BSA and the Kupffer cells for the M-BSA. However, a conjugate between MTX and
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the G-BSA or M-BSA could not be synthesised using the carbodiimide reaction. The 
BSA-MTX (11.55%w/w) conjugate was found to accumulate in the liver (60% in 15 
minutes). This accumulation was associated with both the hepatocytes (40% of the liver 
activity) and the non-parenchymal cells (the remainder), thus the non-parenchymal cells 
were exposed to a greater concentration of the BSA-MTX because they actually 
represent a smaller proportion of the liver mass, than do the hepatocytes. This liver 
cell-type selectivity could be used as the basis of passive targeting to diseased cells 
within the liver such as leishmaniasis infected macrophages.
Some in vitro work, which investigated the uptake of BSA, BSA-MTX, G-BSA and 
M-BSA by rat peritoneal macrophages was carried out. It was hoped that the uptake by 
the macrophages would mimic the uptake of the conjugates in vivo in the liver Kupffer 
cells. It was found that M-BSA was taken up by the macrophages at a faster rate than 
any other of the proteins investigated. (It was 3 times greater than G-BSA and over 200 
times greater than ‘free* BSA.) BSA-MTX (11.55%w/w) was taken up more rapidly 
than BSA or BSA-MTX (4.54%w/w). The rate of uptake was 5 times faster than ‘free* 
BSA. This increased rate of uptake demonstrated by the macrophages for the 
11.55%w/w conjugate was similar to that seen in vivo for the liver, where 61 to 67% of 
the dose accumulated 15 minutes after injection for the BSA-MTX (11.55%w/w) 
conjugate and only 22 to 25 % of the injected BSA-MTX (4.54%w/w) accumulated.
A second in vitro experiment, involved the growth of BAE-1 cells, an endothelial 
cell-line, on filters and using this system as a model for the capillary. The transport of 
BSA, BSA-MTX (4.54%w/w) and BSA-MTX (11.55%w/w) was investigated. It was 
found that ‘free’ BSA was transported across the cell monolayer at a faster rate than 
either of the two conjugates. The slower rate for the conjugates could be explained by 
the larger amount of aggregated protein (BSA only had 7% aggregated protein whereas 
the conjugates had 23 and 33%). In addition, a greater proportion of the conjugates (0.5 
and 2.2%) was found to be associated with the cells themselves compared to BSA 
(0.16%). It is not known whether the conjugate was adsorbed to the cell surface or was 
intracellular but this may also account, at least partly, for the decreased transport of the
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conjugates compared to BSA. This experiment was carried out to determine whether the 
generalised uptake by the organs seen for the low strength conjugates could be 
attributed to an increased ability of the conjugates to extravasate compared to ‘free’ 
BSA. It was shown that BSA-MTX conjugates were actually transported more slowly 
than BSA itself. However there were problems associated with the cell monolayer. 
Electron microscope analysis of the monolayer showed that there were quite large holes 
in it.
The BSA-MTX conjugates appear to have achieved, what was initially outlined in the 
introduction. The lower strength conjugates do increase circulation half-life and 
decrease Vd and so fulfill the criteria for a successful drug delivery system. Below are 
some suggestions for future work.
Suggestions for Future Work.
1. One of the problems associated with synthesis of the BSA-MTX conjugates using the 
carbodiimide method was the production of protein aggregates. In these experiments the 
aggregates were not removed and in some cases it is not known whether the distribution 
could be attributed to the conjugate itself or the aggregated material that it contained. 
For instance, the increased liver uptake demonstrated for the 11.55%w/w conjugate 
could be due, at least partly to the aggregated material. 61-67% of the injected dose was 
taken up by the liver in the first 15 minutes and the conjugate contained approximately 
33% of aggregated material. A better fractionation technique could be used to separate 
the aggregated material from monomeric conjugate or a different method for synthesis 
of the conjugates could be used. Then conjugates with a low percentage of aggregated 
material could be administered and compared to the original data.
2. Several possibilities to explain the increased cellular uptake of the BSA-MTX 
compared to free BSA have been described. One suggestion was, that the increased 
uptake was due to the MTX actually helping the conjugate into the cell using the folate 
transporter. Because this is a receptor mediated process, then if cellular uptake was due 
to this transporter it could be inhibited using high concentrations of unlabelled MTX or
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the natural substrate, folate. If extravasation and cellular uptake for the conjugates was 
inhibited by high concentrations of folate, then this may suggest that cellular uptake did 
occur by this route.
3. Following uptake of the 125I-BSA-3H-MTX (7.16%w/w) conjugate by the liver it was 
shown that the 125I portion was cleaved from the conjugate and released as iodotyrosine 
or iodide whereas the 3H isotope was retained. However, it is not known what form the 
isotope took. It may have been cleaved from the MTX, it may have been bound to free 
active drug or it may have been bound to MTX which was still linked to oligopeptides. 
One way of determining in what form the 3H was present would be to homogenise the 
liver and to analyse the homogenate by HPLC, for free MTX, polyglutamates of MTX 
and oligopeptides of MTX.
4. There was a significant difference between the amounts of BSA-MTX (4.54%w/w) 
and BSA-MTX (11.55%w/w) taken up by the liver (20% and 61-67% respectively). 
Although the increased liver uptake could be used to passively target drug to this organ, 
the lower strength conjugates did appear to exhibit better overall distribution 
characteristics. A generalised uptake into most organs was demonstrated. Providing that 
the cellular uptake was limited to pinocytosis then the conjugates would exhibit 
decreased toxicity than free drug but they would be present in the tissue fluid for uptake 
by the target cell. The highest loading of MTX in the conjugate that would achieve this 
generalised organ uptake rather than liver uptake would probably be the optimal 
conjugate. Further work needs to be carried out to find out the optimal MTX 
concentration in the conjugate.
5. Experiments were carried out to try and target the BSA conjugates. Galactose 
covalently linked to BSA was found to selectively accumulate in the liver hepatocytes. 
Unfortunately, a conjugate between MTX and G-BSA could not be synthesised using 
the established ECDI method. Further work needs to be carried out to achieve selective 
delivery of the BSA-MTX conjugates. This work could utilise the galactose system or a 
mAb could be used. It was demonstrated that the BSA-MTX conjugates were able to 
extravasate. However, if an IgG molecule was attached to the conjugate, extravasation
-255-
may be inhibited because of the large molecular weight of the complex. Perhaps a better 
alternative would be to use a Fab fragment of a mAb since these have a lower 
molecular weight.
6. Although BSA has been shown to demonstrate quite good properties as a drug carrier 
in this experimental situation, there is the possibility (even when using homologous 
albumin) that on repeated application an immune response could be precipitated. It is 
generally considered that synthetic polymers have a lower potential for immunogenicity 
and so further work could be carried out on synthetic conjugates. There are many 
examples of synthetic carriers in the literature. The ideal carrier would probably be 
without molecular charge, since cationic carriers e.g. poly-lysine are actually toxic 
themselves and should be biodegradable, to avoid long term toxicity problems.
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APPENDIX 1. CALIBRATION CURVES AND REACTION MECHANISMS.
A 1.1 The Reaction Involved in the Iodination of Proteins.
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A 1.2 UV Assay of Methotrexate solutions.
Solutions of Methotrexate were prepared at a range of concntrations (5-60pg/ml) in 
0.1M NaOH. Each standard solution was prepared from its own concentrated stock 
solution. The absorbance of the solutions were determined in a PYE Unicam (PU8610) 
UV/VIS kinetics spectrophotometer at 375nm against a blank of 0.1M NaOH.
Table A 1.1 Absorbance of the standards.
Cone, o f Soln. (pg/ml) Absorbance at 375nm
4.99 0.083
10.12 0.165
14.94 0.245
20.16 0.330
24.9 0.398
30.42 0.473
34.51 0.564
39.84 0.645
50.0 0.800
60.0 0.980
A graph of Absorbance at 375nm against concentration of MTX in the standard solution 
is shown in Figure A 1.2. The plot was used to determine the MTX content of the 
conjugates.
Figure A 1.2 Absorbance of Standard Methotrexate solutions in 0.1M NaOH 
at 375nm.
Absorbance 
at 375nm
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Concentration of MTX (pg/ml) in 0 .1M NaOH
Equation of line: y= 0.016165x - 0.000267
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A1.3 Calibration of the Superose 12 Column.
The superose 12 column was calibrated using a series of proteins of known molecular 
weight. Solutions of 500pg/ml were prepared in PBS. These were injected onto the 
column via a 20pl loop. The elution time was recorded using a Gilson 113 UV detector 
set at 280nm attached to a chart recorder. Flow rate was 0.83ml/minute. Total Volume 
(Vt) of the column was 23.6ml. Kav was calculated for each of the proteins using the 
formula.
Kav = £Y£..7,Y a)
(Vt - Vo)
Where Ve is the Elution Volume, calculated by multiplying the elution time by the flow 
rate. Vo is the void volume which was determined by injecting dextran (molecular 
weight, 2 000 000). Since the dextran is excluded from the gel bed, it is eluted from the 
column at the same time as the solvent front. The void volume was calculated by 
multiplying the elution time of blue dextran by the flow rate. Vt is the total volume of 
the column. Kav indicates the fraction of stationary phase that is available to the solute.
Table 1.2 Calculated Kav for the injected proteins and for blue dextran.
Standard Mol Wt. Log Mol 
Weight
Elution 
time (min)
Ve (ml) Kav
Dextran 2000K 6.301 9.38 7.79 0
BSA 67K 4.826 15.60 12.95 0.326
Ovalbumin 45K 4.653 16.43 13.64 0.370
Trypsinogen 24K 4.380 18.23 15.13 0.464
Cytochrome C 12.4K 4.093 18.57 15.41 0.482
Aprotinin 6.5K 3.813 20.75 17.22 0.596
Insulin Bchain 3496 3.544 22.62 18.77 0.694
Vitamin B 12 1355.4 3.132 24.45 20.29 0.791
A plot o f Kav versus log molecular weight (figure A 1.3) was linear over the molecular 
weight range indicated. This plot could be used to determine molecular weight of the 
conjugates.
Figure A 1.3 Kav versus log molecular weight of standard proteins injected onto the 
Superose 12 column. 0.800 '
Kav
0.700 ’
0.600 - 
0.500 '
0.400 '
0.300 '
0200 "I 1 T r- t 1
2.500 3.000 3.500 4.000 4.500 5.000 
-A3- Log Molecular Weight
R =0.9855
Eqn of line: y=-0.277x + 1.6557
A 1.4 The Calibration Curve used for Determination of MTX Concentration in
Plasma.
The assay used was an HPLC assay as described in the Methods. Standard solutions of 
MTX were prepared in 'blank' (diluted one in two ) plasma. These were spiked with 
AMN as internal standard at the concentration described in the methods. The standards 
were injected onto the column, and the peak heights for MTX and AMN were 
determined. Peak height ratios (MTX/AMN) were calculated.
Table A 1.1 Peak Height and Peak Height Ratio for MTX, AMN and MTX/AMN.
Cone. MTX MTX Peak Height AMN Peak Height Peak height Ratio
(pg/ml) (arbitary values determined by integrator)
0.1 1433 8602 0.1666
0.2 2349 7852 0.2992
0.3 2332 6063 0.3846
0.4 5371 9236 0.5815
0.5 5105 7305 0.6915
0.6 6920 8707 0.7948
0.7 6754 7529 0.8971
0.8 8433 8118 1.0388
0.9 10948 9075 1.2064
1.0 12399 9910 1.2512
The plot of peak height ratio versus concentration of MTX in the standard (figure A 1.4) 
was linear over the range used. The calibration curve was used to determine the 
concentration of MTX in the plasma of rats which had been injected with 2.5mg of 
drug.
Peak height 
ratio
MTX/AMN
Figure A 1.4 Calibration Curve for the Determination of 
MTX Concentration in Plasma Samples.
Each sample was injected onto an Apex ODS column 
and detected at 306nm.1.250
1.000
0.750
R2= 0.9947
0.500
0.250
0.000
0.000 0.125 0.250 0.375 0.500 0.625 0.750 0.875 1.00C
MTX Cone, in Standard Solutions (pg/ml) 
Equation of line: y=1.2384x +0.0050073
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A1.5 Calibration Curve used to determine the MTX Concentration in Urine.
Methotrexate concentration in urine samples was determined using an HPLC assay. A 
series o f standard solutions (upto 2.0pg/ml) were prepared in 1 in 500 diluted urine. 
These were spiked with AMN as internal standard as desribed in the methods and were 
injected onto the column. Peak height ratios (MTX/AMN) were determined.
Table A 1.4 Peak Height Ratios o f Standard MTX Solutions.
1C. o f  MTX Peak Height Ratio
(pg/ml) MTX/AMN
0.01 0.031
0.05 0.058
0.10 0.096
0.20 0.238
0.30 0.363
0.50 0.462
0.80 0.633
1.0 0.786
1.5 1.073
2.0 1.319
The plot of peak height ratio versus concentration of MTX in the standard (figure A 1.5) 
was linear over the range used. The calibration curve was used to determine MTX 
concentration in urine samples of rats which had been injected with 2.5mg of MTXNa2.
Figure A1.5Peak Height Ratio of MTX/Aminopterin of standard solutions
1.500
Peak Height j 250 
Ratio
MTX/AMN
1.000
0.750
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0.250
0.000
of MTX prepared in 1 in 500 diluted urine. Injected onto a 15cm
Apex u d s  column and detected at JUOnm.
R = 0.9841
0.000 0.250 0.500 0.750 1.000 1.250 1.500 1.750 2.00C
concentration of MTX in diluted urine (pg/ml) 
Equation of line: y= 0.65023x + 0.08585
A1.6 Calibration Curve used to determine Digoxin Concentration in Serum.
Digoxin concentration was determined in serum samples using an ELISA kit obtained 
from Boehringer Mannheim. The kit instructions have been photocopied and are shown 
on the next page.
Table A 1.5 The UV absorbance of standard Digoxin serum samples.
:. of Digoxin 
(ng/ml)
Absorbance at 405nm
0 1.393
0.3 1.141
0.9 0.898
2.2 0.585
2.8 0.493
4.6 0.261
A plot of Digoxin concentration versus absorbance gave a curve which could be used to 
determine digoxin concentration of serum samples from rats which had been injected 
with 250ng of drug.
1.500
AK k U 5 0Absorbance 
at 405nm
1.000
0.750
0.500
0.250
0.000
0.000 0.500 1.000 1.500 2.000 2.500 3.000 3.500 4.000 4.500 5.00C 
Concentration of Digoxin in Serum (ng/ml)
Figure A 1.6 Absorbance of standard digoxin solutions prepared in 
serum and subjected to the ELISA Digoxin Assay.
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A1.6b: The Instructions for Determination of Digoxin in Serum by ELISA 
(Boehringer Mannheim).
Procedure
Wavelength: Hg 405 nm (see Note 2)
Spectrophotom eter: 420 nrri ‘(see Note 2)
Semimicro cuvette: 1 cm light path (see Note 3)
Incubation temperature: +20 to 25°C (see Note 4)
Construct a new calibration curve for each assay series. Dupli­
cate determinations are recommended for both sam ples and 
standards.
Reagents and antibody-coated tubes from different kits having 
the sam e lot number can be pooled.
It is recom m ended that the following schem e be adhered to 
for the pipetting of sam ples (or standards and control sera) 
and solution 1a:
Sample 1 +  solution 1 a; sample 2 +  solution 1 a ;... sample n +  
solution 1a. Alternatively, the use of a sam ple/reagent dispen­
ser is recommended.
Add solution 1a rapidly or mix thoroughly with the sample 
material. The pipetting and aspiration steps must take place 
at the sam e intervals to ensure that all tubes have been in­
cubated for the sam e length of time.
Tap-water at +20 to 25°C is required to flush out the tubes.
P ipette into tubes:
a b
Standard
c d
I 6
Sam ple/ 
Control serum
solution 3 a 0.1 ml - - -
solution 3 b - 0.1 ml - -
r
- -
solution 3 c - 0.1 ml - - -
solution 3 d - J - 0.1 ml
j
-
solution 3 e - - - - 0.1 ml -
sam ple - - - - - 0.1 ml
solution 1 a 1.0 ml 1.0 ml 1.0 ml 1.0 ml 1.0 ml 1.0 ml
Incubate for 25 min at +20-25°C  (see Note 5).
A spirate tube contents, d iscard , and rinse tubes once with tap-water within 
5 min. at the  latest. The w ash water should not stand in the tubes  for more 
than (at most) 20  min. Aspirate carefully and com m ence the next pipetting 
within 10 min at the latest. (See Note 6).
Add solution 4a to each  tube in succession , keeping the time interval con ­
s tan t (see Note 7):
solution 4a  | 1.0 ml | 1.0 ml | 1.0 ml ! 1.0 ml { 1.0 ml 1.0 ml
Do not shake. Avoid exposure to direct sunlight.
Incubate for 25 min at + 20-25°C  (see Note 5).
Mix well prior to  m easurem ent.
Zero the  photom eter against solution 4 a.
Transfer tube con ten ts to cuvettes at the sam e time intervals a s  solution 4a I 
was added  and read abso rb an ces  A,.
T est principle
This test is based on the competition principle.
In the first incubation step  (immunological reaction), serum 
digoxin and POD-labelled digoxin (digoxin-POD conjugate, 
soln. 1 a) com pete for a  given limited quantity of digoxin-speci- 
fic antibodies coated onto the inside wall of the tube. The 
amount of antibody-digoxin-POD complex formed is a m eas­
ure of the digoxin content of the sample. The digoxin-POD con­
jugate not bound by the antibodies is removed along with all 
other serum constituents in a  "bound/free” separation step. 
In the second  incubation step  (indicator reaction, soln. 4a), 
the addition of H20 2 and a  chromogen (ABTS”5) results in for­
mation of a  coloured complex whose concentration is propor­
tional to the enzyme activity bound to the tube wall.
The colour intensity that develops within a certain time is mea­
sured against the substrate-chrom ogen solution (4a).
It follows from the competition principle that increasing serum 
digoxin concentrations will result in less digoxin-POD conju­
gate-binding by the antibodies and hence in lower enzyme 
activities.
The results are obtained from a calibration curve that must be 
set up by investigator using the standards provided in the 
kit.
Range of m easurem ent
0 -5  ng/ml (0-6.4 nmol/l)
1 Buffer for incubation
(colour code red) 
phosphate buffer
2  Digoxin-POD conjugate
(colour code red)
POD
3 Standards
a _e (colour code yellow) 
digoxin in human serum
4 Substrate/Buffer
(colour code green) 
phosphate/citrate buffer 
sodium perborate
5  Chromogen
(colour code green) 
ABTS®*
40 mmol/l, pH 6.8
^  0.6 U/ml
see  vial labels 
for concentrations
100 mmol/l, pH 4.4 
3.2 mmol/l
1.9 mmol/l
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A1.7: Calibration Curve for Lowry Protein Determination.
This assay was used to determine the total protein concentration in rat serum. Standard 
solutions o f BSA (20pg-400pg/ml) were prepared in 0.9% NaCl. The standards were 
incubated as described in the methods (2.7.1a) using the method described by 
L o w r y 0 2 8 )  an(j then the absorbance measured at 650nm against a reagent blank.
Table A 1.7: The UV Absorbance of Standard BSA Samples.
nc. of BSA Absorbance at 650nm
(pg/ml)
20 0.026
60 0.085
100 0.126
150 0.195
200 0.230
250 0.295
300 0.338
350 0.408
400 0.447
A plot of absorbance of BSA standards versus concentration was linear.
Figure A 1.7
Absorbance o f standard protein solutions subjected 
to the Lowry Assay for Protein
0.4500
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Equation o f line: y=0.001114x +0.01 111
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A1.8: Calibration curve used to determine the concentration of Evan's Blue in 
Serum.
Solutions o f Evan's Blue were prepared in one tenth diluted rat serum at a range of 
500ng/ml to 20pg/ml. The absorbance was determined at 612nm against a blank of one 
tenth diluted serum in water.
Table A 1.8: Absorbance of Standard Evan's Blue Solutions.
Cone. Evan's Blue Absorbance at 612nm
(pg/ml)
0.5 0.026
1.0 0.060
3.0 0.209
6.0 0.448
8.0 0.589
10.0 0.762
15.0 1.130
20.0 1.546 
A plot of absorbance against concentration was linear.
Figure A 1.8; Absorbance of Standard Solutions of Evan's Blue 
in plasma diluted to one tenth strength in water.
at 612nm
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Equation of line: y=0.077307x - 0.015444
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A1.9: Calibration Curve used for molecular weight determination of PEGs on 
TSK3000.
PEGs of molecular weights ranging from 600 to 20,000D (500pg/ml in water) were 
injected onto the TSK 3000 column and the retention time determined. Detection was 
by refractive index. Results are means of two injections.
Table A 1.9: Retention time of standard molecular weight PEGs on TSK 3000.
Molecular weight Retention time 
(minutes)
20,000 15.5
12,600 16.35
10,000 16.6
9,200 17.5
6,000 17.4
4,250 18.3
4,000 18.5
2,000 19.65
1,470 20.0
960 20.4
600 21.4
A graph of Retention time versus log molecular weight o f standards is shown in figure 
A 1.9 In the range of molecular weights shown the graph is a straight line and can be 
used as a calibration curve to determine the molecular weight o f unknowns.
Figure A 1.9: Retention time of PEG Standards on TSK 3000 Column. (R2 =0.9828)
Retention
time
(min)
- 3 . 7 7 2 4 6 6 * X  + 3 1 . 9 0 4 4 7 6
log molecular weight
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Appendix 2: Formulae and Procedures for calculating Pharmacokinetics and 
Statistics.
2.1 Calculation of Pharmacokinetic Parameters.
When a drug is administered by the IV route, then its pharmacokinetics are due solely 
to distribution and elimination. For IP and SC administration there is always an 
absorption step to get drug into the vascular compartment. However this absorption 
phase may occur very rapidly and may not be detected, if blood samples are not taken 
early enough.
All the drugs, proteins and conjugates investigated in this work showed a biexponential 
clearance from serum, i.e. 2 phases were seen. (This was identified on a plot of log 
serum concentration versus time, where the slope was initially non-linear and then 
became linear after the first phase was complete). Figure A2.1 is a plot of log serum 
concentration versus time for RSA, following IV injection. Phase 1 (distribution) and 2 
(elimination) are shown. For all substrates investigated the first phase, or alpha phase 
was thought to be due to distribution in the central compartment (i.e. rapidly 
equilibrating organs) and the second phase or beta phase was thought to be due to 
distribution in the tissue compartment and to elimination. Four pharmacokinetic 
parameters were routinely calculated. These were the Volume of Distribution (Vd), the 
half-life (t1̂2), the rate constants for the distribution and elimination phases (Kel) and 
the Clearance (Cl).
Parameters were calculated using linear regression analysis. For the plot of Log serum 
concentration versus time (see figure A2.1), the second phase (beta) was shown to be 
linear and the slope and constants determined from this line were used to calculate the 
parameters for the beta phase.
a) V olum e o f  Distribution fVd^
At time 0 after injection, the concentration of drug in the body is equivalent to the 
injected dose. The serum concentration at time 0 (Co) could be determined by 
extrapolating the linear section of the log serum concentration versus time plot back to 
the y axis and taking its antilog. Thus the constant for the linear section of the plot 
could be used to determine Vd.
Vd (ml) = Administered dose 
Co
-A ll-
log
 
jj
g/
ml
FIGURE A2.1: Serum Clearance of RSA following administration of 5mg of 125I-RSA
to rats by the IV route. This graph shows the feathered plot for the alpha phase.
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Values are means +/- S.E.M. (n=2)
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Elimination Rate Constant (KeD
The Kel is directly proportional to the slope of the linear section of the log serum 
versus time plot. It was determined using the equation:
kel (hr1) = 2.303 x slope
cl Half-life (tW)
The half-life for the elimination phase can be determined from the Kel.
ti/2(hr)= n m  
Kel
d) Clearance TCP.
Clearance is a measure of the body’s ability to remove the drug. It represents that 
volume of plasma cleared of drug in unit time. For most drugs this value is constant.
Cl (ml/hr) = Kel x Vd
Parameters for the alpha phase involved a more complex calculation. A feathering plot 
was used to make the alpha phase linear. During the alpha phase, the drug or conjugate 
was being cleared from plasma or serum by distribution 4«to the central compartment, 
but in addition the drug was being cleared by the same mechanisms which occur during 
the beta phase. In order to calculate the alpha phase parameters, the clearance due to the 
beta phase had to be removed. The hypothetical values for the beta phase at each time 
point were subtracted from the actual serum concentrations determined during the alpha 
phase by extrapolating the linear section of the log serum versus time plot back to the y 
axis.
This feathering of the data for the alpha phase allowed a linear plot for the log serum 
concentration versus time graph. The parameters were then calculated as described for 
the beta phase parameters.
For the proteins and conjugates, the alpha phase changed into the beta phase prior to the 
24 hour sampling time. Thus beta phase parameters were calculated from time points 
between 24 hours and usually 96 hours. The alpha phase time points were taken from 
the remaining sampling times, but care was taken not to include a sampling time which 
actually fell into the beta phase. It was obvious on carrying out the feathering 
calculation and ploting the log serum concentration versus time graph, if a point did 
actually fall into the other phase.
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2.2 Test for Parallelism.
I
I
This test was used to determine whether BSA induced an inflammatory reaction when 
injected into male wistar rats. Two groups consisting of an equal number of weight 
matched rats were obtained. To group 1 Evan’s Blue was injected and in group 2, dye 
plus 20mg of BSA was injected. Serum levels of dye were determined for both groups 
at the same time points. A plot of log10 serum concentration against time was obtained 
for both groups. The plot was biexponential and was divided into 2 sections, one for 
each phase. The slopes for each phase were compared by means of a test for 
parallelism.
n  Alpha Phase.
The test for parallelism was performed between the 20 minute and 4 hour points. A 
series of factors were calculated in order to perform the analysis of variance. Table 
A2.1 lists the data required to calculate the F values for the analysis of variance.
Table A2.1 Sample Results for 4 point Assay of Evans Blue in Plasma.
Log10 Evan Blue Concentration (% of dose/ml) (y)
Observation El Eh a l a h Q (Totals)
1 0.6445 0.8537 0.5681 0.8615 2.9278
2 0.5495 0.8319 0.5119 0.7939 2.6872
T (totals) 1.1940 1.6856 1.0800 1.6554 5.6150
Where EL = Low concentration (4 hour) of Evans Blue only. 
Eh = High concentration (20 minutes) of Evans Blue only. 
Al = Low concentration (4 hour) of Evans Blue + BSA.
Ajj = High concentration (20 minutes) of Evans Blue + BSA.
Correction Factor (CF) = (£y)2
N
= (5.615)2/8 
= 3.941 
E =  1.194 + 1.6856 = 2.8796 
A = 1.08 + 1.6554 = 2.7354 
H = 1.6856 + 1.6554 = 3.341 
L =  1.194+ 1.08 = 2.274
-A14-
There were 8 observations, therefore the total degrees of freedom (d.f.) was 7. This d.f. 
is subject to 2 independent classifications; between animals (2 animals in each group) 
which has 1 d.f. and between times ( 4 time points) which has 3 d.f..An interaction 
(residual or error) d.f. was also required. This was calculated as the product of the 2 
sets of d.f. i.e. 3. in addition the 4 time points were subject to 2 independent criteria of 
classification i.e. one of two injected preparations (ld.f.) and one of two time points 
(ld.f.).
Table A2.2 The Analysis of Variance Table.
Source of 
variation
d.f. Sum of Squares 
(SS)
V (SS/d.f.) F (V/res 
error)
Total 7 £ y 2-CF=0.1544 (1) 0.0221 -
Between
animals
1 (CQ2/4)-CF 
= 0.00726 (2)
0.00726 15.75
(significant)
Between Sam­
pling times
3 (iT2/2)-CF 0.0486 
= 0.146 (3)
0.0486 -
Slope 1 ((*L)2+( H)2/4) 
-CF = 0.142 (4)
0.142 309.78 
(H. Sig)
Preparations 1 m ) 2H  A)2/4) 
-CF = 0.00260 (5)
0.00260 5.658
(non-sig)
Parallelism 1 (3)-(4)-(5)
= 8.778 x 10-4
8.778xl0-4 1.910
(non-sig)
Residual 3 (l)-(2)-(3)
=1.378xl0-3
4.594x10"4 -
The divisor for each of the sum of square terms was the number of observations in the 
group used to calculate the SS. The F values in the final column were compared to 
reference values tabulated in Variance Ratio Tables. The test for parallelism over the 
distribution phase showed that the slopes for group 1 and group 2 were parallel. The 
highly significant value for the slope F ratio showed that this test was a valid test for 
the data (the lines must have a slope for the test to be valid). There was no difference in 
the potency of the preparations used for groups 1 and 2. The significant difference 
obtained for the between observations was possibly due to differences in the rats used.
The analysis of variance was repeated for the elimination phase. Time points of 6 and 
24 hours were used. The slopes for the two groups were parallel. There was a 
significant difference for the between preparations F value. This could be due to the 
nature of the injection solution for group 2. Because contained BSA it was more 
viscous than the injection solution containing Evans Blue only and thus the whole dose 
may not have been administered to the group 2 rats.
APPENDIX 3: EXPERIMENTAL DATA FOR CHAPTERS 3 TO 6.
Table A3.1.1: The plasma concentration (% dose remaining/ml) of MTXNa2 after 
administration of 2.5mg of drug by IV, IP, SC injection. (n=8 for each route). Each value 
represents the concentration determined by HPLC for one ra t
Time
(min)
rv
%dose
/ml
Time
(min)
IP
%dose
/ml
Time
(min)
SC
%dose
/ml
10 0.630 15 0.465 15 0.523
20 0.410 15 0.378 15 0.549
30 0.268 30 0.318 30 0.441
40 0.186 30 0.194 30 0.323
50 0.123 45 0.220 45 0.236
60 0.112 45 0.234 45 0.229
75 0.0877 60 0.184 60 0.156
90 0.0489 60 0.0762 60 0.165
105 0.0292 75 0.0998 75 0.0932
120 0.0242 75 0.0650 75 0.0933
135 0.0255 90 0.0547 90 0.0546
150 0.0309 90 0.0649 90 0.0524
165 0.0220 105 0.0325 105 0.0443
195 0.0189 105 0.0385 105 0.0480
120 0.0377 120 0.0315
120 0.0306 120 0.0208
150 0.0251 165 0.0164
150 0.0298 165 0.0211
180 0.0202 180 0.0180
180 0.0228 180 0.0157
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Table A3.1.2: The plasma concentrations (%dose remaining/ml) of 3H-MTX after 
administration of a total dose of MTXNa2 of 2.5mg by IV, IP and SC. (n=8 for each route). 
Each value represents the results obtained for one rat
Time
(min)
IV
%dose
/ml
Time
(min)
IP
%dose
/ml
Time
(min)
SC
%dose
/ml
15 0.400 15 0.271 15 0.331
15 0.421 15 0.246 15 0.480
30 0.195 30 0.174 30 0.273
30 0.186 30 0.192 30 0.235
45 0.157 50 0.136 50 0.162
45 0.143 50 0.159 50 0.0777
60 0.0866 65 0.0874 65 0.0622
60 0.115 65 0.0802 65 0.125
90 0.0488 90 0.0551 90 0.0496
90 0.0518 90 0.0587 90 0.0594
120 0.0551 120 0.0366 120 0.0282
120 0.0447 120 0.0382 120 0.0226
150 0.0379 165 0.0287 165 0.0171
150 0.0302 165 0.0275 165 0.0226
180 0.0225 225 0.0235 225 0.0161
180 0.0458 225 0.0170 225 0.0128
210 0.0267
210 0.0239
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Table A3.1.3: The plasma levels obtained (% dose remaining/ml) after injecting 0.5mg of 
3H-MTX by IV, IP, SC to male wistar rats. (n=8 for each route).
IV
Time
(min)
%dose
/ml
IP
Time
(min)
%dose
/ml
SC
Time
(min)
%dose
/ml
15 0.425 5 0.239 10 0.347
15 0.521 7 0.362 10 0.407
30 0.295 11 0.479 20 0.312
30 0.205 12 0.324 20 0.357
45 0.143 20 0.354 30 0.229
45 0.154 23 0.400 30 0.196
60 0.0898 29 0.227 40 0.159
60 0.108 30 0.284 40 0.204
80 0.0598 45 0.214 50 0.129
80 0.0511 50 0.198 50 0.174
100 0.0367 60 0.169 60 0.134
100 0.0338 61 0.150 60 0.136
120 0.0348 84 0.126 75 0.117
120 0.0304 85 0.102 75 0.0848
140 0.0246 107 0.0478 85 0.0962
140 0.0247 107 0.0738 90 0.0651
160 0.0242 125 0.0746 105 0.0495
165 0.0213 126 0.0508 105 0.0471
180 0.0460 145 0.0574 120 0.0391
180 0.0227 148 0.0558 120 0.0340
210 0.0401 160 0.0542 150 0.0326
210 0.0180 163 0.0417 160 0.0265
240 0.0146 180 0.0332 180 0.0237
240 0.0162 180 0.0418 180 0.0244
215 0.0359 210 0.0213
216 0.0282 210 0.0226
240 0.0336 240 0.0182
240 0.0318 240 0.0199
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Table A3.1.4: The Urine Excretion of MTX following Administration of 2.5mg of
MTXNa2 by the IV route and measurement using the HPLC assay for urine samples.
Results are expressed as mean % dose excreted. (n=4)
Time (hours) Mean (% of dose excreted) S.E.M.
6.5 59.5 7.15
24.0 82.3 3.57
48.0 88.7 2.60
Table A3.1.5: The Urine excretion of 3H activity (% of total dose administered) following 
administration of 0.5mg of 3H-MTX by IV, IP and SC routes.
Results are expressed as mean % excreted. (n=3 for IP and n=4 for IV and SC).
Time (hr) IV(%) S.E.M. IP(%) S.E.M. SC (%) S.E.M.
7 4.8 2.60 ND 5.4 2.11
24 14.63 2.03 10.48 2.18 14.93 4.11
48 15.7 1.91 12.73 2.33 16.92 3.78
72 16.1 1.94 13.40 2.40 17.33 3.62
Table A3.1.6: The Urine Excretion of 3H activity (% of total dose administered) following 
administration of 2.5mg of 3H-MTX by IV, IP and SC Injection.
Results are expressed as mean % excreted. (n=3 for IV and n=4 for IP and SC).
Time (hr) IV(%) S.E.M. IP(%) S.E.M. SC (%) S.E.M.
6 3.8 1.92 7.56 4.23 7.88 3.03
24 14.54 4.70 21.99 4.90 17.04 5.19
48 17.90 5.12 25.01 5.12 18.95 5.84
72 19.55 5.42 25.85 5.12 19.37 5.92
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Table A3.2.1: The serum concentration (% dose remaining/ml) of Digoxin after injecting 
male wistar rats with 250ng of drug by IV, IP or SC routes.
Serum levels were determined using an ELISA technique. Each value represents the results 
obtained for one rat
IV IP SC
Time (hr) %dose/ml %dose/ml %dose/ml
0.5 1.56 0.702 0.32
0.5 1.70 1.28 0.40
1.0 1.24 0.88 0.22
1.0 1.04 0.66 0.48
1.5 0.90 ND ND
1.5 0.96 ND ND
2.0 0.66 0.65 0.80
2.0 0.40 0.52 1.48
2.5 0.44 0.90 0.78
2.5 0.38 0.46 0.64
4.0 0.32 ND ND
4.0 0.20 ND ND
4.5 0.22 ND ND
4.5 0.21 ND ND
5.0 0.14 0.62 0.36
5.0 0.20 0.33 ND
5.5 0.18 ND ND
5.5 0.26 ND ND
6.0 0.24 ND ND
6.0 0.16 ND ND
7.0 0.24 0.18 0.12
7.0 0.18 0.22 0.20
17.0 ND Ndig 0.
17.0 ND Ndig 0.14
ND= Not determined.
Ndig= Digoxin was not detected.
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Table A3.3.1: The plasma concentration of 125I (%of dose remaining/ml) after administr­
ation of 0.654ng of 125INa to male wistar rats by the IV route. Each value represents the 
plasma concentration determined for one ra t Eight rats were dosed. Four 0.3ml blood 
samples were taken from each rat.
Time (hr) % dose/ml
0.25 0.779
0.25 0.646
0.5 0.490
0.5 0.607
0.75 0.528
0.75 0.366
1.167 0.488
1.167 0.406
1.5 0.449
1.5 0.398
1.833 0.445
1.833 0.442
2.0 0.368
2.0 0272
2.367 0.338
2.417 0.438
3.0 0.319
3.0 0.238
4.0 0.247
4.0 0.395
5.0 0.266
5.0 0.272
6.0 0.227
6.0 0.179
23.0 0.059
23.0 0.073
27.0 0.069
27.0 0.083
30.75 0.052
30.75 0.073
48.0 0.028
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Table A3.3.2: The Urine Excretion of radioactivity following administration of 0.654ng of
125I-Na to rats by the IV route.
Values are mean % excretion (n=4).
Time (hr) Mean % excreted S.E.M.
24 45.54 7.18
48 51.66 7.18
72 56.42 7.74
96 59.35 8.50
Table A3.3.3: The Excretion of radioactivity in the faeces following administration of
0.654ng of 125I-Na to rats by the IV route.
Values are mean % excretion (n=4).
Time (hr) Mean % excreted S.E.M.
24 3.755 1.290
48 5.600 1.489
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Table A3.3.4: The Organ Distribution of radioactivity following administration of 0.654ng of
125I-Na to rats by the IV route.
Results are expressed in 2 forms as a % of the total activity injected in either lg  or the whole 
tissue and as a ratio of the activity found in lg  (or whole tissue) divided by the activity found 
in 1ml of whole blood.
Organ % in lg CPM in lg / 
CPM in 1ml WB
% in total CPM in total/ 
CPM in 1ml WB
1. Distribution 4 hours post injection.
Thyroid ND ND 5.06 18.88
6.21 14.14
Whole Blood ND ND 0.268%/ml 1
0.439%/ml 1
Serum ND ND 0.247%/ml 0.922
0.395%/ml 0.900
Liver 0.182 0.679 2.36 8.826
0.193 0.439 2.17 4.937
Kidney 0.205 0.767 0.404 1.509
0.199 0.453 0.438 0.997
2. Distribution 27 hours post injection.
Thyroid ND ND 9.40 101.5
8.52 110.6
Whole Blood ND ND 0.0926%/ml 1
0.0770%/ml 1
Serum ND ND 0.083%/ml 0.896
0.069%/ml 0.896
Liver 0.0471 0.509 0.46 4.966
0.0453 0.588 0.54 7.000
Kidney 0.0446 0.482 0.094 1.013
0.0397 0.516 0.083 1.083
3. Distribution 52 hours post injection.
Thyroid ND ND 7.96 169.4
8.45 325
Whole Blood ND ND 0.047%/ml 1
0.026%/ml 1
Serum ND ND 0.042%/ml 0.894
0.028%/ml 1.077
Liver 0.0221 0.470 0.24 5.100
0.0153 0.589 0.23 8.930
Kidney 0.0227 0.484 0.055 1.174
0.0128 0.491 0.027 1.032
-A23-
Table A3.4.1: The plasma concentration of 14C- Inulin (% dose remaining/ml) after
administration of 40mg of drug to male wistar rats by SC or IP injection.
(n=8 for each route), Each value represents the plasma concentration determined for one rat.
Time
SC
% dose/ml S.E.M % dose/ml
IP
S.E.M.
1 0.0279 0.0382
1 0.0337 0.0758
2 0.00541 0.0498
2 0.00596 0.0314
3 0.00650 0.0352
3 0.00866 0.0148
4 0.00650 0.0265
4 0.00541 0.0127
5 0.00571 0.00135a 0.0101
6 0.00363 0.00463
6 0.00355
7.5 0.00571 0.0017b 0.00781 0.00208a
10.66 0.00317 0.00374 0.00131a
10.66 0.00417
Note where S.E.M. are expressed the values for % dose remaining/ml are expressed as the 
mean of at least three plasma samples for different rats.
a) n=3
b) n=4
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Table A3.5.1: The serum concentrations (% of 125I activity remaining/ml) determined after
administration of 5mg of 125I-Lactalbumin to male wistar rats by IV, SC or IP routes.
Each value represents the result obtained for one rat (n=8 for each route).
Time (hour) IV(%dose/ml) EP(%dose/ml) SC(%dose/ml)
0.25 1.0992 ND ND
0.25 1.205
033 ND 0.286 ND
0.33 0.296
0.5 1.041 ND 0.173
03 1.104 0.274
0.66 ND 0.400 ND
0.66 0.348
1.0 0.852 0.674 0.446
1.0 0.839 0.593 0.833
2.0 0.659 0.511 0.380
2.0 0.534 0.533 0.481
3.0 0.493 0.463 0.458
3.0 0.391 0.439 0.369
4.0 0.412 0.361 0.350
4.0 0.467 0.386 0.309
6.0 0.350 0.396 0.322
6.0 0.362 0.397 0.238
8.0 0.302 0.258 0.201
8.0 0.319 0.331 0.221
10.0 0.237 0.310 0.152
10.0 0.270 0.309 0.171
25.0 0.243 0.113 0.106
25.0 0.173 0.148 0.111
28.0 0.201 0.161 0.101
28.0 0.139 0.128 0.122
31.5 0.125 0.108 0.115
31.5 0.113 0.126 0.128
473 0.076 0.089 0.064
47.5 0.087 0.097 0.080
55.0 0.094 0.096 0.082
55.0 0.103 0.100 0.098
72.0 0.046 0.057 0.039
72.0 0.037 0.050 0.059
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Table A3.5.2: The Urine Excretion of 125I acivity (% of total dose administered) after
administration of 5mg of 125I-Lactalbumin to male wistar rats by IV, IP or SC injection.
Values expressed are means (n=3) ± S.E.M.
Time (hr) IV(%) S.E.M. IP(%) S.E.M. SC (%) S.E.M.
24 28.53 3.267 42.87a 8.510 51.96b 2.549
48 39.84 4.309 55.54 7.773 63.70 2.860
72 45.73 3.788 63.48a 7.500 68.45b 2.517
Notes
a= values were non-significandy different from rats dosed IV.(P>0.05) 
b= values were highly significantly different from rats dosed IV. (P<0.02)
There was no significant difference in urine excretion for rats dosed IP and SC.
Table A3.5.3: The excretion of 125I activity in the faeces (% total dose administered) after 
administration of 5mg of 125I-Lactalbumin to male wistar rats by IV, IP or SC routes.
Values expressed are means (n=3) ±  S.E.M.
Time (hr) IV(%) S.E.M. IP(%) S.E.M. SC (%) S.E.M.
24 3.32 1.488 3.36 0.460 4.29 0.142
48 4.90 1.708 5.38 0.435 6.97 0.880
72 6.31 1.410 6.70 0.690 8.08 0.907
Note
There was no significant difference for the faecal excretion of 125I for any route of 
administration.
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Table A3.5.4: The organ distribution of 125I activity after administration of 5mg of
125I-Lactalbumin to male wistar rats by IV, SC or IP injection.
The results are expressed in 2 forms; as a % of the administered dose in lg  or the 
whole organ and as a ratio of the activity in the organ /  the activity in 1ml of whole 
blood.
Organ % of dose 
/g
CPM in lg  
CPM/ml WB
% of dose 
(total)
CPMftntan 
CPM/ml WB
1. Distribution 28 hours post IV injection.
THYROID ND ND 6.750 23.85
4.070 19.66
WHOLE BLOOD ND ND 0.283%/ml 1
0.207%/ml 1
PLASMA ND ND 0.201%/ml 0.710
0.139%/ml 0.671
LIVER 0.114 0.404 0.862 3.046
0.099 0.478 0.940 4.543
SPLEEN 0.0857 0.303 0.075 0.265
0.0626 0.302 0.068 0.330
HEART 0.0719 0.254 0.063 0.22
0.0317 0.153 0.058 0.281
LUNG 0.107 0.378 0.160 0.562
0.0855 0.412 0.130 0.645
KIDNEY 0.426 1.508 0.865 3.061
0.460 2.218 0.960 4.637
STOMACH 0.888 3.144 3.24 11.45
0.348 1.677 1.33 6.417
SM. INTESTINE 0.158 0.559 1.184 4.183
0.156 0.751 1.22 5.873
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Table A3.5.4 Cont (Organ Distribution following administration of LA).
Organ %dose
/g
CPM/ff 
CPM/ml WB
% dose 
(total)
CPM ftotaD 
CPM/ml WB
2. IV Distribution after 72 hours.
THYROID ND ND 3.81 42.33
4.25 57.43
WHOLE BLOOD ND ND 0.090%/ml 1
0.074%/ml 1
PLASMA ND ND 0.0459%/ml 0.51
0.0373%/ml 0504
LIVER 0.0520 0375 0.528 5.63
0.0496 0.647 0.530 6.95
SPLEEN 0.0303 0.335 0.023 0348
0.0303 0.396 0.029 0.384
HEART 0.0220 0.243 0.022 0.245
0.0405 0.529 0.034 0.447
LUNG 0.036 0.398 0.0468 0.518
0.032 0.419 0.051 0.662
KIDNEY 0.314 3.48 0.655 7.24
0.374 4.88 0.770 10.05
STOMACH 0.0588 0.617 0360 0347
0.0374 0.487 0.220 2.895
SM. INTESTINE 0.0537 0.594 0.509 5.62
0.0593 0.774 0.540 7.082
3. Distribution 28 hours after SC administration.
THYROID ND ND 5.70 35.63
8.63 47.94
WHOLE BLOOD ND ND 0.16%/ml 1
0.18%/ml 1
PLASMA ND ND 0.101%/ml 0.631
0.122%/ml 0.678
LIVER 0.052 0.325 0.550 3.442
0.092 0.500 0.831 4.511
SPLEEN 0.035 0321 0.045 0382
0.051 0379 0.051 0376
HEART 0.039 0.244 0.034 0.213
0.054 0.292 0.047 0.256
LUNG 0.050 0.315 0.068 0.425
0.067 0362 0.093 0.508
KIDNEY 0.422 2367 0.980 6.136
0398 2.164 0.939 5.106
STOMACH 0356 1.601 0.910 5.694
0.294 1.600 0.884 4.807
SM. INTESTINE 0.078 0.486 0.620 3.862
0.0819 0.445 0.690 3.781
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Table A3.5.4 Cont. (tissue Distribution of LA).
ORGAN % dose 
/g
CPM/g/ 
CPM/ml WB
%dose
(total)
CPM (total) 
CPM/ml WB
4. Distribution 72 hours post SC Administration.
THYROID ND ND 6.98 81.16
7.42 82.44
WHOLE BLOOD ND ND 0.086%/ml 1
0.090%/ml 1
PLASMA ND ND 0.039%/ml 0.455
0.059%/ml 0.658
LIVER 0.030 0.340 0.320 3.604
0.086 0.922 0.721 7.653
SPLEEN 0.018 0.199 0.021 0.238
0.039 0.413 0.038 0.406
HEART 0.026 0.289 0.019 0.217
0.027 0386 0.018 0.188
LUNG 0.031 0.346 0.042 0.472
0.034 0.360 0.041 0.437
KIDNEY 0.305 3.43 0.627 7.049
0.484 5.18 0.86 9.165
STOMACH 0.033 0372 0.141 1.582
0.113 1.208 0340 2363
SM. INTESTINE 0.028 0314 0328 2.563
0.045 0.478 0330 2.476
5. Distribution 28 hours after IP administration.
THYROID ND ND 731 3333
8.06 44.78
WHOLE BLOOD ND ND 032%/ml 1
0.18%/ml 1
PLASMA ND ND 0.16%/ml 0.725
0.13%/ml 0.711
LIVER 0.080 0.361 0.992 4.470
0.093 0320 1.25 6.949
SPLEEN 0.056 0352 0.053 0339
0.066 0.366 0.111 0387
HEART 0.044 0.197 0.042 0.189
0.056 0310 0.045 0355
LUNG 0.0721 0325 0.099 0.448
0.082 0.454 0.098 0343
KIDNEY 0.482 2.172 1.114 5.022
0.498 2.771 1.167 6.491
STOMACH 0.298 1345 1353 6.998
0351 1.954 2.53 14.05
SM. INTESTINE 0.303 1.367 3376 16.11
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Table A3.5.4 cont. (Organ Distribution of LA)
ORGAN % dose in lg  CPM in 1 g % dose in CPM ftotaB
CPM/ml WB total CPM/ml WB
6. Distribution 72hours after IP administration
THYROID ND ND 5.33 54.39
7.28 77.45
WHOLE BLOOD ND ND 0.098%/ml 1
0.094%/ml 1
PLASMA ND ND 0.056%/ml 0.576
0.050%/ml 0.529
LIVER 0.050 0.489 0.531 5.178
0.046 0.475 0.436 4.492
SPLEEN 0.032 0.317 0.023 0.223
0.025 0.259 0.039 0.397
HEART 0.021 0.205 0.017 0.165
0.030 0.313 0.022 0.227
LUNG 0.0358 0.351 0.049 0.475
0.101 1.045 0.121 1.233
KIDNEY 0.375 3.684 0.842 8.253
0.328 3.379 0.673 6.867
STOMACH 0.123 1.210 0.282 2.797
0.086 0.881 0.401 4.112
SM. INTESTINE 0.050 0.491 0.432 4.193
0.038 0.388 0.364 3.750
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Table A3.6.1: The Serum concentration (% 125I activity remaining/ml) determined after
administration of 5mg 125I-Carbonic Anhydrase to rats by IV, IP or SC routes.
Each value represents the result obtained for one rat (n=8 for each route).
Time (hour) IV (%dose/ml) IP (% dose/ml) SC (% dose/ml)
1.0 0.980 1.084 0.804
1.0 0.948 0.795 0.755
2.0 0.906 0.983 0.755
2.0 0.972 0.955 0.728
4.0 0.640 0.839 0.720
4.0 0.675 0.906 0.712
6.0 0.704 0.710 0.647
6.0 0.578 0.724 0.665
8.0 ND ND 0.582
8.0 ND ND 0.616
10.0 0.431 0.657 0.562
10.0 0.488 0.592 0.611
18.75 0.298 0.272 0.272
18.75 0.271 0.356 0.278
21.0 0.263 0.210 0.229
21.0 0.284 0.214 0.253
24.0 0.238 0.247 0.205
24.0 0.211 0.181 0.209
27.0 ND 0.198 0.144
27.0 ND 0.167 0.161
30.75 0.255 0.172 0.130
30.75 0.232 0.177 0.172
48.0 0.0841 0.0830 0.0528
48.0 0.106 0.0732 0.0566
55.5 0.124 0.0564 0.0602
55.5 0.0970 0.0733 0.0542
72.0 0.0653 0.0640 0.0400
72.0 0.0667 0.0558 0.0478
97.5 0.0437 0.0415 0.0383
97.5 0.0392 0.0318 0.0321
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Table A3.6.2: The Urine Excretion of 125I activity (% of total dose administered) after 
administration of 5mg 125I-Carbonic Anhydrase to rats by IV, IP or SC injection.
Values are means (n=3) ±  S.E.M.
Time (hr) IV(%) S.E.M. IP(%) S.E.M. SC(%) S.E.M.
24 22.95 125 33.31 7.22 20.55 2.38
48 34.22 3.70 41.17 8.24 23.89 2.84
72 36.12 3.83 45.59 7.11 29.47 2.40
96 37.61 4.25 47.15 6.84 30.71 2.44
There was no significant difference for the % of 125I activity excreted in the urine for 
each of the routes when analysed using a Students T-test.
Table A3.6.3: The Excretion of 125I activity in the faeces (% total dose administered) after 
administration of 5mg of 125I-Carbonic Anhydrase to rats dosed IV, IP or SC.
Values are expressed as means (n=3) ± S.E.M.
Time (hr) IV(%) S.E.M. IP(%) S.E.M. SC(%) S.E.M.
24 3.24 0.18 4.05 1.85 6.61 0.44
48 5.07 0.14 4.94 2.03 8.81 0.54
72 5.83 0.34 6.88 2.08 10.29 0.90
96 6.96 0.25 7.61 2.12 11.21 0.99
Analysis of different routes of administration at same time points using a Students T-test 
showed no significant difference.
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Table A3.6.4: The Organ Distribution of 125I-activity after administration of 5mg of
125I-Carbonic anhydrase to rats by IV, IP or SC routes.
The results are expressed in 2 forms: as a % of the total dose present in either lg  or the 
whole organ and as a ratio of the activity in the organ divided by the activity in 1ml of 
whole blood.
1. Distribution 24 hours post IV injection.
ORGAN % of dose 
/g
CPM/g 
CPM/ml WB
% of dose 
(total)
CPM ftntaB 
CPM/ml WB
THYROID ND ND 7.66 26.41
8.21 30.41
WHOLE BLOOD ND ND 0.29%/ml 1
0.27%/ml 1
SERUM ND ND 0.24%/ml 0.821
0.21%/ml 0.781
LIVER 0.0580 0.198 0.618 2.105
0.0494 0.183 0.527 1.952
SPLEEN 0.0557 0.189 0.082 0.279
0.0538 0.198 0.078 0.288
HEART 0.0612 0.208 0.060 0.205
0.0548 0.203 0.053 0.197
LUNG 0.0886 0.301 0.149 0.508
0.107 0.397 0.150 0.556
KIDNEY 0.209 0.712 0.436 1.735
0.223 0.826 0.468 1.735
STOMACH 0.268 0.912 1.144 3.893
0.499 1.848 1.599 5.922
SM. INTESTINE 0.125 0.424 0.970 3.300
0.135 0.501 1.042 3.811
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Table A3.6.4 Cont. (Organ Distribution of CA).
2. Distribution 24 hours post SC injection.
ORGAN % of dose 
/g
rPM/g 
CPM/ml WB
% of dose 
(total)
rPMrtotaB 
CPM/ml WB
THYROID ND ND 9.39 64.32
7.87 63.98
WHOLE BLOOD ND ND 0.146%/ml 1
0.123%ml 1
SERUM ND ND 0.205%/ml 1.404
0.209%/ml 1.699
LIVER 0.0556 0.382 0.478 3.280
0.0525 0.425 0.434 3.517
SPLEEN 0.0449 0.308 0.0298 0.204
0.0478 0.387 0.0375 0.304
HEART 0.0458 0.314 0.0348 0.239
0.0333 0.270 0.0287 0.233
LUNG 0.0617 0.423 0.0820 0.562
0.0603 0.488 0.108 0.875
KIDNEY 0.134 0.917 0.270 1.852
0.174 1.408 0.281 2.276
STOMACH 0.266 1.826 0.729 5.004
0.536 4.342 1.907 15.443
SM. INTESTINE 0.112 0.768 0.992 6.805
0.085 0.688 0.577 4.674
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Table A3.7.1: The Plasma Concentration (% of 14C activity remaining/ml) after
administration of 0.04mg of 14C-CEA by the IV route to rats.
Tabulated values are means from 3 different rats. 4 rats were injected.
Time (hr) Mean %/ml S.E.M.
0.5 2.377 0.192
1.0 0.896 0.125
2.0 0.330 0.049
4.0 0.213 0.031
6.0 0.151 0.021
24.0 0.087 0.0136
Table A3.7.2: The Urinary Excretion of 14C activity (% of total dose administered) after 
administration of 14C-CEA to rats.
Tabulated values are means (n=3)iS. E.M.
Time (hr) Mean % excreted S.E.M.
24 1.44 0.460
48 2.20 0.404
72 2.85 0.375
96 3.30 0.289
120 3.60 0.327
144 3.85 0.202
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Table A3.8.1 The Serum Concentration (% 125I activity remaining/ml) after administration 
of 5mg of 125I-BSA to rats by each of the three routes. (n=8) for each route. Each value 
represents the plasma concentration determined from one rat
Time
(hr)
IV %dose 
/ml
Time
(hr)
IP %dose 
/ml
Time
(hr)
SC %dose 
/ml
0.75 8.899 0.75 0.306 0.75 0.0476
1.0 7.556 0.75 0.308 0.75 0.0417
1.0 7.925 2.0 0.302 2.0 0.505
3.0 6.685 2.0 0.422 2.0 0.413
3.0 5.702 4.0 3.272 4.0 0.736
6.0 4.548 4.0 4.169 4.0 0.879
6.0 4.841 6.0 4.689 6.0 0.938
23.5 2.077 6.0 3.869 6.0 0.907
23.5 1.935 8.0 4.288 8.0 1.146
31.0 1.652 8.0 4.220 8.0 1.005
31.0 1.409 11.0 3.198 11.0 1.262
48.0 0.755 11.0 3.875 11.0 1.461
48.0 0.935 22.5 2.097 22.5 1.272
54.25 0.589 22.5 1.985 22.5 1.281
54.25 0.617 31.0 2.018 25.0 1.126
72.0 0.351 31.0 1.209 25.0 1.166
72.0 0.317 48.0 0.681 28.0 0.963
79.5 0.265 48.0 0.859 28.0 1.324
79.5 0.315 54.5 0.660 30.0 1.151
97.0 0.244 54.5 0.618 30.0 1.129
97.0 0.219 71.5 0.395 48.0 0.627
71.5 0.362 48.0 0.693
78.5 0.401 54.5 0.515
78.5 0.288 54.5 0.476
96 0.214 71.5 0.277
97 0.219 71.5 0.270
97 0.156 78.5 0.253
78.5 0.248
97 0.185
97 0.156
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Table A3.8.2 The Urine Excretion (% of total 125I dose administered) after administration of
5mg of 125I-BSA to rats by each of the three routes.
Values are expressed as means (n=3) ± S.E.M.
Time
(hr)
IV % dose 
excreted
S.E.M. IP % dose 
excreted
S.E.M. SC % dose 
excreted
S.E.M.
24 15.33 1.424 18.50 0.929 19.33 1.889
48 32.83 1.822 37.23 4.896 39.40 2.577
72 45.51 2.046 46.73 7.824 49.30 2.150
96 53.27 2.888 52.30 9.515 55.37 2.080
Table A3.8.3 The Faecal Excretion (% of total 125I activity administered) after 
administration of 5mg of 125I-BSA to rats by each of the three routes.
Values are means (n=3) ± S.E.M.
Time
(hr)
IV % dose 
excreted
S.E.M. IP % dose 
excreted
S.E.M. SC % dose 
excreted
S.E.M.
24 0.612 0.298 1.75 0.23 1.24 0.34
48 3.62 0.559 4.39 0.71 3.51 0.077
72 5.54 0.52 6.48 1.15 5.53 0.26
96 6.70 0.51 7.89 1.33 6.65 0.51
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Table A3.8.4: The Organ Distribution after administration of 5mg of 125I-BSA to rats.
Results are expressed in 2 forms; as % of 125I activity found in lg  or in whole organ and as a ratio 
of activity in lg  (or whole) of organ divided by the activity in 1ml of whole blood.
Organ % of dose 
in lg
CPM inJg 
CPM/ml WB
% of dose 
in total
CPM in total 
CPM in 1ml WB
1. Distribution 25 hours post TV administration.
Thyroid ND ND 2.13 1.059
4.12 3.12
Whole blood ND ND 2.0%/ml 1
1.23%/ml 1
Plasma ND ND 2.14%/ml 1.07
2.02%/ml 1.64
Liver 0.375 0.187 4.16 2.07
0.383 0.312 3.85 3.13
Spleen 0.258 0.128 0.27 0.13
0.253 0.205 0.26 0.21
Heart 0.595 0.296 0.59 0.29
0.520 0.426 0.49 0.40
Lung 1.673 0.832 2.23 1.12
0.508 0.413 0.72 0.59
Kidney 0.355 0.176 0.85 0.42
0.375 0.305 0.71 0.57
Stomach 1.600 0.796 8.92 4.44
0.657 0.535 2.72 2.21
Sm. Intestine 0.202 0.100 2.20 1.09
0.745 0.606 4.65 3.78
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Table A3.8.4 Continued. (Organ Distribution of 125I-BSA).
Organ % dose 
in lg
CPM inJLg 
CPM/ml WB
% dose 
in total
CPM in total 
CPM/ml WB
2. Distribution 97 hours post IV injection.
Thyroid ND ND 8.91 50.91
5.29 30.22
Whole Blood ND ND 0.175 1
0.175 1
Plasma ND ND 0.219 1.251
0.244 1394
Liver 0.058 0.330 0.799 4.555
0.070 0.398 0.749 4.284
Spleen 0.036 0.206 0.038 0.220
0.037 0.212 0.040 0330
Heart 0.052 0.296 0.046 0.261
0.054 0.374 0.074 0.424
Lung 0.078 0.445 0.112 0.641
0.095 0.541 0.165 0.943
Kidney 0.062 0.354 0.150 0.856
0.055 0.313 0.119 0.683
Stomach 0.109 0.623 0.801 4.568
0.087 0.498 0.521 2.982
Sm. Intestine 0.079 0.452 0.761 4.338
0.094 0.536 0.896 5.124
3. Distribution 25 hours post SC dosage.
Thyroid ND ND 6.88 5.64
6.68 6.96
Whole blood ND ND 1.22%/ml 1
0.96%/ml 1
Plasma ND ND 1.13%/ml 0.923
1.17%/ml 1319
Liver 0.210 0.172 2.340 1.922
0.282 0.294 3.491 3.639
Spleen 0.167 0.137 0.170 0.138
0.147 0.153 0.152 0.159
Heart 0.247 0.203 0.291 0.239
0.278 0.290 0.293 0.305
Lung 0.649 0.533 1.121 0.921
0.597 0.622 1.090 1.136
Kidney 0.237 0.194 0.552 0.448
0.281 0.293 0.616 0.643
Stomach 1.528 1.254 3.291 2.697
0.837 0.872 2.404 2.505
Sm. Intestine 0.245 0.201 1.900 1362
0.482 0.503 5.607 5.845
Table A3.8.4 Continued (Organ Distribution of BSA).
Organ % dose 
in lg
CPM in lg  
CPM/ml WB
% dose 
in total
CPM in total 
CPM/ml WB
4. Distribution 97 hours post SC injection.
Thyroid ND ND 7.61 81.83
6.05 79.61
Whole Blood ND ND 0.093%/ml 1
0.076%/ml 1
Plasma ND ND 0.185%/ml 1.989
0.156%/ml 2.053
Liver 0.0426 0.458 0.569 6.124
0.0310 0.409 0.299 3.942
Spleen 0.0194 0.209 0.0185 0.199
0.0168 0.222 0.0223 0.294
Heart 0.0370 0398 0.0409 0.441
0.0277 0.365 0.0234 0.309
Lung 0.0573 0.617 0.109 1.170
0.0596 0.785 0.102 1.348
Kidney 0.0437 0.470 0.123 1.321
0.0378 0.498 0.0755 0.994
Stomach 0.0519 0.558 0.397 4.266
0.103 1.350 0.618 8.140
Sm. Intestine 0.0591 0.636 0380 6337
0.0435 0.572 0.456 6.000
5. Distribution 97 hours post IP dosage.
Thyroid ND ND 8.586 93.73
5.060 76.67
Whole Blood ND ND 0.0916%/ml 1
0.0660%/ml 1
Plasma ND ND 0.219%/ml 2380
0.156%/ml 2360
Liver 0.0353 0.385 0.530 5.787
0.0417 0.632 0.416 6307
Spleen 0.0199 0.218 0.0235 0357
0.0314 0.477 0.0344 0322
Heart 0.0371 0.405 0.0410 0.448
0.0417 0.631 0.0429 0.648
Lung 0.0557 0.608 0.0729 0.796
0.0774 1.173 0.0904 1369
Kidney 0.0391 0.427 0.0967 1.056
0.0493 0.747 0.103 1357
Stomach 0.0692 0.756 0.584 6.382
0.150 2.272 0.395 5.981
Sm. Intestine 0.0596 0.651 0.643 7.022
0.0970 1.470 0.860 13.025
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Table A3.9.1: The Whole Blood Concentration (% 125I activity remaining/ml) after 
administration of 0.4mg of 125I-HSA to rats by each of the three routes.
Each value represents the result obtained for one rat unless stated otherwise. n=8 for each 
route.
Time (hr) IV % dose/ml IP % dose/ml SC % dose/ml
3 3.95 1.527 0.161
3 3.231 1.845 0.145
6 3.332 1.641 0.240
6 3.224 1.641 0.253
23.5 0.887 0.984 0.588
23.5 0.903 1.090 0.518
30.5 0.742 0.890 0.691
30.5 0.679 0.944 0.536
47.5 0.510 0.302 0.429
47.5 0.417 0.302 0.350
53.5 0.275 0.343 0.259
53.5 0.358 0.467 0.245
71.75 0.139 0.190 0.246
71.75 0.188 0.196 0.221
77.0 0.191 0.100 0.124
77.0 0.158 0.099 0.161
143.75 0.0264 0.0648 0.114
143.75 0.0468 0.0292 0.0333
149.0a 0.0313±0.0048 0.025710.0051 0.035410.0044
Note:
a) Value is the mean (n=4) ± S.E.M.
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Table A3.10.1: The whole blood (WB) and serum (S) concentration (% 125I activity 
remaining/ml) after administration of 5mg of 125I-RSA to rats by each of the three routes. 
Each value represents the concentration determined for one rat (the same rat was used to 
determine both plasma and whole blood conc. at each time point). n=8 for each route.
IV IP SC
Time (hr) WB %/ml S %/ml WB %/ml S %/ml WB%/ml S %/ml
0.25 5.285 11.419 0.024 0.0695 0.0430 0.0633
0.25 4.710 9.496 0.045 0.0583 0.106 0.147
1 3.924 7.694 0.306 0.554 0.0989 0.176
1 2.801 7.202 - 0.885 0.102 0.170
2 3.862 6.924 0.112 2.196 0.162 0.272
2 - 7.002 0.166 2.346 0.339 0.600
4 2.661 4.826 1.808 3.940 0.373 0.710
4 2.436 4.698 - - 0.594 0.759
7.25 2.209 3.916 1.574 3.039 0.571 1.272
7.25 - 4.028 1.579 3.175 - 2.557
18.75 - 2.230 0.904 2.176 0.992 1.396
18.75 - 2.225 0.837 2.203 - 1.664
24 1.056 1.863 1.278 1.932 - 1.449
24 0.987 1.919 - - - 1.468
30 0.940 1.665 0.629 1.431 0.679 1.417
30 0.842 1.603 0.470 1.464 1.025 2.191
42.75 0.487 1.145 0.514 1.066 0.688 1.068
42.75 0.666 1.133 0.664 1.151 0.600 1.052
48 0.540 1.039 0.770 0.926 0.606 1.038
48 - 1.188 - 1.319 0.638 1.131
54.5 0.465 0.929 0.275 0.845 0.411 0.881
54.5 0.506 0.972 - 0.895 - 1.306
70.75 - 0.848 - 0.635 - 0.644
70.75 - 0.784 - 0.668 - 0.661
79 0.355 0.586 - 0.549 0.362 0.633
79 0.347 0.677 - 0.485 0.370 0.884
91 - 0.629 - 0.404 - 0.459
91 - 0.625 - 0.495 - 0.446
96 0.315 0.512 0.363 0.589 0.210 0.470
96 0.223 0.454 0.186 0.397 0.299 0.515
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Table A3.10.2: The Urine Excretion of 125I activity (% of total activity injected) after 
administration of 5mg of 125I-RSA to rats by each of the three routes.
Values are means (n=4 for IV, n=3 for IP and SC).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 10.48 1.128 11.9 0.231 8.54 1.184
48 23.43 2.107 22.66 1.925 22.85 1.555
72 31.55 2.850 27.90 4.213 29.98 1.945
96 37.04 2.611 31.17 6.285 33.85 2.725
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Table 3.10.3. The Organ Distribution of 125I activity after administration of 5mg of 
125I-RSA to rats by each of the three routes.Results are expressed in 2 ways; as a % 
of the total dose administered in lg  or total organ or as a ratio of the activity in lg  
(or whole tissue) divided by the activity in 1ml of whole blood.
Organ % dose 
in lg
CPM in lg  
CPM/ml WB
%dose 
in total
PPM in total 
CPM/ml WB
1. Distribution 96 hours after IV administration.
Thyroid 118 374 7.77 24.63
100 450 6.62 29.73
Whole Blood ND ND 0.315%/ml 1
0.223%/ml 1
Serum ND ND 0.512%/ml 1.625
ND ND 0.454%/ml 2.036
Liver 0.194 0.616 2.328 7.390
0.158 0.710 1.758 7.885
Spleen 0.0270 0.0859 0.0395 0.125
0.0275 0.121 0.0482 0.216
Heart 0.141 0.447 0.148 0.470
0.101 0.453 0.101 0.452
Lung 0.220 0.699 0.310 0.986
0.177 0.794 0.239 1.071
Kidney 0.131 0.415 0.294 0.935
0.095 0.426 0.219 0.984
2. Distribution 168 hours post IV injection.
Thyroid ND ND 5.511 44.09
5.791 44.21
Whole Blood ND ND 0.111%/ml 1
0.087%/ml 1
Serum ND ND 0.201%/ml 1.811
0.157%/ml 1.804
Liver 0.0432 0.389 0.532 4.793
0.0459 0.527 0.608 6.990
Spleen 0.0200 0.180 0.0171 0.154
0.0347 0.399 0.0343 0.394
Heart 0.0407 0.366 0.0611 0.550
0.0562 0.646 0.145 1.667
Lung 0.0575 0.518 0.0732 0.659
0.0807 0.928 0.113 1.299
Kidney 0.0292 0.263 0.0672 0.605
0.0400 0.459 0.088 1.011
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Table A3.10.3 Cont (Organ Distribution of 125I-RSA).
Organ %dose 
in lg
CPM in 1 g 
CPM in 1ml WB
%dose 
in total
CPM in total 
CPM in 1ml WB
3. Distribution 168 hours post SC injection.
Thyroid ND ND 5.1 55.73
7.4 94.03
Whole Blood ND ND 0.0915%/ml 1
0.0787%/ml 1
Serum ND ND 0.167%/ml 1.825
0.144%/ml 1.830
Liver 0.0538 0.588 0.759 8.297
0.0345 0.439 0.456 5.793
Spleen 0.0243 0.265 0.0344 0.376
0.0187 0.238 0.0262 0.333
Heart 0.0619 0.676 0.0804 0.879
0.0331 0.421 0.0431 0.547
Lung 0.0375 0.410 0.0533 0.583
0.0489 0.622 0.111 1.410
Kidney 0.0393 0.429 0.0983 1.074
0.0413 0.525 0.0991 1.259
4. Distribution 168 hours after IP dosage.
Thyroid ND ND 3.9 41.44
5.2 78.79
Whole Blood ND ND 0.0941%/ml 1
0.066%/ml 1
Serum ND ND 0.174%/ml 1.849
0.122%/ml 1.848
Liver 0.0342 0.364 0.355 3.772
0.0674 1.021 0.854 12.94
Spleen 0.0248 0.264 0.0292 0.310
0.0201 0.304 0.0243 0.368
Heart 0.0492 0.523 0.0704 0.748
0.0940 1.424 0.141 2.136
Lung 0.0203 0.216 0.0473 0.503
0.158 2.399 0.221 3.351
Kidney 0.0351 0.373 0.0913 0.970
0.0161 0.244 0.0455 0.689
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Table A3.11.1 Whole Blood and Serum Concentrations (% 125I activity remaining/ml) after
administration of 20mg of 125I-RSA to rats by the IV route.
Each value represents data obtained from one rat. Eight rats were injected.
Time (hr) Whole Blood 
%dose/ml
Serum
%dose/ml
0.25 7.071 13.29
0.25 6.319 13.44
2.0 5.628 10.73
2.0 5.185 10.06
4.0 5.369 9.973
4.0 4.519 8.417
6.75 3.946 7.181
6.75 3.778 7.463
23.5 1.959 3.683
23.5 1.787 3.429
30.75 1.998 3.422
30.75 1.710 3.082
49.75 1.308 2.041
49.75 1.293 2.393
73.0 1.000 1.527
73.0 0.896 1.711
96.0 0.429 0.982
96.0 0.591 1.147
168.0 0.265 0.478
168.0 0.221 0.412
Table A3.11.2 The % of 125I activity excreted in the urine following administration of 20 mg of 
125I-RSA to rats by the IV route.
Each value represents the mean % excreted (n=3) ±  S.E.M.
Time (hours) Mean % excreted S.E.M.
24 12.4 1.65
48 20.8 4.44
72 30.5 4.76
96 37.6 5.07
-A46-
Table A3.12.1 The Measurements for total serum protein concentration, after administration of 
0.9% saline (group 2), 20mg BSA in saline (group 3) or for untreated rats (group 1). Each rat had a 
blood sample taken at the same time and the protein concentration was determined using the 
Lowry method.
Time (hours) Concentration of Protein in serum (mg/ml)
Control (1) Saline (2) 20mgBSA(3)
2 83.19 90.71 87.08
81.73 97.34 90.97
87.57 82.30 73.53
88.54 105.75 83.67
80.75 81.42 75.37
Mean 84.35 91.50 82.12
SD 3.500 10.298 6.704
4 85.69 83.40 93.59
78.55 96.51 86.91
70.46 69.76 78.16
62.84 87.07 75.08
87.12 93.89 94.10
Mean 76.93 86.13 85.57
SD 10.291 10.539 8.716
7 86.93 96.90 75.69
92.05 78.13 84.96
87.93 84.18 94.75
86.39 77.45 70.03
86.38 77.24 75.70
Mean 85.03 82.78 80.48
SD 6.072 8.302 9.594
-A47-
Tabic A3.13.1 The Concentration of Evans Blue in serum (% dose remaining/ml) following
administration of lmg of Evans Blue alone or lmg of dye with 20mg BSA.
Each value represents data from one rat. (n=8 for each route)
% of EB remaining/ml 
Time (hours) EB only EB + BSA
0.33 7.14 7.27
0.33 6.79 6.22
1 5.34 4.98
1 6.57 5.41
2 5.58 4.32
2 4.76 4.15
3 - 4.73
3 - 3.86
4 4.41 3.70
4 3.54 3.25
6 3.05 2.72
6 3.48 2.48
7.5 3.23 3.32
7.5 2.70 2.37
24 1.22 1.02
24 1.09 0.996
28.5 0.918 0.841
28.5 0.905 0.660
-A48-
Table A3.14.1 Plasma concentration ( % 125I activity reamining/ml) following administr­
ation of 5mg of 125I-BSA-MTX (3.4%w/w) to male wistar rats by each of the three routes.
Each value was measured from 1 ra t (n=8 for each route).
Time IV %/ml IP %/ml SC %/ml
0.5 8.694 0.115 0.151
0.5 8.641 0.281 0.122
1 7.195 0.872 0.174
1 6.785 0.414 0.158
2 6.049 1.539 0.264
2 5.561 1.925 0.357
4 4.433 2.611 0.339
4 4.341 2.539 0.339
6 3.765 - -
6 3.642 - -
7 - 3.112 0.429
7 - 2.235 0.694
23.5 1.261 1.084 0.690
23.5 1.311 0.859 0.732
26 - 1.188 0.583
26 - 0.873 0.927
28 - 1.176 0.505
28 - 0.798 0.784
31 0.755 0.816 0.568
31 0.935 0.603 0.636
48 0.442 0.559 0.327
48 0.583 0.412 0.437
55 - 0.444 0.266
55 - 0.365 0.401
72 - 0.181 0.137
72 - 0.192 0.212
79 - 0.130 0.128
79 - 0.181 0.167
96 - 0.098 0.077
96 - 0.105 0.116
-A49-
Table A3.14.2 The urine excretion (% of total 125I activity injected) following administr­
ation of 5mg of 125I-BSA-MTX (3.4%w/w) to rats by each of the three routes.
Values are expressed as means of three rats.
Time IV % 
excreted
S.E.M n>%
excreted
S.E.M. SC%
excreted
S.E.M.
24 24.55 2.15 29.32 0.64 32.73 3.22
48 37.03 2.16 50.31 1.04 52.39 0.89
72 - - 57.97 1.47 65.08 1.21
96 - - 60.02 2.27 67.16 0.36
-A50-
Table A3.15.1 The Serum Concentrations (% of 125I activity remaining/ml) after
administration of 5mg of 125I-BSA-MTX (5.1%w/w) to male wistar rats by each of the
three routes (n=8 for each route).
Time (hours) IV %/ml IP %/ml SC %/ml
1 6.933 0.556 0.496
1 9.007 0.905 0.424
3 5.899 3.336 0.458
3 4.129 3.220 0.458
5 4.757 1.952 -
5 3.775 3.486 -
7 2.934 2.514 0.497
7 3.335 1.534 0.566
10 - - 0.953
10 - - 0.789
23.5 0.678 0.545 0.787
23.5 0.737 0.877 0.727
27.3 - - 0.625
27.3 - - 0.647
30.5 0.572 0.599 0.508
30.5 0.590 0.367 0.515
48 0.230 0.206 0.195
48 0.275 0.225 0.175
52.5 0.234 0.233 0.204
52.5 0.236 0.219 0.230
55 0.179 0.210 0.221
55 0.174 0.182 0.221
71.75 0.0989 0.0976 0.0888
71.75 0.126 0.0976 0.0880
97.5 0.0604 0.0464 0.0670
97.5 0.0824 0.0487 0.0617
-A51-
Table A3.15.2 The Urine Excretion (%125I injected) following administration of 5mg of
125I-BSA-MTX (5.1%w/w).
Values are mean % excreted for 3 rats.
Time IV % 
(hours)
S.E.M.
excreted
IP% S.E.M.
excreted
SC% S.E.M.
excreted
24 37.13 0.58 38.16 1.17 32.52 2.61
48 57.96 0.59 59.71 3.47 54.0 1.78
72 66.66 0.84 69.90 4.22 63.56 2.19
96 69.84 0.90 73.40 3.90 67.50 2.75
Table A3.15.3 The excretion in the faeces (% 125I activity injected) following administr­
ation of 5mg of 125I-BSA-MTX (5.1%w/w).
Values are mean % excreted in the faeces for 3 rats.
Time
(hours)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 4.03 1.10 1.37 0.688 2.53 0.75
48 6.57 1.06 4.60 1.44 7.10 0.65
72 8.07 1.02 6.17 1.21 8.63 0.49
96 8.87 1.04 7.23 1.26 9.97 0.27
-A52-
Table A3.15.4 Organ Distribution of 125I activity following administration of 125I- 
BSA-MTX (5.1%w/w) by the three routes. Results are expressed in 2 forms; as a % of the 
total radioactivity injected found in lg  of organ or the whole organ and as a ratio of the 
activity found in lg  (or whole organ) divided by the activity found in 1ml of whole blood.
Organ % dose 
in lg
CPM in lg  
CPM in 1ml WB
% dose 
in total
CPM in total 
CPM in 1ml WB
1. Distribution 52 hours post IV injection.
Thyroid ND ND 10.00 66.67
9.47 62.75
Whole Blood ND ND 0.15%/ml 1
0.15%/ml 1
Serum ND ND 0.234%/ml 1.563
0.236%/ml 1.563
Liver 0.0765 0.510 0.759 5.063
0.0764 0.506 0.880 5.828
Spleen 0.0409 0.273 0.0474 0.316
0.0786 0.520 0.0464 0.307
Heart 0.0637 0.425 0.0629 0.419
0.0691 0.461 0.0614 0.407
Lung 0.0780 0.520 0.105 0.699
0.0891 0.590 0.100 0.665
Kidney 0.151 1.004 0.335 2.236
0.178 1.183 0.335 2.221
Stomach 0.166 1.109 0.706 4.705
0.292 1.936 1.525 10.10
Sm. Intestine 0.104 0.693 1.074 7.164
0.151 1.000 1.117 7.397
-A53-
Table A3.15.4 Cent. (Organ Distribution of BSA-MTX 5.1%w/w).
Organ % dose 
in lg
CPM in 1 g 
CPM in 1ml WB
% dose 
in total
CPM in total 
CPM in 1ml WB
2. Distribution 97J5 hours post IV injection.
Thyroid ND ND 7.201 186.3
10.59 200.9
Whole Blood ND ND 0.0386%/ml 1
0.0527%/ml 1
Serum ND ND 0.0604%/ml 1.563
0.0824%/ml 1.563
Liver 0.0280 0.724 0.356 9.210
0.0299 0.567 0.317 6.020
Spleen 0.0182 0.470 0.0207 0.535
0.0279 0.529 0.0186 0.354
Heart 0.0157 0.406 0.0179 0.340
0.0313 0.809 0.0174 0.329
Lung 0.0298 0.772 0.0389 1.007
0.0226 0.429 0.0409 0.776
Kidney 0.101 2.618 0.233 6.034
0.133 2.522 0.244 4.635
Stomach 0.0602 1.558 0.351 9.079
0.0620 1.176 0.605 11.478
Sm. Intestine 0.0443 1.146 0.488 12.639
0.0565 1.071 0.516 9.788
3. Distribution 193 hours post IV injection.
Thyroid ND ND 4.186 528.5
4.865 587.8
Whole Blood ND ND 0.00792%/ml 1
0.00828%/ml 1
Serum ND ND 0.0123%/ml 1.563
0.0129%/ml 1.563
Liver 0.0109 1.383 0.125 15.81
0.0106 1.343 0.155 18.69
Spleen 0.0079 1.008 0.0075 0.954
0.0070 0.845 0.0075 0.912
Heart 0.0063 0.793 0.0060 0.756
0.0081 0.981 0.0091 1.098
Lung 0.0068 0.856 0.0103 1.303
0.0083 1.005 0.0114 1.377
Kidney 0.0767 9.680 0.176 22.20
0.0717 8.665 0.169 20.47
-A54-
Table A3.15.4 Cont. (Organ Distribution of BSA-MTX 5.1%w/w).
Organ % dose 
in lg
CPM in 1 p 
CPM in 1ml WB
% dose 
in total
CPM in total 
CPM in 1ml WB
2. Distribution 52.5 hour post IP injection.
Thyroid ND ND 7.20 48.29
9.00 64.21
Whole Blood ND ND 0.149%/ml 1
0.140%/ml 1
Serum ND ND 0.233%/ml 1.562
0.219%/ml 1.563
Liver 0.0645 0.433 0.702 4.711
0.0516 0.346 0.785 5.603
Spleen 0.0588 0.394 0.0501 0.336
0.0276 0.197 0.0460 0.328
Heart 0.0880 0.590 0.0539 0.362
0.0472 0.336 0.0559 0.399
Lung 0.111 0.744 0.0911 0.611
0.0604 0.431 0.101 0.724
Kidney 0.109 0.729 0.225 1.507
0.0896 0.639 0.214 1.525
Stomach 0.187 1.252 0.871 5.838
0.209 0.822 0.822 5.865
Sm. Intestine 0.197 1.323 1.853 12.43
0.154 1.098 1.678 11.97
5. Distribution 97.5 hours post IP injection.
Thyroid ND ND 6.429 205.4
5.807 176.5
Whole Blood ND ND 0.0313%/ml 1
0.0329%/ml 1
Serum ND ND 0.0464%/ml 1.481
0.0487%/ml 1.480
Liver 0.0214 0.684 0.233 7.452
0.0235 0.716 0.249 7.578
Spleen 0.0111 0.355 0.0094 0.301
0.0169 0.516 0.0173 0.527
Heart 0.0119 0.379 0.0099 0.317
0.0113 0.346 0.0085 0.259
Lung 0.0154 0.493 0.0191 0.612
0.0160 0.488 0.0274 0.835
Kidney 0.0556 1.779 0.116 3.704
0.0618 1.882 0.128 3.903
Stomach 0.0715 2.285 0.201 6.426
0.100 3.056 0.519 15.82
Sm. Intestine 0.0281 0.898 0.271 8.646
0.0472 1.437 0.491 14.95
-A55-
Table A3.15.4 ConL (Organ Distribution of BSA-MTX 5.1%w/w).
Organ % dose 
in lg
CPM in lg  
CPM in 1ml WB
% dose 
in total
CPM in total 
CPM in 1ml WB
6. Distribution 194 hours post IP injection.
Thyroid ND ND 4.39 654.2
6.00 688.1
Whole Blood ND ND 0.00671%/ml 1
0.00872%/ml 1
Serum ND ND 0.0105%/ml 1.562
0.0136%/ml 1.562
Liver 0.0064 0.962 0.107 16.01
0.0077 0.902 0.109 12.60
Spleen 0.0053 0.788 0.0068 1.006
0.0090 1.033 0.0072 0.827
Heart 0.0044 0.660 0.0066 0.978
0.0052 0.597 0.0054 0.622
Lung 0.0068 1.018 0.0090 1.347
0.0083 0.954 0.0083 0.951
Kidney 0.0528 7.871 0.144 21.50
0.0622 7.133 0.166 19.01
7. Distribution 52.5 hours post SC injection.
Thyroid ND ND 6.429 54.1
7.827 58.5
Whole Blood ND ND 0.119%/ml 1
0.134%/ml 1
Serum ND ND 0.204%/ml 1.718
0.230%Anl 1.715
Liver 0.0515 0.433 0.639 5.377
0.0701 0.524 0.666 4.985
Spleen 0.0314 0.264 0.0393 0.331
0.0498 0.372 0.0473 0.354
Heart 0.0393 0.331 0.0411 0.346
0.0456 0.341 0.0447 0.334
Lung 0.0639 0.538 0.0774 0.652
0.0958 0.717 0.119 0.894
Kidney 0.112 0.939 0.258 2.171
0.186 1.393 0.356 2.666
Stomach 0.248 2.086 1.101 9.263
0.211 1.576 0.733 5.482
Sm. Intestine 0.109 0.915 1.050 8.837
0.169 1.268 1.125 9.410
-A56-
Table A3.15.4 ConL (Organ Distribution of BSA-MTX 5.1%w/w).
8. Distribution 97.5 hours post SC injection.
Organ % dose 
in lg
CPM in lg  
CPM in 1ml WB
% dose 
in total
CPM in total 
CPM in 1ml WB
Thyroid ND ND 8.183 191.1
8.182 207.9
Whole Blood ND ND 0.0428%/ml 1
0.0393%/ml 1
Serum ND ND 0.0670%/ml 1.566
0.0617%/ml 1.569
Liver 0.0230 0.537 0.278 6.489
0.0267 0.678 0.357 9.089
Spleen 0.0135 0.315 0.0189 0.441
0.0204 0.519 0.0152 0.387
Heart 0.0157 0.366 0.0160 0.406
0.0202 0.513 0.0204 0.519
Lung 0.0180 0.421 0.0296 0.692
0.0263 0.669 0.0275 0.699
Kidney 0.0792 1.849 0.168 3.935
0.0808 2.053 0.179 4.560
Stomach 0.0672 1.570 0.354 8.282
0.117 2.983 0.995 25.30
Sm. Intestine 0.0576 1.345 0.579 13.53
0.0669 1.700 0.748 19.01
9. Distribution 193.5 hours post SC injection.
Thyroid ND ND 4.50 725
4.39 645
Whole Blood ND ND 0.0062%/ml 1
0.0068%/ml 1
Serum ND ND 0.0097%/ml 1.572
0.0106%/ml 1.569
Liver 0.0054 0.874 0.0715 11.49
0.0072 1.065 0.0767 11.28
Spleen 0.0032 0.517 0.0033 0.526
0.0046 0.677 0.0060 0.877
Heart 0.0043 0.690 0.0041 0.658
0.0045 0.661 0.0041 0.608
Lung 0.0061 0.976 0.0088 1.413
0.011 1.618 0.0090 1.331
Kidney 0.0470 7.556 0.118 18.93
0.0589 8.668 0.144 21.24
-A57-
Table A3.16.1 The Plasma Concentration (% of 125I activity remaining/ml) following
administration of 5mg of 125I-BSA-MTX (6.2%w/w) to rats by each of the three routes (n=
8 for ech route) .Note a) Value is expressed as mean (n=3) ±  S.E.M.
Time (hours) IV %/ml IP %/ml SC %/ml
0.5 5.725 0.205 0.0700
05 5.787 2.111 0.192
2.0 3.553 1.736 0.354
2.0 3.995 1.199 0.247
4.0 2.978 1.907 0.296
4.0 2.712 1.989 0.260
6.5 1.623 - -
6.5 1.847 - -
8 - 0.968 0.399
8 - 1.093 0.575
11 - 1.023 0.506
11 - 1.141 0.427
22.5 0.413 0.433 0.335
22.5 0.375 0.438 0.411
24.5 0.294 0.458 0.352
24.5 0.377 0.315 0.291
28 0.245 0.359 0.294
28 0.245 0.296 0.328
32 0.212 0.173 0.292
32 0.210 0.240 0.239
47 0.0952 0.0762 0.106
47 0.0894 0.0951 0.122
54 0.0791 ±0.0014a 0.0868 0.0937
54 - 0.0737 0.0933
71 0.0473 0.0632 0.0490
71 0.0524 0.0519 0.0529
96 0.0188 0.0261 0.0354
96 0.0174 0.0272 0.0311
-A58-
Table A3.16.2 The Excretion of 125I activity (% of total injected) in the Urine following
administration of 5mg of 125I-BSA-MTX (6.2%w/w) to rats by each of the three routes.
Values arc means (n=3).
Time (hr) IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 23.66 4.05 29.76 1.24 22.56 1.50
48 37.97 3.07 42.41 3.31 32.80 5.08
72 41.90 2.65 45.76 3.74 38.23 6.14
96 43.87 2.48 48.22 3.88 40.6 6.67
Table A3.16.3: The Excretion of 125I activity (% of dose administered) in the faeces 
following administration of 5mg of 125I-BSA-MTX (6.2%w/w) to rats by each of the 
three routes.
Values arc means (n=3).
Time (hr) IV % 
excreted
S.E.M. IP%
excreted
S.E.M SC%
excreted
S.E.M.
24 2.3 0.32 3.3 0.41 1.9 0.50
48 5.1 0.34 4.8 0.40 4.3 0.35
72 6.3 0.49 7.1 0.94 5.2 0.39
96 7.3 0.66 7.9 1.06 5.9 0.49
-A59-
Table A3.16.4: The Organ Distribution of 125I activity following administration of 5mg of
125I-BSA-MTX (6.2%w/w) to male wistar rats by each of the three routes.
Results are expressed in 2 forms; as a % of the total radioactivity injected that was found in 
lg  or the whole organ and as a ratio of the activity found in lg  of organ (or the whole 
organ) divided by the activity found in 1ml of whole blood.
Organ % dose 
in lg
CPMinJg 
CPM in 1ml WB
% dose 
in total
CPM in total 
CPM in 1ml WB
l.Distribution 24 hours post IV injection.
Thyroid ND ND 7.13 34.14
4.36 17.18
Whole Blood ND ND 0.208%/ml 1
0.241%/ml 1
Serum ND ND 0.294%/ml 1.408
0.377%/ml 1.563
Liver 0.332 1.592 3.887 18.61
0.273 1.131 3.577 14.81
Spleen 0.152 0.729 0.181 0.867
0.139 0.575 0.178 0.738
Heart 0.106 0.509 0.125 0.602
0.101 0.417 0.137 0.568
Lung 0.174 0.831 0.306 1.465
0.183 0.761 0.265 1.096
Kidney 1.314 6.289 3.787 18.13
0.995 4.121 3.138 12.99
Stomach 0.677 3.243 1.417 6.786
0.069 0.288 0.441 1.826
Sm. Intestine 0.089 0.425 0.885 4.239
0.088 0.365 1.247 5.163
-A60-
Table A3.16.4 Cont (Organ Distribution of BSA-MTX 6.2%w/w)
Organ % dose 
in lg
CPMinJLfi 
CPM in 1ml WB
% dose 
in total
CPM in total 
CPM in 1ml WB
2. Distribution 96 hours post IV injection.
Thyroid ND ND 4.247 355.8
6.522 575.1
Whole Blood ND ND 0.0119%/ml 1
0.0113%/ml 1
Serum ND ND 0.0188%/ml 1.577
0.0174%/ml 1.537
Liver 0.189 15.84 2.226 186.5
0.226 19.96 2.851 251.4
Spleen 0.103 8.614 0.125 10.48
0.0678 5.977 0.0963 8.496
Heart 0.0288 2.412 0.0418 3.507
0.0365 3.222 0.0695 6.128
Lung 0.0550 4.606 0.0610 5.109
0.0626 5.521 0.0649 5.720
Kidney 1.234 103.4 5.271 441.7
1.409 124.2 3.592 316.7
Stomach 0.0269 2.254 0.119 10.47
0.0985 8.684 0.249 21.96
Sm. Intestine 0.0538 4.505 0.693 58.09
0.0419 3.690 0.479 42.23
3. Distribution 171 hours post IV injection.
rhyroid ND ND 2.745 199.5
2.882 219.8
Whole Blood ND ND 0.0137%/ml 1
0.0131 %/ml 1
Serum ND ND 0.0226%/ml 1.647
0.0199%/ml 1.521
Liver 0.152 11.05 1.763 128.3
0.0931 7.094 1.327 101.2
Spleen 0.071 5.168 0.112 8.154
0.094 7.170 0.108 8.210
Heart 0.0177 1.285 0.0431 3.135
0.0256 1.948 0.0271 2.067
Lung 0.0379 2.760 0.0529 3.851
0.0306 2.338 0.0532 4.054
Kidney 1.177 85.66 2.855 207.8
1.002 76.39 2.799 213.3
Stomach 0.020 1.473 0.130 9.497
0.0196 1.494 0.144 10.98
Sm. Intestine 0.0244 1.777 0.382 27.78
0.0294 2.244 0.494 37.66
-A O  I -
Table A3.16.4 Cont (organ distribution of BSA-MTX 6.2%w/w)
Organ % in lg CPM in lg % in total CPM in total
CPM in 1ml WB CPM/ml WB
4. Distribution 48 hours post IP injection.
Thyroid ND ND 5.982 125.7
6.311 109.6
Whole Blood ND ND 0.0476%/ml 1
0.0576%/ml 1
Seram ND ND 0.0762%/ml 1.600
0.0949%/ml 1.649
Liver 0.0994 2.088 1.196 25.13
0.107 1.859 1.262 21.93
Spleen 0.0607 1.276 0.0789 1.658
0.0551 0.957 0.0628 1.091
Heart 0.0251 0.527 0.0240 0.504
0.0334 0.580 0.0367 0.638
Lung 0.0453 0.953 0.0697 1.464
0.0444 0.771 0.0613 1.064
Kidney 0.856 17.98 1.868 39.24
0.958 16.64 1.935 33.62
Stomach 0.0755 1.587 0.252 5.295
0.0516 0.896 0.223 3.881
Sm. Intestine 0.0458 0.962 0.534 11.22
0.0632 1.098 0.619 10.76
5. Distribution 96 hours post IP injection.
Thyroid ND ND 5.846 345.3
4.844 295.5
Whole Blood ND ND 0.0169%/ml 1
0.0164%/ml 1
Serum ND ND 0.0261%/ml 1.546
0.0272%/ml 1.659
Liver 0.141 8.321 1.376 0.0123
0.120 7.325 1.329 0.0123
Spleen 0.105 6.189 0.152 8.984
0.126 7.698 0.119 7.287
Heart 0.023 1.353 0.023 1.413
0.031 1.893 0.033 2.016
Lung 0.033 1.938 0.033 1.978
0.029 1.787 0.033 2.043
Kidney 1.330 78.6 2.976 175.9
0.839 51.3 1.907 116.5
Stomach 0.091 5.411 0.443 26.16
0.094 5.725 0.299 18.29
Sm. Intestine 0.052 3.104 0.564 33.34
0.055 3.359 0.658 40.20
-A62^
Table A3.16.4 Cont. (Organ Distribution of BSA-MTX 6.2%w/w)
Organ % in lg CPMinlg 
CPM in 1ml WB
% in total CPM in total 
CPM/ml WB
6. Distribution 171 hours post IP injection.
Thyroid ND ND 3.721 364.8
3.395 340.2
Whole Blood ND ND 0.0102%/ml 1
0.00998%/ml 1
Serum ND ND 0.0154%/ml 1.512
0.0152%/ml 1.522
Liver 0.0661 6.481 0.640 62.76
0.0966 9.698 1.414 141.9
Spleen 0.0315 3.086 0.0569 5.577
0.0747 7.495 0.0943 9.464
Heart 0.0091 0.888 0.0154 1.509
0.0296 2.97 0.0334 3.355
Lung 0.0133 1.307 0.0268 2.628
0.0220 2.205 0.0266 2.671
Kidney 0.485 47.52 1.355 132.8
0.836 83.85 2.261 226.9
Stomach 0.0186 1.828 0.167 16.4
0.0244 2.445 0.223 22.4
Sm. Intestine 0.0160 1.572 0.234 22.99
0.0316 3.171 0.364 36.58
7. Distribution 96 hours post SC injection.
Thyroid ND ND 4.01 173.6
6.15 304.3
Whole Blood ND ND 0.0231%/ml 1
0.0202%/ml 1
Serum ND ND 0.0353%/ml 1.528
0.0311%/ml 1.540
Liver 0.0433 1.882 0.465 20.16
0.0707 3.506 0.691 34.29
Spleen 0.0171 0.743 0.0338 1.464
0.0234 1.162 0.0422 2.093
Heart 0.0154 0.668 0.0144 0.625
0.0168 0.831 0.0174 0.865
Lung 0.0219 0.949 0.0265 1.151
0.0244 1.209 0.0349 1.730
Kidney 0.761 33.02 1.674 72.59
0.803 39.82 1.734 85.96
Stomach 0.0280 1.214 0.0530 2.298
0.0524 2.270 0.234 11.62
Sm. Intestine 0.0206 0.895 0.221 9.596
0.0372 1842 o 0.411 20.40
Table A3.16.4 Cont (organ distribution of 6.2%w/w conjugate).
Organ % in lg C!PM in 1 p 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
8. Distribution 171 hours post SC injection.
Thyroid ND ND 3.779 373
4.293 421
Whole Blood ND ND 0.0101%/ml 1
0.0102%/ml 1
Serum ND ND 0.0146%/ml 1.447
0.0155%/ml 1.519
Liver 0.0306 3.021 0.355 35
0.0328 3.221 0.536 52.7
Spleen 0.0209 2.065 0.0184 1.815
0.0264 2.597 0.0229 2.254
Heart 0.0095 0.943 0.0117 1.150
0.0208 2.042 0.0255 2.503
Lung 0.0137 1.351 0.0158 1.564
0.0132 1.296 0.0172 1.688
Kidney 0.542 53.47 1.472 145.3
0.688 67.58 1.822 179.0
Stomach 0.0091 0.897 0.0669 6.599
0.0208 2.05 0.153 14.99
Sm. Intestine 0.0121 1.199 0.135 13.38
0.0137 1.343 0.237 23.27
-A64-
Table A3.17.1 The Serum Concentration (% 125I activity remaining/ml) following administr­
ation of 5mg of 125I-BSA-MTX (9.18%w/w) to rats by IV and SC routes. (n=8 for both routes).
Time (hr) IV %/ml SC %/ml
1 3.609 0.177
1 3.846 0.122
2 1.515 0.185
2 1.595 0.172
4 0.778 0.181
4 0.712 0.221
6 0.426 0.286
6 0.419 0.298
8 0.370 0.172
8 0.330 0.190
10 0.236 0.194
10 0.261 0.228
23.5 0.109 0.142
23.5 0.104 0.101
27.5 0.0795 0.0879
27.5 0.0873 0.102
32.5 0.0748 0.0928
32.5 0.0815 0.0682
48 0.0363 0.0402
48 0.0411 0.0502
51.5 0.0395 -
51.5 0.0315 -
56.5 0.0349 0.0291
56.5 0.0231 0.0199
71.5 0.0259 0.0191
71.5 0.0227 0.0189
79.5 0.0185 0.0224
79.5 0.0213 0.0158
97 0.0108 0.0187
97 0.0184 0.0133
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Table A3.17.2: The % of 125I activity excreted in the urine following administration of
5mg of 125I-BSA-MTX (9.18%w/w) to rats by IV and SC routes. (n=4 for IV and n=3
for SC route).
Values are mean cummulative % excreted.
Time (hr)
IV
% excreted S.E.M.
SC 
% excreted S.E.M.
24 36.41 4.46 27.5 8.92
48 42.04 4.24 34.9 5.46
72 46.04 4.02 37.47 5.48
96 46.58 4.05 39.76 6.08
Table A3.17.3: The % 125I activity excreted in the faeces following administration of 
5mg of 125I-BSA-MTX (9.18%w/w) to rats by IV and SC routes.
Values are mean cummulative % excreted (n=4 IV, n=3 SC).
Time (hr)
IV
% excreted S.E.M.
SC
% excreted S.E.M.
24 3.51 0.33 3.82 0.82
48 5.10 0.29 5.78 0.94
72 6.22 0.53 6.41 1.26
96 6.78 0.57 7.43 1.15
-A66-
Table A3.18.1 The Serum Concentration (% dose 125I remaining/ml) following administr­
ation of 5mg of 125I-BSA-MTX (11.74%w/w) to male wistar rats by each of the three routes.
(n=8 for each route).
Each value was determined from one rat.
Time (hr) IV %/ml IP %/ml SC %/ml
1 2.955 0.0819 0.0782
1 2.089 0.104 0.0645
3 0.584 0.154 0.120
3 0.498 0.190 0.0939
6 - 0.366 0.102
6 - 0.401 0.103
6.75 0.329 - -
6.75 0.297 - -
8 - 0.368 0.105
8 - 0.256 0.0964
19 0.116 0.0759 0.179
19 0.108 0.129 0.132
21 - 0.0934 0.127
21 - 0.182 0.136
24 0.0821 0.0829 0.151
24 0.0924 0.0915 0.160
30.5 0.121 0.0642 0.122
30.5 0.129 0.0828 0.0945
48 0.0506 0.0252 0.0541
48 0.0713 0.0504 0.0385
54.5 0.0494 0.0364 0.0487
54.5 0.0303 0.0408 0.0475
71.75 0.0319 0.0197 0.0298
71.75 0.0215 0.0274 0.0294
76 0.0331 0.0181 0.0302
76 0.0182 0.0233 0.0241
96 0.0402 0.00976 0.0201
96 0.0142 0.0238 0.0183
-A67-
Table A3.18.2 The Urine Excretion of 125I activity (% of total dose administered) following
administration of 5mg of 125I-BSA-MTX (11.74%w/w) to male wistar rats by each of the
three routes.
Results are expressed as mean cummulative % excreted (n=3).
Time
(hr)
IV % 
excreted
S.E.M. i p %
excreted
S.E.M. SC%
excreted
S.E.M.
24 21.33 6.49 20.45 4.44 21.62 5.99
48 34.78 4.77 33.97 7.78 39.12 0.51
72 42.33 4.28 37.91 8.52 44.51 0.80
96 45.07 4.24 39.83 8.98 46.53 1.43
Table A3.18.3 The Excretion of 125I activity in the faeces following the administration of 
5mg of 125I-BSA-MTX (11.74%w/w) to rats by each of the three routes.
Results are expressed as mean % of dose excreted (n=3).
Time
(hr)
IV % 
excreted
S.E.M IP % 
excreted
S.E.M. SC%
excreted
S.E.M.
24 4.45 0.92 3.56 0.98 2.29 0.33
48 6.39 0.83 6.30 0.43 4.42 0.27
72 7.90 0.94 7.30 0.81 5.67 0.18
96 8.48 0.95 8.00 0.81 6.33 0.12
-A68-
Table A3.18.4 The Organ Distribution following administration of 125I-BSA-MTX 
(11.74%w/w) to rats by each of the three routes. Two rats from each group were analysed 
for each time point. Results were expressed in 2 ways; as a % of the radioactive dose found 
in lg  or the whole tissue and as a ratio of activity found in lg  (or whole organ) divided by 
the activity found in 1ml Whole Blood.
Organ % in lg f!PM in 1 g 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
1. Distribution 30.5 hours post IV administration.
Thyroid ND ND 9.412 70.77
8.423 59.32
Whole Blood ND ND 0.133%/ml 1
0.142%/ml 1
Serum ND ND 0.121%/ml 0.906
0.129%/ml 0.906
Liver 0.157 1.179 1.814 13.58
0.171 1.201 1.925 13.52
Spleen 0.175 1.314 0.169 1.263
0.144 1.013 0.127 0.889
Heart 0.0632 0.473 0.0583 0.436
0.0304 0.213 0.0280 0.196
Lung 0.0689 0.516 0.118 0.884
0.0463 0.325 0.0758 0.532
Kidney 0.104 0.781 0.247 1.850
0.0799 0.562 0.155 1.087
Stomach 0.427 3.201 1.391 10.42
0.429 3.011 1.960 13.76
Sm. Intestine 0.137 1.028 1.442 10.80
0.0699 0.491 0.814 5.72
-A69-
Table A3.18.4 Cont. (Organ Distribution of BSA-MTX 11.74%w/w)
Organ % in lg CPM in lg/ 
CPM in 1ml WB
% in total CPM in total/ 
CPM/ml WB
2. Distribution 76 hours post IV injection.
Thyroid ND ND 3.834 119.8
5.722 154.2
Whole Blood ND ND 0.032%Anl 1
0.037%/ml 1
Serum ND ND 0.033%/ml 1.034
0.018%/ml 0.486
Liver 0.0671 2.082 0.813 25.26
0.0590 1.591 0.608 16.39
Spleen 0.0392 1.217 0.0610 1.893
0.0653 1.759 0.0568 1332
Heart 0.0125 0.388 0.0120 0.372
0.0095 0.257 0.0097 0.260
Lung 0.0120 0.375 0.0273 0.848
0.0115 0.309 0.0161 0.433
Kidney 0.0311 0.964 0.0742 2.303
0.0249 0.670 0.0552 1.487
Stomach 0.0963 2.991 0.442 13.73
0.0464 1.249 0.414 11.17
Sm. Intestine 0.0660 2.051 0.711 22.08
0.0130 0.351 0.129 3.479
3.Distribution 168 hours post IV injection.
Thyroid ND ND 3.382 312.4
3.451 376.7
Whole Blood ND ND 0.0108%/ml 1
0.0092%/ml 1
Serum ND ND 0.0104%/ml 0.961
0.0087%/ml 0.955
Liver 0.0276 2.545 0.347 32.10
0.0477 5.214 0.473 51.69
Spleen 0.0101 0.931 0.0118 1.093
0.0118 1.288 0.0205 2.243
Heart 0.0042 0.385 0.0050 0.459
0.0053 0385 0.0056 0.608
Lung 0.0069 0.634 0.0950 0.878
0.0071 0.778 0.0116 1.263
Kidney 0.0160 1.479 0.0374 3.451
0.0179 1.960 0.0381 4.162
Stomach 0.0197 1.824 0.152 14.00
0.0182 1.989 0.0413 4.509
Sm. Intestine 0.0435 4.017 0.474 43.79
0.0127 1.384 0.115 12.60
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Table A3.18.4 Cont (Organ Distribution of BSA-MTX 11.74%w/w)
Organ % in lg CPMinJLc 
CPM in 1ml WB
% in total C!PM in total 
CPM/mlWB
4. Distribution 24 hours post IP injection.
Thyroid ND ND 5.58 64.88
7.80 81.25
Whole Blood ND ND 0.086%Anl 1
0.096%/ml 1
Serum ND ND 0.083%/ml 0.965
0.092%/ml 0.958
Liver 0.127 1.475 1.529 17.79
0.0604 0.629 0.697 7.273
Spleen 0.0801 0.932 0.106 1.234
0.0657 0.685 0.0814 0.849
Heart 0.0408 0.475 0.0433 0.504
0.0314 0.328 0.0283 0.295
Lung 0.0470 0.547 0.0753 0.876
0.0476 0.497 0.0669 0.698
Kidney 0.0717 0.835 0.186 2.166
0.0710 0.740 0.156 1.635
Stomach 0.287 3.338 1.036 12.06
0.270 2.812 1.317 13.73
Sm. Intestine 0.356 4.149 4.344 50.55
0.139 1.452 1.657 17.28
5 . Distribution 76 hours post IP injection.
Thyroid ND ND 9.12 480
4.92 189
Whole Blood ND ND 0.019%/inl 1
0.026%/ml 1
Serum ND ND 0.018%/ml 0.947
0.023%/ml 0.896
Liver 0.0288 1.535 0.360 19.17
0.0290 1.116 0.347 13.36
Spleen 0.0185 0.982 0.0306 1.630
0.0113 0.435 0.0148 0.568
Heart 0.0088 0.469 0.0090 0.480
0.0074 0.286 0.0063 0.242
Lung 0.0137 0.729 0.0247 1.314
0.0116 0.445 0.0185 0.712
Kidney 0.0272 1.451 0.0687 3.659
0.0233 0.894 0.0587 2.256
Stomach 0.0652 3.473 0.374 19.92
0.0443 1.701 0.206 7.923
Sm. Intestine 0.0287 1.530 0.321 17.07
0.0201 0.772 (pagetfl) 0.224 8.59
Table A3.18.4 Cont. (Organ Distribution of BSA-MTX 11.74%w/w)
Organ % in lg  CPM in lg % in total CPM in total
CPM in 1ml WB CPM in 1ml WB
5. Distribution 168 hours post IP injection.
Thyroid ND ND 5.07 520
6.34 659
Whole Blood ND ND 0.0098%/ml 1
0.0096%/ml 1
Serum ND ND 0.0089%/ml 0.912
0.0087%/ml 0.905
Liver 0.008 0.902 0.077 8.711
0.0062 0.711 0.089 9.302
Spleen 0.0039 0.399 0.0045 0.465
0.0046 0.482 0.0053 0.552
Heart 0.0055 0.570 0.0046 0.472
0.0045 0.466 0.0052 0.538
Lung 0.0061 0.622 0.0108 1.113
0.0074 0.772 0.0100 1.044
Kidney 0.0176 1.812 0.0365 3.753
0.0155 1.611 0.0375 3.902
Stomach 0.0165 1.70 0.0914 9.381
0.0164 1.712 0.104 10.855
Sm. Intestine 0.0089 0.913 0.0844 8.660
0.0120 0.808 0.148 15.41
7. Distribution 24 Hours post SC injection.
Thyroid ND ND 4.689 28.13
4.041 23.09
Whole Blood ND ND 0.167%/ml 1
0.175%/ml 1
Serum ND ND 0.151%/ml 0.904
0.160%/ml 0.914
Liver 0.0685 0.411 0.765 4.590
0.111 0.633 1.080 6.175
Spleen 0.0887 0.532 0.107 0.641
0.112 0.640 0.125 0.713
Heart 0.0668 0.401 0.0692 0.415
0.0651 0.372 0.0646 0.369
Lung 0.0728 0.436 0.138 0.828
0.108 0.617 0.204 1.167
Kidney 0.113 0.678 0.265 1.589
0.149 0.853 0.333 1.905
Stomach 1.132 6.792 8.607 51.62
1.221 6.980 5.158 29.47
Sm. Intestine 0.182 1.089 1.972 11.83
0.353 2.017 4.082 23.33
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Table A3.18.4 Cont (Organ Distribution of BSA-MTX 11.74%w/w).
Organ % in lg C1PM in 1 p 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
8. Distribution 76 hours post SC injection.
Thyroid ND ND 8.65 233.8
8.05 322.1
Whole Blood ND ND 0.037%/ml 1
0.025%/ml 1
Serum ND ND 0.0302%/ml 0.816
0.0241%/ml 0.964
Liver 0.0182 0.491 0.175 4.742
0.0245 0.993 0.211 8.579
Spleen 0.0121 0.328 0.0075 0.202
0.0115 0.468 0.0139 0.564
Heart 0.0099 0.269 0.0083 0.225
0.0133 0.539 0.0131 0.533
Lung 0.0203 0.549 0.0247 0.667
0.0137 0.556 0.0174 0.706
Kidney 0.0306 0.828 0.0593 1.602
0.0296 1.202 0.0645 2.615
Stomach 0.0871 2.355 0.246 6.657
0.0370 1.501 0.0876 3.554
Sm. Intestine 0.0359 0.970 0.330 8.928
0.0521 2.115 0.432 1735
9. Distribution 168 hours post SC administration.
Thyroid ND ND 6.29 446
2.92 278
Whole Blood ND ND 0.0141%/ml 1
0.0105%/ml 1
Serum ND ND 0.0127%/ml 0.905
0.0097%/ml 0.919
Liver 0.0107 0.758 0.157 11.12
0.0119 1.124 0.173 16.44
Spleen 0.0107 0.758 0.0073 0.520
0.0059 0.557 0.0075 0.528
Heart 0.0053 0.378 0.0056 0.397
0.0033 0.313 0.0034 0.317
Lung 0.0081 0.576 0.0109 0.769
0.0065 0.615 0.0100 0.949
Kidney 0.0185 1.308 0.0434 3.074
0.0138 1.312 0.0321 3.037
Stomach 0.0179 1.266 0.123 8.687
0.0144 1.364 0.0532 5.046
Sm. Intestine 0.0158 1.116 0.160 11.34
0.0088 0.836 0.0908 8.597
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Table A3.19.1 The Serum Concentration (% 125I activity remaining/ml) following administration of
5mg of 125I-BSA-MTX (11.76%w/w) to rats by IV, IP and SC injection. (n=8 for each route).
Each value was determined from one rat.
Time (hr) IV %/ml Time (hr) IP %/ml Time (hr) SC %/ml
1 6.266 1.5 0.250 1.5 0.127
1 6.389 1.5 0.564 1.5 0.117
2 2.906 3.75 0.580 3.75 0.183
2 3.311 3.75 0.210 3.75 0.154
4 1.472 6 0.732 8 0.190
4 0.888 6 0.724 8 0.189
7 0.531 8 0.697 23 0.207
7 1.099 8 0.659 23 0.187
24.5 0.449 24 0.289 27.5 0.210
24.5 0.308 24 0.340 27.5 0.205
30.75 0.295 30.5 0.211 30.5 0.191
30.75 0.324 30.5 0.232 30.5 0.171
48 0.187 48 0.195 48 0.119
48 0.187 48 0.0899 48 0.134
52.5 0.176 52 0.141 52 0.154
52.5 0.164 52 0.151 52 0.142
71.5 0.107 71.5 0.102 71.5 0.0778
71.5 0.111 71.5 0.0927 71.5 0.0927
79 0.103 79 0.101 79 0.0623
79 0.110 79 0.0922 79 0.0683
96 0.0741 96 0.0697 96 0.0564
96 0.0579 96 0.0693 96 0.0742
100 0.0801 100 0.0549 100 0.0619
100 0.0667 100 0.0543 100 0.0354
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Table A3.19.2 The Urine Excretion (% of 125I administered) following administration of
5mg of 125I-BSA-MTX (11.76%w/w) to male wistar rats by each of three routes.
Values are cummulative mean % excreted in the urine (n=3
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 30.99 2.06 38.32 2.54 33.10 2.64
48 43.63 2.84 51.05 2.55 46.67 2.62
72 47.31 2.94 54.35 2.42 51.02 2.01
96 49.09 2.56 55.96 2.64 52.40 1.83
Table A3.19.3 The Excretion of 125I activity in the faeces (% of radioactivity adminis­
tered) following administration of 5mg 125I-BSA-MTX (11.76%w/w) to rats by each of 
the three routes.
Values are cummulative mean (n=3) % excreted in the faeces.
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M SC%
excreted
S.E.M.
24 2.47 0.54 4.70 1.59 3.59 1.39
48 4.85 1.10 6.22 1.81 5.96 1.76
72 5.96 1.17 7.14 1.86 7.20 1.58
96 6.70 1.26 7.91 1.90 8.13 1.31
-A75-
Table A3.19.4 The Organ Distribution of 125I activity following administration of 5mg of
125I-BSA-MTX (11.76%w/w) to male wistar rats by each of the three routes.
Results are expressed in 2 ways; as a % of the total radioactivity found in lg  or total organ 
and as a ratio of the activity in lg  (or whole organ) divided by activity in 1ml whole blood. 
Two rats from each group were analysed at each time point
Organ % in lg CPM in 1 g 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
1. Distribution 100 hours post IV injection.
Thyroid ND ND 6.74 75.73
7.34 133.45
Whole Blood ND ND 0.089%/ml 1
0.055%/ml 1
Serum ND ND 0.081%/ml 0.910
0.067%/ml 1.213
Liver 0.0945 1.063 0.793 8.922
0.0362 0.661 0.474 8.635
Spleen 0.0523 0.588 0.0578 0.650
0.0128 0.233 0.0188 0.342
Heart 0.0275 0.310 0.0281 0.317
0.0135 0.247 0.0163 0.297
Lung 0.0261 0.294 0.0304 0.343
0.0211 0.384 0.0288 0.525
Kidney 0.177 1.992 0.328 3.686
0.0904 1.647 0.267 4.868
Stomach 0.0395 0.444 0.174 1.954
0.0240 0.438 0.104 1.902
Sm. Intestine 0.0278 0.312 0.191 2.149
0.0266 0.485 0.227 4.131
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Table 3.19.4 Cont. (Organ Distribution of BSA-MTX 11.76%w/w).
Organ % in lg CPM in Is 
CPM in 1ml WB
% in total CPM in total 
CPM/mlWB
2. Distribution 100 hours post DP injection.
Thyroid ND ND 5.46 218.4
4.82 109.5
Whole Blood ND ND 0.025%/ml 1
0.044%Anl 1
Serum ND ND 0.055%ytal 2.196
0.054%/ml 1,239
Liver 0.0087 0.355 0.122 4.973
0.0302 0.690 0.389 8.875
Spleen 0.0026 0.106 0.0021 0.087
0.0143 0.326 0.0196 0.448
Heart 0.0042 0.170 0.0044 0.178
0.0128 0.292 0.0143 0.326
Lung 0.0076 0.309 0.0154 0.626
0.0282 0.644 0.0670 1.528
Kidney 0.0078 0.318 0.0217 0.882
0.113 2.589 0.306 6.978
Stomach 0.0338 1.373 0.124 5.026
0.0506 1.155 0.219 4.991
Sm. Intestine 0.0082 0.334 0.0915 3.716
0.0591 1.348 0.714 16.30
3. Distribution 100 hours post SC injection.
Thyroid ND ND 5.86 90.15
5.67 163.5
Whole Blood ND ND 0.065%/ml 1
0.035%/ml 1
Serum ND ND 0.062%/ml 0.952
0.035%/ml 1.022
Liver 0.0325 0.502 0.310 4.789
0.0187 0.538 0.231 6.659
Spleen 0.0148 0.229 0.0162 0.250
0.0073 0.212 0.0079 0221
Heart 0.0166 0.256 0.0164 0.253
0.0088 0.254 0.0113 0.327
Lung 0.0276 0.426 0.0443 0.684
0.0126 0.363 0.0231 0.666
Kidney 0.0812 1.253 0.229 3.540
0.0678 1.953 0.215 6.209
Stomach 0.0383 0.592 0.206 3.186
0.0420 1211 0.0984 2.837
Sm. Intestine 0.0290 0.448 0.296 4.564
0.0143 0.412 0.159 4.579
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Table A3.20.1 The Serum Concentration (% 125I activity injected) following administr­
ation of 5mg of 125I-BSA-MTX (13.63%w/w) to male wistar rats by each of the three
routes.
Each concentration was determined from one rat. (n=8 for each route).
Time (hr) IV %/ml IP %/ml SC %/ml
0.75 6.921 0.0990 0.0869
0.75 5.919 0.0702 0.0620
3.0 5.998 0.167 0.0908
3.0 5.784 0.217 0.0784
4.75 1.351 0.499 -
4.75 1.730 0.348 -
7.5 0.499 0.467 0.164
7.5 0.562 0.533 0.193
18.5 0.198 0.237 0.234
18.5 0.184 0.231 0.226
19 0.173 - -
22.5 - - 0.146
22.5 - - 0.188
29 0.117 0.102 0.145
29 0.106 0.156 0.163
43 0.0735 0.0883 0.104
43 0.0637 0.103 0.108
48 0.0725 0.0895 0.0965
48 0.0541 0.0760 0.0716
67.5 0.0471 0.0622 0.0716
67.5 0.0625 0.0507 0.0580
78.75 0.0443 0.0513 0.0636
78.75 0.0532 0.0686 0.0675
94 0.0362 0.0395 0.0417
94 0.0283 0.0284 0.0330
96 0.0446 0.0384 0.0440
96 0.0397 0.0455 0.0423
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Table A3.20.2 The Urine excretion of 125I activity (% total dose administered) following
administration of 5mg of 125I-BSA-MTX (13.63%w/w) to rats by each of three routes.
Values are mean % cummulative excretion (n=3).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 38.6 9.54 33.9 7.87 24.4 4.02
48 57.1 7.32 48.7 10.33 48.2 2.67
72 63.5 6.45 57.2 9.29 58.2 2.69
96 65.3 6.40 60.2 8.67 61.6 2.78
Table A3.20.3 The excretion of 125I activity (% of administered dose) in the faeces 
following administration of 125I-BSA-MTX (13.63%w/w) to rats by each of the three 
routes.
Values are mean % cummulative excretion (n-3).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 2.17 0.163 4.91 2.35 1.66 0.67
48 5.73 0.76 6.46 2.18 6.80 0.42
72 7.20 0.80 7.74 2.39 9.04 0.45
96 8.03 0.83 8.60 2.41 10.14 0.45
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Table A3.20.4 The Organ Distribution of 125I activity following administration of
125I-BSA-MTX (13.63%w/w) to rats by each of the three routes.
Results are expressed in 2 ways; as a % of the total radioactivity found in lg  or total 
organ and as a ratio of the activity in lg  (or whole organ) divided by radioactivity in 1ml 
whole blood. Two rats were analysed from each group at each time point
Organ % in lg PPM in 1 p 
CPM in 1ml WB
% in total CPM in total 
CPM/ml WB
1. Distribution 24 hours post IV injection.
Thyroid ND ND 7.43 41.05
6.81 43.10
Whole Blood ND ND 0.181%/ml 1
0.156%/ml 1
Serum ND ND 0.173%/ml 0.952
0.151%/ml 0.968
Liver 0.416 2.298 5.31 29.31
0.365 2.339 5.29 33.93
Spleen 0.375 2.071 0.61 3.365
0.331 2.122 0.34 2.207
Heart 0.067 0.370 0.061 0.340
0.059 0.378 0.058 0.374
Lung 0.099 0.547 0.12 0.641
0.087 0.557 0.13 0.836
Kidney 0.118 0.655 0.25 1.357
0.099 0.635 0.20 1.282
Stomach 0.692 3.825 3.39 18.71
0.541 3.468 2.35 15.05
Sm. Intestine 0.340 1.879 3.87 21.39
0.256 1.641 2.53 16.25
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Table A3.20.4 ConL (Organ Distribution of 13.63%w/w).
Organ % in lg  CPM in lg  % in total CPM in total
CPM in 1ml WB
2. Distribution 48 hours post IV injection.
Thyroid ND ND 9.28 98.7
5.91 73.8
Whole Blood ND ND 0.094%/ml 1
0.080%/ml 1
Serum ND ND 0.072%/ml 0.805
0.054%/ml 0.676
Liver 0.235 2.50 2.16 22.95
0.190 2.38 2.08 26.09
Spleen 0.183 1.947 0.19 1.986
0.232 2.908 0.29 3.677
Heart 0.026 0.276 0.023 0.243
0.038 0.483 0.046 0.490
Lung 0.0721 0.766 0.082 0.875
0.040 0.508 0.050 0.578
Kidney 0.047 0.500 0.098 1.044
0.046 0.577 0.099 1.546
Stomach 0.243 2.580 0.66 7.063
0.099 1.248 0.45 5.685
Sm. Intestine 0.058 0.613 0.49 5.199
0.090 1.135 0.73 9.096
3. Distribution 94 hours post IV injection.
Thyroid ND ND 6.14 122.8
3.10 62.0
Whole Blood ND ND 0.050%/ml 1
0.050%/ml 1
Serum ND ND 0.033%Anl 0.655
0.039%/ml 0.794
Liver 0.185 3.674 1.374 27.28
0.276 5.562 2.9 58.64
Spleen 0.170 3.371 0.0894 1.775
0.119 2.394 0.17 3.385
Heart 0.0178 0.353 0.011 0.221
0.0125 0.252 0.012 0.243
Lung 0.0227 0.451 0.028 0.570
0.0196 0.394 0.023 0.470
Kidney 0.0350 0.695 0.065 1.295
0.0253 0.508 0.060 1.206
Stomach 0.0778 1.546 0.240 4.760
0.0423 0.851 0.081 1.624
Sm. Intestine 0.0325 0.646 0.231 .4.483
0.0311 0.625 0.307 6.302
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Table A3.20.4 Cont (Organ Distribution of BSA-MTX 13.63%w/w)
Organ % in lg CPM in 1 g 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
4. Distribution 174 hours post IV injection.
Thyroid ND ND 7.83 145
10.07 197
Whole Blood ND ND 0.054%/ml 1
0.051 %/ml 1
Serum ND ND 0.031%Anl 0.574
0.030%/ml 0.588
Liver 0.127 2.338 1.15 21.28
0.138 2.731 1.26 30.05
Spleen 0.094 1.733 0.068 1.259
0.146 2.895 0.19 3.743
5. Distribution 48 hours post IP injection.
Thyroid ND ND 5.91 72.07
8.12 83.71
Whole Blood ND ND 0.082%/ml 1
0.097%/ml 1
Serum ND ND 0.0895%/ml 1.092
0.076%/ml 0.783
Liver 0.0791 0.968 0.87 10.66
0.144 1.492 1.44 14.95
Spleen 0.0194 0.238 0.017 0.208
0.0689 0.713 0.083 0.855
Heart 0.0308 0.377 0.033 0.404
0.0218 0.226 0.025 0.263
Lung 0.0300 0.368 0.030 0.347
0.0694 0.718 0.13 1.359
Kidney 0.0579 0.709 0.127 1.560
0.570 0.590 0.160 1.644
Stomach 0.196 2.401 0.73 8.93
0.354 3.667 1.828 18.92
Sm. Intestine 0.179 2.187 1.86 22.81
0.138 1.435 1.18 12.21
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Table A3.20.4 Cont (Organ Distribution of BSA-MTX 13.63%w/w Conjugate).
Organ % in lg CPM in lg 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
6. Distribution 94 hours post IP injection.
Thyroid ND ND 8.44 156.3
2.17 98.6
Whole Blood ND ND 0.054%/ml 1
0.0225%/ml 1
Serum ND ND 0.0395%/ml 0.731
0.028%/ml 1.289
Liver 0.0299 0.558 0.41 7.55
0.101 0.462 0.11 4.819
Spleen 0.0156 0.291 0.026 0.481
0.0092 0.430 0.011 0.4545
Heart 0.0123 0.228 0.014 0.265
0.0076 0.348 0.0080 0.368
Lung 0.0188 0.351 0.030 0.563
0.0112 0.513 0.011 0.524
Kidney 0.0353 0.658 0.084 1.561
0.0141 0.644 0.029 1.313
Stomach 0.0660 1227 0.50 9.388
0.0390 1.787 0.27 12.38
Sm. Intestine 0.0725 1.350 0.79 14.86
0.0279 1.279 0.27 12.38
7. Distribution 174 hours post IP injection.
Thyroid ND ND 8.81 151.9
7.04 167.6
Whole Blood ND ND 0.058%/knl 1
0.042%/ml 1
Serum ND ND 0.044%/ml 0.759
0.037%/ml 0.881
Liver 0.0435 0.749 0.45 7.683
0.0310 0.722 0.39 9.19
Spleen 0.0214 0.368 0.016 0.280
0.015 0.366 0.016 0.372
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Table A3.20.4 Cont. (Organ Distribution of BSA-MTX 13.63%w/w).
Organ % in lg CPM in lg  
CPM in 1ml WB
% in total C!PM in total 
CPM in 1ml WB
8. Distribution 48 hours SC administration.
Thyroid ND ND 8.96 74.67
9.28 77.33
Whole Blood ND ND 0.13%/ml 1
0.12%/ml 1
Serum ND ND 0.0965%/ml 0.743
0.0716%/ml 0.597
Liver 0.0457 0.344 0.57 4.271
0.0573 0.463 0.55 4.421
Spleen 0.0433 0.326 0.032 0.242
0.0768 0.621 0.086 0.698
Heart 0.0317 0.239 0.031 0.230
0.0269 0.218 0.024 0.195
Lung 0.0556 0.419 0.079 0.593
0.050 0.404 0.066 0.530
Kidney 0.0705 0.531 0.13 0.998
0.0557 0.450 0.12 0.999
Stomach 0.311 2.346 1.87 14.12
0.389 3.138 1.52 12.27
Sm. Intestine 0.406 3.061 3.46 26.09
0.124 1.000 1.48 11.96
9. Distribution 94 hours post SC injection.
Thyroid ND ND 4.13 60.73
5.30 84.13
Whole Blood ND ND 0.068%/ml 1
0.063%/ml 1
Serum ND ND 0.042%/inl 0.613
0.033%/ml 0.524
Liver 0.0270 0.398 0.29 4.361
0.0182 0.287 0.22 3.471
Spleen 0.0147 0.218 0.020 0.295
0.0106 0.167 0.014 0.224
Heart 0.0157 0.231 0.016 0.232
0.0137 0.216 0.012 0.183
Lung 0.0306 0.452 0.046 0.674
0.0237 0.374 0.035 0.550
Kidney 0.0320 0.473 0.077 1.136
0.0319 0.504 0.065 1.025
Stomach 0.096 1.424 0.40 5.962
0.108 1.704 0.65 10.24
Sm. Intestine 0.065 0.956 0.66 9.733
0.119 1.889 1.09 17.24
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Table A3.20.4 cont (Organ Distribution of BSA-MTX 13.63%w/w).
Organ % in lg CPM inJg 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
10. Distribution 174 hours post SC injection.
Thyroid ND ND 8.06 158
3.18 70.7
Whole Blood ND ND 0.053%/ml 1
0.045%/ml 1
Serum ND ND 0.021 %/ml 0.396
0.022%/ml 0.489
Liver 0.0106 0.201 0.11 2.147
0.0096 0.214 0.14 3.083
Spleen 0.0056 0.107 0.008 0.159
0.0079 0.175 0.012 0.271
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Table 3.21.1 Serum Concentration (% 125I activity remaining/ml) following administration of
5mg of 125I-BSA-MTX (13.64%w/w) to rats by each of the three routes.
Each value was determined from one rat. There were 8 rats in each group.
Time (hr) IV %/ml IP %/ml SC %/ml
1 2.558 0.399 0.138
1 1.614 0.151 0.161
3 0.668 0.305 -
3 0.634 0.393 -
5 0.552 0.327 0.172
5 0.535 0.493 0.225
8 0.424 0.370 0.334
8 0.436 0.375 0.152
23 0.160 0.141 0.227
23 0.177 0.191 0.130
26.5 0.154 0.131 0.114
26.5 0.183 0.127 0.111
31.75 0.124 0.124 0.120
31.75 0.197 0.127 0.142
48 0.0791 0.109 0.0834
48 0.0959 0.0464 0.0736
49.5 0.0712 - -
49.5 0.0793 - -
54 0.0899 0.0595 0.0643
54 0.102 0.0771 0.0697
71 0.0508 0.0512 0.0575
71 0.0564 0.0498 0.0495
79.5 0.0558 0.0363 -
79.5 0.0692 0.0535 -
96 0.0375 0.0456 0.0382
96 0.0353 0.0366 0.0321
97 0.0416 0.0271 0.0328
97 0.0374 0.0311 0.0341
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Table A3.21.2 The urine excretion of 125I activity (% of dose administered) following
administration of 5mg of 125I-BSA-MTX (13.64%w/w) to rats by each of the three routes.
Each value is mean % excreted (n=3).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 48.72 1.61 36.47 6.89 31.31a 4.61
48 64.28 1.53 54.81 9.65 54.83 6.98
72 69.69 1.83 60.30 10.48 63.23 7.46
96 72.39 1.99 63.15 10.92 66.45 7.41
Note a) The % excretion for the SC group was compared to the IV group using a T-test at 
24 hours and was found to be significant All other times were non-significant
Table A3.21.3 The excretion of 125I activity in the faeces (% of administered dose) 
following administration of 5mg of 125I-BSA-MTX (13.64%w/w) to rats by each of the 
three routes.
Results are expressed as mean % excreted (n=3).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 3.35 0.25 2.65 1.77 3.77 0.71
48 6.97 0.39 6.91 1.47 9.10 2.52
72 9.07 0.51 9.08 2.20 11.62 1.74
96 10.41 0.51 10.38 2.11 12.71 1.89
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Table A3.21.4 The organ distribution of 125I activity following administration of 5mg of
125I-BSA-MTX (13.64%w/w) to rats by each of the three routes.
Results are expressed in 2 ways; as a % of the total radioactivity found in lg  or the whole 
organ and as a ratio of the activity found in lg  (or whole organ) divided by the activity 
found in 1ml whole blood. Two rats were analysed for each group for each time point
Organ % in lg CPM in 1 g 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
1. Distribution 48 hours post IV injection.
Thyroid ND ND 9.26 71.23
6.65 55.42
Whole Blood ND ND 0.13%/ml 1
0.12%/ml 1
Serum ND ND 0.0712%/ml 0.548
0.0793%/ml 0.649
Liver 0.147 1.113 1.54 11.54
0.165 1.354 1.37 11.09
Spleen 0.152 1.153 0.14 1.075
0.340 2.783 0.22 1.781
Heart 0.0249 0.189 0.030 0.222
0.0303 0.248 0.028 0.228
Lung 0.0401 0.304 0.069 0.516
0.0479 0.393 0.075 0.609
Kidney 0.0598 0.454 0.15 1.129
0.0645 0.528 0.13 1.046
Stomach 0.109 0.832 0.47 3.501
0.341 2.791 0.98 7.917
Sm. Intestine 0.080 0.610 0.60 4.539
0.057 0.467 0.37 3.007
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Table A3.21.4 Cont. (Organ distribution of BSA-MTX 13.64%w/w).
Organ
Serum
Liver
Spleen
Heart
Lung
Kidney
Stomach 
Sm. Intestine
% in lg
ND
0.0980
0.111
0.119
0.133
0.043
0.038
0.073
0.081
0.0864
0.0755
1.175
1.335
0.380
0.292
CPM in lg  
CPM in 1ml WB
ND
0.626
0.702
0.760
0.842
0.275
0.241
0.468
0.513
0.552
0.478
7.50
8.449
2.425
1.848
% in total
5.23
5.78
0.0898%/ml
0.091%/ml
0.0416%/ml
0.0374%/ml
1.10
1.35
0.076
0.101
0.015
0.021
0.043
0.061
0.11
0.26
0.32
0.42
0.32
0.30
8.35 
8.61
0.156%Anl
0.158%Anl
0.124%/ml
0.127%Anl
1.08
1.365
0.21
0.134
0.0487
0.0494
0.11
0.122
0.21
0.174
4..55
5.74
2.67
2.89
CPM in total 
CPM in 1ml WB
58.24
63.52
1
1
0.463
0.411
11.67
14.78
0.808
1.134
0.160
0.235
0.455
0.669
1.179
2.820
3.358
4.614
3.362
3.322
52.19
54.44
1
1
0.793
0.804
6.804
8.641
1.315
0.850
0.309
0.313
0.694
0.772
1.333
1.099
29.08
36.33
17.05
18.29
2. Distribution 97 hours post IV administration.
Thyroid ND ND
Whole Blood ND ND
Serum ND ND
Liver 0.105 1.169
0.149 1.720
Spleen 0.0468 0.522
0.0890 1.019
Heart 0.0148 0.164
0.0165 0.189
Lung 0.0264 0.294
0.0291 0.334
Kidney 0.0426 0.475
0.106 1.223
Stomach 0.0559 0.623
0.155 1.777
Sm. Intestine 0.0410 0.457
0.0511 0.587
3. Distribution 31.75 hours post IP injection.
Thyroid ND ND
Whole Blood ND ND
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Table A3.21.4 Cont (Organ distribution of BSA-MTX 13.64%w/w).
Organ % in lg CPM in lg  
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
4. Distribution 97 hours post IP injection.
Thyroid ND ND 2.76 42.46
5.24 143.2
Whole Blood ND ND 0.065%Anl 1
0.084%Anl 1
Serum ND ND 0.0366%/ml 0.563
0.0456%/ml 0.543
Liver 0.0125 0.201 0.14 2202
0.0442 0.553 0.596 7.132
Spleen 0.0096 0.155 0.012 0.187
0.0238 0.297 0.052 0.624
Heart 0.0099 0.159 0.013 0.203
0.0124 0.156 0.016 0.193
Lung 0.0234 0.376 0.039 0.598
0.0255 0.319 0.048 0.571
Kidney 0.0185 0.298 0.054 0.939
0.0348 0.435 0.097 1.161
Stomach 0.0519 0.836 0.22 3.312
0.131 1.634 0.961 11.53
Sm. Intestine 0.0144 0.231 0.111 1.757
0.0298 0.373 0.27 3.284
5. Distribution 97 hours post SC injection.
Thyroid ND ND 4.45 60.96
7.06 102.3
Whole Blood ND ND 0.0727%/ml 1
0.0692%/ml 1
Serum ND ND 0.0328%/ml 0.450
0.0341%/ml 0.493
Liver 0.0367 0.523 0.59 7.972
0.0174 0.262 0.21 3.060
Spleen 0.0099 0.141 0.022 . 0.225
0.0164 0.247 0.019 0.281
Heart 0.0120 0.171 0.022 0.226
0.0145 0.218 0.018 0.258
Lung 0.0213 0.304 0.035 0.471
0.0287 0.432 0.039 0.566
Kidney 0.0356 0.509 0.11 1.543
0.0382 0.575 0.11 1.530
Stomach 0.108 1.540 0.44 6.055
0.0373 0.563 0.20 2.886
Sm. Intestine 0.0374 0.532 0.43 5.840
0.0447 0.673 0.53 7.675
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Table A3.22.1 the Serum Concentration of 125I activity (% of administered dose) following
administration of 5mg of 125I-LA-MTX (4.52%w/w) to male rats by each of the three routes.
Each value was determined from one rat (n=8 for each route.)
Time (hr) IV %/ml IP % /ml SC %/ml
0.667 - 0.399 0.437
0.667 - 0.322 0.412
1 0.439 - -
1 0.630 - -
1.5 0.483 0.597 0.473
1.5 0.453 0.573 0.481
2 0.452 0.486 0.522
2 0.512 0.426 0.481
3 0.433 - 0.438
3 0.454 - 0.348
4 0.269 0.369 0.479
4 0.335 0.417 0.363
6 0.448 0.270 0.363
6 0.271 0.326 0.338
8 0.316 0.256 0.349
8 0.341 0.359 0.298
23.5 0.157 0.108 0.155
23.5 0.112 0.222 0.144
27.5 0.0932 0.108 0.158
27.5 0.0927 0.174 0.118
32.25 0.114 0.0812 0.108
32.25 0.138 0.0960 0.102
48.25 0.0497 0.0379 0.0438
48.25 0.0583 0.0251 0.0490
56.75 0.0324 0.0366 0.0405
56.75 0.0508 0.0443 0.0540
72 0.0345 0.0289 0.0368
72 0.0367 0.0381 0.0286
96 0.0211 0.0233 0.0320
96 0.0224 0.0268 0.0226
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Table A3.22.2 the Urine Excretion of 125I activity (% of total injected dose) following
administration of 5mg of 125I-LA-MTX (4.52%w/w) to rats by each of the three routes.
Values are mean % excreted (n=3).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 39.95 6.62 31.16 8.91 38.07 7.73
48 50.45 7.74 45.00 8.85 46.40 5.37
72 54.07 8.06 48.97 7.40 50.80 4.17
96 60.53 9.30 53.97 6.85 56.94 2.74
Table A3.22.3 The excretion of 125I activity in the faeces (% of total radioactivity 
injected) following administration of 5mg of 125I-LA-MTX (4.52%w/w) to rats by each 
of the 3 routes.
Values are mean % excreted (n=3).
Time IV % S.E.M. JP% S.E.M. SC% S.E.M.
(hr) excreted excreted excreted
24 2.93 1.51 3.24 0.77 1.94 1.08
96 6.57 1.84 8.42 0.34 10.20 1.75
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Table A3.23.1 Serum Concentration (% 125I activity remaining/ml) following administration
of 5mg of 125I-LA-MTX (13.69%w /w ) to male wistar rats by each of the three routes.
Each concentration was determined from one rat (n=8 for IV and SC, n=6 for IP).
Time (hr) IV %/ml IP %/ml SC %/ml
0.333 2.259 0.242 0.216
0.333 2.381 0.364 0.318
0.833 1.309 0.658 0.497
0.917 1.753 - 0.447
1 - 0.506 -
2 0.580 0.537 0.383
2 0.613 0.602 0.841
4 0.460 0.484 0.389
4 0.343 0.495 0.372
6.5 0.251 0.338 0.310
6.5 0.196 0.372 0.380
8 0.278 - 0.309
8 0.262 - 0.324
10 0.242 0.266 0.414
10 0.301 0.309 0.394
23.5 0.0818 0.0617 0.0545
23.5 0.0992 0.116 0.0947
28 0.0650 - 0.0714
28 0.0620 - 0.0705
31 0.0661 0.0923 0.0651
31 0.0671 0.0896 0.0654
47.5 0.0250 0.0300 0.0313
47.5 0.0264 0.0387 0.0347
55 0.0263 0.0471 0.0313
55 0.0309 0.0454 0.0363
72 0.0154 0.0263 0.0176
72 0.0182 0.0219 0.0213
80 0.0197 - 0.0271
80 0.0170 - 0.0269
97 0.0145 0.0208 0.0227
97 0.0176 0.0157 0.0223
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Table A3.23.2 The Urine excretion of 125I activity ( % of total dose administered) following
adminstration of 5mg of 125I-LA-MTX (13.69%w/w) to rats by each of the routes.
Values are mean % excretion (n=3).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. SC%
excreted
S.E.M.
24 38.43 1.84 42.81 3.70 45.47 8.34
48 44.17 2.78 50.00 3.61 51.86 8.60
72 46.05 3.00 52.54 3.48 53.72 8.47
96 46.84 3.07 53.85 2.98 54.51 8.42
Table A3.23.3 The excretion of 125I activity ( % of dose administered) in the faeces 
following administration of 5mg of 125I-LA-MTX (13.69%w/w) to rats by each of the 
three routes.
Values are mean % excretion (n=3).
Time
(hr)
IV % 
excreted
S.E.M. IP%
excreted
S.E.M. sc%
excreted
S.E.M.
24 4.18 1.48 2.62 0.97 5.47 1.14
48 5.37 1.55 4.75 0.99 8.29 1.90
72 6.11 1.61 6.12 0.63 9.60 1.86
96 6.63 1.65 7.20 0.51 10.21 1.91
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Table A3.24.1 The Serum concentration (% radioactivity remaining/ml) following
administration of 5mg of 125I-RSA-MTX (6.94%w/w) to rats by the IV route. (n=8).
Each concentration was determined from one rat.
Time (hr) % 125I dose/ml
1 3.833
1 4.561
2 3.312
2 3.492
3.75 1.630
3.75 1.628
5.75 1.159
5.75 0.874
18 0.228
18 0.215
21 0.189
21 0.159
24 0.178
24 0.149
27 0.150
27 0.153
42 0.101
42 0.0995
48 0.0962
48 0.0875
50 0.0786
50 0.107
66.25 0.0527
66.25 0.0512
74 0.0535
74 0.0837
95 0.0399
95 0.0343
-A95-
Table A3.24.2 The Urine Excretion of 125I (% of total injected) following administration of
5mg of 125I-RSA-MTX (6.94%w/w) to rats by the IV route.
Each value is mean % excreted (n=3).
Time (hr) % 125I excreted S.E.M.
24 25.46 2.69
48 33.49 3.16
72 39.61 3.89
96 40.78 4.05
Table A3.24.3 The excretion of 125I activity in the faeces (% of radioactivity injected) 
following administration of 5mg of 125I-RSA-MTX (6.94%w/w) to rats by the IV route.
Each value is mean % excreted (n=3).
Time (hr) % 125I excreted S.E.M.
24 3.27 1.108
48 6.65 0.657
72 8.53 0.709
96 9.54 0.622
-A96-
Table A3.24.4 The Organ Distribution of radioactivity following administration of 5mg of
125I-RSA-MTX (6.94%w/w) to rats by the IV route.
Results are expressed in 2 forms; as a % of the radioactivity injected found in lg  or the 
whole organ and as a ratio of the activity found in lg  (or the whole organ) divided by 
activity in 1ml whole blood. Two rats were analysed at each time point for each group.
Organ % in lg CPM in lg 
CPM in 1ml WB
% in total % in total 
CPM in 1ml WB
1. Distribution 24 hours post administration.
Thyroid ND ND 9.761 83.50
12.81 103.7
Whole Blood ND ND 0.117%/ml 1
0.123%/ml 1
Serum ND ND 0.178%/ml 1.521
0.149%/ml 1.211
Liver 0.0901 0.790 0.939 8.03
0.0865 0.718 0.980 7.94
Spleen 0.0594 0.521 0.0615 0.526
0.0635 0.527 0.0542 0.435
Heart 0.0450 0.394 0.0539 0.461
0.0412 0.342 0.0503 0.407
Lung 0.0608 0.533 0.0674 0.577
0.0667 0.554 0.0907 0.734
Kidney 0.0736 0.645 0.172 1.468
0.0670 0.556 0.177 1.435
Stomach 0.439 3.854 1.310 11209
0.607 5.042 4.643 37.59
Sm. Intestine 0.113 0.993 1.028 8.798
0.354 2.935 3.368 2121
2. Distribution 48 hours post administration.
Thyroid ND ND 13.67 156.6
12.82 152.6
Whole Blood ND ND 0.0873%/ml 1
0.0840%/ml 1
Serum ND ND 0.0962%/ml 1.102
0.0875%/ml 1.042
Liver 0.0754 0.885 0.765 8.72
0.0628 0.767 0.627 7.46
Spleen 0.0543 0.638 0.036 0.412
0.0439 0.536 0.035 0.417
Heart 0.0326 0.382 0.031 0.355
0.0326 0.398 0.033 0.391
Lung 0.0447 0.525 0.051 0.584
0.0440 0.538 0.0698 0.831
Kidney 0.0542 0.636 0.128 1.466
0.0487 0.595 0.101 1.202
Stomach 0.279 3.278 0.597 6.838
0.262 3.195 0.605 7.202
Sm. Intestine 0.123 1.452 0.778 8.912
0.0675 0.825 0.417 4.964
-A97-
Table A3.25.1 The Serum and Whole Blood Concentrations (% radioactivity remaining/ml)
following administration of 250pg of 125I-BSA to male wistar rats by the IV route.
Each value is the serum concentration determined for one rat. Ten rats were injected. 
Note: Where Means and S.E.M. are quoted n=4.
Time (minutes) Whole Blood %/ml Serum %/ml
1 7.30 12.734
1 6.856 13.08
2 7.552 11.835
2 5.038 12.977
5 7.100 12.284
5 4.736 12.356
8 6.770 8.704
8 4.754 7.862
10 6.668 10.855
10 6.104 11.910
15 6.735±0.175 10.75910.938
20 6.707 10.942
20 6.165 11.425
30 6.166±0.205 11.31410.405
60 5.667 10.953
60 5.621 10.681
90 4.639 8.140
90 4.491 7.838
120 4.598 8.247
120 4.496 8.696
150 4.435 8.662
150 4.010 7.982
180 4.075 7.750
180 4.962 9.875
210 4.043 8.323
210 3.851 8.648
240 3.995 7.503
240 3.453 7.975
300 3.688 6.337
300 3.696 6.693
-A98-
Table A3.25.2 The Organ Distribution following administration of 250pg of 125I-BSA to rats
by the IV route. Two rats were analysed for each time point.
Values are expressed in 2 forms as a % of the total 125I found in lg  or the whole organ and as 
a ratio of the activity found in lg  (or the whole tissue) divided by activity found in 1ml whole 
blood.
Organ % in lg CPM in lg  
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
1. Distribution 15 minutes post injection.
Thyroid ND ND 0.102 0.0159
0.108 0.0160
Bladder ND ND 0.136 0.0212
0.286 0.0424
Whole Blood ND ND 6.405%/ml 1
6.743%/ml 1
Serum ND ND 8.354%/ml 1.304
11.50%/ml 1.706
Liver 1.487 0.232 16.59 2.590
1.242 0.184 14.24 2.112
Spleen 1.146 0.179 0.878 0.137
1.008 0.149 1.390 0.206
Heart 1.813 0.283 2.040 0.318
1.645 0.244 1.809 0.268
Lung 2.082 0.325 2.823 0.440
2.088 0.310 3.094 0.459
Kidney 1.779 0.278 3.684 0.575
1.838 0.273 4.468 0.663
Stomach 0.243 0.038 0.988 0.154
0.343 0.0509 1.210 0.179
Sm. Intestine 0.340 0.0531 3.101 0.484
0.389 0.0577 3.600 0.534
-A99-
Table A3.25.2 Cont. (Organ Distribution for BSA)
Organ % in lg CPM in 1 ft 
CPM in 1 ml WB
% in total CRM in total
CPM in 1ml WB
2. Distribution 30 minutes post injection.
Thyroid ND ND 0.168 0.0267
0.208 0.0195
Bladder ND ND 0.116 0.0184
0.302 0.0473
Whole Blood ND ND 6.301%/ml 1
6.391%/ml 1
Serum ND ND 10.589%/ml 1.680
10.644%/ml 1.665
Liver 1.070 0.170 12.898 2.047
1.703 0.266 20.513 3.210
Spleen 1.023 0.163 0.752 0.119
1.218 0.190 0.995 0.156
Heart 1.356 0.215 1.403 0.223
1.515 0.237 1.708 0.267
Lung 2.202 0.349 3.731 0.592
1.421 0.222 1.583 0.247
Kidney 1.829 0.290 3.905 0.620
1.143 0.179 3.448 0.540
Stomach 0.191 0.0303 1.522 0.241
0.349 0.0546 0.872 0.136
Sm. Intestine 0.336 0.0534 3.081 0.489
0.318 0.0498 2.577 0.403
3. Distribution 1 hour post injection.
Thyroid ND ND 0.454 0.0801
0.345 0.0614
Bladder ND ND 0.854 0.151
0.199 0.0354
Whole Blood ND ND 5.667%/ml 1
5.621%/ml 1
Serum ND ND 10.953%/ml 1.933
10.681%/ml 1.900
Liver 1.364 0.241 15.419 2.721
1.450 0.258 18.91 3.364
Spleen 0.922 0.163 0.774 0.137
0.659 0.117 0.683 0.122
Heart 1.686 0.298 1.901 0.335
2.097 0.373 2.622 0.466
Lung 1.823 0.322 3.065 0.541
1.957 0.348 3.128 0.556
Kidney 1.445 0.255 3.232 0.570
1.485 0.264 3.474 0.618
Stomach 0.455 0.0802 1.746 0.308
0.254 0.0452 1.642 0.292
Sm. Intestine 0.579 0.102 5.296 0.935
0.712 0.127 8.478 1.508
-A100-
Table A3.25.2 Cont. (Organ Distribution of BSA)
Organ % in lg CPM in J.g
rP M in 1m1 WB
in tntnl CPM in total 
TPM in 1ml WB
4. Distribution 3 hours post injection
Thyroid ND ND 1.19 0.292
1.05 0.212
Bladder ND ND 0.419 0.103
0.333 0.0671
Whole Blood ND ND 4.075%/ml 1
4.962%/ml 1
Serum ND ND 7.750%/ml 1.902
9.875%/ml 1.990
Liver 1.184 0.290 15.866 3.893
0.893 0.180 11.551 2.328
Spleen 0.638 0.157 0.493 0.121
0.678 0.137 0.644 0.130
Heart 1.448 0.355 1.569 0.385
1.431 0.288 1.953 0.394
Lung 1.695 0.416 2.924 0.718
1.626 0.328 2.735 0.551
Kidney 1.042 0.256 2.356 0.578
1.076 0.217 2.541 0.512
Stomach 0.715 0.176 4.229 1.038
0.846 0.171 5.637 1.136
Sm. Intestine 0.681 0.167 7.197 1.766
0.529 0.106 4.696 0.946
5. Distribution 5 hours post administration.
Thyroid ND ND 1.11 0.301
1.36 0.368
Bladder ND ND 0.379 0.103
0.195 0.0527
Whole Blood ND ND 3.688%/ml 1
3.696%/ml 1
Serum ND ND 6.337%/ml 1.718
6.693%/ml 1.811
Liver 0.732 0.199 8.169 2.215
0.918 0.248 11.949 3.233
Spleen 0.406 0.110 0.523 0.142
0.875 0.237 0.628 0.170
Heart 1.117 0.303 1.286 0.349
1.316 0.356 1.392 0.377
Lung 1.707 0.463 2.698 0.732
1.353 0.366 2.194 0.593
Kidney 1.308 0.355 2.717 0.737
0.600 0.162 1.262 0.341
Stomach 0.712 0.193 6.087 1.650
0.765 0.207 5.047 1.366
Sm. Intestine 0.665 0.180 5.846 1.585
0.511 0.138 5.413 .. 1.464
-A101-
Table A3.26.1 The Serum and Whole Blood concentrations (% of radioactivity remaining/
ml) following administration of 250pg of 125I-BSA-MTX (4.54%w/w) to rats by the IV
route. Ten rats were injected. Each value was determined from one rat.
Note where Mean and S.E.M. are quoted n=4.
Time (minutes) Whole Blood %/ml Serum %/ml
1 5.077 10.031
1 5.558 9.597
2 4.563 8.336
2 4.692 8.717
5 4.954 7.997
5 4.195 7.675
8 3.852 7.191
8 3.748 6.996
10 4.063 6.915
10 3.595 6.963
15 3.671 6.592
15 3.731 6.390
20 3.44710.0817 6.35810.0947
30 3.553 5.946
30 3.032 5.681
40 2.842 5.575
40 3.020 5.707
60 2.494 4.712
60 2.383 4.411
90 2.379 4.752
90 2.158 4.100
120 2.269 4.262
120 2.094 3.747
150 1.704 3.328
150 1.848 3.041
180 1.418 2.533
180 1.835 3.280
240 1.407 2.356
240 1.624 2.960
300 1.017 2.239
300 1.381 2.279
-A102-
Table A3.26.2. Organ Distribution following administration of 250pg of 125I-BSA-MTX
(4.54%w/w) to rats by the IV route.
Results are expressed in 2 forms; as a % of the radioactive dose found in lg  or the whole 
organ and as a ratio of the activity found in lg  (or the whole tissue) divided by the activity 
in 1ml whole blood. Two rats were analysed at each time point.
Organ % in lg PPM in 1 p 
PPM in 1 ml WR
% in total PPM in total 
PPM in Itnl WR
1 Distribution 15 minutes following administration.
Thyroid ND ND 0.224 0.0610
0.415 0.111
Bladder ND ND 0.284 0.0774
1.182 0.317
Whole Blood ND ND 3.671%/ml 1
3.731%/ml 1
Serum ND ND 6.592%/ml 1.796
6.390%/ml 1.713
Liver 1.895 0.516 25.111 6.842
1.413 0.354 22.304 5.980
Spleen 1.608 0.438 1.289 0.351
1.320 0.354 1.270 0.340
Heart 0.947 0.258 1.599 0.436
1.261 0.338 1.515 0.406
Lung 1.053 0.287 1.260 0.343
1.175 0.315 1.842 0.494
Kidney 1.547 0.421 3.843 1.047
1.556 0.424 3.814 1.023
Stomach 0.341 0.0928 2.701 0.736
0.143 0.0382 1.742 0.467
Sm. Intestine 0.345 0.0939 4.694 1.279
0.346 0.0927 4.196 1.125
-A 103-
Table A3.26.2 Cont (Organ Distribution of BS A-MTX (4.54%w/w)
Organ % in lg  CPM in 1 g 
__________ CPM in 1 ml WB
% in total CPM in total 
_________ CPM in 1ml WB
Thyroid ND ND 0.366 0.103
0.427 0.141
Bladder ND ND 1.580 0.445
2.371 0.782
Whole Blood ND ND 3.553%/ml 1
3.032%/ml 1
Serum ND ND 5.946%/ml 1.673
5.681%/ml 1.874
Liver 1.684 0.474 22.41 6.307
1.349 0.445 20.53 6.771
Spleen 1.501 0.424 1.231 0.346
1.477 0.487 1.925 0.635
Heart 1.152 0.324 1.385 0.390
0.834 0.275 1.243 0.410
Lung 1.185 0.334 1.869 0.526
1.021 0.337 1.811 0.597
Kidney 1.509 0.425 3.408 0.959
1.070 0.353 2.709 0.893
Stomach 0.530 0.149 5.331 1.500
0.528 0.174 5.265 1.736
Sm. Intestine 0.780 0.219 8.423 2.371
1.216 0.401 13.588 4.482
3. Distribution 1 hour post administration.
Thyroid ND ND 0.700 0.281
0.977 0.410
Bladder ND ND 1.780 0.714
1.963 0.824
Whole Blood ND ND 2.493%/ml 1
2.383%/ml 1
Serum ND ND 4.712%/ml 1.890
4.411%/ml 1.851
Liver 1.319 0.529 18.093 7.254
1.157 0.485 14.497 6.084
Spleen 1.062 0.426 1.463 0.587
1.740 0.730 1.087 0.456
Heart 0.868 0.348 1.010 0.405
0.798 0.335 0.804 0.337
Lung 0.833 0.334 1.482 0.594
0.921 0.386 1.448 0.608
Kidney 1.218 0.488 3.353 1.344
1.148 0.482 2.817 1.182
Stomach 0.483 0.194 2.288 0.917
1.088 0.456 4.840 2.031
Sm. Intestine 0.717 0.288 7.506 3.010
0.652 0.274 6.276 2.634
-A 104-
Table A3.26.2 Cont. (Organ Distribution for BSA-MTX (4.54%w/w))
Organ % in lg PPM in 1 g 
PPM in 1ml WR
% in total PPM in total 
PPM in 1ml WR
4. Distribution 3 hours post injection.
Thyroid ND ND 1.672 1.179
3.287 1.791
Bladder ND ND 0.891 0.628
0.151 0.0823
Whole Blood ND ND 1.418%/ml 1
1.835%/ml 1
Serum ND ND 2.533 1.786
3.280 1.787
Liver 0.512 0.361 6.274 4.424
0.629 0.343 9.070 4.948
Spleen 0.446 0.314 0.487 0.343
0.521 0.284 0.506 0.276
Heart 0.636 0.449 0.609 0.430
0.644 0.351 0.748 0.408
Lung 0.628 0.443 0.937 0.661
0.768 0.419 1.314 0.717
Kidney 0.726 0.512 1.657 1.169
1.235 0.674 2.931 1.599
Stomach 1.295 0.913 9.261 6.531
1.817 0.991 13.332 7.274
Sm. Intestine 0.719 0.507 6.737 4.751
1.501 0.819 16.933 9.238
5. Distribution 5 hours post administration.
Thyroid ND ND 3.754 3.690
3.753 2.718
Bladder ND ND 0.891 0.876
0.151 0.109
Whole Blood ND ND 1.017%/ml 1
1.381%/ml 1
Serum ND ND 2.240%/ml 2.202
2.279%/ml 1.650
Liver 0.555 0.546 7.526 7.400
0.612 0.443 7.288 5.279
Spleen 0.357 0.351 0.350 0.344
0.582 0.422 0.429 0.311
Heart 0.429 0.422 0.529 0.520
0.456 0.330 0.582 0.422
Lung 0.531 0.522 0.672 0.660
0.860 0.623 1.552 1.124
Kidney 0.709 0.698 1.641 1.613
0.708 0.512 1.679 1.216
Stomach 1.928 1.896 12.864 12.649
2.551 1.847 12.033 8.715
Sm. Intestine 0.603 0.592 5.467 5.376
1.016 0.736 8.565 6.203
-A 105-
Table A3.27.1 the Serum and Whole Blood Concentration (% of radioactivity remaining/
ml) following administration of 250pg of 125I -BSA-MTX (11.55%w/w) to male wistar rats
by IV injection. Each point is a single determination
Time (minutes) Whole Blood %/ml Serum %/ml
1 4.508 7.257
1 4.574 6.901
2 3.345 7.312
2 3.192 5.378
5 2.907 4.655
5 1.900 3.288
8 1.953 3.152
8 1.394 2.101
10 1.430 1.527
10 0.989 2.419
15 1.021 1.733
15 0.764 1.197
20 0.753 1.243
20 0.602 0.9088
24 0.571 0.697
24 0.645 0.973
30 0.724 1.006
30 0.640 0.838
40 0.522 0.704
40 0.599 0.806
60 0.505 0.647
60 0.500 0.710
90 0.347 0.499
90 0.488 0.590
120 0.320 0.334
120 0.254 0.348
150 0.311 0.346
150 0.387 0.421
180 0.245 0.320
180 0.303 0.387
240 0.231 0.245
240 0.220 0.272
300 0.202 0.241
300 0.170 0.239
-A106-
Table A3.27.2 The Organ distribution following administration of 250mg of 125I-
BSA-MTX (11.55%w/w) to rats by the IV route.
Values are expressed in 2 forms; as a % of the the totalradioactive dose found in lg  or the 
whole organ and as a ratio of the activity in lg (or whole organ) divided by the activity in 
lml whole blood.
Organ % in total CPM in 1 g % in total CPM in total
CPM in 1ml WB CPM/ml WB
1. Distribution 15 minutes post injection.
Thyroid ND ND 0.204 0.200
0.137 0.179
Bladder ND ND 0.720 0.705
0.141 0.184
Whole Blood ND ND 1.021%/ml 1
0.764%/ml 1
Serum ND ND 1.733%/ml 1.698
1.197%/ml 1.567
Liver 4.797 4.699 67.15 65.77
4.763 6.234 61.43 80.40
Spleen 2.472 2.421 3.27 3.203
3.113 4.074 3.91 5.118
Heart 0.287 0.281 0.366 0.358
0.284 0.371 0.351 0.459
Lung 0.503 0.493 0.763 0.747
0.441 0.577 0.789 1.033
Kidney 0.503 0.493 1.185 1.161
0.521 0.682 1.310 1.715
Stomach 0.318 0.311 3.706 3.630
0.174 0.228 1.750 2.304
Sm. Intestine 0.251 0.246 2.633 2.579
0.350 0.458 5.450 7.133
-A 107-
Table A3.27.2 Cont. (Organ Distribution of MTX-BSA (11.55%w/w))
Organ % in lg PPM in 1 p 
PPM in 1ml WB
% in total PPM in total 
PPM in 1ml WB
2. Distribution 30 minutes post injection.
Thyroid ND ND 0.36 0.497
0.45 0.703
Bladder ND ND 0.928 1.282
0.921 1.439
Whole Blood ND ND 0.724%/ml 1
0.640%/ml 1
Serum ND ND 1.006%/ml 1.389
0.838%/ml 1.309
Liver 4.337 5.994 49.776 68.80
3.390 5.169 47.676 74.44
Spleen 2.418 3.341 3.350 4.630
3.311 5.169 3.485 5.441
Heart 0.286 0.395 0.324 0.448
0.305 0.476 0.393 0.614
Lung 0.479 0.662 0.802 1.109
0.381 0.595 0.688 1.075
Kidney 0.642 0.887 1.533 2.119
0.627 0.979 1.880 2.935
Stomach 0.419 0.579 3.763 5.201
0.307 0.480 3.282 5.124
Sm. Intestine 0.481 0.665 5.470 7.560
0.479 0.749 5.317 8.302
3. Distribution 1 hour post administration.
Thyroid ND ND 0.715 1.416
0.837 1.674
Bladder ND ND 4.354 8.622
0.652 1.304
Whole Blood ND ND 0.505%/ml 1
0.500%/ml 1
Serum ND ND 0.647%/ml 1.281
0.710%/ml 1.42
Liver 1.619 3.207 19.749 39.11
1.970 3.937 25.802 51.55
Spleen 2.192 4.340 1.606 3.180
4.031 8.055 2.058 4.111
Heart 0.267 0.529 0.267 0.529
0.339 0.678 0.257 0.514
Lung 0.351 0.696 0.582 1.153
0.444 0.888 0.665 1.329
Kidney 0.826 1.635 1.774 3.514
0.939 1.875 2.062 4.121
Stomach 1.259 2.492 10.080 19.961
2.039 4.075 21.305 42.567
Sm. Intestine 1.010 2.001 10.709 21.21
0.848 1.694 10.672 21.32
-A108-
Table A3.27.2 Cont. (Organ Distribution of BSA-MTX (11.55%w/w))
Organ % in lg CPM in Ip/
CPM in 1ml WB
% in total CPM iiutotal 
CPM in 1ml WB.
4. Distribution 3 hours post injection.
Thyroid ND ND 3.50 14.29
4.04 13.33
Bladder ND ND 0.516 2.106
0.141 0.465
Whole Blood ND ND 0.245%/ml 1
0.303%/ml 1
Serum ND ND 0.320%/ml 1.307
0.387%/ml 1.277
Liver 0.567 2.316 6.643 27.13
0.504 1.665 6.718 22.19
Spleen 0.509 2.078 0.342 1.397
0.837 2.763 0.660 2.180
Heart 0.119 0.485 0.136 0.556
1.667 0.550 0.208 0.687
Lung 0.223 0.910 0.332 1.355
0.226 0.748 0.319 1.053
Kidney 0.374 1.526 0.843 3.442
0.423 1.398 1.028 3.394
Stomach 3.949 16.126 21.488 87.74
2.858 9.440 12.561 41.49
Sm. Intestine 0.953 3.893 6.956 28.40
0.840 2.776 7.545 24.92
5. Distribution 5 hours post administration.
Thyroid ND ND 6.999 34.65
5.960 35.06
Bladder ND ND 0.198 0.980
1.010 5.941
Whole Blood ND ND 0.202%/ml 1
0.170%/ml 1
Serum ND ND 0.241%/ml 1.193
0.239%/ml 1.406
Liver 0.368 1.821 5.133 25.39
0.291 1.712 4.217 24.76
Spleen 0.240 1.185 0.206 1.018
0.265 1.555 0.199 1.170
Heart 0.0857 0.424 0.112 0.557
0.0850 0.499 0.101 0.594
Lung 0.149 0.736 0.271 1.342
0.135 0.794 0.246 1.443
Kidney 0.239 1.182 0.658 3.253
0.223 1.307 0.590 3.466
Stomach 2.124 10.507 12.349 61.08
1.821 10.693 13.002 76.35
Sm. Intestine 0.548 2.709 6.144 30.39
0.813 4.772 8.019 47.09
-A109-
Table A3.28.1 The Serum and Whole Blood concentrations (% of radioactivity remaining/
ml) following administration of 250pg of 125I-G-BSA to rats by the IV route.
Where mean and S.E.M are quoted, 3 animals were sampled at the same time point. 10 rats 
were dosed altogether.
Time (minutes) Whole Blood %/ml Serum %/ml
1 2.406 3.885
1 4.270 6.577
2 1.059 1.550
2 1.113 1.795
5 0.365 0.525
5 0.360 0.525
8 0.278 0.372
8 0.271 0.371
9 0.232 0.290
10 0.342±0.104 0.435±0.124
15 0.287 0.327
15 0.253 0.294
20 0.360 0.440
20 0.482 0.624
21 0.565 0.767
21 0.761 0.912
30 0.604 0.717
30 0.729 0.892
36 0.577 0.755
36 0.602 0.769
60 0.530 0.695
60 0.552 0.642
105 0.489 0.633
105 0.507 0.685
120 0.485 0.444
120 0.491 0.457
165 0.561 0.558
165 0.534 0.544
180 0.356 0.420
180 0.391 0.402
300 0.471 0.367
300 0.330 0.457
-A110-
Table A3.28.2 The Organ Distribution following administration of 250jig of 125I-G-BS A to
rats by the IV route. 10 rats were dosed. Two animals were sampled at each time point
Results are tabulated in 2 forms; as a % of the total radioactivity found in a particular 
organ and as a ratio of the activity found in lg  (or the whole organ) divided by the activity 
in 1ml whole blood.
Organ % in lg C!PM in 1 g 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
1. Distribution 15 minutes post injection.
Thyroid ND ND 0.187 0.652
0.128 0.508
Bladder ND ND 0.017 0.0592
0.018 0.0714
Whole Blood ND ND 0.287%/ml 1
0.252%/ml 1
Serum ND ND 0.327%/ml 1.139
0.294%/ml 1.167
Liver 6.721 23.417 81.21 283.0
6.867 27.143 87.59 346.2
Spleen 3.407 11.873 2.402 8.370
3.016 11.923 2.636 10.42
Heart 0.245 0.854 0.255 0.890
0.252 0.996 0.278 1.099
Lung 0.658 2.294 0.904 3.150
0.621 2.453 0.781 3.088
Kidney 0.933 3.251 2.322 8.090
0.908 3.591 2.149 8.493
Stomach 0.457 1.594 1.345 4.687
0.273 1.078 0.863 3.412
Sm. Intestine 0.310 1.082 3.119 10.87
0.243 0.961 2.314 9.146
-A lll-
Table A3.28.2 Cont. (Organ distribution of G-BSA).
Organ % in lg CPM in le  
CPM in 1 ml WB
% in total CPM in total 
CPM in 1ml WB
2. Distribution 30 minutes post injection
Thyroid ND ND 0.742 1.228
0.386 0.529
Bladder ND ND 0136 0.225
0.073 0.0818
Whole Blood ND ND 0.604%/ml 1
0.729%/ml 1
Serum ND ND 0.717%/ml 1.187
0.892%/ml 1.224
Liver 4.304 7.126 42.02 69.57
4.254 5.835 54.96 75.39
Spleen 3.168 5.245 1.903 3.151
2.835 3.889 2.003 2.748
Heart 0.581 0.962 0.620 1.027
0.445 0.610 0.531 0.728
Lung 1.072 1.775 1.477 2.445
0.841 1.153 0.956 1.312
Kidney 1.044 1.729 2.366 3.917
0.818 1.123 2.061 2.827
Stomach 0.702 1.162 1.672 2.768
0.486 0.666 2.311 3.170
Sm. Intestine 0.796 1.318 5.764 9.543
1.278 1.753 12.33 16.91
3. Distribution 1 hour post administration.
Thyroid ND ND 1.89 3.565
1.962 3.554
Bladder ND ND 1.486 2.804
0.420 0.761
Whole Blood ND ND 0.530%/ml 1
0.552%/ml 1
Serum ND ND 0.695%/ml 1.311
0.642%/ml 1.163
Liver 0.603 1.138 8.607 16.24
0.674 1.222 8.594 15.57
Spleen 0.821 1.549 0.541 1.020
0.955 1.731 0683 1.238
Heart 0.224 0.422 0.230 0.434
0.220 0.398 0.248 0.450
Lung 0.452 0.853 0.670 1.264
0.425 0.770 0.540 0.978
Kidney 0.561 1.059 1.418 2.675
0.478 0.866 1.297 2.350
Stomach 2.442 4.607 12.858 24.26
2.576 4.666 22.48 40.72
Sm. Intestine 1.090 2.057 11.131 21.00
2.090 3.786 22.35 40.48
-A112-
Table A3.28.2 Cont (organ distribution of G-BSA)
Organ % in lg CPM in lg  
CPM in lm lW R
% in total CPM in total 
CPM in 1ml WB.
4. Distribution 3 hours post injection.
Thyroid ND ND 8.320 23.44
7.975 20.40
Bladder ND ND 0.615 1.733
0.0636 0.162
Whole Blood ND ND 0.356%/ml 1
0.391%/ml 1
Serum ND ND 0.420%/ml 1.180
0.402%/ml 1.028
Liver 0.262 0.738 3.403 9.567
0.276 0.705 4.008 10.239
Spleen 0.258 0.726 0.221 0.622
0.404 1.031 0.190 0.486
Heart 0.132 0.371 0.136 0.383
0.161 0.412 0.165 0.421
Lung 0.270 0.759 0.561 1.576
0.267 0.683 0.457 1.167
Kidney 0.308 0.866 0.738 2.074
0.289 0.739 0.755 1.928
Stomach 1.218 3.425 10.341 29.07
3.076 7.859 19.74 50.43
Sm. Intestine 1.224 3.442 10.667 29.99
1.157 2.955 11.815 30.19
5. Distribution 5 hours post administration.
Thyroid ND ND 11.13 23.64
11.12 33.69
Bladder ND ND 0.469 0.997
0.117 0.356
Whole Blood ND ND 0.471%/ml 1
0.659%/ml 1
Serum ND ND 0.367%/ml 0.779
' 0.456%/ml 0.692
Liver 0.214 0.455 2.349 4.987
0.206 0.623 2.339 3.549
Spleen 0.198 0.421 0.136 0.289
0.250 0.758 0.130 0.198
Heart 0.125 0.265 0.122 0.259
0.164 0.249 0.195 0.296
Lung 0.244 0.518 0.351 0.745
0.272 0.412 0.319 0.485
Kidney 0.248 0.528 0.515 1.093
0.274 0.416 0.675 1.024
Stomach 2.451 5.204 10.334 21.94
2.350 3.565 9.375 14.23
Sm. Intestine 1.240 2.632 10.640 22.59
1.394 2.115 10.859 16.48
-A113-
Table A3.29.1 The Serum and Whole Blood Concentration (% of 125I dose remaining/ml)
following administration of 250pg of 125I-M-BSA to rats by the IV route.
Where mean and S.E.M. are quoted four animals were sampled at the same time point Ten 
rats were dosed altogether. Whole Blood and serum concentrations were determined from 
the same animals at each time point
Time (minutes) Whole Blood %/ml Serum%ml
1 2.581 4.358
1 2.377 3.504
2 1.739 2.702
2 1.447 2.145
5 1.108 1.702
5 1.157 1.482
8 0.884 1.156
9 0.681 0.890
10 0.558 0.894
10 0.328 0.487
15 0.32110.0579 0.50510.0968
20 0.318 0.469
20 0.181 0.263
30 0.315 0.403
30 0.285 0.331
45 0.365 0.375
45 0.457 0.487
60 0.362 0.470
60 0.436 0.565
90 0.514 0.496
90 0.363 0.464
120 0.435 0.556
120 0.337 0.431
150 0.221 0.291
150 0.205 0.262
180 0.448 0.420
180 0.304 0.548
240 0.151 0.225
240 0.154 0.245
300 0.160 0.188
300 0.164 0.195
-A114-
Table A3.29.2 The Organ Distribution following administration of 250pg of 125I-M-BSA to
rats by the IV route.
Ten rats were dosed. Results are expressed in 2 forms; as a % of the radioactivity injected 
found in lg  or the whole organ and as a ratio of the activity found in lg  (or the whole 
tissue) divided by the activity found in 1ml of whole blood.
Organ % in lg CPM in 1 g 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
1. Distribution 15 minutes post administration
Thyroid ND ND 0.086 0.199
0.107 0.265
Bladder ND ND 0.0614 0.142
0.113 0.280
Whole Blood ND ND 0.431%/ml 1
0.404%/ml 1
Serum ND ND 0.744%/ml 1.726
0.581 1.438
Liver 5.825 13.516 71.40 165.65
4.693 11.617 62.71 155.21
Spleen 3.353 7.779 2.851 6.615
5.090 12.600 4.148 10.27
Heart 0.398 0.923 0.357 0.827
0.324 0.803 0.344 0.852
Lung 1.564 3.628 2.560 5.940
1.818 4.499 2.777 6.873
Kidney 1.377 3.195 3.556 8.251
0.731 1.810 1.936 4.791
Stomach 0.184 0.426 2.252 5.225
0.157 0.390 2.093 5.182
Sm. Intestine 0.207 0.481 2.184 5.067
0.249 0.617 3.033 7.508
-A115-
Table A3.29.2 Cont. (Organ Distribution of M-BSA)
Organ % in lg CPM in lg/
PPM in 1ml WR
% in total CPM in total/ 
CPM inlmlWR
2. Distribuion 30 minutes post administration.
Thyroid ND ND 0.441 1.4
0.289 1.014
Bladder ND ND 0.209 0.663
0.232 0.814
Whole Blood ND ND 0.315%/ml 1
0.285%/ml 1
Serum ND ND 0.403%/ml 1.279
0.331%/ml 1.161
Liver 3.742 11.879 50.09 159.03
2.690 9.440 43.83 153.78
Spleen 7.611 24.16 5.357 17.01
8.688 30.48 8.394 29.45
Heart 0.313 0.994 0.396 1.257
0.312 1.095 0.465 1.633
Lung 1.587 5.037 2.234 7.092
1.180 4.140 1.899 6.664
Kidney 0.720 2.285 1.784 5.664
0.571 2.004 1.475 5.177
Stomach 0.329 1.045 4.799 15.23
0.358 1.257 2.601 9.125
Sm. Intestine 0.479 1.520 4.915 15.61
0.454 1.595 5.535 19.42
3. Distribution 1 hour post administration.
Thyroid ND ND 1.678 4.635
1.780 4.083
Bladder ND ND 0.765 2.113
0.894 2.050
Whole Blood ND ND 0.362%/ml 1
0.436%/ml 1
Serum ND ND 0.470%/ml 1.298
0.565%/ml 1.296
Liver 1.603 4.427 22.435 61.975
1.818 4.179 23.475 54.587
Spleen 3.572 9.868 2.524 6.974
4.597 10.568 2.559 5.883
Heart 0.358 0.989 0.486 1.343
0.329 0.757 0.342 0.786
Lung 1.072 2.960 1.734 4.791
1.071 2.3910 1.346 3.095
Kidney 0.704 1.945 1.976 5.459
0.371 0.852 0.952 2.190
Stomach 1.686 4.658 14.178 39.17
0.360 0.828 3.568 8.202
Sm. Intestine 0.857 2.369 9.741 26.91
2.099 4.826 20.37 46.83
-A116-
Table A3.29.1 Cont. (Organ Distribution of M-BS A)
Organ % in lg CPM in lg  
CPM in 1 ml WR
% in total CPM in total 
CPM in 1ml WB
4. Distribution 3 hours post administration.
Thyroid ND ND 9.906 22.11
6.230 20.49
Bladder ND ND 0.762 1.700
0.177 0.582
Whole Blood ND ND 0.448%/ml 1
0.304%/ml 1
Serum ND ND 0.548%/ml 1.223
0.420%/ml 1.382
Liver 0.501 1.119 5.276 11.777
0.485 1.596 5.423 17.858
Spleen 1.345 3.002 0.775 1.729
0.943 3.101 0.968 3.186
Heart 0.226 0.505 0.238 0.530
0.203 0.667 0.228 0.749
Lung 0.322 0.718 0.419 0.934
0.433 1.426 0.752 2.474
Kidney 0.539 1.203 1.246 2.780
0.457 1.503 1.172 3.855
Stomach 2.767 6.177 10.334 23.066
6.316 20.776 24.678 81.179
Sm. Intestine 1.319 2.944 9.048 20.197
1.127 3.707 9.408 30.947
5. Distribution 5 hours post administration.
Thyroid ND ND 9.210 57.56
12.555 76.52
Bladder ND ND 0.518 3.238
0.137 0.835
Whole Blood ND ND 0.160%/ml 1
0.164%/ml 1
Serum ND ND 0.188%/ml 1.175
0.195%/ml 1.189
Liver 0.211 1.319 3.271 20.445
0.217 1.321 3.567 21.751
Spleen 0.552 3.452 0.405 2.534
0.506 3.089 0.401 2.443
Heart 0.0524 0.327 0.0797 0.499
0.0764 0.466 0.118 0.717
Lung 0.174 1.087 0.314 1.963
0.158 0.964 0.292 1.782
Kidney 0.136 0.847 0.445 2.780
0.169 1.033 0.533 3.248
Stomach 1.109 6.931 7.220 45.13
1.422 8.669 7.713 47.03
Sm. Intestine 0.749 4.684 7.970 49.81
0.239 1.454 2.581 15.74
-A117-
Table A3.30.1 The Whole Blood and Serum Concentration (% of radioactivity/ml)
following administration of 250pg of 125I-LA to rats by the IV route. Eight rats were
injected. Each value was determined from one rat. (Except see note a below).
Time (min) Whole Blood %/ml Serum %/ml
1 3.620 8.52
1 4.505 10.51
2 2.837 6.118
2 2.800 7.338
5 1.801 2.771
5 2.195 3.618
8. 1.339 1.915
8 1.185 1.857
10 0.991 2.167
15 0.619 1.261
15 0.688 1.182
20 0.541 1.138
20 0.553 0.898
30 0.484±0.031a 0.908±0.0666a
60 0.485 0.936
60 0.367 0.708
120 . 0.659
120 - 0.534
180 _ 0.493
180 - 0.391
270 _ 0.412
270 - 0.467
300 0.335 0.410
300 0.345 0.431
Note
a) Value is mean ± S.E.M. (n= 3)
-A118-
Table A3.30.2 The Organ Distribution following administration of 250pg of 125I-LA to rats
by the IV route.
Eight rats were dosed. Two animals were used for each time point Results arc expressed in 
2 forms; as a % of the total radioactivity found in lg or the whole tissue and as a ratio of 
the activity in lg (or the whole organ) divided by the activity found in 1ml of whole blood.
Organ % in lg CP-MinJLg 
CPM in 1ml WB
% in total CPM in total 
CPM in 1ml WB
1. Distribution 15 minutes post administration.
Thyroid ND ND 0.136 0.220
0.137 0.199
Bladder ND ND 0.301 0.486
0.301 0.438
Whole Blood ND ND 0.619%/ml 1
0.688%/ml 1
Serum ND ND 1.261%/ml 2.037
1.182%/ml 1.718
Liver 0.424 0.684 4.421 7.142
0.426 0.619 5.150 7.485
Spleen 0.443 0.715 0.256 0.419
0.518 0.753 0.356 0.517
Heart 0.504 0.813 0.500 0.808
0.386 0.561 0.417 0.606
Lung 0.659 1.065 0.853 1.378
0.596 0.869 0.860 1.250
Kidney 24.644 39.81 48.46 78.32
21.809 31.70 52.14 75.78
Stomach 0.218 0.352 1.271 2.053
0.227 0.367 1.338 1.930
Sm. Intestine 0.425 0.687 3.455 5.591
0.270 0.392 2.289 3.327
-A119-
Table A.3.30.2 Cont. (organ distribution of LA).
Organ % in lg CPM in 1 g 
CPM in 1ml WR
% in total CPM in total 
CPM/1 ml WB
2. Distribution 30 mnutes following administration.
Thyroid ND ND 0.055
0.150
0.117
0.342
Bladder ND ND 0.269
0.312
0.571
0.712
Whole Blood ND ND 0.471%/ml
0.438%/ml
1
1
Serum ND ND 0.982%/ml
0.967%/ml
2.085
2.208
Liver 0.340 0.722 4.412 9.367
0.516 1.178 4.257 9.719
Spleen 0.576 1.223 0.261 0.554
0.288 0.657 0.270 0.616
Heart 0.387 0.822 0.332 0.705
0.385 0.879 0.274 0.626
Lung 1.128 2.395 1.562 3.316
0.556 1.269 0.718 1.639
Kidney 5.089 10.80 11.53 24.48
6.463 14.76 11.27 25.73
Stomach 3.454 7.333 16.92 35.92
4.388 10.02 21.22 48.45
Sm. Intestine 4.035 8.567 32.27 68.51
3.638 8.306 
3. Distribution 1 hour post administration.
24.88 56.80
Thyroid ND ND 1.353
1.609
2.789
4.384
Bladder ND ND 1.493
3.299
3.078
8.990
Whole Blood ND ND 0.485%/ml
0.367%/ml
1
1
Seram ND ND 0.936%/ml
0.708%/ml
1.930
1.929
Liver 0.610 1.258 4.543 9.367
0.278 0.757 3.095 8.435
Spleen 0.966 1.992 0.416 0.859
0.887 2.418 0.531 1.448
Heart 0.488 1.007 0.456 0.941
0.493 1.342 0.303 0.825
Lung 0.518 1.069 0.475 0.980
0.651 1.774 0.734 2.000
Kidney 13.996 28.86 23.98 49.44
21.80 59.39 46.81 127.5
Stomach 0.145 0.300 0.426 0.879
0.288 0.784 1.141 3.108
Sm. Intestine 0.256 0.528 1.858 3.830
0.283 0.771 2.762 7.525
-A 120-
Table A330,2  Cont. (organ distribution of LA).
Organ % in lg CPM in lg % in total CPM in total
CPM in 1ml WB CPM in 1ml WB
4. Distribution 5 hours post administration.
Thyroid ND ND 6.886
7.321
20.55
21.21
Bladder ND ND 0.128
0.154
0.83
0.446
Whole Blood ND ND 0.335%/ml
0.345%/ml
1
1
Serum ND ND 0.410%/ml
0.431%/ml
1.224
1.249
Liver 0.208 0.620 2.217 6.619
0.199 0.577 2.306 6.685
Spleen 0.193 0.575 0.144 0.430
0.209 0.606 0.211 0.612
Heart 0.163 0.487 0.103 0.307
0.177 0.513 0.139 0.404
Lung 0.222 0.663 0.277 0.827
0.208 0.603 0.293 0.850
Kidney 0.633 1.890 1.193 3.560
0.599 1.736 1.369 3.969
Stomach 2.799 8.355 7.578 22.62
2.845 8.246 13.09 37.93
Sm. Intestine 1.240 3.702 9.100 27.17
1.332 3.450 11.32 32.82
-A121-
Table A3.31.1: The Serum Concentrations determined following administration of 
125I-B SA-3H-MTX (7.16%w/w) to rats by the IV route. The concentration for both isotopes 
was determined and compared. Ten rats were injected with the conjugate. Two rats were 
sampled at each time point
Time (hours) 3H activity %/ml 125I activity %/ml
0.5 4.618 5.496
0.5 7.204 6.097
1.0 4.477 4.449
1.0 4.780 4.270
2.0 3.034 3.100
2.0 3.575 3.530
4.0 1.916 1.714
6.0 1.426 1.293
6.0 1.013 1.117
8.0 1.048 0.911
8.0 0.690 0.870
11.5 0.785 0.705
11.5 0.796 0.613
24 0.182 0.321
24 0.188 0.251
28 0.198 0.235
28 0.312 0.235
31 0.157 0.150
31 0.155 0.174
48 0.120 0.111
48 0.104 0.104
55 0.0587 0.0869
55 0.0682 0.0675
72 0.0637 0.0686
72 0.0695 0.0547
79 0.0479 0.0472
79 0.0409 0.0469
96 0.0404 0.0420
96 0.0379 0.0357
-A122-
Table A3.31.2 The Urine Excretion of radioactivity following administration of 125I-
BSA^H-MTX (7.16%w/w) to rats by the IV route. The percentage of isotope excreted by
each rat is listed as well as the mean isotope excretion at each time point.
Time
(hours)
3H % activity 
excreted
125I % activity 
excreted
24 23.47 45.50
31.50 55.44
29.49 52.20
Mean 28.15 51.05a
S.E.M. 2.412 2.927
48 25.84 47.59
35.24 62.52
36.64 62.66
Mean 32.57 57.59
S.E.M. 3.391 5.000b
72 26.97 49.52
36.35 64.71
39.52 66.34
Mean 34.28 60.19
S.E.M. 3.768 5.356c
96 37.61 65.90
40.58 68.57
Mean 39.10 67.23
Notes
a) t value for 3H versus 125I excreted at 24 hours is 6.04. Probability 
<0.1%, highly significant
b) t value for 3H versus 125I at 48 hours is 4.19. Probability <1%, 
highly significant
c) t value for 3H versus 125I at 72 hours is 3.955. Probability <1%, 
highly significant.
-A123-
Table A3.31.3 The Organ Distribution following administration of ^I-BSA^H-MTX (7.16%w/w) to rats by the IV route. Results are expressed 
in 2 forms; as a % of the total radioactivty found in lg or the whole organ and as a ratio of the activity found in lg (or the whole organ) divided 
by the activity in 1ml of Serum (S). One rat was analysed at one hour and six hours. Two rats were analysed at 24, 48,72 and 96 hours.
Organ % 3H in lg % 125I in lg 3h  p p m  in 1g 1251 CPM in lg % 3H in total % 125I in total 3H PPM in total 125j PPM in total
CPM in 1ml S CPM in 1ml S CPM in 1ml S CPM in 1ml S
1. Distribution 1 hour post administration.
Thyroid - - - - - 1.788 - 0.402
Bladder - - - - - 0.100 0.0225
Serum - - - - 4.477%/ml 4.449%/ml 1 1
Liver 0.169 1.150 0.038 0.258 1.850 12.53 0.413 2.82
Spleen 0.432 1.955 0.096 0.439 0.261 1.181 0.0117 0.265
Kidney 0.317 0.969 0.071 0.32 0.694 2.118 0.155 0.476
Stomach 0 0.901 0 0.203 0 8.35 0 1.869
Sm. Intestine 0 0.915 0 0.206 0 10.66 0 2.390
2. Distribution 6 hours post administration.
Thyroid - - - - - 5.667 - 4.383
Bladder - - - - - 0.218 - 0.169
Serum - - - - 1.426%/ml 1.117%/ml 1 1
Liver 0.341 0.495 0.238 0.443 3.193 4.638 2.239 4.152
Spleen 0.255 0.447 0.179 0.400 0.149 0.261 0.104 0.234
Kidney 0.206 0.548 0.145 0.491 0.423 1.124 0.297 1.006
Stomach 0.396 3.06 0.278 2.74 3.05 23.57 2.14 21.10
Sm. Intestine 0.0243 1.795 0.017 1.607 0.143 10.58 0.100 9.47
Table A3.31.3 Cont. (Organ distribution of 125I-BSA-3H-MTX)
Organ % 3H in lg % 125I in lg 3H CPM in lg  
CPM in 1ml S
125I CPM in lg 
CPM in 1ml S
% 3H in total % 125I in total 3H CPM in.tmal 
CPM in 1ml S
125J CPM in total 
CPM in 1ml S
3. Distribution 24 hours post administration.
Thyroid • - - - 14.55 - 45.33
15.46 - 61.59
Bladder _ _ • 0.145 0.452
0.117 0.466
Serum _ . 0.182%/ml 0.321%/ml 1 1
0.188%/ml 0.251%/ml 1 1
Liver 0.131 0.140 0.722 0.436 1.517 1.616 8.34 5.03
0.124 0.124 0.661 0.494 1.455 1.452 7.739 5.784
Spleen 0.048 0.104 0.265 0.325 0.0237 0.0514 0.130 0.160
0.0557 0.102 0.296 0.406 0.0307 0.0561 0.163 0.223
Kidney 0.053 0.204 0.290 0.637 0.0927 0.359 0.509 1.118
0.0149 0.206 0.0797 0.820 0.0337 0.463 0.179 1.845
Stomach 0 0.788 0 0.245 0 2.632 0 8.199
0 0.294 0 1.172 0 1.063 0 4.235
Sm. Intestine 0 0.324 0 1.011 0 3.024 0 9.42
0 0.689 0 3.668 0 5.82 0 23.18
Table A3.31.3 Cont. (Organ Distribution of 125I-BSA-3H-MTX)
Organ % 3H in lg % 125I in lg ?H CRM.inJg 
CPM in 1ml S
125J CPM in lg  
CPM in 1ml S
% 3H in total % 125I in total ?H CPM.in.total 
CPM in 1ml S
125J PPM in total 
CPM in 1ml S
4. Distribution 48 hours post administration.
Thyroid - - - - - 16.18 - 145.8
11.56 111.1
Bladder _ _ _ _ 0.219 _ 1.973
0.207 1.990
Serum _ _ _ . 0.120%/ml 0.111%/ml 1 1
0.104%/ml 0.104%/ml 1 1
Liver 0.0726 0.0749 0.607 0.673 0.864 0.891 7.218 8.005
0.082 0.064 0.785 0.612 1.226 0.957 11.79 9.202
Spleen 0.0438 0.0*465 0.366 0.418 0.0259 0.0275 0.216 0.247
0.0188 0.0323 0.181 0.311 0.0117 0.0201 0.238 0.193
Kidney 0.062 0.133 0.519 1.197 0.126 0.270 1.053 2.426
0.064 0.116 0.618 1.113 0.163 0.294 1.567 2.822
Stomach 0 0.0986 0 0.886 0 0.674 0 6.056
0.0214 0.0760 0.206 0.731 0.216 0.768 2.077 7.385
Sm. Intestine 0 0.0803 0 0.721 0 0.641 0 5.760
0.0108 0.0562 0.104 0.540 0.110 0.570 1.058 5.480
-A
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Table A3.31.3 Cont (Organ Distribution of 125I-BSA-3H-MTX)
Organ % 3H in lg % 125I in lg 3H CPM in 1 g 125J CPM in lg % 3H in total % 125I in total 3H CPM in total 125J PPM in total
CPM in 1ml S CPM in 1ml S CPM in 1ml S CPM in 1ml S
5 Distribution 72 hours post administration.
Thyroid - - - - - 16.38 - 238.8
17.78 326.0
Bladder • _ • 0.0249 - 0.363
0.0558 1.020
Serum _ • • 0.0637%/ml 0.0686%/ml 1 1
0.0695%/ml 0.0547%/ml 1 1
Liver 0.101 0.0548 1.590 0.799 1.307 0.707 20.52 10.31
0.106 0.0402 1.525 0.739 1.484 0.562 21.35 10.33
Spleen 0.0225 0.0240 0.353 0.350 0.0117 0.0125 0.184 0.182
0.0263 0.0298 0.378 0547 0.0121 0.0137 0.174 0.252
Kidney 0.102 0.104 1.601 1.516 0.233 0.239 3.658 3.484
0.0802 0.0848 1.154 1.559 0.193 0.204 2.777 3.751
Stomach 0 0.062 0 0.904 0 0.197 0 2.872
0.0136 0.0268 0.196 0.493 0.104 0.205 1.496 3.770
Sm. Intestine 0 0.0366 0 0.488 0 0.301 0 4.008
0.0144 0.0258 0.207 0.474 0.115 0.206 1.655 3.787
Table A331.3 Cont. (Organ Distribution of 125I-BSA-3H-MTX)
Organ % 3H in lg % 125I in lg 3H TPM in 1 g
CPM in 1ml S
125TPPMin lg  
CPM in 1ml S
% 3H in total % 125I in total 3H PPM in total
CPM in 1ml S
i 25! CPM in total 
CPM in 1ml S
6. Distribution 96 hours post administration.
Thyroid - - - - - 11.8 280.9
15.1 421.8
Bladder _ _ _ . - 0.387 . 9.214
0.334 9.356
Serum - - - 0.0404%/ml 0.0420%/ml 1 1
0.0379%/ml 0.0357%/ml 1 1
Liver 0.111 0.0302 2.75 0.718 1.309 0.356 32.4 8.476
0.247 0.0549 6.528 1.537 2.340 0.519 61.74 14.54
Spleen 0.0388 0.0176 0.96 0.42 0.0176 0.0080 0.436 0.190
0.0429 0.0315 1.134 0.883 0.0255 0.0187 0.673 0.524
Kidney 0.193 0.070 4.78 1.675 0.453 0.165 11.21 3.928
0.164 0.0991 4.316 2.776 0.345 0.209 9.103 5.850
Stomach 0.0189 0.008 0.469 0.191 0.116 0.0492 2.87 1.17
0.071 0.091 1.86 2.55 0.129 0.166 3.40 4.65
Sm. Intestine 0.0098 0.0184 0.244 0.438 0.091 0.170 2.252 4.048
0.0302 0.058 0.796 1.626 0.197 0.379 5.198 10.62
Table A3.32.1 The Uptake of 125I following exposure of rat peritoneal macrophages,in
vitro, to 75pg of 125I-HSA in RPMI media without serum. The uptake was determined
at 37°C and 4°C. Results are means for 3 wells at each time point ± S.E.M..
Time (min) Uptake at 37°C 
% 125I applied
Uptake at 4°C 
% 125I applied
15 0.076±0.018 0.075±0.0036
30 0.120±0.024 0.104±0.034
45 0.122±0.007 0.108±0.029
60 0.173±0.020 0.159±0.009
Table A3.32.2: The Degradation of 125I-HSA by rat peritoneal macrophages in vitro. 
Macrophages were exposed to RPMI media which contained 75pg of 125I-HSA for a 1 
hour period. Measurement of TCA soluble 125I was carried out at various time points on 
3 wells. Results are expressed as mean ± S.E.M.
Time (min) % 125I present as TCA 
Soluble (37°Q
% 125I present as TCA 
Soluble (4°C)
0 9.58 9.58
15 33.5±2.69 11.52±3.58
30 38.6±6.26 11.8613.83
45 45.4±4.58 20.8313.49
60 48.6±6.00 32.9312.77
-A129-
Table A3.32.3: The Uptake of 125I following exposure of rat peritoneal macrophages, in
vitro, to 8pg of 125I-BSA in RPMI media without serum. The uptake was determined at
37°C and 4°C. Results are means for 3 wells at each time point ± S.E.M..
Time (min) Uptake at 37°C 
% 125I applied
Uptake at 4°C 
% 125I applied
15 0.038±0.0036 0.07210.0016
30 0.080±0.00608 0.11010.024
45 0.12210.0152 0.10810.031
60 0.18010.0127 0.17510.010
Table A3.32.4: The Degradation of 125I-BSA by rat peritoneal macrophages in vitro. 
Macrophages were exposed to RPMI media which contained 8pg of 125I-BSA for a 1 
hour period. Measurement of TCA soluble 125I was carried out at various time points on 
3 wells. Results are means ± S.E.M.
Time (min) % 125I present as TCA 
Soluble (37°Q
% 125I present as TCA 
Soluble (4°C)
0 5.3 5.3
15 30.611.73 8.5612.58
30 33.212.65 11.9311.83
45 39.314.33 19.2311.49
60 44.015.37 29.9212.97
-A130-
Table A3.32.5: The Uptake of 125I following exposure of rat peritoneal macrophages, in 
vitro, to 8pg of 125I-BSA-MTX (4.54%w/w) in RPMI media without serum. The uptake 
was determined at 37°C and 4°C. Results are means for 3 wells at each time point ± 
S.E.M..
Time (min) Uptake at 37°C 
% 125I applied
Uptake at 4°C 
% 125I applied
10 0.072210.00386 0.090510.0114
20 0.090810.0075 0.093710.0018
30 0.10710.00465 0.13210.0193
40 0.13110.00902 0.14010.0079
50 0.14510.005 0.15810.0102
60 0.17410.0086 0.16810.0265
Table A3.32.6: The Degradation of 125I-BSA-MTX (4.54%w/w) by rat peritoneal 
macrophages in vitro. Macrophages were exposed to RPMI media which contained 8pg 
of 125I-BSA-MTX (4.54%w /w ) for a 1 hour period. Measurement of TCA soluble 125I 
was carried out at various time points on 3 wells. Results are means ± S.E.M.
Time (min) % 125I present as TCA 
Soluble (37°Q
% 125I present as TCA 
Soluble (4°C)
0 7.4 7.4
10 26.3111.19 7.3312.58
20 32.8514.27 10.8511.83
30 38.5310.729 15.2311.67
40 40.6111.513 25.9212.97
50 42.1512.11 25.3911.92
60 47.7213.60 30.1113.33
-A131-
Table A3.32.7: The Uptake of 125I following exposure of rat peritoneal macrophages, in 
vitro, to 8pg of 125I-BSA-MTX (11.55%w/w) in RPMI media without serum. The 
uptake was determined at 37°C and 4°C. Results are means for 3 wells at each time 
point ± S.E.M..
Time (min) Uptake at 37°C 
% 125I applied
Uptake at 4°C 
% 125I applied
15 0.161±0.00463 0.12410.0113
30 0.192±0.0077 0.20910.0246
45 0.23910.0034 0.21110.0221
60 0.29510.0154 0.25410.019
Table A3.32.8: The Degradation of 125I-BSA-MTX (11.55%w/w) by rat peritoneal 
macrophages in vitro. Macrophages were exposed to RPMI media which contained 8pg 
of 125I-BSA-MTX (11.55%w/w) for a 1 hour period. Measurement of TCA soluble 125I 
was carried out at various time points on 3 wells. Results are means ± S.E.M.
Time (min) % 125I present as TCA 
Soluble (37°Q
% 125I present as TCA 
Soluble (4°C)
0 8.54 8.54
15 31.312.25 9.5611.42
30 35.6716.63 19.7312.83
45 40.2613.33 18.7311.67
60 45.3014.66 25.4213.07
-A132-
Table A3.32.9: The Uptake of 125I following exposure of rat peritoneal macrophages, in
vitro, to 8pg of 125I-G-BSA in RPMI media without serum. The uptake was determined
at 37°C and 4°C. Results are means for 3 wells at each time point ± S.E.M..
Time (min) Uptake at 37°C 
% 125I applied
Uptake at 4°C 
% 125I applied
15 2.204±0.0483 1.46810.0105
30 3.844±0.331 1.54410.0321
45 3.742±0.318 1.51210.0263
60 2.93210.0588 1.86410.055
Table A3.32.10: The Degradation of 125I-G-BSA by rat peritoneal macrophages in vitro. 
Macrophages were exposed to RPMI media which contained 8pg of 125I-G-BSA for a 1 
hour period. Measurement of TCA. soluble 125I was carried out at various time points on 
3 wells. Results are means ± S.E.M.
Time (min) % 125I present as TCA 
Soluble (37°Q
% 125I present as TCA 
Soluble (4°C)
0 10.12 10.12
15 46.6312.512 43.912.176
30 51.3616.387 41.2117.23
45 49.9911.238 40.8711.226
60 51.1111.284 42.811.462
-A133-
Table A3.32.ll: The Uptake of 125I following exposure of rat peritoneal macrophages,
in vitro, to 8pg of 125I-M-BSA in RPMI media without serum. The uptake was
determined at 37°C and 4°C. Results are means for 3 wells at each time point ± S.E.M..
Time (min) Uptake at 37°C 
% 125I applied
Uptake at 4°C 
% 125I applied
10 5.13±0.0921 3.9410.11
20 9.2710.264 6.2110.386
30 12.9210.514 7.3710.49
40 15.0410.369 8.3010.069
50 16.3910.345 7.0910.202
60 18.8010.0463 6.9010.152
Table A3.32.12: The Degradation of 125I-M-BSA by rat peritoneal macrophages in 
vitro. Macrophages were exposed to RPMI media which contained 8pg of 125I-M-BSA 
for a 1 hour period. Measurement of TCA soluble 125I was carried out at various time 
points on 3 wells. Results are means ± S.E.M.
Time (min) % 125I present as TCA 
Soluble (37°C)
% 125I present as TCA 
Soluble (4°C)
0 11.12 11.12
10 31.413.67 30.8411.731
20 30.5013.17 42.5111.075
30 36.0011.83 47.7011.34
40 40.5311.51 51.5913.35
50 40.3712.05 47.3010.682
60 45.1210.464 46.812.32
-A134-
